<?xml version='1.0' encoding='UTF-8'?>
<!DOCTYPE rdf:RDF [
	 <!ENTITY rdf 'http://www.w3.org/1999/02/22-rdf-syntax-ns#'>
	 <!ENTITY kb 'http://protege.stanford.edu/kb#'>
	 <!ENTITY rdfs 'http://www.w3.org/2000/01/rdf-schema#'>
]>
<rdf:RDF xmlns:rdf="&rdf;"
	 xmlns:kb="&kb;"
	 xmlns:rdfs="&rdfs;">
<kb:Concept rdf:about="&kb;Concept253"
	 kb:ConceptID="253"
	 kb:concept="retinopathy"
	 kb:guideline_definition="ICD-9 codes"
	 kb:needs_research="false"
	 rdfs:label="253: retinopathy">
	<kb:is_used_in rdf:resource="&kb;Recommendation1"/>
	<kb:is_used_in rdf:resource="&kb;Recommendation15"/>
	<kb:is_used_in rdf:resource="&kb;Recommendation17"/>
	<kb:is_used_in rdf:resource="&kb;Recommendation252"/>
	<kb:is_used_in rdf:resource="&kb;Recommendation253"/>
	<kb:is_used_in rdf:resource="&kb;Recommendation3"/>
	<kb:is_used_in rdf:resource="&kb;Recommendation5"/>
	<kb:annotates rdf:resource="&kb;annotation_library_Instance_30130"/>
</kb:Concept>
<kb:Concept rdf:about="&kb;Concept254"
	 kb:ConceptID="254"
	 kb:concept="diabetes type 1"
	 kb:guideline_definition="ICD-9 codes"
	 kb:needs_research="false"
	 rdfs:label="254: diabetes type 1">
	<kb:is_used_in rdf:resource="&kb;Recommendation2"/>
	<kb:annotates rdf:resource="&kb;annotation_library_Class60014"/>
</kb:Concept>
<kb:Concept rdf:about="&kb;Concept255"
	 kb:ConceptID="255"
	 kb:needs_research="false">
	<kb:concept>patients with increased rate of progression or prevalence of retinopathy, </kb:concept>
	<kb:guideline_definition>including patients with uncontrolled hypertension, chronic severe hyperglycemia, recent initiation or intensification of insulin therapy, or other known microvascular disease (e.g., albuminuria or neuropathy). </kb:guideline_definition>
	<rdfs:label>255: patients with increased rate of progression or prevalence of retinopathy, </rdfs:label>
	<kb:is_used_in rdf:resource="&kb;Recommendation18"/>
</kb:Concept>
<kb:Concept rdf:about="&kb;Concept256"
	 kb:ConceptID="256"
	 kb:concept="Acute ocular changes"
	 kb:needs_research="false"
	 rdfs:label="256: Acute ocular changes">
	<kb:guideline_definition>Acute changes in vision can be arbitrarily defined as those occurring suddenly or over a period of up to 72 hours. The rapid onset of new visual symptoms such as blurring, distortion, floaters, or light flashes should prompt an urgent referral to an eye care provider as they may indicate a serious ocular problem</kb:guideline_definition>
	<kb:is_used_in rdf:resource="&kb;Recommendation7"/>
	<kb:annotates rdf:resource="&kb;annotation_library_Instance_30000"/>
</kb:Concept>
<kb:Concept rdf:about="&kb;Concept257"
	 kb:ConceptID="257"
	 kb:concept="early onset dm type 1"
	 kb:needs_research="false"
	 rdfs:label="257: early onset dm type 1">
	<kb:guideline_definition xml:space='preserve'><![CDATA[age<30 years]]></kb:guideline_definition>
	<kb:is_used_in rdf:resource="&kb;Recommendation8"/>
</kb:Concept>
<kb:Concept rdf:about="&kb;Concept258"
	 kb:ConceptID="258"
	 kb:needs_research="false">
	<kb:concept>high risk indicators for advanced retinopathy also defined as ocular risk factors</kb:concept>
	<kb:guideline_definition>if they have at least one of the following: • DM for 15 years or more
• Any evidence of diabetic nephropathy (including microproteinuria)
• Type 2 DM and cardiovascular autonomic neuropathy
• Lower extremity amputation related to DM
• History of any diabetic retinopathy
• Pregnancy and pre-existing diabetes
Existence of at least one of the listed risk factors is sufficient to define the patient as high-risk. (Evidence III  Poor C)</kb:guideline_definition>
	<rdfs:label>258: high risk indicators for advanced retinopathy also defined as ocular risk factors</rdfs:label>
</kb:Concept>
<kb:Concept rdf:about="&kb;Concept259"
	 kb:ConceptID="259"
	 kb:needs_research="false">
	<kb:concept>ophthalmologist or optometrist knowledgeable and experienced in detecting diabetic eye disease.</kb:concept>
	<rdfs:label>259: ophthalmologist or optometrist knowledgeable and experienced in detecting diabetic eye disease.</rdfs:label>
	<kb:is_used_in rdf:resource="&kb;Recommendation11"/>
</kb:Concept>
<kb:Concept rdf:about="&kb;Concept260"
	 kb:ConceptID="260"
	 kb:concept="dilated fundus examination (dilated eye exam- in library)"
	 kb:guideline_definition="procedure codes?"
	 kb:needs_research="false">
	<rdfs:label>260: dilated fundus examination (dilated eye exam- in library)</rdfs:label>
	<kb:is_used_in rdf:resource="&kb;Recommendation12"/>
	<kb:annotates rdf:resource="&kb;annotation_library_Class60001"/>
</kb:Concept>
<kb:Concept rdf:about="&kb;Concept261"
	 kb:ConceptID="261"
	 kb:concept="comprehensive eye exam"
	 kb:guideline_definition="procedure codes?"
	 kb:needs_research="false"
	 rdfs:label="261: comprehensive eye exam">
	<kb:is_used_in rdf:resource="&kb;Recommendation13"/>
	<kb:is_used_in rdf:resource="&kb;Recommendation6"/>
	<kb:annotates rdf:resource="&kb;annotation_library_Class60002"/>
</kb:Concept>
<kb:Concept rdf:about="&kb;Concept262"
	 kb:ConceptID="262"
	 kb:concept="ocular risk factors"
	 kb:needs_research="false"
	 rdfs:label="262: ocular risk factors">
	<kb:guideline_definition>if they have at least one of the following: • DM for 15 years or more
• Any evidence of diabetic nephropathy (including microproteinuria)
• Type 2 DM and cardiovascular autonomic neuropathy
• Lower extremity amputation related to DM
• History of any diabetic retinopathy
• Pregnancy and pre-existing diabetes
Existence of at least one of the listed risk factors is sufficient to define the patient as high-risk. (Evidence III  Poor C)</kb:guideline_definition>
	<kb:is_used_in rdf:resource="&kb;Recommendation15"/>
</kb:Concept>
<kb:Concept rdf:about="&kb;Concept265"
	 kb:ConceptID="265"
	 kb:concept="Breaks in the skin"
	 kb:needs_research="false"
	 rdfs:label="265: Breaks in the skin">
	<kb:is_used_in rdf:resource="&kb;Recommendation19"/>
	<kb:annotates rdf:resource="&kb;annotation_library_Instance_100000"/>
</kb:Concept>
<kb:Concept rdf:about="&kb;Concept266"
	 kb:ConceptID="266"
	 kb:concept="foot risk assessment"
	 kb:needs_research="false"
	 rdfs:label="266: foot risk assessment">
	<kb:guideline_definition>Evaluation of the skin for breakdown
• Assessment of protective sensation using the Semmes-Weinstein 5.07 monofilament
• Evaluation for LE arterial disease
• Evaluation for foot deformity
• Prior history of ulcers or amputations</kb:guideline_definition>
	<kb:is_used_in rdf:resource="&kb;Recommendation20"/>
	<kb:annotates rdf:resource="&kb;annotation_library_Instance_70299"/>
</kb:Concept>
<kb:Concept rdf:about="&kb;Concept267"
	 kb:ConceptID="267"
	 kb:concept="Acute Ischemia or Rest Pain"
	 kb:needs_research="false"
	 rdfs:label="267: Acute Ischemia or Rest Pain">
	<kb:guideline_definition xml:space='preserve'><![CDATA[Absence of palpable pedal pulses - Examine the patient to determine presence of dorsalis pedis and posterior tibial pulses. Absent pulses and signs of acute ischemia, e.g., rest pain associated with dependent rubor with pallor or palpably cold extremities, warrant urgent referral to a vascular surgeon.     Acute ischemia or rest pain – Evidence of arterial insufficiency: lower limb pain at rest, dusky/blue or purple/black color, gangrene, or cold extremity. Pain in the toes or forefoot may be relieved by dependency of the limb. Assessment is needed for prompt vascular/surgical intervention. Patient with acute arterial occlusion will present with pain, pallor, pulseless, paresthesia, and/or paralysis (Orchard & Strandness, 1993).
Claudication - Severe claudication is determined as pain in the thigh or calf that occurs when walking less than one block and is relieved by rest.
]]></kb:guideline_definition>
	<kb:is_used_in rdf:resource="&kb;Recommendation21"/>
	<kb:is_used_in rdf:resource="&kb;Recommendation22"/>
	<kb:annotates rdf:resource="&kb;annotation_library_Class60003"/>
</kb:Concept>
<kb:Concept rdf:about="&kb;Concept268"
	 kb:ConceptID="268"
	 kb:concept="Foot Ulceration"
	 kb:needs_research="false"
	 rdfs:label="268: Foot Ulceration">
	<kb:guideline_definition xml:space='preserve'><![CDATA[Active foot ulcer - A cutaneous erosion with a loss of epithelium that extends to or through the dermis can involve deeper tissue and is characterized by an inability to self-repair in a timely and orderly manner (ADA, 2002; Brodsky & Schneidler, 1991; Caputo et al., 1994; Eckman et al., 1995; Reiber et al., 1995).]]></kb:guideline_definition>
	<kb:is_used_in rdf:resource="&kb;Recommendation23"/>
	<kb:annotates rdf:resource="&kb;annotation_library_Class110001"/>
</kb:Concept>
<kb:Concept rdf:about="&kb;Concept269"
	 kb:ConceptID="269"
	 kb:concept="Ingrown toenail"
	 kb:needs_research="false"
	 rdfs:label="269: Ingrown toenail">
	<kb:guideline_definition>Ingrown toenail - Presents as a nail plate that has pierced the surrounding periungual tissue with associated erythema and drainage or an area of thick or discolored callus. The primary care provider should consider referral to a podiatrist for excision of infected ingrown nails, especially in the case of high-risk patients (Giacalone, 1997).</kb:guideline_definition>
	<kb:is_used_in rdf:resource="&kb;Recommendation24"/>
	<kb:is_used_in rdf:resource="&kb;Recommendation33"/>
	<kb:annotates rdf:resource="&kb;annotation_library_Instance_90088"/>
</kb:Concept>
<kb:Concept rdf:about="&kb;Concept270"
	 kb:ConceptID="270"
	 kb:concept="Systemic or Ascending (Worsening) Infection"
	 kb:needs_research="false"
	 rdfs:label="270: Systemic or Ascending (Worsening) Infection">
	<kb:guideline_definition xml:space='preserve'><![CDATA[Limb-threatening conditions could include signs and symptoms of systemic infection including gas gangrene, ascending cellulitis and lymphangitis, or gangrene.
Although infection is not always clinically apparent, common signs and symptoms include perilesional warmth, erythema, purulent drainage, odor, and involvement of bone. Pain may or may not be present. There may or may not be lymphangitis and lymphadenopathy, and fever and white blood cell count may or may not be present. Sudden loss of glycemic control often heralds serious infections (Orchard & Strandness, 1993).
]]></kb:guideline_definition>
	<kb:is_used_in rdf:resource="&kb;Recommendation25"/>
	<kb:annotates rdf:resource="&kb;annotation_library_Instance_100544"/>
</kb:Concept>
<kb:Concept rdf:about="&kb;Concept271"
	 kb:ConceptID="271"
	 kb:concept="foot care specialist"
	 kb:needs_research="false"
	 rdfs:label="271: foot care specialist">
	<kb:guideline_definition>foot care specialist is defined as a podiatrist, vascular surgeon, orthopedic surgeon, or other healthcare provider with demonstrated training, competence, and licensure in foot care.</kb:guideline_definition>
	<kb:is_used_in rdf:resource="&kb;Recommendation26"/>
	<kb:is_used_in rdf:resource="&kb;Recommendation29"/>
	<kb:annotates rdf:resource="&kb;annotation_library_Instance_90154"/>
</kb:Concept>
<kb:Concept rdf:about="&kb;Concept272"
	 kb:ConceptID="272"
	 kb:needs_research="false">
	<kb:concept>Lack of sensation to Semmes-Weinstein 5.07 monofilament at one or more noncallused plantar sites</kb:concept>
	<rdfs:label>272: Lack of sensation to Semmes-Weinstein 5.07 monofilament at one or more noncallused plantar sites</rdfs:label>
	<kb:is_used_in rdf:resource="&kb;Recommendation28"/>
	<kb:annotates rdf:resource="&kb;annotation_library_Instance_70000"/>
</kb:Concept>
<kb:Concept rdf:about="&kb;Concept273"
	 kb:ConceptID="273"
	 kb:concept="minor lesion"
	 kb:needs_research="false"
	 rdfs:label="273: minor lesion">
	<kb:guideline_definition>1. Minor lesions or wounds that could possibly be treated by the primary care provider are blisters, erosions, and/or minor cuts that do not extend beyond subcutaneous tissue. Pulses are present, there are no signs of acute infection, and there is no severe lower limb pain and no sign of a worsening lesion.</kb:guideline_definition>
	<kb:is_used_in rdf:resource="&kb;Recommendation32"/>
	<kb:is_used_in rdf:resource="&kb;Recommendation34"/>
	<kb:is_used_in rdf:resource="&kb;Recommendation40"/>
	<kb:is_used_in rdf:resource="&kb;Recommendation41"/>
	<kb:is_used_in rdf:resource="&kb;Recommendation42"/>
	<kb:is_used_in rdf:resource="&kb;Recommendation44"/>
	<kb:annotates rdf:resource="&kb;annotation_library_Instance_100162"/>
</kb:Concept>
<kb:Concept rdf:about="&kb;Concept275"
	 kb:ConceptID="275"
	 kb:concept="Patient and family foot education"
	 kb:needs_research="false"
	 rdfs:label="275: Patient and family foot education">
	<kb:guideline_definition>Patient and family foot education should include the following components and considerations:
• Keep it simple and appropriate for the patient's educational level.
• Make it interactive, including demonstrations in washing, drying, and inspecting feet; nail cutting; and suitable footwear selection, including footwear for temperature extremes.
• Provide opportunities for the patient to state the need for what are basics of daily skin and foot care and preventive measures.
• Include practice time during the educational session to demonstrate and have the patient, in return, demonstrate safe toenail trimming.
• Provide repetitive examples of and messages about how care of the feet can prevent complications. Include recommendations that distinguish minor foot problems from more serious problems that require early or immediate professional treatment, together with a name and telephone number for prompt assistance.
• Make realistic recommendations (appropriate to the patient's physical and visual capabilities) while personalizing information and highlighting key points. This may include a referral to home healthcare.
• Provide written guidelines in large print and/or graphics that the patient can hang in the bathroom as a reference and reprints of lay articles. Patients should be alerted that elevation in blood sugar might be a sign of an active or impending infection. Use of a night-light or turning on lights when getting up at night may prevent foot injuries. Patients should be made aware of potential dangers in the home.
• For patients with high-risk feet, twice-daily inspection in good light is recommended, looking for any redness or drainage and running the hands over the foot to detect any swelling or increased local warmth. Patients with neuropathic fingers may need to enlist help or use a mirror to inspect their feet.
• Before putting on shoes, inspect for torn linings, rough spots, and foreign objects (e.g., gravel, stones, glass, and children’s toys).
• Alternating between pairs of shoes during the day is recommended. A minimum of two serviceable pairs of shoes, insoles, and orthoses are required.
• Educators can utilize numerous publications on patient foot care instruction that are free of charge and have no copyright restrictions. The following publications are available through the U.S. Department of Health and Human Services, Centers for Disease Control and Prevention (CDC), and American Association of Diabetes Education (AADE): 
o Take Charge of Your Diabetes: Prevent Foot Problems
o Taking Care of Your Feet
o Tips on Good Foot Care: from Feet Can Last a Lifetime
</kb:guideline_definition>
	<kb:is_used_in rdf:resource="&kb;Recommendation36"/>
	<kb:is_used_in rdf:resource="&kb;Recommendation37"/>
	<kb:is_used_in rdf:resource="&kb;Recommendation38"/>
	<kb:is_used_in rdf:resource="&kb;Recommendation47"/>
	<kb:annotates rdf:resource="&kb;annotation_library_Instance_100176"/>
</kb:Concept>
<kb:Concept rdf:about="&kb;Concept276"
	 kb:ConceptID="276"
	 kb:concept="diabetes type 2"
	 kb:guideline_definition="ICD-9"
	 kb:needs_research="false"
	 rdfs:label="276: diabetes type 2">
	<kb:is_used_in rdf:resource="&kb;Recommendation2"/>
	<kb:annotates rdf:resource="&kb;annotation_library_Class60004"/>
</kb:Concept>
<kb:Concept rdf:about="&kb;Concept277"
	 kb:ConceptID="277"
	 kb:concept="change in ocular function"
	 kb:expert_definition_concept="? SBM- slow onset change in ocular function since last visit"
	 kb:needs_research="false"
	 rdfs:label="277: change in ocular function">
	<kb:is_used_in rdf:resource="&kb;Recommendation7"/>
	<kb:annotates rdf:resource="&kb;annotation_library_Instance_30016"/>
</kb:Concept>
<kb:Concept rdf:about="&kb;Concept278"
	 kb:ConceptID="278"
	 kb:guideline_definition="icd9 codes"
	 kb:needs_research="false">
	<kb:concept>diabetic nephropathy  (including microproteinuria) (in library as diabetes with renal manifestations)</kb:concept>
	<rdfs:label>278: diabetic nephropathy  (including microproteinuria) (in library as diabetes with renal manifestations)</rdfs:label>
	<kb:annotates rdf:resource="&kb;annotation_library_Class60005"/>
</kb:Concept>
<kb:Concept rdf:about="&kb;Concept279"
	 kb:ConceptID="279"
	 kb:concept="validated fundus imaging technique"
	 kb:guideline_definition="procedure codes?"
	 kb:needs_research="false"
	 rdfs:label="279: validated fundus imaging technique">
	<kb:is_used_in rdf:resource="&kb;Recommendation12"/>
</kb:Concept>
<kb:Concept rdf:about="&kb;Concept280"
	 kb:ConceptID="280"
	 kb:concept="using insulin"
	 kb:guideline_definition="prescription data"
	 kb:needs_research="false"
	 rdfs:label="280: using insulin">
	<kb:is_used_in rdf:resource="&kb;Recommendation15"/>
	<kb:annotates rdf:resource="&kb;annotation_library_Class60006"/>
</kb:Concept>
<kb:Concept rdf:about="&kb;Concept281"
	 kb:ConceptID="281"
	 kb:concept="eye care provider defined follow-up"
	 kb:needs_research="false"
	 rdfs:label="281: eye care provider defined follow-up">
	<kb:guideline_definition>The eye care provider should determine the optimal screening intervals based on the patient’s severity of retinopathy and risk factors associated with retinopathy progression</kb:guideline_definition>
	<kb:is_used_in rdf:resource="&kb;Recommendation16"/>
</kb:Concept>
<kb:Concept rdf:about="&kb;Concept282"
	 kb:ConceptID="282"
	 kb:concept="poorly controlled htn"
	 kb:expert_definition_concept="??"
	 kb:guideline_definition="not defined?"
	 kb:needs_research="false"
	 rdfs:label="282: poorly controlled htn">
	<kb:is_used_in rdf:resource="&kb;Recommendation18"/>
</kb:Concept>
<kb:Concept rdf:about="&kb;Concept283"
	 kb:ConceptID="283"
	 kb:concept="Erythema"
	 kb:needs_research="false"
	 rdfs:label="283: Erythema">
	<kb:is_used_in rdf:resource="&kb;Recommendation19"/>
	<kb:annotates rdf:resource="&kb;annotation_library_Instance_100028"/>
</kb:Concept>
<kb:Concept rdf:about="&kb;Concept284"
	 kb:ConceptID="284"
	 kb:guideline_definition="??"
	 kb:needs_research="false">
	<kb:concept>Assessment of protective sensation using the Semmes-Weinstein 5.07 monofilament</kb:concept>
	<rdfs:label>284: Assessment of protective sensation using the Semmes-Weinstein 5.07 monofilament</rdfs:label>
	<kb:is_used_in rdf:resource="&kb;Recommendation20"/>
</kb:Concept>
<kb:Concept rdf:about="&kb;Concept285"
	 kb:ConceptID="285"
	 kb:concept="Puncture Wound"
	 kb:needs_research="false"
	 rdfs:label="285: Puncture Wound">
	<kb:guideline_definition>A lesion through the epidermis, dermis, and other tissues caused by a piercing or penetrating object. Patients with diabetes with puncture wounds can quickly develop severe limb-threatening complications.</kb:guideline_definition>
	<kb:is_used_in rdf:resource="&kb;Recommendation25"/>
	<kb:annotates rdf:resource="&kb;annotation_library_Instance_90074"/>
</kb:Concept>
<kb:Concept rdf:about="&kb;Concept286"
	 kb:ConceptID="286"
	 kb:concept="Evidence of LE arterial disease"
	 kb:needs_research="false"
	 rdfs:label="286: Evidence of LE arterial disease">
	<kb:guideline_definition>(absence of both dorsalis pedis and tibialis posterior pulses, dependent rubor with pallor on elevation, history of rest pain or claudication, and prior history of LE bypass surgery)</kb:guideline_definition>
	<kb:is_used_in rdf:resource="&kb;Recommendation28"/>
	<kb:annotates rdf:resource="&kb;annotation_library_Instance_70022"/>
</kb:Concept>
<kb:Concept rdf:about="&kb;Concept287"
	 kb:ConceptID="287"
	 kb:concept="urgently referred to an eye care provider."
	 kb:expert_definition_concept="immediately"
	 kb:needs_research="false"
	 rdfs:label="287: urgently referred to an eye care provider.">
	<kb:is_used_in rdf:resource="&kb;Recommendation7"/>
</kb:Concept>
<kb:Concept rdf:about="&kb;Concept288"
	 kb:ConceptID="288"
	 kb:concept="cardiovascular autonomic neuropathy"
	 kb:guideline_definition="icd9 codes"
	 kb:needs_research="false"
	 rdfs:label="288: cardiovascular autonomic neuropathy">
	<kb:annotates rdf:resource="&kb;annotation_library_Class60007"/>
</kb:Concept>
<kb:Concept rdf:about="&kb;Concept290"
	 kb:ConceptID="290"
	 kb:concept="chronic severe hyperglycemia"
	 kb:expert_definition_concept="??"
	 kb:guideline_definition="not defined?"
	 kb:needs_research="false"
	 rdfs:label="290: chronic severe hyperglycemia">
	<kb:is_used_in rdf:resource="&kb;Recommendation18"/>
	<kb:annotates rdf:resource="&kb;annotation_library_Class60008"/>
</kb:Concept>
<kb:Concept rdf:about="&kb;Concept291"
	 kb:ConceptID="291"
	 kb:concept="Trauma"
	 kb:needs_research="false"
	 rdfs:label="291: Trauma">
	<kb:is_used_in rdf:resource="&kb;Recommendation19"/>
	<kb:annotates rdf:resource="&kb;annotation_library_Class80000"/>
</kb:Concept>
<kb:Concept rdf:about="&kb;Concept292"
	 kb:ConceptID="292"
	 kb:concept="Evaluation for LE arterial disease"
	 kb:guideline_definition="icd9 codes"
	 kb:needs_research="false"
	 rdfs:label="292: Evaluation for LE arterial disease">
	<kb:is_used_in rdf:resource="&kb;Recommendation20"/>
	<kb:annotates rdf:resource="&kb;annotation_library_Instance_100058"/>
</kb:Concept>
<kb:Concept rdf:about="&kb;Concept293"
	 kb:ConceptID="293"
	 kb:concept="Hemorrhagic Callus With or Without Cellulitis"
	 kb:needs_research="false"
	 rdfs:label="293: Hemorrhagic Callus With or Without Cellulitis">
	<kb:guideline_definition>The provider must determine if the cellulitis may be associated with callus tissue or necrotic tissue that may obscure an underlying ulceration or deeper infection.
The callus tissue must be debrided to properly assess the extent of an underlying ulcerati</kb:guideline_definition>
	<kb:is_used_in rdf:resource="&kb;Recommendation25"/>
	<kb:annotates rdf:resource="&kb;annotation_library_Instance_90102"/>
</kb:Concept>
<kb:Concept rdf:about="&kb;Concept294"
	 kb:ConceptID="294"
	 kb:needs_research="false">
	<kb:concept>Foot deformities (specifically hammer toes, claw toe, Charcot's arthropathy, bunions, and metatarsal head deformities)</kb:concept>
	<kb:guideline_definition>(specifically hammer toes, claw toe, Charcot's arthropathy, bunions, and metatarsal head deformities)</kb:guideline_definition>
	<rdfs:label>294: Foot deformities (specifically hammer toes, claw toe, Charcot's arthropathy, bunions, and metatarsal head deformities)</rdfs:label>
	<kb:is_used_in rdf:resource="&kb;Recommendation28"/>
	<kb:annotates rdf:resource="&kb;annotation_library_Class60009"/>
</kb:Concept>
<kb:Concept rdf:about="&kb;Concept295"
	 kb:ConceptID="295"
	 kb:concept="Lower extremity amputation related to DM"
	 kb:guideline_definition="icd9 codes"
	 kb:needs_research="false"
	 rdfs:label="295: Lower extremity amputation related to DM">
	<kb:annotates rdf:resource="&kb;annotation_library_Instance_30116"/>
</kb:Concept>
<kb:Concept rdf:about="&kb;Concept296"
	 kb:ConceptID="296"
	 kb:concept="recent initiation of insulin therapy"
	 kb:expert_definition_concept="??"
	 kb:guideline_definition="not defined?"
	 kb:needs_research="false"
	 rdfs:label="296: recent initiation of insulin therapy">
	<kb:is_used_in rdf:resource="&kb;Recommendation18"/>
</kb:Concept>
<kb:Concept rdf:about="&kb;Concept297"
	 kb:ConceptID="297"
	 kb:concept="Pallor on elevation"
	 kb:needs_research="false"
	 rdfs:label="297: Pallor on elevation">
	<kb:is_used_in rdf:resource="&kb;Recommendation19"/>
	<kb:annotates rdf:resource="&kb;annotation_library_Instance_100102"/>
</kb:Concept>
<kb:Concept rdf:about="&kb;Concept298"
	 kb:ConceptID="298"
	 kb:concept="Evaluation for foot deformity"
	 kb:guideline_definition="icd9 codes"
	 kb:needs_research="false"
	 rdfs:label="298: Evaluation for foot deformity">
	<kb:is_used_in rdf:resource="&kb;Recommendation20"/>
	<kb:annotates rdf:resource="&kb;annotation_library_Instance_100042"/>
</kb:Concept>
<kb:Concept rdf:about="&kb;Concept299"
	 kb:ConceptID="299"
	 kb:concept="History of foot ulcer or non-traumatic LEA at any level"
	 kb:needs_research="false"
	 rdfs:label="299: History of foot ulcer or non-traumatic LEA at any level">
	<kb:is_used_in rdf:resource="&kb;Recommendation28"/>
	<kb:annotates rdf:resource="&kb;annotation_library_Class60010"/>
</kb:Concept>
<kb:Concept rdf:about="&kb;Concept300"
	 kb:ConceptID="300"
	 kb:concept="diabetic retinopathy"
	 kb:guideline_definition="diabetic retinopathy"
	 kb:needs_research="false"
	 rdfs:label="300: diabetic retinopathy"/>
<kb:Concept rdf:about="&kb;Concept301"
	 kb:ConceptID="301"
	 kb:concept="icd9 codes"
	 kb:guideline_definition="icd9 codes"
	 kb:needs_research="false"
	 rdfs:label="301: icd9 codes"/>
<kb:Concept rdf:about="&kb;Concept302"
	 kb:ConceptID="302"
	 kb:concept="Pregnancy and pre-existing diabetes"
	 kb:guideline_definition="icd9 codes"
	 kb:needs_research="false"
	 rdfs:label="302: Pregnancy and pre-existing diabetes"/>
<kb:Concept rdf:about="&kb;Concept303"
	 kb:ConceptID="303"
	 kb:guideline_definition="icd 9 codes, labs?"
	 kb:needs_research="false">
	<kb:concept>other known microvascular disease (albuminuria or neuropathy).</kb:concept>
	<rdfs:label>303: other known microvascular disease (albuminuria or neuropathy).</rdfs:label>
	<kb:is_used_in rdf:resource="&kb;Recommendation18"/>
	<kb:annotates rdf:resource="&kb;annotation_library_Class110003"/>
</kb:Concept>
<kb:Concept rdf:about="&kb;Concept304"
	 kb:ConceptID="304"
	 kb:concept="Changes in the size of foot"
	 kb:expert_definition_concept="changes in the shape of the foot"
	 kb:needs_research="false"
	 rdfs:label="304: Changes in the size of foot">
	<kb:is_used_in rdf:resource="&kb;Recommendation19"/>
	<kb:annotates rdf:resource="&kb;annotation_library_Instance_100014"/>
</kb:Concept>
<kb:Concept rdf:about="&kb;Concept305"
	 kb:ConceptID="305"
	 kb:concept="patient’s footwear"
	 kb:guideline_definition="??"
	 kb:needs_research="false"
	 rdfs:label="305: patient’s footwear">
	<kb:is_used_in rdf:resource="&kb;Recommendation20"/>
	<kb:annotates rdf:resource="&kb;annotation_library_Instance_100190"/>
</kb:Concept>
<kb:Concept rdf:about="&kb;Concept306"
	 kb:ConceptID="306"
	 kb:concept="dm >15 years"
	 kb:needs_research="false"
	 rdfs:label="306: dm >15 years">
	<kb:guideline_definition>The impact of these factors should be considered for each patient when assessing the duration of the disease as a risk factor for advanced retinopathy, and the physician should consider a lower threshold for high-risk status for patients whose disease is </kb:guideline_definition>
</kb:Concept>
<kb:Concept rdf:about="&kb;Concept307"
	 kb:ConceptID="307"
	 kb:concept="Extensive callus"
	 kb:needs_research="false"
	 rdfs:label="307: Extensive callus">
	<kb:is_used_in rdf:resource="&kb;Recommendation19"/>
	<kb:annotates rdf:resource="&kb;annotation_library_Instance_100074"/>
</kb:Concept>
<kb:Concept rdf:about="&kb;Concept308"
	 kb:ConceptID="308"
	 kb:concept="Tinea pedis"
	 kb:needs_research="false"
	 rdfs:label="308: Tinea pedis">
	<kb:guideline_definition>• Tinea pedis
</kb:guideline_definition>
	<kb:is_used_in rdf:resource="&kb;Recommendation19"/>
	<kb:annotates rdf:resource="&kb;annotation_library_Instance_100130"/>
</kb:Concept>
<kb:Concept rdf:about="&kb;Concept309"
	 kb:ConceptID="309"
	 kb:concept="Pitting edema"
	 kb:needs_research="false"
	 rdfs:label="309: Pitting edema">
	<kb:is_used_in rdf:resource="&kb;Recommendation19"/>
	<kb:annotates rdf:resource="&kb;annotation_library_Instance_100116"/>
</kb:Concept>
<kb:Concept rdf:about="&kb;Concept310"
	 kb:ConceptID="310"
	 kb:concept="Nail deformities"
	 kb:needs_research="false"
	 rdfs:label="310: Nail deformities">
	<kb:is_used_in rdf:resource="&kb;Recommendation19"/>
	<kb:annotates rdf:resource="&kb;annotation_library_Instance_100088"/>
</kb:Concept>
<kb:Concept rdf:about="&kb;Concept311"
	 kb:ConceptID="311"
	 kb:concept="circulatory symptoms that limit their lifestyle"
	 kb:needs_research="false"
	 rdfs:label="311: circulatory symptoms that limit their lifestyle">
	<kb:is_used_in rdf:resource="&kb;Recommendation27"/>
	<kb:annotates rdf:resource="&kb;annotation_library_Class110002"/>
</kb:Concept>
<kb:Concept rdf:about="&kb;Concept312"
	 kb:ConceptID="312"
	 kb:concept="minor foot problem"
	 kb:needs_research="false"
	 rdfs:label="312: minor foot problem">
	<kb:guideline_definition>(e.g., onychomycosis, painful corns, dry skin, athlete’s foot, minor calluses, uncomplicated nail trimming and improper foot hygiene</kb:guideline_definition>
	<kb:is_used_in rdf:resource="&kb;Recommendation46"/>
	<kb:is_used_in rdf:resource="&kb;Recommendation48"/>
	<kb:annotates rdf:resource="&kb;annotation_library_Instance_140000"/>
</kb:Concept>
<kb:Concept rdf:about="&kb;Concept313"
	 kb:ConceptID="313"
	 kb:concept="painful corns"
	 kb:needs_research="false"
	 rdfs:label="313: painful corns">
	<kb:annotates rdf:resource="&kb;annotation_library_Instance_120042"/>
</kb:Concept>
<kb:Concept rdf:about="&kb;Concept314"
	 kb:ConceptID="314"
	 kb:concept="athlete's foot"
	 kb:needs_research="false"
	 rdfs:label="314: athlete's foot">
	<kb:annotates rdf:resource="&kb;annotation_library_Class60011"/>
</kb:Concept>
<kb:Concept rdf:about="&kb;Concept315"
	 kb:ConceptID="315"
	 kb:concept="onychomycosis"
	 kb:needs_research="false"
	 rdfs:label="315: onychomycosis">
	<kb:annotates rdf:resource="&kb;annotation_library_Instance_120000"/>
</kb:Concept>
<kb:Concept rdf:about="&kb;Concept316"
	 kb:ConceptID="316"
	 kb:concept="dry skin"
	 kb:needs_research="false"
	 rdfs:label="316: dry skin">
	<kb:annotates rdf:resource="&kb;annotation_library_Instance_120028"/>
</kb:Concept>
<kb:Concept rdf:about="&kb;Concept317"
	 kb:ConceptID="317"
	 kb:concept="minor calluses"
	 kb:needs_research="false"
	 rdfs:label="317: minor calluses">
	<kb:annotates rdf:resource="&kb;annotation_library_Instance_120056"/>
</kb:Concept>
<kb:Concept rdf:about="&kb;Concept318"
	 kb:ConceptID="318"
	 kb:concept="uncomplicated nail trimming"
	 kb:needs_research="false"
	 rdfs:label="318: uncomplicated nail trimming">
	<kb:annotates rdf:resource="&kb;annotation_library_Instance_120070"/>
</kb:Concept>
<kb:Concept rdf:about="&kb;Concept319"
	 kb:ConceptID="319"
	 kb:concept="improper foot hygiene"
	 kb:needs_research="false"
	 rdfs:label="319: improper foot hygiene">
	<kb:annotates rdf:resource="&kb;annotation_library_Instance_120084"/>
</kb:Concept>
<kb:Concept rdf:about="&kb;Concept321"
	 kb:ConceptID="321"
	 kb:concept="limb threatening conditions"
	 kb:needs_research="false"
	 rdfs:label="321: limb threatening conditions">
	<kb:is_used_in rdf:resource="&kb;Recommendation31"/>
	<kb:annotates rdf:resource="&kb;annotation_library_Class60012"/>
</kb:Concept>
<kb:Concept rdf:about="&kb;Concept322"
	 kb:ConceptID="322"
	 kb:needs_research="false">
	<kb:concept>high risk for LE amputation (in library as Limb threatening condition)</kb:concept>
	<rdfs:label>322: high risk for LE amputation (in library as Limb threatening condition)</rdfs:label>
	<kb:is_used_in rdf:resource="&kb;Recommendation29"/>
	<kb:is_used_in rdf:resource="&kb;Recommendation30"/>
	<kb:is_used_in rdf:resource="&kb;Recommendation31"/>
	<kb:is_used_in rdf:resource="&kb;Recommendation34"/>
</kb:Concept>
<kb:Concept rdf:about="&kb;Concept323"
	 kb:ConceptID="323"
	 kb:concept="risk for foot ulcer"
	 kb:needs_research="false"
	 rdfs:label="323: risk for foot ulcer">
	<kb:is_used_in rdf:resource="&kb;Recommendation31"/>
	<kb:annotates rdf:resource="&kb;annotation_library_Class60013"/>
</kb:Concept>
<kb:Concept rdf:about="&kb;Concept324"
	 kb:ConceptID="324"
	 kb:concept="footwear prescriptions"
	 kb:needs_research="false"
	 rdfs:label="324: footwear prescriptions">
	<kb:is_used_in rdf:resource="&kb;Recommendation35"/>
	<kb:annotates rdf:resource="&kb;annotation_library_Instance_120098"/>
</kb:Concept>
<kb:Concept rdf:about="&kb;Concept325"
	 kb:ConceptID="325"
	 kb:needs_research="false">
	<kb:concept>visual inspection and peripheral sensation evaluation of foot (in library as 'Visual inspection (foot dm)' and 'Sensory exam (foot dm)'</kb:concept>
	<rdfs:label>325: visual inspection and peripheral sensation evaluation of foot (in library as 'Visual inspection (foot dm)' and 'Sensory exam (foot dm)'</rdfs:label>
	<kb:is_used_in rdf:resource="&kb;Recommendation39"/>
</kb:Concept>
<kb:Concept rdf:about="&kb;Concept326"
	 kb:ConceptID="326"
	 kb:needs_research="false">
	<kb:concept>wound healing progress (in library have 'Minor wound healed')</kb:concept>
	<rdfs:label>326: wound healing progress (in library have 'Minor wound healed')</rdfs:label>
	<kb:is_used_in rdf:resource="&kb;Recommendation45"/>
	<kb:annotates rdf:resource="&kb;annotation_library_Class70014"/>
</kb:Concept>
<kb:Concept rdf:about="&kb;Concept327"
	 kb:ConceptID="327"
	 kb:concept="local wound care"
	 kb:needs_research="false"
	 rdfs:label="327: local wound care">
	<kb:is_used_in rdf:resource="&kb;Recommendation43"/>
</kb:Concept>
<kb:Concept rdf:about="&kb;Concept331"
	 kb:ConceptID="331"
	 kb:concept="PPG - Postprandial plasma glucose"
	 kb:needs_research="false"
	 kb:patient_data="Labs"
	 rdfs:label="331: PPG - Postprandial plasma glucose">
	<kb:is_used_in rdf:resource="&kb;Recommendation251"/>
	<kb:annotates rdf:resource="&kb;annotation_library_Class70015"/>
</kb:Concept>
<kb:Concept rdf:about="&kb;Concept334"
	 kb:ConceptID="334"
	 kb:concept="Mild microvascular disease"
	 kb:needs_research="false"
	 rdfs:label="334: Mild microvascular disease">
	<kb:guideline_definition>early background retinopathy, and/or microalbuminuria, and/or mild neuropathy.</kb:guideline_definition>
	<kb:annotates rdf:resource="&kb;annotation_library_Class70016"/>
</kb:Concept>
<kb:Concept rdf:about="&kb;Concept335"
	 kb:ConceptID="335"
	 kb:concept="Moderate microvascular disease"
	 kb:needs_research="false"
	 rdfs:label="335: Moderate microvascular disease">
	<kb:guideline_definition>pre-proliferative (without severe hemorrhage, intra-retinal microvascular anomalies [IRMA], or venous bleeding) retinopathy or persistent, fixed proteinuria (macroalbuminuria) and/or demonstrable peripheral neuropathy (sensory loss).</kb:guideline_definition>
	<kb:annotates rdf:resource="&kb;annotation_ATHENA_GlycemicControl_Instance_230700"/>
</kb:Concept>
<kb:Concept rdf:about="&kb;Concept336"
	 kb:ConceptID="336"
	 kb:concept="Advanced microvascular disease"
	 kb:needs_research="false"
	 rdfs:label="336: Advanced microvascular disease">
	<kb:guideline_definition>severe non-proliferative (with severe hemorrhage, IRMA, or venous bleeding) or proliferative retinopathy and/or renal insufficiency (serum creatinine level > 2.0 mg/dL) and/or insensate extremities or autonomic neuropathy (e.g., gastroparesis, impaired sweating, or orthostatic hypotension).</kb:guideline_definition>
	<kb:annotates rdf:resource="&kb;annotation_library_Instance_230070"/>
</kb:Concept>
<kb:Concept rdf:about="&kb;Concept337"
	 kb:ConceptID="337"
	 kb:concept="Major comorbidity"
	 kb:needs_research="false"
	 rdfs:label="337: Major comorbidity">
	<kb:guideline_definition>cardiovascular disease, chronic obstructive pulmonary disease, chronic liver disease, stroke, and malignancy</kb:guideline_definition>
</kb:Concept>
<kb:Concept rdf:about="&kb;Concept342"
	 kb:ConceptID="342"
	 kb:guideline_definition="interval for follow up should be individualized"
	 kb:needs_research="true">
	<kb:concept>Follow-up for pts at target and no unstable chronic complications</kb:concept>
	<rdfs:label>342: Follow-up for pts at target and no unstable chronic complications</rdfs:label>
	<kb:is_used_in rdf:resource="&kb;Recommendation258"/>
</kb:Concept>
<kb:Concept rdf:about="&kb;Concept344"
	 kb:ConceptID="344"
	 kb:needs_research="false">
	<kb:concept>When there is a sudden change in health status or when changes are made to the treatment regimen, follow-up within one month or sooner may be appropriate</kb:concept>
	<rdfs:label>344: When there is a sudden change in health status or when changes are made to the treatment regimen, follow-up within one month or sooner may be appropriate</rdfs:label>
</kb:Concept>
<kb:Concept rdf:about="&kb;Concept345"
	 kb:ConceptID="345"
	 kb:concept="adherence to therapy"
	 kb:needs_research="false"
	 rdfs:label="345: adherence to therapy"/>
<kb:Concept rdf:about="&kb;Concept346"
	 kb:ConceptID="346"
	 kb:concept="adverse drug reactions"
	 kb:needs_research="false"
	 rdfs:label="346: adverse drug reactions"/>
<kb:Concept rdf:about="&kb;Concept347"
	 kb:ConceptID="347"
	 kb:concept="patient preference"
	 kb:needs_research="false"
	 rdfs:label="347: patient preference"/>
<kb:Concept rdf:about="&kb;Concept348"
	 kb:ConceptID="348"
	 kb:concept="Mild neuropathy"
	 kb:needs_research="false"
	 rdfs:label="348: Mild neuropathy">
	<kb:annotates rdf:resource="&kb;annotation_library_Instance_230002"/>
</kb:Concept>
<kb:Concept rdf:about="&kb;Concept349"
	 kb:ConceptID="349"
	 kb:concept="peripheral neuropathy"
	 kb:needs_research="false"
	 rdfs:label="349: peripheral neuropathy">
	<kb:annotates rdf:resource="&kb;annotation_library_Instance_230034"/>
</kb:Concept>
<kb:Concept rdf:about="&kb;Concept352"
	 kb:ConceptID="352"
	 kb:concept="Hypoglycemia"
	 kb:needs_research="false"
	 rdfs:label="352: Hypoglycemia">
	<kb:annotates rdf:resource="&kb;annotation_library_Instance_230134"/>
</kb:Concept>
<kb:Concept rdf:about="&kb;Concept353"
	 kb:ConceptID="353"
	 kb:needs_research="false">
	<kb:concept>Elevated HbA1c (not at target) but a normal fasting plasma glucose level</kb:concept>
	<rdfs:label>353: Elevated HbA1c (not at target) but a normal fasting plasma glucose level</rdfs:label>
</kb:Concept>
<kb:Concept rdf:about="&kb;Concept354"
	 kb:ConceptID="354"
	 kb:needs_research="false">
	<kb:concept>Frequent troublesome hypoglycemic symptoms during waking active hours.</kb:concept>
	<rdfs:label>354: Frequent troublesome hypoglycemic symptoms during waking active hours.</rdfs:label>
</kb:Concept>
<kb:Concept rdf:about="&kb;Concept355"
	 kb:ConceptID="355"
	 kb:concept="non-proliferative retinopathy"
	 kb:needs_research="false"
	 rdfs:label="355: non-proliferative retinopathy"/>
<kb:Concept rdf:about="&kb;Concept356"
	 kb:ConceptID="356"
	 kb:concept="proliferative retinopathy"
	 kb:needs_research="false"
	 rdfs:label="356: proliferative retinopathy"/>
<kb:Concept rdf:about="&kb;Concept357"
	 kb:ConceptID="357"
	 kb:concept="Glycemic target (HBA1c)"
	 kb:needs_research="false"
	 rdfs:label="357: Glycemic target (HBA1c)"/>
<kb:Concept rdf:about="&kb;Concept358"
	 kb:ConceptID="358"
	 kb:concept="sudden change in health status"
	 kb:needs_research="false"
	 rdfs:label="358: sudden change in health status"/>
<kb:Concept rdf:about="&kb;Concept359"
	 kb:ConceptID="359"
	 kb:concept="barriers to patient adherence"
	 kb:needs_research="false"
	 rdfs:label="359: barriers to patient adherence"/>
<kb:Concept rdf:about="&kb;Concept360"
	 kb:ConceptID="360"
	 kb:concept="recurrent or severe hypoglycemia"
	 kb:needs_research="false"
	 rdfs:label="360: recurrent or severe hypoglycemia"/>
<kb:Concept rdf:about="&kb;Concept361"
	 kb:ConceptID="361"
	 kb:concept="very mild or no microvascular complications of diabetes"
	 kb:needs_research="false"
	 rdfs:label="361: very mild or no microvascular complications of diabetes"/>
<kb:Concept rdf:about="&kb;Concept362"
	 kb:ConceptID="362"
	 kb:concept="advanced microvascular complications"
	 kb:needs_research="false"
	 rdfs:label="362: advanced microvascular complications"/>
<kb:Concept rdf:about="&kb;Concept363"
	 kb:ConceptID="363"
	 kb:concept="major comorbid illness"
	 kb:needs_research="false"
	 rdfs:label="363: major comorbid illness"/>
<kb:Concept rdf:about="&kb;Concept364"
	 kb:ConceptID="364"
	 kb:concept="rapid weight loss"
	 kb:needs_research="false"
	 rdfs:label="364: rapid weight loss"/>
<kb:Concept rdf:about="&kb;Concept365"
	 kb:ConceptID="365"
	 kb:concept="diabetic clinic"
	 kb:needs_research="false"
	 rdfs:label="365: diabetic clinic"/>
<kb:Concept rdf:about="&kb;Concept366"
	 kb:ConceptID="366"
	 kb:concept="diabetologist"
	 kb:needs_research="false"
	 rdfs:label="366: diabetologist"/>
<kb:Concept rdf:about="&kb;Concept367"
	 kb:ConceptID="367"
	 kb:concept="diabetic nurse"
	 kb:needs_research="false"
	 rdfs:label="367: diabetic nurse"/>
<kb:Concept rdf:about="&kb;Concept368"
	 kb:ConceptID="368"
	 kb:concept="diabetic educator"
	 kb:needs_research="false"
	 rdfs:label="368: diabetic educator"/>
<kb:Concept rdf:about="&kb;Concept369"
	 kb:ConceptID="369"
	 kb:concept="diabetic manager"
	 kb:needs_research="false"
	 rdfs:label="369: diabetic manager"/>
<kb:Concept rdf:about="&kb;Concept370"
	 kb:ConceptID="370"
	 kb:concept="registered dietitian"
	 kb:needs_research="false"
	 rdfs:label="370: registered dietitian"/>
<kb:Concept rdf:about="&kb;Concept371"
	 kb:ConceptID="371"
	 kb:concept="overweight"
	 kb:needs_research="false"
	 rdfs:label="371: overweight"/>
<kb:Concepts rdf:about="&kb;Concepts_Instance_1"
	 kb:ConceptID="311"
	 kb:Guideline_Concept="circulatory symptoms that limit their lifestyle"
	 kb:InLibrary="true"
	 kb:NeedsResearch="false"
	 rdfs:label="311: circulatory symptoms that limit their lifestyle"/>
<kb:Concepts rdf:about="&kb;Concepts_Instance_10"
	 kb:ConceptID="321"
	 kb:Guideline_Concept="limb threatening conditions"
	 kb:InLibrary="true"
	 kb:NeedsResearch="false"
	 rdfs:label="321: limb threatening conditions"/>
<kb:Concepts rdf:about="&kb;Concepts_Instance_100"
	 kb:ConceptID="308"
	 kb:Guideline_Concept="Tinea pedis"
	 kb:InLibrary="true"
	 kb:NeedsResearch="false"
	 rdfs:label="308: Tinea pedis">
	<kb:Guideline_definition>• Tinea pedis
</kb:Guideline_definition>
</kb:Concepts>
<kb:Concepts rdf:about="&kb;Concepts_Instance_101"
	 kb:ConceptID="309"
	 kb:Guideline_Concept="Pitting edema"
	 kb:InLibrary="true"
	 kb:NeedsResearch="false"
	 rdfs:label="309: Pitting edema"/>
<kb:Concepts rdf:about="&kb;Concepts_Instance_102"
	 kb:ConceptID="310"
	 kb:Guideline_Concept="Nail deformities"
	 kb:InLibrary="true"
	 kb:NeedsResearch="false"
	 rdfs:label="310: Nail deformities"/>
<kb:Concepts rdf:about="&kb;Concepts_Instance_11"
	 kb:ConceptID="322"
	 kb:InLibrary="true"
	 kb:NeedsResearch="false">
	<kb:Guideline_Concept>high risk for LE amputation (in library as Limb threatening condition)</kb:Guideline_Concept>
	<rdfs:label>322: high risk for LE amputation (in library as Limb threatening condition)</rdfs:label>
</kb:Concepts>
<kb:Concepts rdf:about="&kb;Concepts_Instance_12"
	 kb:ConceptID="323"
	 kb:Guideline_Concept="risk for foot ulcer"
	 kb:InLibrary="true"
	 kb:NeedsResearch="false"
	 rdfs:label="323: risk for foot ulcer"/>
<kb:Concepts rdf:about="&kb;Concepts_Instance_13"
	 kb:ConceptID="324"
	 kb:Guideline_Concept="footwear prescriptions"
	 kb:InLibrary="true"
	 kb:NeedsResearch="false"
	 rdfs:label="324: footwear prescriptions"/>
<kb:Concepts rdf:about="&kb;Concepts_Instance_14"
	 kb:ConceptID="325"
	 kb:InLibrary="false"
	 kb:NeedsResearch="false">
	<kb:Guideline_Concept>visual inspection and peripheral sensation evaluation of foot (in library as 'Visual inspection (foot dm)' and 'Sensory exam (foot dm)'</kb:Guideline_Concept>
	<rdfs:label>325: visual inspection and peripheral sensation evaluation of foot (in library as 'Visual inspection (foot dm)' and 'Sensory exam (foot dm)'</rdfs:label>
</kb:Concepts>
<kb:Concepts rdf:about="&kb;Concepts_Instance_15"
	 kb:ConceptID="326"
	 kb:InLibrary="true"
	 kb:NeedsResearch="false">
	<kb:Guideline_Concept>wound healing progress (in library have 'Minor wound healed')</kb:Guideline_Concept>
	<rdfs:label>326: wound healing progress (in library have 'Minor wound healed')</rdfs:label>
</kb:Concepts>
<kb:Concepts rdf:about="&kb;Concepts_Instance_16"
	 kb:ConceptID="327"
	 kb:Guideline_Concept="local wound care"
	 kb:InLibrary="false"
	 kb:NeedsResearch="false"
	 rdfs:label="327: local wound care"/>
<kb:Concepts rdf:about="&kb;Concepts_Instance_17"
	 kb:ConceptID="331"
	 kb:Guideline_Concept="PPG - Postprandial plasma glucose"
	 kb:InLibrary="true"
	 kb:NeedsResearch="false"
	 kb:Patient_data="Labs"
	 rdfs:label="331: PPG - Postprandial plasma glucose"/>
<kb:Concepts rdf:about="&kb;Concepts_Instance_18"
	 kb:ConceptID="334"
	 kb:Guideline_Concept="Mild microvascular disease"
	 kb:InLibrary="true"
	 kb:NeedsResearch="false"
	 rdfs:label="334: Mild microvascular disease">
	<kb:Guideline_definition>early background retinopathy, and/or microalbuminuria, and/or mild neuropathy.</kb:Guideline_definition>
</kb:Concepts>
<kb:Concepts rdf:about="&kb;Concepts_Instance_19"
	 kb:ConceptID="335"
	 kb:Guideline_Concept="Moderate microvascular disease"
	 kb:InLibrary="false"
	 kb:NeedsResearch="false"
	 rdfs:label="335: Moderate microvascular disease">
	<kb:Guideline_definition>pre-proliferative (without severe hemorrhage, intra-retinal microvascular anomalies [IRMA], or venous bleeding) retinopathy or persistent, fixed proteinuria (macroalbuminuria) and/or demonstrable peripheral neuropathy (sensory loss).</kb:Guideline_definition>
</kb:Concepts>
<kb:Concepts rdf:about="&kb;Concepts_Instance_2"
	 kb:ConceptID="312"
	 kb:Guideline_Concept="minor foot problem"
	 kb:InLibrary="true"
	 kb:NeedsResearch="false"
	 rdfs:label="312: minor foot problem">
	<kb:Guideline_definition>(e.g., onychomycosis, painful corns, dry skin, athlete’s foot, minor calluses, uncomplicated nail trimming and improper foot hygiene</kb:Guideline_definition>
</kb:Concepts>
<kb:Concepts rdf:about="&kb;Concepts_Instance_20"
	 kb:ConceptID="336"
	 kb:Guideline_Concept="Advanced microvascular disease"
	 kb:InLibrary="false"
	 kb:NeedsResearch="false"
	 rdfs:label="336: Advanced microvascular disease">
	<kb:Guideline_definition>severe non-proliferative (with severe hemorrhage, IRMA, or venous bleeding) or proliferative retinopathy and/or renal insufficiency (serum creatinine level > 2.0 mg/dL) and/or insensate extremities or autonomic neuropathy (e.g., gastroparesis, impaired sweating, or orthostatic hypotension).</kb:Guideline_definition>
</kb:Concepts>
<kb:Concepts rdf:about="&kb;Concepts_Instance_21"
	 kb:ConceptID="337"
	 kb:Guideline_Concept="Major comorbidity"
	 kb:InLibrary="false"
	 kb:NeedsResearch="false"
	 rdfs:label="337: Major comorbidity">
	<kb:Guideline_definition>cardiovascular disease, chronic obstructive pulmonary disease, chronic liver disease, stroke, and malignancy</kb:Guideline_definition>
</kb:Concepts>
<kb:Concepts rdf:about="&kb;Concepts_Instance_22"
	 kb:ConceptID="342"
	 kb:Guideline_definition="interval for follow up should be individualized"
	 kb:InLibrary="false"
	 kb:NeedsResearch="true">
	<kb:Guideline_Concept>Follow-up for pts at target and no unstable chronic complications</kb:Guideline_Concept>
	<rdfs:label>342: Follow-up for pts at target and no unstable chronic complications</rdfs:label>
</kb:Concepts>
<kb:Concepts rdf:about="&kb;Concepts_Instance_23"
	 kb:ConceptID="344"
	 kb:InLibrary="false"
	 kb:NeedsResearch="false">
	<kb:Guideline_Concept>When there is a sudden change in health status or when changes are made to the treatment regimen, follow-up within one month or sooner may be appropriate</kb:Guideline_Concept>
	<rdfs:label>344: When there is a sudden change in health status or when changes are made to the treatment regimen, follow-up within one month or sooner may be appropriate</rdfs:label>
</kb:Concepts>
<kb:Concepts rdf:about="&kb;Concepts_Instance_24"
	 kb:ConceptID="345"
	 kb:Guideline_Concept="adherence to therapy"
	 kb:InLibrary="false"
	 kb:NeedsResearch="false"
	 rdfs:label="345: adherence to therapy"/>
<kb:Concepts rdf:about="&kb;Concepts_Instance_25"
	 kb:ConceptID="346"
	 kb:Guideline_Concept="adverse drug reactions"
	 kb:InLibrary="false"
	 kb:NeedsResearch="false"
	 rdfs:label="346: adverse drug reactions"/>
<kb:Concepts rdf:about="&kb;Concepts_Instance_26"
	 kb:ConceptID="348"
	 kb:Guideline_Concept="Mild neuropathy"
	 kb:InLibrary="true"
	 kb:NeedsResearch="false"
	 rdfs:label="348: Mild neuropathy"/>
<kb:Concepts rdf:about="&kb;Concepts_Instance_27"
	 kb:ConceptID="349"
	 kb:Guideline_Concept="peripheral neuropathy"
	 kb:InLibrary="true"
	 kb:NeedsResearch="false"
	 rdfs:label="349: peripheral neuropathy"/>
<kb:Concepts rdf:about="&kb;Concepts_Instance_28"
	 kb:ConceptID="347"
	 kb:Guideline_Concept="patient preference"
	 kb:InLibrary="false"
	 kb:NeedsResearch="false"
	 rdfs:label="347: patient preference"/>
<kb:Concepts rdf:about="&kb;Concepts_Instance_29"
	 kb:ConceptID="352"
	 kb:Guideline_Concept="Hypoglycemia"
	 kb:InLibrary="true"
	 kb:NeedsResearch="false"
	 rdfs:label="352: Hypoglycemia"/>
<kb:Concepts rdf:about="&kb;Concepts_Instance_3"
	 kb:ConceptID="313"
	 kb:Guideline_Concept="painful corns"
	 kb:InLibrary="true"
	 kb:NeedsResearch="false"
	 rdfs:label="313: painful corns"/>
<kb:Concepts rdf:about="&kb;Concepts_Instance_30"
	 kb:ConceptID="353"
	 kb:InLibrary="false"
	 kb:NeedsResearch="false">
	<kb:Guideline_Concept>Elevated HbA1c (not at target) but a normal fasting plasma glucose level</kb:Guideline_Concept>
	<rdfs:label>353: Elevated HbA1c (not at target) but a normal fasting plasma glucose level</rdfs:label>
</kb:Concepts>
<kb:Concepts rdf:about="&kb;Concepts_Instance_31"
	 kb:ConceptID="354"
	 kb:InLibrary="false"
	 kb:NeedsResearch="false">
	<kb:Guideline_Concept>Frequent troublesome hypoglycemic symptoms during waking active hours.</kb:Guideline_Concept>
	<rdfs:label>354: Frequent troublesome hypoglycemic symptoms during waking active hours.</rdfs:label>
</kb:Concepts>
<kb:Concepts rdf:about="&kb;Concepts_Instance_32"
	 kb:ConceptID="355"
	 kb:Guideline_Concept="non-proliferative retinopathy"
	 kb:InLibrary="false"
	 kb:NeedsResearch="false"
	 rdfs:label="355: non-proliferative retinopathy"/>
<kb:Concepts rdf:about="&kb;Concepts_Instance_33"
	 kb:ConceptID="356"
	 kb:Guideline_Concept="proliferative retinopathy"
	 kb:InLibrary="false"
	 kb:NeedsResearch="false"
	 rdfs:label="356: proliferative retinopathy"/>
<kb:Concepts rdf:about="&kb;Concepts_Instance_34"
	 kb:ConceptID="357"
	 kb:Guideline_Concept="Glycemic target (HBA1c)"
	 kb:InLibrary="false"
	 kb:NeedsResearch="false"
	 rdfs:label="357: Glycemic target (HBA1c)"/>
<kb:Concepts rdf:about="&kb;Concepts_Instance_35"
	 kb:ConceptID="358"
	 kb:Guideline_Concept="sudden change in health status"
	 kb:InLibrary="false"
	 kb:NeedsResearch="false"
	 rdfs:label="358: sudden change in health status"/>
<kb:Concepts rdf:about="&kb;Concepts_Instance_36"
	 kb:ConceptID="359"
	 kb:Guideline_Concept="barriers to patient adherence"
	 kb:InLibrary="false"
	 kb:NeedsResearch="false"
	 rdfs:label="359: barriers to patient adherence"/>
<kb:Concepts rdf:about="&kb;Concepts_Instance_37"
	 kb:ConceptID="360"
	 kb:Guideline_Concept="recurrent or severe hypoglycemia"
	 kb:InLibrary="false"
	 kb:NeedsResearch="false"
	 rdfs:label="360: recurrent or severe hypoglycemia"/>
<kb:Concepts rdf:about="&kb;Concepts_Instance_38"
	 kb:ConceptID="361"
	 kb:Guideline_Concept="very mild or no microvascular complications of diabetes"
	 kb:InLibrary="false"
	 kb:NeedsResearch="false"
	 rdfs:label="361: very mild or no microvascular complications of diabetes"/>
<kb:Concepts rdf:about="&kb;Concepts_Instance_39"
	 kb:ConceptID="362"
	 kb:Guideline_Concept="advanced microvascular complications"
	 kb:InLibrary="false"
	 kb:NeedsResearch="false"
	 rdfs:label="362: advanced microvascular complications"/>
<kb:Concepts rdf:about="&kb;Concepts_Instance_4"
	 kb:ConceptID="314"
	 kb:Guideline_Concept="athlete's foot"
	 kb:InLibrary="true"
	 kb:NeedsResearch="false"
	 rdfs:label="314: athlete's foot"/>
<kb:Concepts rdf:about="&kb;Concepts_Instance_40"
	 kb:ConceptID="363"
	 kb:Guideline_Concept="major comorbid illness"
	 kb:InLibrary="false"
	 kb:NeedsResearch="false"
	 rdfs:label="363: major comorbid illness"/>
<kb:Concepts rdf:about="&kb;Concepts_Instance_41"
	 kb:ConceptID="364"
	 kb:Guideline_Concept="rapid weight loss"
	 kb:InLibrary="false"
	 kb:NeedsResearch="false"
	 rdfs:label="364: rapid weight loss"/>
<kb:Concepts rdf:about="&kb;Concepts_Instance_42"
	 kb:ConceptID="365"
	 kb:Guideline_Concept="diabetic clinic"
	 kb:InLibrary="false"
	 kb:NeedsResearch="false"
	 rdfs:label="365: diabetic clinic"/>
<kb:Concepts rdf:about="&kb;Concepts_Instance_43"
	 kb:ConceptID="366"
	 kb:Guideline_Concept="diabetologist"
	 kb:InLibrary="false"
	 kb:NeedsResearch="false"
	 rdfs:label="366: diabetologist"/>
<kb:Concepts rdf:about="&kb;Concepts_Instance_44"
	 kb:ConceptID="367"
	 kb:Guideline_Concept="diabetic nurse"
	 kb:InLibrary="false"
	 kb:NeedsResearch="false"
	 rdfs:label="367: diabetic nurse"/>
<kb:Concepts rdf:about="&kb;Concepts_Instance_45"
	 kb:ConceptID="368"
	 kb:Guideline_Concept="diabetic educator"
	 kb:InLibrary="false"
	 kb:NeedsResearch="false"
	 rdfs:label="368: diabetic educator"/>
<kb:Concepts rdf:about="&kb;Concepts_Instance_46"
	 kb:ConceptID="369"
	 kb:Guideline_Concept="diabetic manager"
	 kb:InLibrary="false"
	 kb:NeedsResearch="false"
	 rdfs:label="369: diabetic manager"/>
<kb:Concepts rdf:about="&kb;Concepts_Instance_47"
	 kb:ConceptID="370"
	 kb:Guideline_Concept="registered dietitian"
	 kb:InLibrary="false"
	 kb:NeedsResearch="false"
	 rdfs:label="370: registered dietitian"/>
<kb:Concepts rdf:about="&kb;Concepts_Instance_48"
	 kb:ConceptID="371"
	 kb:Guideline_Concept="overweight"
	 kb:InLibrary="false"
	 kb:NeedsResearch="false"
	 rdfs:label="371: overweight"/>
<kb:Concepts rdf:about="&kb;Concepts_Instance_49"
	 kb:ConceptID="253"
	 kb:Guideline_Concept="retinopathy"
	 kb:Guideline_definition="ICD-9 codes"
	 kb:InLibrary="true"
	 kb:NeedsResearch="false"
	 rdfs:label="253: retinopathy"/>
<kb:Concepts rdf:about="&kb;Concepts_Instance_5"
	 kb:ConceptID="315"
	 kb:Guideline_Concept="onychomycosis"
	 kb:InLibrary="true"
	 kb:NeedsResearch="false"
	 rdfs:label="315: onychomycosis"/>
<kb:Concepts rdf:about="&kb;Concepts_Instance_50"
	 kb:ConceptID="254"
	 kb:Guideline_Concept="diabetes type 1"
	 kb:Guideline_definition="ICD-9 codes"
	 kb:InLibrary="true"
	 kb:NeedsResearch="false"
	 rdfs:label="254: diabetes type 1"/>
<kb:Concepts rdf:about="&kb;Concepts_Instance_51"
	 kb:ConceptID="255"
	 kb:InLibrary="false"
	 kb:NeedsResearch="false">
	<kb:Guideline_Concept>patients with increased rate of progression or prevalence of retinopathy, </kb:Guideline_Concept>
	<kb:Guideline_definition>including patients with uncontrolled hypertension, chronic severe hyperglycemia, recent initiation or intensification of insulin therapy, or other known microvascular disease (e.g., albuminuria or neuropathy). </kb:Guideline_definition>
	<rdfs:label>255: patients with increased rate of progression or prevalence of retinopathy, </rdfs:label>
</kb:Concepts>
<kb:Concepts rdf:about="&kb;Concepts_Instance_52"
	 kb:ConceptID="256"
	 kb:Guideline_Concept="Acute ocular changes"
	 kb:InLibrary="true"
	 kb:NeedsResearch="false"
	 rdfs:label="256: Acute ocular changes">
	<kb:Guideline_definition>Acute changes in vision can be arbitrarily defined as those occurring suddenly or over a period of up to 72 hours. The rapid onset of new visual symptoms such as blurring, distortion, floaters, or light flashes should prompt an urgent referral to an eye care provider as they may indicate a serious ocular problem</kb:Guideline_definition>
</kb:Concepts>
<kb:Concepts rdf:about="&kb;Concepts_Instance_53"
	 kb:ConceptID="257"
	 kb:Guideline_Concept="early onset dm type 1"
	 kb:InLibrary="false"
	 kb:NeedsResearch="false"
	 rdfs:label="257: early onset dm type 1">
	<kb:Guideline_definition xml:space='preserve'><![CDATA[age<30 years]]></kb:Guideline_definition>
</kb:Concepts>
<kb:Concepts rdf:about="&kb;Concepts_Instance_54"
	 kb:ConceptID="258"
	 kb:InLibrary="false"
	 kb:NeedsResearch="false">
	<kb:Guideline_Concept>high risk indicators for advanced retinopathy also defined as ocular risk factors</kb:Guideline_Concept>
	<kb:Guideline_definition>if they have at least one of the following: • DM for 15 years or more
• Any evidence of diabetic nephropathy (including microproteinuria)
• Type 2 DM and cardiovascular autonomic neuropathy
• Lower extremity amputation related to DM
• History of any diabetic retinopathy
• Pregnancy and pre-existing diabetes
Existence of at least one of the listed risk factors is sufficient to define the patient as high-risk. (Evidence III  Poor C)</kb:Guideline_definition>
	<rdfs:label>258: high risk indicators for advanced retinopathy also defined as ocular risk factors</rdfs:label>
</kb:Concepts>
<kb:Concepts rdf:about="&kb;Concepts_Instance_55"
	 kb:ConceptID="259"
	 kb:InLibrary="false"
	 kb:NeedsResearch="false">
	<kb:Guideline_Concept>ophthalmologist or optometrist knowledgeable and experienced in detecting diabetic eye disease.</kb:Guideline_Concept>
	<rdfs:label>259: ophthalmologist or optometrist knowledgeable and experienced in detecting diabetic eye disease.</rdfs:label>
</kb:Concepts>
<kb:Concepts rdf:about="&kb;Concepts_Instance_56"
	 kb:ConceptID="260"
	 kb:Guideline_Concept="dilated fundus examination (dilated eye exam- in library)"
	 kb:Guideline_definition="procedure codes?"
	 kb:InLibrary="true"
	 kb:NeedsResearch="false">
	<rdfs:label>260: dilated fundus examination (dilated eye exam- in library)</rdfs:label>
</kb:Concepts>
<kb:Concepts rdf:about="&kb;Concepts_Instance_57"
	 kb:ConceptID="261"
	 kb:Guideline_Concept="comprehensive eye exam"
	 kb:Guideline_definition="procedure codes?"
	 kb:InLibrary="true"
	 kb:NeedsResearch="false"
	 rdfs:label="261: comprehensive eye exam"/>
<kb:Concepts rdf:about="&kb;Concepts_Instance_58"
	 kb:ConceptID="262"
	 kb:Guideline_Concept="ocular risk factors"
	 kb:InLibrary="false"
	 kb:NeedsResearch="false"
	 rdfs:label="262: ocular risk factors">
	<kb:Guideline_definition>if they have at least one of the following: • DM for 15 years or more
• Any evidence of diabetic nephropathy (including microproteinuria)
• Type 2 DM and cardiovascular autonomic neuropathy
• Lower extremity amputation related to DM
• History of any diabetic retinopathy
• Pregnancy and pre-existing diabetes
Existence of at least one of the listed risk factors is sufficient to define the patient as high-risk. (Evidence III  Poor C)</kb:Guideline_definition>
</kb:Concepts>
<kb:Concepts rdf:about="&kb;Concepts_Instance_59"
	 kb:ConceptID="265"
	 kb:Guideline_Concept="Breaks in the skin"
	 kb:InLibrary="true"
	 kb:NeedsResearch="false"
	 rdfs:label="265: Breaks in the skin"/>
<kb:Concepts rdf:about="&kb;Concepts_Instance_6"
	 kb:ConceptID="316"
	 kb:Guideline_Concept="dry skin"
	 kb:InLibrary="true"
	 kb:NeedsResearch="false"
	 rdfs:label="316: dry skin"/>
<kb:Concepts rdf:about="&kb;Concepts_Instance_60"
	 kb:ConceptID="266"
	 kb:Guideline_Concept="foot risk assessment"
	 kb:InLibrary="true"
	 kb:NeedsResearch="false"
	 rdfs:label="266: foot risk assessment">
	<kb:Guideline_definition>Evaluation of the skin for breakdown
• Assessment of protective sensation using the Semmes-Weinstein 5.07 monofilament
• Evaluation for LE arterial disease
• Evaluation for foot deformity
• Prior history of ulcers or amputations</kb:Guideline_definition>
</kb:Concepts>
<kb:Concepts rdf:about="&kb;Concepts_Instance_61"
	 kb:ConceptID="267"
	 kb:Guideline_Concept="Acute Ischemia or Rest Pain"
	 kb:InLibrary="true"
	 kb:NeedsResearch="false"
	 rdfs:label="267: Acute Ischemia or Rest Pain">
	<kb:Guideline_definition xml:space='preserve'><![CDATA[Absence of palpable pedal pulses - Examine the patient to determine presence of dorsalis pedis and posterior tibial pulses. Absent pulses and signs of acute ischemia, e.g., rest pain associated with dependent rubor with pallor or palpably cold extremities, warrant urgent referral to a vascular surgeon.     Acute ischemia or rest pain – Evidence of arterial insufficiency: lower limb pain at rest, dusky/blue or purple/black color, gangrene, or cold extremity. Pain in the toes or forefoot may be relieved by dependency of the limb. Assessment is needed for prompt vascular/surgical intervention. Patient with acute arterial occlusion will present with pain, pallor, pulseless, paresthesia, and/or paralysis (Orchard & Strandness, 1993).
Claudication - Severe claudication is determined as pain in the thigh or calf that occurs when walking less than one block and is relieved by rest.
]]></kb:Guideline_definition>
</kb:Concepts>
<kb:Concepts rdf:about="&kb;Concepts_Instance_62"
	 kb:ConceptID="268"
	 kb:Expert_defining="HCUP: Chronic ulcer of leg or foot"
	 kb:Guideline_Concept="Foot Ulceration"
	 kb:InLibrary="true"
	 kb:NeedsResearch="false"
	 rdfs:label="268: Foot Ulceration">
	<kb:Guideline_definition xml:space='preserve'><![CDATA[Active foot ulcer - A cutaneous erosion with a loss of epithelium that extends to or through the dermis can involve deeper tissue and is characterized by an inability to self-repair in a timely and orderly manner (ADA, 2002; Brodsky & Schneidler, 1991; Caputo et al., 1994; Eckman et al., 1995; Reiber et al., 1995).]]></kb:Guideline_definition>
</kb:Concepts>
<kb:Concepts rdf:about="&kb;Concepts_Instance_63"
	 kb:ConceptID="269"
	 kb:Guideline_Concept="Ingrown toenail"
	 kb:InLibrary="true"
	 kb:NeedsResearch="false"
	 rdfs:label="269: Ingrown toenail">
	<kb:Guideline_definition>Ingrown toenail - Presents as a nail plate that has pierced the surrounding periungual tissue with associated erythema and drainage or an area of thick or discolored callus. The primary care provider should consider referral to a podiatrist for excision of infected ingrown nails, especially in the case of high-risk patients (Giacalone, 1997).</kb:Guideline_definition>
</kb:Concepts>
<kb:Concepts rdf:about="&kb;Concepts_Instance_64"
	 kb:ConceptID="270"
	 kb:Guideline_Concept="Systemic or Ascending (Worsening) Infection"
	 kb:InLibrary="true"
	 kb:NeedsResearch="false"
	 rdfs:label="270: Systemic or Ascending (Worsening) Infection">
	<kb:Guideline_definition xml:space='preserve'><![CDATA[Limb-threatening conditions could include signs and symptoms of systemic infection including gas gangrene, ascending cellulitis and lymphangitis, or gangrene.
Although infection is not always clinically apparent, common signs and symptoms include perilesional warmth, erythema, purulent drainage, odor, and involvement of bone. Pain may or may not be present. There may or may not be lymphangitis and lymphadenopathy, and fever and white blood cell count may or may not be present. Sudden loss of glycemic control often heralds serious infections (Orchard & Strandness, 1993).
]]></kb:Guideline_definition>
</kb:Concepts>
<kb:Concepts rdf:about="&kb;Concepts_Instance_65"
	 kb:ConceptID="271"
	 kb:Guideline_Concept="foot care specialist"
	 kb:InLibrary="true"
	 kb:NeedsResearch="false"
	 rdfs:label="271: foot care specialist">
	<kb:Guideline_definition>foot care specialist is defined as a podiatrist, vascular surgeon, orthopedic surgeon, or other healthcare provider with demonstrated training, competence, and licensure in foot care.</kb:Guideline_definition>
</kb:Concepts>
<kb:Concepts rdf:about="&kb;Concepts_Instance_66"
	 kb:ConceptID="272"
	 kb:InLibrary="true"
	 kb:NeedsResearch="false">
	<kb:Guideline_Concept>Lack of sensation to Semmes-Weinstein 5.07 monofilament at one or more noncallused plantar sites</kb:Guideline_Concept>
	<rdfs:label>272: Lack of sensation to Semmes-Weinstein 5.07 monofilament at one or more noncallused plantar sites</rdfs:label>
</kb:Concepts>
<kb:Concepts rdf:about="&kb;Concepts_Instance_67"
	 kb:ConceptID="273"
	 kb:Guideline_Concept="minor lesion"
	 kb:InLibrary="true"
	 kb:NeedsResearch="false"
	 rdfs:label="273: minor lesion">
	<kb:Guideline_definition>1. Minor lesions or wounds that could possibly be treated by the primary care provider are blisters, erosions, and/or minor cuts that do not extend beyond subcutaneous tissue. Pulses are present, there are no signs of acute infection, and there is no severe lower limb pain and no sign of a worsening lesion.</kb:Guideline_definition>
</kb:Concepts>
<kb:Concepts rdf:about="&kb;Concepts_Instance_68"
	 kb:ConceptID="275"
	 kb:Guideline_Concept="Patient and family foot education"
	 kb:InLibrary="true"
	 kb:NeedsResearch="false"
	 rdfs:label="275: Patient and family foot education">
	<kb:Guideline_definition>Patient and family foot education should include the following components and considerations:
• Keep it simple and appropriate for the patient's educational level.
• Make it interactive, including demonstrations in washing, drying, and inspecting feet; nail cutting; and suitable footwear selection, including footwear for temperature extremes.
• Provide opportunities for the patient to state the need for what are basics of daily skin and foot care and preventive measures.
• Include practice time during the educational session to demonstrate and have the patient, in return, demonstrate safe toenail trimming.
• Provide repetitive examples of and messages about how care of the feet can prevent complications. Include recommendations that distinguish minor foot problems from more serious problems that require early or immediate professional treatment, together with a name and telephone number for prompt assistance.
• Make realistic recommendations (appropriate to the patient's physical and visual capabilities) while personalizing information and highlighting key points. This may include a referral to home healthcare.
• Provide written guidelines in large print and/or graphics that the patient can hang in the bathroom as a reference and reprints of lay articles. Patients should be alerted that elevation in blood sugar might be a sign of an active or impending infection. Use of a night-light or turning on lights when getting up at night may prevent foot injuries. Patients should be made aware of potential dangers in the home.
• For patients with high-risk feet, twice-daily inspection in good light is recommended, looking for any redness or drainage and running the hands over the foot to detect any swelling or increased local warmth. Patients with neuropathic fingers may need to enlist help or use a mirror to inspect their feet.
• Before putting on shoes, inspect for torn linings, rough spots, and foreign objects (e.g., gravel, stones, glass, and children’s toys).
• Alternating between pairs of shoes during the day is recommended. A minimum of two serviceable pairs of shoes, insoles, and orthoses are required.
• Educators can utilize numerous publications on patient foot care instruction that are free of charge and have no copyright restrictions. The following publications are available through the U.S. Department of Health and Human Services, Centers for Disease Control and Prevention (CDC), and American Association of Diabetes Education (AADE): 
o Take Charge of Your Diabetes: Prevent Foot Problems
o Taking Care of Your Feet
o Tips on Good Foot Care: from Feet Can Last a Lifetime
</kb:Guideline_definition>
</kb:Concepts>
<kb:Concepts rdf:about="&kb;Concepts_Instance_69"
	 kb:ConceptID="276"
	 kb:Guideline_Concept="diabetes type 2"
	 kb:Guideline_definition="ICD-9"
	 kb:InLibrary="true"
	 kb:NeedsResearch="false"
	 rdfs:label="276: diabetes type 2"/>
<kb:Concepts rdf:about="&kb;Concepts_Instance_7"
	 kb:ConceptID="317"
	 kb:Guideline_Concept="minor calluses"
	 kb:InLibrary="true"
	 kb:NeedsResearch="false"
	 rdfs:label="317: minor calluses"/>
<kb:Concepts rdf:about="&kb;Concepts_Instance_70"
	 kb:ConceptID="277"
	 kb:Expert_definition="? SBM- slow onset change in ocular function since last visit"
	 kb:Guideline_Concept="change in ocular function"
	 kb:InLibrary="false"
	 kb:NeedsResearch="false"
	 rdfs:label="277: change in ocular function"/>
<kb:Concepts rdf:about="&kb;Concepts_Instance_71"
	 kb:ConceptID="278"
	 kb:Guideline_definition="icd9 codes"
	 kb:InLibrary="true"
	 kb:NeedsResearch="false">
	<kb:Guideline_Concept>diabetic nephropathy  (including microproteinuria) (in library as diabetes with renal manifestations)</kb:Guideline_Concept>
	<rdfs:label>278: diabetic nephropathy  (including microproteinuria) (in library as diabetes with renal manifestations)</rdfs:label>
</kb:Concepts>
<kb:Concepts rdf:about="&kb;Concepts_Instance_72"
	 kb:ConceptID="279"
	 kb:Guideline_Concept="validated fundus imaging technique"
	 kb:Guideline_definition="procedure codes?"
	 kb:InLibrary="false"
	 kb:NeedsResearch="false"
	 rdfs:label="279: validated fundus imaging technique"/>
<kb:Concepts rdf:about="&kb;Concepts_Instance_73"
	 kb:ConceptID="280"
	 kb:Guideline_Concept="using insulin"
	 kb:Guideline_definition="prescription data"
	 kb:InLibrary="true"
	 kb:NeedsResearch="false"
	 rdfs:label="280: using insulin"/>
<kb:Concepts rdf:about="&kb;Concepts_Instance_74"
	 kb:ConceptID="281"
	 kb:Guideline_Concept="eye care provider defined follow-up"
	 kb:InLibrary="false"
	 kb:NeedsResearch="false"
	 rdfs:label="281: eye care provider defined follow-up">
	<kb:Guideline_definition>The eye care provider should determine the optimal screening intervals based on the patient’s severity of retinopathy and risk factors associated with retinopathy progression</kb:Guideline_definition>
</kb:Concepts>
<kb:Concepts rdf:about="&kb;Concepts_Instance_75"
	 kb:ConceptID="282"
	 kb:Expert_definition="??"
	 kb:Guideline_Concept="poorly controlled htn"
	 kb:Guideline_definition="not defined?"
	 kb:InLibrary="false"
	 kb:NeedsResearch="false"
	 rdfs:label="282: poorly controlled htn"/>
<kb:Concepts rdf:about="&kb;Concepts_Instance_76"
	 kb:ConceptID="283"
	 kb:Guideline_Concept="Erythema"
	 kb:InLibrary="true"
	 kb:NeedsResearch="false"
	 rdfs:label="283: Erythema"/>
<kb:Concepts rdf:about="&kb;Concepts_Instance_77"
	 kb:ConceptID="284"
	 kb:Guideline_definition="??"
	 kb:InLibrary="true"
	 kb:NeedsResearch="false">
	<kb:Guideline_Concept>Assessment of protective sensation using the Semmes-Weinstein 5.07 monofilament</kb:Guideline_Concept>
	<rdfs:label>284: Assessment of protective sensation using the Semmes-Weinstein 5.07 monofilament</rdfs:label>
</kb:Concepts>
<kb:Concepts rdf:about="&kb;Concepts_Instance_78"
	 kb:ConceptID="285"
	 kb:Guideline_Concept="Puncture Wound"
	 kb:InLibrary="true"
	 kb:NeedsResearch="false"
	 rdfs:label="285: Puncture Wound">
	<kb:Guideline_definition>A lesion through the epidermis, dermis, and other tissues caused by a piercing or penetrating object. Patients with diabetes with puncture wounds can quickly develop severe limb-threatening complications.</kb:Guideline_definition>
</kb:Concepts>
<kb:Concepts rdf:about="&kb;Concepts_Instance_79"
	 kb:ConceptID="286"
	 kb:Guideline_Concept="Evidence of LE arterial disease"
	 kb:InLibrary="true"
	 kb:NeedsResearch="false"
	 rdfs:label="286: Evidence of LE arterial disease">
	<kb:Guideline_definition>(absence of both dorsalis pedis and tibialis posterior pulses, dependent rubor with pallor on elevation, history of rest pain or claudication, and prior history of LE bypass surgery)</kb:Guideline_definition>
</kb:Concepts>
<kb:Concepts rdf:about="&kb;Concepts_Instance_8"
	 kb:ConceptID="318"
	 kb:Guideline_Concept="uncomplicated nail trimming"
	 kb:InLibrary="true"
	 kb:NeedsResearch="false"
	 rdfs:label="318: uncomplicated nail trimming"/>
<kb:Concepts rdf:about="&kb;Concepts_Instance_80"
	 kb:ConceptID="287"
	 kb:Expert_definition="immediately"
	 kb:Guideline_Concept="urgently referred to an eye care provider."
	 kb:InLibrary="false"
	 kb:NeedsResearch="false"
	 rdfs:label="287: urgently referred to an eye care provider."/>
<kb:Concepts rdf:about="&kb;Concepts_Instance_81"
	 kb:ConceptID="288"
	 kb:Guideline_Concept="cardiovascular autonomic neuropathy"
	 kb:Guideline_definition="icd9 codes"
	 kb:InLibrary="true"
	 kb:NeedsResearch="false"
	 rdfs:label="288: cardiovascular autonomic neuropathy"/>
<kb:Concepts rdf:about="&kb;Concepts_Instance_82"
	 kb:ConceptID="290"
	 kb:Expert_definition="??"
	 kb:Guideline_Concept="chronic severe hyperglycemia"
	 kb:Guideline_definition="not defined?"
	 kb:InLibrary="true"
	 kb:NeedsResearch="false"
	 rdfs:label="290: chronic severe hyperglycemia"/>
<kb:Concepts rdf:about="&kb;Concepts_Instance_83"
	 kb:ConceptID="291"
	 kb:Expert_defining="sbm- updated to trauma of lower extremity in KB"
	 kb:Guideline_Concept="Trauma"
	 kb:InLibrary="true"
	 kb:NeedsResearch="false"
	 rdfs:label="291: Trauma"/>
<kb:Concepts rdf:about="&kb;Concepts_Instance_84"
	 kb:ConceptID="292"
	 kb:Guideline_Concept="Evaluation for LE arterial disease"
	 kb:Guideline_definition="icd9 codes"
	 kb:InLibrary="true"
	 kb:NeedsResearch="false"
	 rdfs:label="292: Evaluation for LE arterial disease"/>
<kb:Concepts rdf:about="&kb;Concepts_Instance_85"
	 kb:ConceptID="293"
	 kb:Guideline_Concept="Hemorrhagic Callus With or Without Cellulitis"
	 kb:InLibrary="true"
	 kb:NeedsResearch="false"
	 rdfs:label="293: Hemorrhagic Callus With or Without Cellulitis">
	<kb:Guideline_definition>The provider must determine if the cellulitis may be associated with callus tissue or necrotic tissue that may obscure an underlying ulceration or deeper infection.
The callus tissue must be debrided to properly assess the extent of an underlying ulcerati</kb:Guideline_definition>
</kb:Concepts>
<kb:Concepts rdf:about="&kb;Concepts_Instance_86"
	 kb:ConceptID="294"
	 kb:InLibrary="true"
	 kb:NeedsResearch="false">
	<kb:Guideline_Concept>Foot deformities (specifically hammer toes, claw toe, Charcot's arthropathy, bunions, and metatarsal head deformities)</kb:Guideline_Concept>
	<kb:Guideline_definition>(specifically hammer toes, claw toe, Charcot's arthropathy, bunions, and metatarsal head deformities)</kb:Guideline_definition>
	<rdfs:label>294: Foot deformities (specifically hammer toes, claw toe, Charcot's arthropathy, bunions, and metatarsal head deformities)</rdfs:label>
</kb:Concepts>
<kb:Concepts rdf:about="&kb;Concepts_Instance_87"
	 kb:ConceptID="295"
	 kb:Guideline_Concept="Lower extremity amputation related to DM"
	 kb:Guideline_definition="icd9 codes"
	 kb:InLibrary="true"
	 kb:NeedsResearch="false"
	 rdfs:label="295: Lower extremity amputation related to DM"/>
<kb:Concepts rdf:about="&kb;Concepts_Instance_88"
	 kb:ConceptID="296"
	 kb:Expert_definition="??"
	 kb:Guideline_Concept="recent initiation of insulin therapy"
	 kb:Guideline_definition="not defined?"
	 kb:InLibrary="false"
	 kb:NeedsResearch="false"
	 rdfs:label="296: recent initiation of insulin therapy"/>
<kb:Concepts rdf:about="&kb;Concepts_Instance_89"
	 kb:ConceptID="297"
	 kb:Guideline_Concept="Pallor on elevation"
	 kb:InLibrary="true"
	 kb:NeedsResearch="false"
	 rdfs:label="297: Pallor on elevation"/>
<kb:Concepts rdf:about="&kb;Concepts_Instance_9"
	 kb:ConceptID="319"
	 kb:Guideline_Concept="improper foot hygiene"
	 kb:InLibrary="true"
	 kb:NeedsResearch="false"
	 rdfs:label="319: improper foot hygiene"/>
<kb:Concepts rdf:about="&kb;Concepts_Instance_90"
	 kb:ConceptID="298"
	 kb:Guideline_Concept="Evaluation for foot deformity"
	 kb:Guideline_definition="icd9 codes"
	 kb:InLibrary="true"
	 kb:NeedsResearch="false"
	 rdfs:label="298: Evaluation for foot deformity"/>
<kb:Concepts rdf:about="&kb;Concepts_Instance_91"
	 kb:ConceptID="299"
	 kb:Guideline_Concept="History of foot ulcer or non-traumatic LEA at any level"
	 kb:InLibrary="true"
	 kb:NeedsResearch="false"
	 rdfs:label="299: History of foot ulcer or non-traumatic LEA at any level"/>
<kb:Concepts rdf:about="&kb;Concepts_Instance_92"
	 kb:ConceptID="300"
	 kb:Guideline_Concept="diabetic retinopathy"
	 kb:Guideline_definition="diabetic retinopathy"
	 kb:InLibrary="false"
	 kb:NeedsResearch="false"
	 rdfs:label="300: diabetic retinopathy"/>
<kb:Concepts rdf:about="&kb;Concepts_Instance_93"
	 kb:ConceptID="301"
	 kb:Guideline_Concept="icd9 codes"
	 kb:Guideline_definition="icd9 codes"
	 kb:InLibrary="false"
	 kb:NeedsResearch="false"
	 rdfs:label="301: icd9 codes"/>
<kb:Concepts rdf:about="&kb;Concepts_Instance_94"
	 kb:ConceptID="302"
	 kb:Guideline_Concept="Pregnancy and pre-existing diabetes"
	 kb:Guideline_definition="icd9 codes"
	 kb:InLibrary="false"
	 kb:NeedsResearch="false"
	 rdfs:label="302: Pregnancy and pre-existing diabetes"/>
<kb:Concepts rdf:about="&kb;Concepts_Instance_95"
	 kb:ConceptID="303"
	 kb:Guideline_definition="icd 9 codes, labs?"
	 kb:InLibrary="true"
	 kb:NeedsResearch="false">
	<kb:Guideline_Concept>other known microvascular disease (albuminuria or neuropathy).</kb:Guideline_Concept>
	<rdfs:label>303: other known microvascular disease (albuminuria or neuropathy).</rdfs:label>
</kb:Concepts>
<kb:Concepts rdf:about="&kb;Concepts_Instance_96"
	 kb:ConceptID="304"
	 kb:Expert_definition="changes in the shape of the foot"
	 kb:Guideline_Concept="Changes in the size of foot"
	 kb:InLibrary="true"
	 kb:NeedsResearch="false"
	 rdfs:label="304: Changes in the size of foot"/>
<kb:Concepts rdf:about="&kb;Concepts_Instance_97"
	 kb:ConceptID="305"
	 kb:Guideline_Concept="patient’s footwear"
	 kb:Guideline_definition="??"
	 kb:InLibrary="true"
	 kb:NeedsResearch="false"
	 rdfs:label="305: patient’s footwear"/>
<kb:Concepts rdf:about="&kb;Concepts_Instance_98"
	 kb:ConceptID="306"
	 kb:Guideline_Concept="dm >15 years"
	 kb:InLibrary="false"
	 kb:NeedsResearch="false"
	 rdfs:label="306: dm >15 years">
	<kb:Guideline_definition>The impact of these factors should be considered for each patient when assessing the duration of the disease as a risk factor for advanced retinopathy, and the physician should consider a lower threshold for high-risk status for patients whose disease is </kb:Guideline_definition>
</kb:Concepts>
<kb:Concepts rdf:about="&kb;Concepts_Instance_99"
	 kb:ConceptID="307"
	 kb:Guideline_Concept="Extensive callus"
	 kb:InLibrary="true"
	 kb:NeedsResearch="false"
	 rdfs:label="307: Extensive callus"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_1"
	 kb:Classification="INSULIN"
	 kb:Code="HS501"
	 kb:NAT_ID="64027324"
	 kb:UNITS="VIAL"
	 kb:VA_NAME="CONCENTRATED INSULIN R 500 UNITS/ML"
	 rdfs:label="CONCENTRATED INSULIN R 500 UNITS/ML"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_10"
	 kb:Classification="INSULIN"
	 kb:Code="HS501"
	 kb:NAT_ID="66207240"
	 kb:UNITS="VI"
	 kb:VA_NAME="INSULIN LENTE HUMAN 100 U/ML IJ NOVOLN L"
	 rdfs:label="INSULIN LENTE HUMAN 100 U/ML IJ NOVOLN L"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_100"
	 kb:Classification="INSULIN"
	 kb:Code="HS501"
	 kb:GENERIC_NAME="INSULIN"
	 kb:NAT_ID="849"
	 kb:STRENGTH="100.0"
	 kb:UNITS="UNT/ML"
	 kb:VA_NAME="INSULIN,NPH,BEEF 100UNT/ML INJ"
	 rdfs:label="INSULIN,NPH,BEEF 100UNT/ML INJ"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_101"
	 kb:Classification="INSULIN"
	 kb:Code="HS501"
	 kb:GENERIC_NAME="INSULIN"
	 kb:NAT_ID="830"
	 kb:STRENGTH="100.0"
	 kb:UNITS="UNT/ML"
	 kb:VA_NAME="INSULIN,NPH,BEEF/PORK 100UNT/ML INJ"
	 rdfs:label="INSULIN,NPH,BEEF/PORK 100UNT/ML INJ"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_102"
	 kb:Classification="INSULIN"
	 kb:Code="HS501"
	 kb:GENERIC_NAME="INSULIN"
	 kb:NAT_ID="834"
	 kb:STRENGTH="40.0"
	 kb:UNITS="UNT/ML"
	 kb:VA_NAME="INSULIN,NPH,BEEF/PORK 40UNT/ML INJ"
	 rdfs:label="INSULIN,NPH,BEEF/PORK 40UNT/ML INJ"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_103"
	 kb:Classification="INSULIN"
	 kb:Code="HS501"
	 kb:NAT_ID="64000888"
	 kb:UNITS="VI"
	 kb:VA_NAME="INSULIN,NPH,BEEF/PORK U-100 INJ"
	 rdfs:label="INSULIN,NPH,BEEF/PORK U-100 INJ"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_104"
	 kb:Classification="INSULIN"
	 kb:Code="HS501"
	 kb:GENERIC_NAME="INSULIN"
	 kb:NAT_ID="832"
	 kb:STRENGTH="100.0"
	 kb:UNITS="UNT/ML"
	 kb:VA_NAME="INSULIN,NPH,BEEF/PURIFIED 100UNT/ML INJ"
	 rdfs:label="INSULIN,NPH,BEEF/PURIFIED 100UNT/ML INJ"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_105"
	 kb:Classification="INSULIN"
	 kb:Code="HS501"
	 kb:GENERIC_NAME="INSULIN"
	 kb:NAT_ID="833"
	 kb:STRENGTH="100.0"
	 kb:UNITS="UNT/ML"
	 kb:VA_NAME="INSULIN,NPH,HUMAN 100UNT/ML INJ"
	 rdfs:label="INSULIN,NPH,HUMAN 100UNT/ML INJ"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_106"
	 kb:Classification="INSULIN"
	 kb:Code="HS501"
	 kb:GENERIC_NAME="INSULIN"
	 kb:NAT_ID="831"
	 kb:STRENGTH="100.0"
	 kb:UNITS="UNT/ML"
	 kb:VA_NAME="INSULIN,NPH,PORK/PURIFIED 100UNT/ML INJ"
	 rdfs:label="INSULIN,NPH,PORK/PURIFIED 100UNT/ML INJ"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_107"
	 kb:Classification="INSULIN"
	 kb:Code="HS501"
	 kb:GENERIC_NAME="INSULIN"
	 kb:NAT_ID="821"
	 kb:STRENGTH="100.0"
	 kb:UNITS="UNT/ML"
	 kb:VA_NAME="INSULIN,PROTAMINE ZINC,BEEF/PORK 100UNT/ML INJ"
	 rdfs:label="INSULIN,PROTAMINE ZINC,BEEF/PORK 100UNT/ML INJ"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_108"
	 kb:Classification="INSULIN"
	 kb:Code="HS501"
	 kb:GENERIC_NAME="INSULIN"
	 kb:NAT_ID="824"
	 kb:STRENGTH="40.0"
	 kb:UNITS="UNT/ML"
	 kb:VA_NAME="INSULIN,PROTAMINE ZINC,BEEF/PORK 40UNT/ML INJ"
	 rdfs:label="INSULIN,PROTAMINE ZINC,BEEF/PORK 40UNT/ML INJ"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_109"
	 kb:Classification="INSULIN"
	 kb:Code="HS501"
	 kb:GENERIC_NAME="INSULIN"
	 kb:NAT_ID="823"
	 kb:STRENGTH="100.0"
	 kb:UNITS="UNT/ML"
	 kb:VA_NAME="INSULIN,PROTAMINE ZINC,BEEF/PURIFIED 100UNT/ML INJ"
	 rdfs:label="INSULIN,PROTAMINE ZINC,BEEF/PURIFIED 100UNT/ML INJ"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_11"
	 kb:Classification="INSULIN"
	 kb:Code="HS501"
	 kb:GENERIC_NAME="INSULIN"
	 kb:NAT_ID="877"
	 kb:STRENGTH="100.0"
	 kb:UNITS="UNT/ML"
	 kb:VA_NAME="INSULIN LENTE HUMAN 100 U/ML IJ NOVOLN L"
	 rdfs:label="INSULIN LENTE HUMAN 100 U/ML IJ NOVOLN L"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_110"
	 kb:Classification="INSULIN"
	 kb:Code="HS501"
	 kb:GENERIC_NAME="INSULIN"
	 kb:NAT_ID="822"
	 kb:STRENGTH="100.0"
	 kb:UNITS="UNT/ML"
	 kb:VA_NAME="INSULIN,PROTAMINE ZINC,PORK/PURIFIED 100UNT/ML INJ"
	 rdfs:label="INSULIN,PROTAMINE ZINC,PORK/PURIFIED 100UNT/ML INJ"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_111"
	 kb:Classification="INSULIN"
	 kb:Code="HS501"
	 kb:GENERIC_NAME="INSULIN"
	 kb:NAT_ID="825"
	 kb:STRENGTH="100.0"
	 kb:UNITS="UNT/ML"
	 kb:VA_NAME="INSULIN,REGULAR,BEEF/PORK 100UNT/ML INJ"
	 rdfs:label="INSULIN,REGULAR,BEEF/PORK 100UNT/ML INJ"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_112"
	 kb:Classification="INSULIN"
	 kb:Code="HS501"
	 kb:GENERIC_NAME="INSULIN"
	 kb:NAT_ID="829"
	 kb:STRENGTH="40.0"
	 kb:UNITS="UNT/ML"
	 kb:VA_NAME="INSULIN,REGULAR,BEEF/PORK 40UNT/ML INJ"
	 rdfs:label="INSULIN,REGULAR,BEEF/PORK 40UNT/ML INJ"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_113"
	 kb:Classification="INSULIN"
	 kb:Code="HS501"
	 kb:NAT_ID="64000892"
	 kb:UNITS="VI"
	 kb:VA_NAME="INSULIN,REGULAR,BEEF/PORK,U-100 INJ"
	 rdfs:label="INSULIN,REGULAR,BEEF/PORK,U-100 INJ"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_114"
	 kb:Classification="INSULIN"
	 kb:Code="HS501"
	 kb:GENERIC_NAME="INSULIN"
	 kb:NAT_ID="827"
	 kb:STRENGTH="100.0"
	 kb:UNITS="UNT/ML"
	 kb:VA_NAME="INSULIN,REGULAR,BEEF/PURIFIED 100UNT/ML INJ"
	 rdfs:label="INSULIN,REGULAR,BEEF/PURIFIED 100UNT/ML INJ"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_115"
	 kb:Classification="INSULIN"
	 kb:Code="HS501"
	 kb:GENERIC_NAME="INSULIN"
	 kb:NAT_ID="828"
	 kb:STRENGTH="100.0"
	 kb:UNITS="UNT/ML"
	 kb:VA_NAME="INSULIN,REGULAR,HUMAN 100UNT/ML INJ"
	 rdfs:label="INSULIN,REGULAR,HUMAN 100UNT/ML INJ"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_116"
	 kb:Classification="INSULIN"
	 kb:Code="HS501"
	 kb:GENERIC_NAME="INSULIN"
	 kb:NAT_ID="892"
	 kb:STRENGTH="500.0"
	 kb:UNITS="UNT/ML"
	 kb:VA_NAME="INSULIN,REGULAR,HUMAN 500 UNT/ML INJ HUMULIN R"
	 rdfs:label="INSULIN,REGULAR,HUMAN 500 UNT/ML INJ HUMULIN R"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_117"
	 kb:Classification="INSULIN"
	 kb:Code="HS501"
	 kb:GENERIC_NAME="INSULIN"
	 kb:NAT_ID="855"
	 kb:STRENGTH="100.0"
	 kb:UNITS="UNT/ML"
	 kb:VA_NAME="INSULIN,REGULAR,HUMAN BUFFERED 100UNT/ML INJ"
	 rdfs:label="INSULIN,REGULAR,HUMAN BUFFERED 100UNT/ML INJ"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_118"
	 kb:Classification="INSULIN"
	 kb:Code="HS501"
	 kb:GENERIC_NAME="INSULIN"
	 kb:NAT_ID="18690"
	 kb:STRENGTH="500.0"
	 kb:UNITS="UNT/ML"
	 kb:VA_NAME="INSULIN,REGULAR,HUMAN CONCENTRATED 500 UNIT/ML INJ HUMULIN R"
	 rdfs:label="INSULIN,REGULAR,HUMAN CONCENTRATED 500 UNIT/ML INJ HUMULIN R"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_119"
	 kb:Classification="INSULIN"
	 kb:Code="HS501"
	 kb:GENERIC_NAME="INSULIN"
	 kb:NAT_ID="848"
	 kb:STRENGTH="100.0"
	 kb:UNITS="UNT/ML"
	 kb:VA_NAME="INSULIN,REGULAR,PORK 100UNT/ML INJ"
	 rdfs:label="INSULIN,REGULAR,PORK 100UNT/ML INJ"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_12"
	 kb:Classification="INSULIN"
	 kb:Code="HS501"
	 kb:GENERIC_NAME="INSULIN"
	 kb:NAT_ID="866"
	 kb:STRENGTH="100.0"
	 kb:UNITS="UNT/ML"
	 kb:VA_NAME="INSULIN LENTE PUR PORK 100 U/ML INJ LILY"
	 rdfs:label="INSULIN LENTE PUR PORK 100 U/ML INJ LILY"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_120"
	 kb:Classification="INSULIN"
	 kb:Code="HS501"
	 kb:GENERIC_NAME="INSULIN"
	 kb:NAT_ID="847"
	 kb:STRENGTH="40.0"
	 kb:UNITS="UNT/ML"
	 kb:VA_NAME="INSULIN,REGULAR,PORK 40UNT/ML INJ"
	 rdfs:label="INSULIN,REGULAR,PORK 40UNT/ML INJ"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_121"
	 kb:Classification="INSULIN"
	 kb:Code="HS501"
	 kb:GENERIC_NAME="INSULIN"
	 kb:NAT_ID="826"
	 kb:STRENGTH="100.0"
	 kb:UNITS="UNT/ML"
	 kb:VA_NAME="INSULIN,REGULAR,PORK/PURIFIED 100UNT/ML INJ"
	 rdfs:label="INSULIN,REGULAR,PORK/PURIFIED 100UNT/ML INJ"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_122"
	 kb:Classification="INSULIN"
	 kb:Code="HS501"
	 kb:GENERIC_NAME="INSULIN"
	 kb:NAT_ID="839"
	 kb:STRENGTH="500.0"
	 kb:UNITS="UNT/ML"
	 kb:VA_NAME="INSULIN,REGULAR,PORK/PURIFIED CONC 500UNT/ML INJ"
	 rdfs:label="INSULIN,REGULAR,PORK/PURIFIED CONC 500UNT/ML INJ"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_123"
	 kb:Classification="INSULIN"
	 kb:Code="HS501"
	 kb:GENERIC_NAME="INSULIN"
	 kb:NAT_ID="851"
	 kb:STRENGTH="100.0"
	 kb:UNITS="UNT/ML"
	 kb:VA_NAME="INSULIN,SEMILENTE,BEEF 100UNT/ML INJ"
	 rdfs:label="INSULIN,SEMILENTE,BEEF 100UNT/ML INJ"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_124"
	 kb:Classification="INSULIN"
	 kb:Code="HS501"
	 kb:GENERIC_NAME="INSULIN"
	 kb:NAT_ID="840"
	 kb:STRENGTH="100.0"
	 kb:UNITS="UNT/ML"
	 kb:VA_NAME="INSULIN,SEMILENTE,BEEF/PORK 100UNT/ML INJ"
	 rdfs:label="INSULIN,SEMILENTE,BEEF/PORK 100UNT/ML INJ"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_125"
	 kb:Classification="INSULIN"
	 kb:Code="HS501"
	 kb:GENERIC_NAME="INSULIN"
	 kb:NAT_ID="841"
	 kb:STRENGTH="40.0"
	 kb:UNITS="UNT/ML"
	 kb:VA_NAME="INSULIN,SEMILENTE,BEEF/PORK 40UNT/ML INJ"
	 rdfs:label="INSULIN,SEMILENTE,BEEF/PORK 40UNT/ML INJ"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_126"
	 kb:Classification="INSULIN"
	 kb:Code="HS501"
	 kb:GENERIC_NAME="INSULIN"
	 kb:NAT_ID="845"
	 kb:STRENGTH="100.0"
	 kb:UNITS="UNT/ML"
	 kb:VA_NAME="INSULIN,SEMILENTE,PORK/PURIFIED 100UNT/ML INJ"
	 rdfs:label="INSULIN,SEMILENTE,PORK/PURIFIED 100UNT/ML INJ"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_127"
	 kb:Classification="INSULIN"
	 kb:Code="HS501"
	 kb:NAT_ID="64000896"
	 kb:UNITS="VI"
	 kb:VA_NAME="INSULIN,SEMILENTE,PORK/PURIFIED U-100"
	 rdfs:label="INSULIN,SEMILENTE,PORK/PURIFIED U-100"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_128"
	 kb:Classification="INSULIN"
	 kb:Code="HS501"
	 kb:GENERIC_NAME="INSULIN"
	 kb:NAT_ID="852"
	 kb:STRENGTH="100.0"
	 kb:UNITS="UNT/ML"
	 kb:VA_NAME="INSULIN,ULTRALENTE,BEEF 100UNT/ML INJ"
	 rdfs:label="INSULIN,ULTRALENTE,BEEF 100UNT/ML INJ"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_129"
	 kb:Classification="INSULIN"
	 kb:Code="HS501"
	 kb:GENERIC_NAME="INSULIN"
	 kb:NAT_ID="842"
	 kb:STRENGTH="100.0"
	 kb:UNITS="UNT/ML"
	 kb:VA_NAME="INSULIN,ULTRALENTE,BEEF/PORK 100UNT/ML INJ"
	 rdfs:label="INSULIN,ULTRALENTE,BEEF/PORK 100UNT/ML INJ"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_13"
	 kb:Classification="INSULIN"
	 kb:Code="HS501"
	 kb:NAT_ID="66200964"
	 kb:UNITS="VI"
	 kb:VA_NAME="INSULIN LENTE PUR PORK 100 U/ML INJ LILY"
	 rdfs:label="INSULIN LENTE PUR PORK 100 U/ML INJ LILY"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_130"
	 kb:Classification="INSULIN"
	 kb:Code="HS501"
	 kb:GENERIC_NAME="INSULIN"
	 kb:NAT_ID="843"
	 kb:STRENGTH="40.0"
	 kb:UNITS="UNT/ML"
	 kb:VA_NAME="INSULIN,ULTRALENTE,BEEF/PORK 40UNT/ML INJ"
	 rdfs:label="INSULIN,ULTRALENTE,BEEF/PORK 40UNT/ML INJ"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_131"
	 kb:Classification="INSULIN"
	 kb:Code="HS501"
	 kb:GENERIC_NAME="INSULIN"
	 kb:NAT_ID="846"
	 kb:STRENGTH="100.0"
	 kb:UNITS="UNT/ML"
	 kb:VA_NAME="INSULIN,ULTRALENTE,BEEF/PURIFIED 100UNT/ML INJ"
	 rdfs:label="INSULIN,ULTRALENTE,BEEF/PURIFIED 100UNT/ML INJ"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_132"
	 kb:Classification="INSULIN"
	 kb:Code="HS501"
	 kb:GENERIC_NAME="INSULIN"
	 kb:NAT_ID="856"
	 kb:STRENGTH="100.0"
	 kb:UNITS="UNT/ML"
	 kb:VA_NAME="INSULIN,ULTRALENTE,HUMAN 100UNT/ML INJ"
	 rdfs:label="INSULIN,ULTRALENTE,HUMAN 100UNT/ML INJ"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_133"
	 kb:Classification="INSULIN"
	 kb:Code="HS501"
	 kb:GENERIC_NAME="INSULIN"
	 kb:NAT_ID="16466"
	 kb:STRENGTH="100.0"
	 kb:UNITS="UNT/ML"
	 kb:VA_NAME="INSULIN.LISPRO,HUMAN 100 UNIT/ML INJ,CARTRIDGE,3ML"
	 rdfs:label="INSULIN.LISPRO,HUMAN 100 UNIT/ML INJ,CARTRIDGE,3ML"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_134"
	 kb:Classification="INSULIN"
	 kb:Code="HS501"
	 kb:NAT_ID="64028924"
	 kb:UNITS="SYR"
	 kb:VA_NAME="ZZ EXENATIDE INJ 250MCG/ML 1.2ML"
	 rdfs:label="ZZ EXENATIDE INJ 250MCG/ML 1.2ML"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_135"
	 kb:Classification="INSULIN"
	 kb:Code="HS501"
	 kb:NAT_ID="66205204"
	 kb:UNITS="VI"
	 kb:VA_NAME="ZZ-INSULIN HUMULIN 70/30 (NPH/REG) INJ"
	 rdfs:label="ZZ-INSULIN HUMULIN 70/30 (NPH/REG) INJ"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_136"
	 kb:Classification="INSULIN"
	 kb:Code="HS501"
	 kb:NAT_ID="66204284"
	 kb:UNITS="VI"
	 kb:VA_NAME="ZZ-INSULIN NPH HUMAN 100U/ML INJ HUMULIN"
	 rdfs:label="ZZ-INSULIN NPH HUMAN 100U/ML INJ HUMULIN"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_137"
	 kb:Classification="INSULIN"
	 kb:Code="HS501"
	 kb:NAT_ID="66200960"
	 kb:VA_NAME="ZZ-INSULIN NPH U-100 INJ (BEEF) 10ML"
	 rdfs:label="ZZ-INSULIN NPH U-100 INJ (BEEF) 10ML"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_138"
	 kb:Classification="INSULIN"
	 kb:Code="HS501"
	 kb:NAT_ID="66204288"
	 kb:UNITS="VI"
	 kb:VA_NAME="ZZ-INSULIN REG HUMAN 100U/ML INJ HUMULIN"
	 rdfs:label="ZZ-INSULIN REG HUMAN 100U/ML INJ HUMULIN"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_139"
	 kb:Classification="INSULIN"
	 kb:Code="HS501"
	 kb:NAT_ID="66206756"
	 kb:VA_NAME="ZZ-WS-INSULIN HUMULIN 70/30 (NPH/REG)"
	 rdfs:label="ZZ-WS-INSULIN HUMULIN 70/30 (NPH/REG)"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_14"
	 kb:Classification="INSULIN"
	 kb:Code="HS501"
	 kb:GENERIC_NAME="INSULIN"
	 kb:NAT_ID="881"
	 kb:STRENGTH="100.0"
	 kb:UNITS="UNT/ML"
	 kb:VA_NAME="INSULIN LENTE PUR PORK 100 U/ML INJ NOVO"
	 rdfs:label="INSULIN LENTE PUR PORK 100 U/ML INJ NOVO"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_140"
	 kb:Classification="INSULIN"
	 kb:Code="HS501"
	 kb:NAT_ID="66206756"
	 kb:VA_NAME="ZZ-WS-INSULIN LENTE HUMULIN 100U/ML 10ML"
	 rdfs:label="ZZ-WS-INSULIN LENTE HUMULIN 100U/ML 10ML"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_141"
	 kb:Classification="INSULIN"
	 kb:Code="HS501"
	 kb:NAT_ID="66206756"
	 kb:VA_NAME="ZZ-WS-INSULIN NPH HUMULIN 100U/ML 10ML"
	 rdfs:label="ZZ-WS-INSULIN NPH HUMULIN 100U/ML 10ML"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_142"
	 kb:Classification="INSULIN"
	 kb:Code="HS501"
	 kb:NAT_ID="66206760"
	 kb:VA_NAME="ZZ-WS-INSULIN REG HUMULIN 100U/ML 10ML"
	 rdfs:label="ZZ-WS-INSULIN REG HUMULIN 100U/ML 10ML"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_143"
	 kb:Classification="INSULIN"
	 kb:Code="HS501"
	 kb:NAT_ID="61200960"
	 kb:UNITS="VI"
	 kb:VA_NAME="ZZZ INSULIN LENTE U-100 BEEF 10ML"
	 rdfs:label="ZZZ INSULIN LENTE U-100 BEEF 10ML"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_144"
	 kb:Classification="INSULIN"
	 kb:Code="HS501"
	 kb:NAT_ID="61200964"
	 kb:UNITS="VI"
	 kb:VA_NAME="ZZZ INSULIN LENTE U-100 PORK 10ML"
	 rdfs:label="ZZZ INSULIN LENTE U-100 PORK 10ML"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_145"
	 kb:Classification="INSULIN"
	 kb:Code="HS501"
	 kb:NAT_ID="61204448"
	 kb:UNITS="VI"
	 kb:VA_NAME="ZZZ INSULIN LENTE U-100 PURE PORK 10ML"
	 rdfs:label="ZZZ INSULIN LENTE U-100 PURE PORK 10ML"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_146"
	 kb:Classification="INSULIN"
	 kb:Code="HS501"
	 kb:NAT_ID="61204448"
	 kb:UNITS="VI"
	 kb:VA_NAME="ZZZ INSULIN LENTE U-100 PURIFIED BF/PK"
	 rdfs:label="ZZZ INSULIN LENTE U-100 PURIFIED BF/PK"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_147"
	 kb:Classification="INSULIN"
	 kb:Code="HS501"
	 kb:NAT_ID="61204448"
	 kb:UNITS="VI"
	 kb:VA_NAME="ZZZ INSULIN NPH U-100 PURIFIED PORK 10ML"
	 rdfs:label="ZZZ INSULIN NPH U-100 PURIFIED PORK 10ML"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_148"
	 kb:Classification="INSULIN"
	 kb:Code="HS501"
	 kb:NAT_ID="61204336"
	 kb:UNITS="VI"
	 kb:VA_NAME="ZZZ INSULIN NPH U100 PORK 10CC"
	 rdfs:label="ZZZ INSULIN NPH U100 PORK 10CC"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_149"
	 kb:Classification="INSULIN"
	 kb:Code="HS501"
	 kb:NAT_ID="61200968"
	 kb:UNITS="VI"
	 kb:VA_NAME="ZZZ INSULIN PROTAMINE ZINC U-100 10ML"
	 rdfs:label="ZZZ INSULIN PROTAMINE ZINC U-100 10ML"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_15"
	 kb:Classification="INSULIN"
	 kb:Code="HS501"
	 kb:NAT_ID="64000888"
	 kb:UNITS="VI"
	 kb:VA_NAME="INSULIN LENTE PUR PORK 100 UNIT/ML LILLY"
	 rdfs:label="INSULIN LENTE PUR PORK 100 UNIT/ML LILLY"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_150"
	 kb:Classification="INSULIN"
	 kb:Code="HS501"
	 kb:NAT_ID="61205704"
	 kb:UNITS="VI"
	 kb:VA_NAME="ZZZ INSULIN REG U-500 PORK 20ML"
	 rdfs:label="ZZZ INSULIN REG U-500 PORK 20ML"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_151"
	 kb:Classification="INSULIN"
	 kb:Code="HS501"
	 kb:NAT_ID="61204328"
	 kb:UNITS="VI"
	 kb:VA_NAME="ZZZ INSULIN REGULAR U-100 PORK 10CC"
	 rdfs:label="ZZZ INSULIN REGULAR U-100 PORK 10CC"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_152"
	 kb:Classification="INSULIN"
	 kb:Code="HS501"
	 kb:NAT_ID="61204444"
	 kb:UNITS="VI"
	 kb:VA_NAME="ZZZ INSULIN REGULAR U-100 PURIFIED PORK"
	 rdfs:label="ZZZ INSULIN REGULAR U-100 PURIFIED PORK"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_153"
	 kb:Classification="INSULIN"
	 kb:Code="HS501"
	 kb:NAT_ID="61204176"
	 kb:UNITS="VI"
	 kb:VA_NAME="ZZZ INSULIN SEMI LENTE U-100 10ML"
	 rdfs:label="ZZZ INSULIN SEMI LENTE U-100 10ML"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_154"
	 kb:Classification="INSULIN"
	 kb:Code="HS501"
	 kb:NAT_ID="61200968"
	 kb:UNITS="VI"
	 kb:VA_NAME="ZZZ INSULIN ULTRA LENTE U-100 10ML"
	 rdfs:label="ZZZ INSULIN ULTRA LENTE U-100 10ML"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_155"
	 kb:Classification="INSULIN"
	 kb:Code="HS501"
	 kb:NAT_ID="64027388"
	 kb:UNITS="EA"
	 kb:VA_NAME="ZZZINSULIN LISPRO HUMAN REFILL  100U/ML"
	 rdfs:label="ZZZINSULIN LISPRO HUMAN REFILL  100U/ML"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_156"
	 kb:Classification="INSULIN"
	 kb:Code="HS501"
	 kb:NAT_ID="64026584"
	 kb:UNITS="VIAL"
	 kb:VA_NAME="ZZZINSULIN NPH HUMAN 100 U/ML PENFILL"
	 rdfs:label="ZZZINSULIN NPH HUMAN 100 U/ML PENFILL"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_157"
	 kb:Classification="INSULIN"
	 kb:Code="HS501"
	 kb:NAT_ID="64026256"
	 kb:UNITS="CARTRIDGE"
	 kb:VA_NAME="ZZZINSULIN REG HUMAN 100 U/ML PENFILL"
	 rdfs:label="ZZZINSULIN REG HUMAN 100 U/ML PENFILL"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_158"
	 kb:Classification="INSULIN"
	 kb:Code="HS501"
	 kb:NAT_ID="64000896"
	 kb:UNITS="VI"
	 kb:VA_NAME="ZZZINSULIN ULTRALENTE,BEEF/PURIF U-100"
	 rdfs:label="ZZZINSULIN ULTRALENTE,BEEF/PURIF U-100"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_159"
	 kb:Classification="INSULIN"
	 kb:Code="HS501"
	 kb:NAT_ID="64000888"
	 kb:UNITS="VI"
	 kb:VA_NAME="ZZZINSULIN, (BEEF) NPH, U-100"
	 rdfs:label="ZZZINSULIN, (BEEF) NPH, U-100"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_16"
	 kb:Classification="INSULIN"
	 kb:Code="HS501"
	 kb:GENERIC_NAME="INSULIN"
	 kb:NAT_ID="878"
	 kb:VA_NAME="INSULIN NOVOLIN 70/30 (NPH/REG) INJ NOVO"
	 rdfs:label="INSULIN NOVOLIN 70/30 (NPH/REG) INJ NOVO"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_160"
	 kb:Classification="INSULIN"
	 kb:Code="HS501"
	 kb:NAT_ID="64000884"
	 kb:UNITS="VI"
	 kb:VA_NAME="ZZZINSULIN,LENTE,BEEF/PURIFIED U-100"
	 rdfs:label="ZZZINSULIN,LENTE,BEEF/PURIFIED U-100"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_161"
	 kb:Classification="INSULIN"
	 kb:Code="HS501"
	 kb:NAT_ID="64000896"
	 kb:UNITS="VI"
	 kb:VA_NAME="ZZZINSULIN,PROTAMINE ZN,BEEF/PORK U-100"
	 rdfs:label="ZZZINSULIN,PROTAMINE ZN,BEEF/PORK U-100"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_162"
	 kb:Classification="INSULIN"
	 kb:Code="HS501"
	 kb:NAT_ID="64000892"
	 kb:UNITS="VI"
	 kb:VA_NAME="ZZZINSULIN,REGULAR,BEEF/PORK U-100 INJ"
	 rdfs:label="ZZZINSULIN,REGULAR,BEEF/PORK U-100 INJ"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_163"
	 kb:Classification="INSULIN"
	 kb:Code="HS501"
	 kb:NAT_ID="64027136"
	 kb:VA_NAME="ZZZINSULIN,REGULAR,BEEF/PORK U-100 INJ"
	 rdfs:label="ZZZINSULIN,REGULAR,BEEF/PORK U-100 INJ"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_164"
	 kb:Classification="ORAL HYPOGLYCEMIC AGENTS,ORAL"
	 kb:Code="HS502"
	 kb:GENERIC_NAME="ACARBOSE"
	 kb:NAT_ID="12469"
	 kb:STRENGTH="100.0"
	 kb:UNITS="MG"
	 kb:VA_NAME="ACARBOSE 100MG TAB"
	 rdfs:label="ACARBOSE 100MG TAB"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_165"
	 kb:Classification="ORAL HYPOGLYCEMIC AGENTS,ORAL"
	 kb:Code="HS502"
	 kb:GENERIC_NAME="ACARBOSE"
	 kb:NAT_ID="12472"
	 kb:STRENGTH="100.0"
	 kb:UNITS="MG"
	 kb:VA_NAME="ACARBOSE 100MG TAB,UD"
	 rdfs:label="ACARBOSE 100MG TAB,UD"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_166"
	 kb:Classification="ORAL HYPOGLYCEMIC AGENTS,ORAL"
	 kb:Code="HS502"
	 kb:GENERIC_NAME="ACARBOSE"
	 kb:NAT_ID="12470"
	 kb:STRENGTH="25.0"
	 kb:UNITS="MG"
	 kb:VA_NAME="ACARBOSE 25MG TAB"
	 rdfs:label="ACARBOSE 25MG TAB"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_167"
	 kb:Classification="ORAL HYPOGLYCEMIC AGENTS,ORAL"
	 kb:Code="HS502"
	 kb:GENERIC_NAME="ACARBOSE"
	 kb:NAT_ID="12468"
	 kb:STRENGTH="50.0"
	 kb:UNITS="MG"
	 kb:VA_NAME="ACARBOSE 50MG TAB"
	 rdfs:label="ACARBOSE 50MG TAB"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_168"
	 kb:Classification="ORAL HYPOGLYCEMIC AGENTS,ORAL"
	 kb:Code="HS502"
	 kb:GENERIC_NAME="ACARBOSE"
	 kb:NAT_ID="12471"
	 kb:STRENGTH="50.0"
	 kb:UNITS="MG"
	 kb:VA_NAME="ACARBOSE 50MG TAB,UD"
	 rdfs:label="ACARBOSE 50MG TAB,UD"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_169"
	 kb:Classification="ORAL HYPOGLYCEMIC AGENTS,ORAL"
	 kb:Code="HS502"
	 kb:GENERIC_NAME="ACETOHEXAMIDE"
	 kb:NAT_ID="576"
	 kb:STRENGTH="250.0"
	 kb:UNITS="MG"
	 kb:VA_NAME="ACETOHEXAMIDE 250MG TAB"
	 rdfs:label="ACETOHEXAMIDE 250MG TAB"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_17"
	 kb:Classification="INSULIN"
	 kb:Code="HS501"
	 kb:GENERIC_NAME="INSULIN"
	 kb:NAT_ID="16437"
	 kb:VA_NAME="INSULIN NOVOLIN 70/30 INJ INNOLET 3ML"
	 rdfs:label="INSULIN NOVOLIN 70/30 INJ INNOLET 3ML"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_170"
	 kb:Classification="ORAL HYPOGLYCEMIC AGENTS,ORAL"
	 kb:Code="HS502"
	 kb:NAT_ID="64024804"
	 kb:UNITS="TAB"
	 kb:VA_NAME="ACETOHEXAMIDE 250MG TAB"
	 rdfs:label="ACETOHEXAMIDE 250MG TAB"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_171"
	 kb:Classification="ORAL HYPOGLYCEMIC AGENTS,ORAL"
	 kb:Code="HS502"
	 kb:NAT_ID="64025196"
	 kb:UNITS="TAB"
	 kb:VA_NAME="ACETOHEXAMIDE 500 MG TAB"
	 rdfs:label="ACETOHEXAMIDE 500 MG TAB"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_172"
	 kb:Classification="ORAL HYPOGLYCEMIC AGENTS,ORAL"
	 kb:Code="HS502"
	 kb:GENERIC_NAME="ACETOHEXAMIDE"
	 kb:NAT_ID="577"
	 kb:STRENGTH="500.0"
	 kb:UNITS="MG"
	 kb:VA_NAME="ACETOHEXAMIDE 500MG TAB"
	 rdfs:label="ACETOHEXAMIDE 500MG TAB"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_173"
	 kb:Classification="ORAL HYPOGLYCEMIC AGENTS,ORAL"
	 kb:Code="HS502"
	 kb:GENERIC_NAME="CHLORPROPAMIDE"
	 kb:NAT_ID="1836"
	 kb:STRENGTH="100.0"
	 kb:UNITS="MG"
	 kb:VA_NAME="CHLORPROPAMIDE 100MG TAB"
	 rdfs:label="CHLORPROPAMIDE 100MG TAB"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_174"
	 kb:Classification="ORAL HYPOGLYCEMIC AGENTS,ORAL"
	 kb:Code="HS502"
	 kb:GENERIC_NAME="CHLORPROPAMIDE"
	 kb:NAT_ID="1837"
	 kb:STRENGTH="250.0"
	 kb:UNITS="MG"
	 kb:VA_NAME="CHLORPROPAMIDE 250MG TAB"
	 rdfs:label="CHLORPROPAMIDE 250MG TAB"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_175"
	 kb:Classification="ORAL HYPOGLYCEMIC AGENTS,ORAL"
	 kb:Code="HS502"
	 kb:GENERIC_NAME="GLIMEPIRIDE"
	 kb:NAT_ID="12483"
	 kb:STRENGTH="1.0"
	 kb:UNITS="MG"
	 kb:VA_NAME="GLIMEPIRIDE 1MG TAB"
	 rdfs:label="GLIMEPIRIDE 1MG TAB"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_176"
	 kb:Classification="ORAL HYPOGLYCEMIC AGENTS,ORAL"
	 kb:Code="HS502"
	 kb:GENERIC_NAME="GLIMEPIRIDE/ROSIGLITAZONE"
	 kb:NAT_ID="17927"
	 kb:VA_NAME="GLIMEPIRIDE 1MG/ROSIGLITAZONE MALEATE 4MG TAB"
	 rdfs:label="GLIMEPIRIDE 1MG/ROSIGLITAZONE MALEATE 4MG TAB"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_177"
	 kb:Classification="ORAL HYPOGLYCEMIC AGENTS,ORAL"
	 kb:Code="HS502"
	 kb:GENERIC_NAME="GLIMEPIRIDE"
	 kb:NAT_ID="12484"
	 kb:STRENGTH="2.0"
	 kb:UNITS="MG"
	 kb:VA_NAME="GLIMEPIRIDE 2MG TAB"
	 rdfs:label="GLIMEPIRIDE 2MG TAB"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_178"
	 kb:Classification="ORAL HYPOGLYCEMIC AGENTS,ORAL"
	 kb:Code="HS502"
	 kb:GENERIC_NAME="GLIMEPIRIDE/ROSIGLITAZONE"
	 kb:NAT_ID="17926"
	 kb:VA_NAME="GLIMEPIRIDE 2MG/ROSIGLITAZONE MALEATE 4MG TAB"
	 rdfs:label="GLIMEPIRIDE 2MG/ROSIGLITAZONE MALEATE 4MG TAB"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_179"
	 kb:Classification="ORAL HYPOGLYCEMIC AGENTS,ORAL"
	 kb:Code="HS502"
	 kb:GENERIC_NAME="GLIMEPIRIDE"
	 kb:NAT_ID="12485"
	 kb:STRENGTH="4.0"
	 kb:UNITS="MG"
	 kb:VA_NAME="GLIMEPIRIDE 4MG TAB"
	 rdfs:label="GLIMEPIRIDE 4MG TAB"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_18"
	 kb:Classification="INSULIN"
	 kb:Code="HS501"
	 kb:GENERIC_NAME="INSULIN"
	 kb:NAT_ID="879"
	 kb:VA_NAME="INSULIN NOVOLIN 70/30 INJ PENFILL 1.5ML"
	 rdfs:label="INSULIN NOVOLIN 70/30 INJ PENFILL 1.5ML"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_180"
	 kb:Classification="ORAL HYPOGLYCEMIC AGENTS,ORAL"
	 kb:Code="HS502"
	 kb:GENERIC_NAME="GLIMEPIRIDE/ROSIGLITAZONE"
	 kb:NAT_ID="17925"
	 kb:VA_NAME="GLIMEPIRIDE 4MG/ROSIGLITAZONE MALEATE 4MG TAB"
	 rdfs:label="GLIMEPIRIDE 4MG/ROSIGLITAZONE MALEATE 4MG TAB"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_181"
	 kb:Classification="ORAL HYPOGLYCEMIC AGENTS,ORAL"
	 kb:Code="HS502"
	 kb:GENERIC_NAME="GLIPIZIDE"
	 kb:NAT_ID="4519"
	 kb:STRENGTH="10.0"
	 kb:UNITS="MG"
	 kb:VA_NAME="GLIPIZIDE 10MG TAB"
	 rdfs:label="GLIPIZIDE 10MG TAB"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_182"
	 kb:Classification="ORAL HYPOGLYCEMIC AGENTS,ORAL"
	 kb:Code="HS502"
	 kb:GENERIC_NAME="GLIPIZIDE"
	 kb:NAT_ID="4521"
	 kb:STRENGTH="10.0"
	 kb:UNITS="MG"
	 kb:VA_NAME="GLIPIZIDE 10MG TAB,SA"
	 rdfs:label="GLIPIZIDE 10MG TAB,SA"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_183"
	 kb:Classification="ORAL HYPOGLYCEMIC AGENTS,ORAL"
	 kb:Code="HS502"
	 kb:GENERIC_NAME="GLIPIZIDE"
	 kb:NAT_ID="14319"
	 kb:STRENGTH="10.0"
	 kb:UNITS="MG"
	 kb:VA_NAME="GLIPIZIDE 10MG TAB,UD"
	 rdfs:label="GLIPIZIDE 10MG TAB,UD"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_184"
	 kb:Classification="ORAL HYPOGLYCEMIC AGENTS,ORAL"
	 kb:Code="HS502"
	 kb:GENERIC_NAME="GLIPIZIDE"
	 kb:NAT_ID="13875"
	 kb:STRENGTH="2.5"
	 kb:UNITS="MG"
	 kb:VA_NAME="GLIPIZIDE 2.5MG TAB,SA"
	 rdfs:label="GLIPIZIDE 2.5MG TAB,SA"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_185"
	 kb:Classification="ORAL HYPOGLYCEMIC AGENTS,ORAL"
	 kb:Code="HS502"
	 kb:GENERIC_NAME="GLIPIZIDE/METFORMIN"
	 kb:NAT_ID="16124"
	 kb:VA_NAME="GLIPIZIDE 2.5MG/METFORMIN HCL 250MG TAB"
	 rdfs:label="GLIPIZIDE 2.5MG/METFORMIN HCL 250MG TAB"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_186"
	 kb:Classification="ORAL HYPOGLYCEMIC AGENTS,ORAL"
	 kb:Code="HS502"
	 kb:GENERIC_NAME="GLIPIZIDE/METFORMIN"
	 kb:NAT_ID="16125"
	 kb:VA_NAME="GLIPIZIDE 2.5MG/METFORMIN HCL 500MG TAB"
	 rdfs:label="GLIPIZIDE 2.5MG/METFORMIN HCL 500MG TAB"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_187"
	 kb:Classification="ORAL HYPOGLYCEMIC AGENTS,ORAL"
	 kb:Code="HS502"
	 kb:GENERIC_NAME="GLIPIZIDE"
	 kb:NAT_ID="4518"
	 kb:STRENGTH="5.0"
	 kb:UNITS="MG"
	 kb:VA_NAME="GLIPIZIDE 5MG TAB"
	 rdfs:label="GLIPIZIDE 5MG TAB"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_188"
	 kb:Classification="ORAL HYPOGLYCEMIC AGENTS,ORAL"
	 kb:Code="HS502"
	 kb:GENERIC_NAME="GLIPIZIDE"
	 kb:NAT_ID="4520"
	 kb:STRENGTH="5.0"
	 kb:UNITS="MG"
	 kb:VA_NAME="GLIPIZIDE 5MG TAB,SA"
	 rdfs:label="GLIPIZIDE 5MG TAB,SA"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_189"
	 kb:Classification="ORAL HYPOGLYCEMIC AGENTS,ORAL"
	 kb:Code="HS502"
	 kb:GENERIC_NAME="GLIPIZIDE"
	 kb:NAT_ID="13579"
	 kb:STRENGTH="5.0"
	 kb:UNITS="MG"
	 kb:VA_NAME="GLIPIZIDE 5MG TAB,UD"
	 rdfs:label="GLIPIZIDE 5MG TAB,UD"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_19"
	 kb:Classification="INSULIN"
	 kb:Code="HS501"
	 kb:GENERIC_NAME="INSULIN"
	 kb:NAT_ID="13113"
	 kb:VA_NAME="INSULIN NOVOLIN 70/30 INJ PENFILL 3ML"
	 rdfs:label="INSULIN NOVOLIN 70/30 INJ PENFILL 3ML"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_190"
	 kb:Classification="ORAL HYPOGLYCEMIC AGENTS,ORAL"
	 kb:Code="HS502"
	 kb:GENERIC_NAME="GLIPIZIDE/METFORMIN"
	 kb:NAT_ID="16126"
	 kb:VA_NAME="GLIPIZIDE 5MG/METFORMIN HCL 500MG TAB"
	 rdfs:label="GLIPIZIDE 5MG/METFORMIN HCL 500MG TAB"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_191"
	 kb:Classification="ORAL HYPOGLYCEMIC AGENTS,ORAL"
	 kb:Code="HS502"
	 kb:GENERIC_NAME="GLUCOSE"
	 kb:NAT_ID="16906"
	 kb:STRENGTH="100.0"
	 kb:UNITS="GM/300ML"
	 kb:VA_NAME="GLUCOSE 100GM/300ML LIQUID,ORAL"
	 rdfs:label="GLUCOSE 100GM/300ML LIQUID,ORAL"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_192"
	 kb:Classification="ORAL HYPOGLYCEMIC AGENTS,ORAL"
	 kb:Code="HS502"
	 kb:GENERIC_NAME="GLUCOSE"
	 kb:NAT_ID="15123"
	 kb:STRENGTH="24.0"
	 kb:UNITS="GM"
	 kb:VA_NAME="GLUCOSE 24GM LIQUID,ORAL"
	 rdfs:label="GLUCOSE 24GM LIQUID,ORAL"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_193"
	 kb:Classification="ORAL HYPOGLYCEMIC AGENTS,ORAL"
	 kb:Code="HS502"
	 kb:GENERIC_NAME="GLUCOSE"
	 kb:NAT_ID="16905"
	 kb:STRENGTH="75.0"
	 kb:UNITS="GM/300ML"
	 kb:VA_NAME="GLUCOSE 75GM/300ML LIQUID,ORAL"
	 rdfs:label="GLUCOSE 75GM/300ML LIQUID,ORAL"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_194"
	 kb:Classification="ORAL HYPOGLYCEMIC AGENTS,ORAL"
	 kb:Code="HS502"
	 kb:GENERIC_NAME="GLYBURIDE"
	 kb:NAT_ID="2876"
	 kb:STRENGTH="1.25"
	 kb:UNITS="MG"
	 kb:VA_NAME="GLYBURIDE 1.25MG TAB"
	 rdfs:label="GLYBURIDE 1.25MG TAB"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_195"
	 kb:Classification="ORAL HYPOGLYCEMIC AGENTS,ORAL"
	 kb:Code="HS502"
	 kb:GENERIC_NAME="GLYBURIDE/METFORMIN"
	 kb:NAT_ID="14537"
	 kb:VA_NAME="GLYBURIDE 1.25MG/METFORMIN HCL 250MG TAB"
	 rdfs:label="GLYBURIDE 1.25MG/METFORMIN HCL 250MG TAB"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_196"
	 kb:Classification="ORAL HYPOGLYCEMIC AGENTS,ORAL"
	 kb:Code="HS502"
	 kb:GENERIC_NAME="GLYBURIDE"
	 kb:NAT_ID="2879"
	 kb:STRENGTH="1.5"
	 kb:UNITS="MG"
	 kb:VA_NAME="GLYBURIDE 1.5MG TAB"
	 rdfs:label="GLYBURIDE 1.5MG TAB"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_197"
	 kb:Classification="ORAL HYPOGLYCEMIC AGENTS,ORAL"
	 kb:Code="HS502"
	 kb:GENERIC_NAME="GLYBURIDE"
	 kb:NAT_ID="2877"
	 kb:STRENGTH="2.5"
	 kb:UNITS="MG"
	 kb:VA_NAME="GLYBURIDE 2.5MG TAB"
	 rdfs:label="GLYBURIDE 2.5MG TAB"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_198"
	 kb:Classification="ORAL HYPOGLYCEMIC AGENTS,ORAL"
	 kb:Code="HS502"
	 kb:GENERIC_NAME="GLYBURIDE"
	 kb:NAT_ID="13580"
	 kb:STRENGTH="2.5"
	 kb:UNITS="MG"
	 kb:VA_NAME="GLYBURIDE 2.5MG TAB,UD"
	 rdfs:label="GLYBURIDE 2.5MG TAB,UD"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_199"
	 kb:Classification="ORAL HYPOGLYCEMIC AGENTS,ORAL"
	 kb:Code="HS502"
	 kb:GENERIC_NAME="GLYBURIDE/METFORMIN"
	 kb:NAT_ID="14538"
	 kb:VA_NAME="GLYBURIDE 2.5MG/METFORMIN HCL 500MG TAB"
	 rdfs:label="GLYBURIDE 2.5MG/METFORMIN HCL 500MG TAB"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_2"
	 kb:Classification="INSULIN"
	 kb:Code="HS501"
	 kb:GENERIC_NAME="INSULIN"
	 kb:NAT_ID="870"
	 kb:VA_NAME="INSULIN HUMULIN 50/50 (NPH/REG) INJ LILY"
	 rdfs:label="INSULIN HUMULIN 50/50 (NPH/REG) INJ LILY"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_20"
	 kb:Classification="INSULIN"
	 kb:Code="HS501"
	 kb:GENERIC_NAME="INSULIN"
	 kb:NAT_ID="871"
	 kb:VA_NAME="INSULIN NOVOLIN 70/30 INJ SYRINGE 1.5ML"
	 rdfs:label="INSULIN NOVOLIN 70/30 INJ SYRINGE 1.5ML"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_200"
	 kb:Classification="ORAL HYPOGLYCEMIC AGENTS,ORAL"
	 kb:Code="HS502"
	 kb:GENERIC_NAME="GLYBURIDE"
	 kb:NAT_ID="2880"
	 kb:STRENGTH="3.0"
	 kb:UNITS="MG"
	 kb:VA_NAME="GLYBURIDE 3MG TAB"
	 rdfs:label="GLYBURIDE 3MG TAB"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_201"
	 kb:Classification="ORAL HYPOGLYCEMIC AGENTS,ORAL"
	 kb:Code="HS502"
	 kb:GENERIC_NAME="GLYBURIDE"
	 kb:NAT_ID="15347"
	 kb:STRENGTH="4.5"
	 kb:UNITS="MG"
	 kb:VA_NAME="GLYBURIDE 4.5MG TAB"
	 rdfs:label="GLYBURIDE 4.5MG TAB"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_202"
	 kb:Classification="ORAL HYPOGLYCEMIC AGENTS,ORAL"
	 kb:Code="HS502"
	 kb:GENERIC_NAME="GLYBURIDE"
	 kb:NAT_ID="2878"
	 kb:STRENGTH="5.0"
	 kb:UNITS="MG"
	 kb:VA_NAME="GLYBURIDE 5MG TAB"
	 rdfs:label="GLYBURIDE 5MG TAB"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_203"
	 kb:Classification="ORAL HYPOGLYCEMIC AGENTS,ORAL"
	 kb:Code="HS502"
	 kb:GENERIC_NAME="GLYBURIDE"
	 kb:NAT_ID="13581"
	 kb:STRENGTH="5.0"
	 kb:UNITS="MG"
	 kb:VA_NAME="GLYBURIDE 5MG TAB,UD"
	 rdfs:label="GLYBURIDE 5MG TAB,UD"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_204"
	 kb:Classification="ORAL HYPOGLYCEMIC AGENTS,ORAL"
	 kb:Code="HS502"
	 kb:GENERIC_NAME="GLYBURIDE/METFORMIN"
	 kb:NAT_ID="14539"
	 kb:VA_NAME="GLYBURIDE 5MG/METFORMIN HCL 500MG TAB"
	 rdfs:label="GLYBURIDE 5MG/METFORMIN HCL 500MG TAB"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_205"
	 kb:Classification="ORAL HYPOGLYCEMIC AGENTS,ORAL"
	 kb:Code="HS502"
	 kb:GENERIC_NAME="GLYBURIDE"
	 kb:NAT_ID="2881"
	 kb:STRENGTH="6.0"
	 kb:UNITS="MG"
	 kb:VA_NAME="GLYBURIDE 6MG TAB"
	 rdfs:label="GLYBURIDE 6MG TAB"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_206"
	 kb:Classification="ORAL HYPOGLYCEMIC AGENTS,ORAL"
	 kb:Code="HS502"
	 kb:GENERIC_NAME="METFORMIN"
	 kb:NAT_ID="12976"
	 kb:STRENGTH="1000.0"
	 kb:UNITS="MG"
	 kb:VA_NAME="METFORMIN HCL 1000MG TAB"
	 rdfs:label="METFORMIN HCL 1000MG TAB"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_207"
	 kb:Classification="ORAL HYPOGLYCEMIC AGENTS,ORAL"
	 kb:Code="HS502"
	 kb:GENERIC_NAME="METFORMIN"
	 kb:NAT_ID="16139"
	 kb:STRENGTH="1000.0"
	 kb:UNITS="MG"
	 kb:VA_NAME="METFORMIN HCL 1000MG TAB,UD"
	 rdfs:label="METFORMIN HCL 1000MG TAB,UD"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_208"
	 kb:Classification="ORAL HYPOGLYCEMIC AGENTS,ORAL"
	 kb:Code="HS502"
	 kb:GENERIC_NAME="METFORMIN/ROSIGLITAZONE"
	 kb:NAT_ID="17220"
	 kb:VA_NAME="METFORMIN HCL 1000MG/ROSIGLITAZONE MALEATE 2MG TAB"
	 rdfs:label="METFORMIN HCL 1000MG/ROSIGLITAZONE MALEATE 2MG TAB"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_209"
	 kb:Classification="ORAL HYPOGLYCEMIC AGENTS,ORAL"
	 kb:Code="HS502"
	 kb:GENERIC_NAME="METFORMIN/ROSIGLITAZONE"
	 kb:NAT_ID="16711"
	 kb:VA_NAME="METFORMIN HCL 1000MG/ROSIGLITAZONE MALEATE 4MG TAB"
	 rdfs:label="METFORMIN HCL 1000MG/ROSIGLITAZONE MALEATE 4MG TAB"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_21"
	 kb:Classification="INSULIN"
	 kb:Code="HS501"
	 kb:GENERIC_NAME="INSULIN"
	 kb:NAT_ID="884"
	 kb:STRENGTH="100.0"
	 kb:UNITS="UNT/ML"
	 kb:VA_NAME="INSULIN NPH BEEF 100 U/ML INJ NOVO"
	 rdfs:label="INSULIN NPH BEEF 100 U/ML INJ NOVO"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_210"
	 kb:Classification="ORAL HYPOGLYCEMIC AGENTS,ORAL"
	 kb:Code="HS502"
	 kb:GENERIC_NAME="METFORMIN"
	 kb:NAT_ID="12369"
	 kb:STRENGTH="500.0"
	 kb:UNITS="MG"
	 kb:VA_NAME="METFORMIN HCL 500MG TAB"
	 rdfs:label="METFORMIN HCL 500MG TAB"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_211"
	 kb:Classification="ORAL HYPOGLYCEMIC AGENTS,ORAL"
	 kb:Code="HS502"
	 kb:GENERIC_NAME="METFORMIN"
	 kb:NAT_ID="14620"
	 kb:STRENGTH="500.0"
	 kb:UNITS="MG"
	 kb:VA_NAME="METFORMIN HCL 500MG TAB,SA"
	 rdfs:label="METFORMIN HCL 500MG TAB,SA"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_212"
	 kb:Classification="ORAL HYPOGLYCEMIC AGENTS,ORAL"
	 kb:Code="HS502"
	 kb:GENERIC_NAME="METFORMIN"
	 kb:NAT_ID="16137"
	 kb:STRENGTH="500.0"
	 kb:UNITS="MG"
	 kb:VA_NAME="METFORMIN HCL 500MG TAB,UD"
	 rdfs:label="METFORMIN HCL 500MG TAB,UD"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_213"
	 kb:Classification="ORAL HYPOGLYCEMIC AGENTS,ORAL"
	 kb:Code="HS502"
	 kb:GENERIC_NAME="METFORMIN"
	 kb:NAT_ID="16635"
	 kb:STRENGTH="500.0"
	 kb:UNITS="MG/5ML"
	 kb:VA_NAME="METFORMIN HCL 500MG/5ML SOLN,ORAL"
	 rdfs:label="METFORMIN HCL 500MG/5ML SOLN,ORAL"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_214"
	 kb:Classification="ORAL HYPOGLYCEMIC AGENTS,ORAL"
	 kb:Code="HS502"
	 kb:GENERIC_NAME="METFORMIN/PIOGLITAZONE"
	 kb:NAT_ID="17542"
	 kb:VA_NAME="METFORMIN HCL 500MG/PIOGLITAZONE HCL 15MG TAB"
	 rdfs:label="METFORMIN HCL 500MG/PIOGLITAZONE HCL 15MG TAB"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_215"
	 kb:Classification="ORAL HYPOGLYCEMIC AGENTS,ORAL"
	 kb:Code="HS502"
	 kb:GENERIC_NAME="METFORMIN/ROSIGLITAZONE"
	 kb:NAT_ID="15981"
	 kb:VA_NAME="METFORMIN HCL 500MG/ROSIGLITAZONE MALEATE 1MG TAB"
	 rdfs:label="METFORMIN HCL 500MG/ROSIGLITAZONE MALEATE 1MG TAB"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_216"
	 kb:Classification="ORAL HYPOGLYCEMIC AGENTS,ORAL"
	 kb:Code="HS502"
	 kb:GENERIC_NAME="METFORMIN/ROSIGLITAZONE"
	 kb:NAT_ID="15982"
	 kb:VA_NAME="METFORMIN HCL 500MG/ROSIGLITAZONE MALEATE 2MG TAB"
	 rdfs:label="METFORMIN HCL 500MG/ROSIGLITAZONE MALEATE 2MG TAB"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_217"
	 kb:Classification="ORAL HYPOGLYCEMIC AGENTS,ORAL"
	 kb:Code="HS502"
	 kb:GENERIC_NAME="METFORMIN/ROSIGLITAZONE"
	 kb:NAT_ID="15983"
	 kb:VA_NAME="METFORMIN HCL 500MG/ROSIGLITAZONE MALEATE 4MG TAB"
	 rdfs:label="METFORMIN HCL 500MG/ROSIGLITAZONE MALEATE 4MG TAB"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_218"
	 kb:Classification="ORAL HYPOGLYCEMIC AGENTS,ORAL"
	 kb:Code="HS502"
	 kb:GENERIC_NAME="METFORMIN"
	 kb:NAT_ID="17191"
	 kb:STRENGTH="750.0"
	 kb:UNITS="MG"
	 kb:VA_NAME="METFORMIN HCL 750MG TAB,SA"
	 rdfs:label="METFORMIN HCL 750MG TAB,SA"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_219"
	 kb:Classification="ORAL HYPOGLYCEMIC AGENTS,ORAL"
	 kb:Code="HS502"
	 kb:GENERIC_NAME="METFORMIN"
	 kb:NAT_ID="12370"
	 kb:STRENGTH="850.0"
	 kb:UNITS="MG"
	 kb:VA_NAME="METFORMIN HCL 850MG TAB"
	 rdfs:label="METFORMIN HCL 850MG TAB"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_22"
	 kb:Classification="INSULIN"
	 kb:Code="HS501"
	 kb:GENERIC_NAME="INSULIN"
	 kb:NAT_ID="862"
	 kb:STRENGTH="100.0"
	 kb:UNITS="UNT/ML"
	 kb:VA_NAME="INSULIN NPH BEEF/PORK 100 U/ML INJ LILLY"
	 rdfs:label="INSULIN NPH BEEF/PORK 100 U/ML INJ LILLY"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_220"
	 kb:Classification="ORAL HYPOGLYCEMIC AGENTS,ORAL"
	 kb:Code="HS502"
	 kb:GENERIC_NAME="METFORMIN"
	 kb:NAT_ID="16138"
	 kb:STRENGTH="850.0"
	 kb:UNITS="MG"
	 kb:VA_NAME="METFORMIN HCL 850MG TAB,UD"
	 rdfs:label="METFORMIN HCL 850MG TAB,UD"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_221"
	 kb:Classification="ORAL HYPOGLYCEMIC AGENTS,ORAL"
	 kb:Code="HS502"
	 kb:GENERIC_NAME="METFORMIN/PIOGLITAZONE"
	 kb:NAT_ID="17543"
	 kb:VA_NAME="METFORMIN HCL 850MG/PIOGLITAZONE HCL 15MG TAB"
	 rdfs:label="METFORMIN HCL 850MG/PIOGLITAZONE HCL 15MG TAB"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_222"
	 kb:Classification="ORAL HYPOGLYCEMIC AGENTS,ORAL"
	 kb:Code="HS502"
	 kb:GENERIC_NAME="MIGLITOL"
	 kb:NAT_ID="12768"
	 kb:STRENGTH="100.0"
	 kb:UNITS="MG"
	 kb:VA_NAME="MIGLITOL 100MG TAB"
	 rdfs:label="MIGLITOL 100MG TAB"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_223"
	 kb:Classification="ORAL HYPOGLYCEMIC AGENTS,ORAL"
	 kb:Code="HS502"
	 kb:GENERIC_NAME="MIGLITOL"
	 kb:NAT_ID="12766"
	 kb:STRENGTH="25.0"
	 kb:UNITS="MG"
	 kb:VA_NAME="MIGLITOL 25MG TAB"
	 rdfs:label="MIGLITOL 25MG TAB"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_224"
	 kb:Classification="ORAL HYPOGLYCEMIC AGENTS,ORAL"
	 kb:Code="HS502"
	 kb:GENERIC_NAME="MIGLITOL"
	 kb:NAT_ID="12767"
	 kb:STRENGTH="50.0"
	 kb:UNITS="MG"
	 kb:VA_NAME="MIGLITOL 50MG TAB"
	 rdfs:label="MIGLITOL 50MG TAB"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_225"
	 kb:Classification="ORAL HYPOGLYCEMIC AGENTS,ORAL"
	 kb:Code="HS502"
	 kb:GENERIC_NAME="NATEGLINIDE"
	 kb:NAT_ID="14941"
	 kb:STRENGTH="120.0"
	 kb:UNITS="MG"
	 kb:VA_NAME="NATEGLINIDE 120MG TAB"
	 rdfs:label="NATEGLINIDE 120MG TAB"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_226"
	 kb:Classification="ORAL HYPOGLYCEMIC AGENTS,ORAL"
	 kb:Code="HS502"
	 kb:GENERIC_NAME="NATEGLINIDE"
	 kb:NAT_ID="14940"
	 kb:STRENGTH="60.0"
	 kb:UNITS="MG"
	 kb:VA_NAME="NATEGLINIDE 60MG TAB"
	 rdfs:label="NATEGLINIDE 60MG TAB"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_227"
	 kb:Classification="ORAL HYPOGLYCEMIC AGENTS,ORAL"
	 kb:Code="HS502"
	 kb:GENERIC_NAME="PIOGLITAZONE"
	 kb:NAT_ID="13712"
	 kb:STRENGTH="15.0"
	 kb:UNITS="MG"
	 kb:VA_NAME="PIOGLITAZONE HCL 15MG TAB"
	 rdfs:label="PIOGLITAZONE HCL 15MG TAB"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_228"
	 kb:Classification="ORAL HYPOGLYCEMIC AGENTS,ORAL"
	 kb:Code="HS502"
	 kb:GENERIC_NAME="PIOGLITAZONE"
	 kb:NAT_ID="13713"
	 kb:STRENGTH="30.0"
	 kb:UNITS="MG"
	 kb:VA_NAME="PIOGLITAZONE HCL 30MG TAB"
	 rdfs:label="PIOGLITAZONE HCL 30MG TAB"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_229"
	 kb:Classification="ORAL HYPOGLYCEMIC AGENTS,ORAL"
	 kb:Code="HS502"
	 kb:GENERIC_NAME="PIOGLITAZONE"
	 kb:NAT_ID="13714"
	 kb:STRENGTH="45.0"
	 kb:UNITS="MG"
	 kb:VA_NAME="PIOGLITAZONE HCL 45MG TAB"
	 rdfs:label="PIOGLITAZONE HCL 45MG TAB"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_23"
	 kb:Classification="INSULIN"
	 kb:Code="HS501"
	 kb:NAT_ID="66205492"
	 kb:UNITS="VI"
	 kb:VA_NAME="INSULIN NPH BEEF/PORK 100 U/ML INJ LILLY"
	 rdfs:label="INSULIN NPH BEEF/PORK 100 U/ML INJ LILLY"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_230"
	 kb:Classification="ORAL HYPOGLYCEMIC AGENTS,ORAL"
	 kb:Code="HS502"
	 kb:GENERIC_NAME="REPAGLINIDE"
	 kb:NAT_ID="12899"
	 kb:STRENGTH="0.5"
	 kb:UNITS="MG"
	 kb:VA_NAME="REPAGLINIDE 0.5MG TAB"
	 rdfs:label="REPAGLINIDE 0.5MG TAB"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_231"
	 kb:Classification="ORAL HYPOGLYCEMIC AGENTS,ORAL"
	 kb:Code="HS502"
	 kb:GENERIC_NAME="REPAGLINIDE"
	 kb:NAT_ID="12900"
	 kb:STRENGTH="1.0"
	 kb:UNITS="MG"
	 kb:VA_NAME="REPAGLINIDE 1MG TAB"
	 rdfs:label="REPAGLINIDE 1MG TAB"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_232"
	 kb:Classification="ORAL HYPOGLYCEMIC AGENTS,ORAL"
	 kb:Code="HS502"
	 kb:GENERIC_NAME="REPAGLINIDE"
	 kb:NAT_ID="12901"
	 kb:STRENGTH="2.0"
	 kb:UNITS="MG"
	 kb:VA_NAME="REPAGLINIDE 2MG TAB"
	 rdfs:label="REPAGLINIDE 2MG TAB"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_233"
	 kb:Classification="ORAL HYPOGLYCEMIC AGENTS,ORAL"
	 kb:Code="HS502"
	 kb:GENERIC_NAME="ROSIGLITAZONE"
	 kb:NAT_ID="13507"
	 kb:STRENGTH="2.0"
	 kb:UNITS="MG"
	 kb:VA_NAME="ROSIGLITAZONE MALEATE 2MG TAB"
	 rdfs:label="ROSIGLITAZONE MALEATE 2MG TAB"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_234"
	 kb:Classification="ORAL HYPOGLYCEMIC AGENTS,ORAL"
	 kb:Code="HS502"
	 kb:GENERIC_NAME="ROSIGLITAZONE"
	 kb:NAT_ID="13508"
	 kb:STRENGTH="4.0"
	 kb:UNITS="MG"
	 kb:VA_NAME="ROSIGLITAZONE MALEATE 4MG TAB"
	 rdfs:label="ROSIGLITAZONE MALEATE 4MG TAB"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_235"
	 kb:Classification="ORAL HYPOGLYCEMIC AGENTS,ORAL"
	 kb:Code="HS502"
	 kb:GENERIC_NAME="ROSIGLITAZONE"
	 kb:NAT_ID="13509"
	 kb:STRENGTH="8.0"
	 kb:UNITS="MG"
	 kb:VA_NAME="ROSIGLITAZONE MALEATE 8MG TAB"
	 rdfs:label="ROSIGLITAZONE MALEATE 8MG TAB"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_236"
	 kb:Classification="ORAL HYPOGLYCEMIC AGENTS,ORAL"
	 kb:Code="HS502"
	 kb:GENERIC_NAME="SITAGLIPTIN"
	 kb:NAT_ID="18010"
	 kb:STRENGTH="100.0"
	 kb:UNITS="MG"
	 kb:VA_NAME="SITAGLIPTIN PHOSPHATE 100MG TAB"
	 rdfs:label="SITAGLIPTIN PHOSPHATE 100MG TAB"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_237"
	 kb:Classification="ORAL HYPOGLYCEMIC AGENTS,ORAL"
	 kb:Code="HS502"
	 kb:GENERIC_NAME="SITAGLIPTIN"
	 kb:NAT_ID="18006"
	 kb:STRENGTH="25.0"
	 kb:UNITS="MG"
	 kb:VA_NAME="SITAGLIPTIN PHOSPHATE 25MG TAB"
	 rdfs:label="SITAGLIPTIN PHOSPHATE 25MG TAB"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_238"
	 kb:Classification="ORAL HYPOGLYCEMIC AGENTS,ORAL"
	 kb:Code="HS502"
	 kb:GENERIC_NAME="SITAGLIPTIN"
	 kb:NAT_ID="18008"
	 kb:STRENGTH="50.0"
	 kb:UNITS="MG"
	 kb:VA_NAME="SITAGLIPTIN PHOSPHATE 50MG TAB"
	 rdfs:label="SITAGLIPTIN PHOSPHATE 50MG TAB"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_239"
	 kb:Classification="ORAL HYPOGLYCEMIC AGENTS,ORAL"
	 kb:Code="HS502"
	 kb:GENERIC_NAME="TOLAZAMIDE"
	 kb:NAT_ID="1779"
	 kb:STRENGTH="100.0"
	 kb:UNITS="MG"
	 kb:VA_NAME="TOLAZAMIDE 100MG TAB"
	 rdfs:label="TOLAZAMIDE 100MG TAB"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_24"
	 kb:Classification="INSULIN"
	 kb:Code="HS501"
	 kb:GENERIC_NAME="INSULIN"
	 kb:NAT_ID="864"
	 kb:STRENGTH="100.0"
	 kb:UNITS="UNT/ML"
	 kb:VA_NAME="INSULIN NPH HUMAN 100 U/ML INJ HUMULIN N"
	 rdfs:label="INSULIN NPH HUMAN 100 U/ML INJ HUMULIN N"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_240"
	 kb:Classification="ORAL HYPOGLYCEMIC AGENTS,ORAL"
	 kb:Code="HS502"
	 kb:GENERIC_NAME="TOLAZAMIDE"
	 kb:NAT_ID="1782"
	 kb:STRENGTH="250.0"
	 kb:UNITS="MG"
	 kb:VA_NAME="TOLAZAMIDE 250MG CAP"
	 rdfs:label="TOLAZAMIDE 250MG CAP"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_241"
	 kb:Classification="ORAL HYPOGLYCEMIC AGENTS,ORAL"
	 kb:Code="HS502"
	 kb:GENERIC_NAME="TOLAZAMIDE"
	 kb:NAT_ID="1780"
	 kb:STRENGTH="250.0"
	 kb:UNITS="MG"
	 kb:VA_NAME="TOLAZAMIDE 250MG TAB"
	 rdfs:label="TOLAZAMIDE 250MG TAB"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_242"
	 kb:Classification="ORAL HYPOGLYCEMIC AGENTS,ORAL"
	 kb:Code="HS502"
	 kb:GENERIC_NAME="TOLAZAMIDE"
	 kb:NAT_ID="1781"
	 kb:STRENGTH="500.0"
	 kb:UNITS="MG"
	 kb:VA_NAME="TOLAZAMIDE 500MG TAB"
	 rdfs:label="TOLAZAMIDE 500MG TAB"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_243"
	 kb:Classification="ORAL HYPOGLYCEMIC AGENTS,ORAL"
	 kb:Code="HS502"
	 kb:GENERIC_NAME="TOLBUTAMIDE"
	 kb:NAT_ID="2079"
	 kb:STRENGTH="250.0"
	 kb:UNITS="MG"
	 kb:VA_NAME="TOLBUTAMIDE 250MG TAB"
	 rdfs:label="TOLBUTAMIDE 250MG TAB"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_244"
	 kb:Classification="ORAL HYPOGLYCEMIC AGENTS,ORAL"
	 kb:Code="HS502"
	 kb:GENERIC_NAME="TOLBUTAMIDE"
	 kb:NAT_ID="2078"
	 kb:STRENGTH="500.0"
	 kb:UNITS="MG"
	 kb:VA_NAME="TOLBUTAMIDE 500MG TAB"
	 rdfs:label="TOLBUTAMIDE 500MG TAB"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_245"
	 kb:Classification="ORAL HYPOGLYCEMIC AGENTS,ORAL"
	 kb:Code="HS502"
	 kb:GENERIC_NAME="TROGLITAZONE"
	 kb:NAT_ID="12592"
	 kb:STRENGTH="200.0"
	 kb:UNITS="MG"
	 kb:VA_NAME="TROGLITAZONE 200MG TAB"
	 rdfs:label="TROGLITAZONE 200MG TAB"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_246"
	 kb:Classification="ORAL HYPOGLYCEMIC AGENTS,ORAL"
	 kb:Code="HS502"
	 kb:NAT_ID="64026672"
	 kb:UNITS="TAB"
	 kb:VA_NAME="TROGLITAZONE 200MG TAB"
	 rdfs:label="TROGLITAZONE 200MG TAB"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_247"
	 kb:Classification="ORAL HYPOGLYCEMIC AGENTS,ORAL"
	 kb:Code="HS502"
	 kb:NAT_ID="64026884"
	 kb:UNITS="TAB"
	 kb:VA_NAME="TROGLITAZONE 300MG TAB"
	 rdfs:label="TROGLITAZONE 300MG TAB"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_248"
	 kb:Classification="ORAL HYPOGLYCEMIC AGENTS,ORAL"
	 kb:Code="HS502"
	 kb:GENERIC_NAME="TROGLITAZONE"
	 kb:NAT_ID="12594"
	 kb:STRENGTH="300.0"
	 kb:UNITS="MG"
	 kb:VA_NAME="TROGLITAZONE 300MG TAB"
	 rdfs:label="TROGLITAZONE 300MG TAB"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_249"
	 kb:Classification="ORAL HYPOGLYCEMIC AGENTS,ORAL"
	 kb:Code="HS502"
	 kb:GENERIC_NAME="TROGLITAZONE"
	 kb:NAT_ID="12593"
	 kb:STRENGTH="400.0"
	 kb:UNITS="MG"
	 kb:VA_NAME="TROGLITAZONE 400MG TAB"
	 rdfs:label="TROGLITAZONE 400MG TAB"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_25"
	 kb:Classification="INSULIN"
	 kb:Code="HS501"
	 kb:GENERIC_NAME="INSULIN"
	 kb:NAT_ID="16200"
	 kb:STRENGTH="100.0"
	 kb:UNITS="UNT/ML"
	 kb:VA_NAME="INSULIN NPH HUMAN 100 U/ML INJ INNOLET 3ML"
	 rdfs:label="INSULIN NPH HUMAN 100 U/ML INJ INNOLET 3ML"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_250"
	 kb:Classification="ORAL HYPOGLYCEMIC AGENTS,ORAL"
	 kb:Code="HS502"
	 kb:NAT_ID="64026716"
	 kb:UNITS="TAB"
	 kb:VA_NAME="TROGLITAZONE 400MG TAB"
	 rdfs:label="TROGLITAZONE 400MG TAB"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_251"
	 kb:Classification="ORAL HYPOGLYCEMIC AGENTS,ORAL"
	 kb:Code="HS502"
	 kb:NAT_ID="66203736"
	 kb:UNITS="TAB"
	 kb:VA_NAME="ZZ-CHLORPROPAMIDE 250MG TAB U/D"
	 rdfs:label="ZZ-CHLORPROPAMIDE 250MG TAB U/D"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_252"
	 kb:Classification="ORAL HYPOGLYCEMIC AGENTS,ORAL"
	 kb:Code="HS502"
	 kb:NAT_ID="66204172"
	 kb:UNITS="TAB"
	 kb:VA_NAME="ZZ-TOLBUTAMIDE 250MG TAB"
	 rdfs:label="ZZ-TOLBUTAMIDE 250MG TAB"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_253"
	 kb:Classification="ORAL HYPOGLYCEMIC AGENTS,ORAL"
	 kb:Code="HS502"
	 kb:NAT_ID="61204064"
	 kb:UNITS="TAB"
	 kb:VA_NAME="ZZZ TOLAZAMIDE 100MG TAB"
	 rdfs:label="ZZZ TOLAZAMIDE 100MG TAB"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_254"
	 kb:Classification="ORAL HYPOGLYCEMIC AGENTS,ORAL"
	 kb:Code="HS502"
	 kb:NAT_ID="61204204"
	 kb:UNITS="TAB"
	 kb:VA_NAME="ZZZ TOLBUTAMIDE 250MG TABS"
	 rdfs:label="ZZZ TOLBUTAMIDE 250MG TABS"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_255"
	 kb:Classification="ORAL HYPOGLYCEMIC AGENTS,ORAL"
	 kb:Code="HS502"
	 kb:NAT_ID="61206420"
	 kb:UNITS="TAB"
	 kb:VA_NAME="ZZZ TROGLITAZONE 200MG TAB"
	 rdfs:label="ZZZ TROGLITAZONE 200MG TAB"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_256"
	 kb:Classification="ORAL HYPOGLYCEMIC AGENTS,ORAL"
	 kb:Code="HS502"
	 kb:NAT_ID="61206752"
	 kb:UNITS="TAB"
	 kb:VA_NAME="ZZZ TROGLITAZONE 300MG TAB"
	 rdfs:label="ZZZ TROGLITAZONE 300MG TAB"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_257"
	 kb:Classification="ORAL HYPOGLYCEMIC AGENTS,ORAL"
	 kb:Code="HS502"
	 kb:NAT_ID="61206572"
	 kb:UNITS="TAB"
	 kb:VA_NAME="ZZZ TROGLITAZONE 400MG TAB"
	 rdfs:label="ZZZ TROGLITAZONE 400MG TAB"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_258"
	 kb:Classification="ORAL HYPOGLYCEMIC AGENTS,ORAL"
	 kb:Code="HS502"
	 kb:NAT_ID="64001240"
	 kb:UNITS="TAB"
	 kb:VA_NAME="ZZZCHLORPROPAMIDE U/D 100 MG TAB"
	 rdfs:label="ZZZCHLORPROPAMIDE U/D 100 MG TAB"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_259"
	 kb:Classification="ORAL HYPOGLYCEMIC AGENTS,ORAL"
	 kb:Code="HS502"
	 kb:NAT_ID="64027136"
	 kb:UNITS="TAB"
	 kb:VA_NAME="ZZZGLUCOTROL(BRAND NAME) 5MG TAB"
	 rdfs:label="ZZZGLUCOTROL(BRAND NAME) 5MG TAB"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_26"
	 kb:Classification="INSULIN"
	 kb:Code="HS501"
	 kb:GENERIC_NAME="INSULIN"
	 kb:NAT_ID="875"
	 kb:STRENGTH="100.0"
	 kb:UNITS="UNT/ML"
	 kb:VA_NAME="INSULIN NPH HUMAN 100 U/ML INJ NOVOLIN N"
	 rdfs:label="INSULIN NPH HUMAN 100 U/ML INJ NOVOLIN N"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_260"
	 kb:Classification="ORAL HYPOGLYCEMIC AGENTS,ORAL"
	 kb:Code="HS502"
	 kb:NAT_ID="64028004"
	 kb:VA_NAME="ZZZGLY 5/METFORMIN 500"
	 rdfs:label="ZZZGLY 5/METFORMIN 500"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_261"
	 kb:Classification="ORAL HYPOGLYCEMIC AGENTS,ORAL"
	 kb:Code="HS502"
	 kb:NAT_ID="64001044"
	 kb:UNITS="TAB"
	 kb:VA_NAME="ZZZTOLBUTAMIDE 250 MG TAB"
	 rdfs:label="ZZZTOLBUTAMIDE 250 MG TAB"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_262"
	 kb:Classification="ORAL HYPOGLYCEMIC AGENTS,ORAL"
	 kb:Code="HS502"
	 kb:NAT_ID="64001264"
	 kb:UNITS="TAB"
	 kb:VA_NAME="ZZZU/D GLIPIZIDE  10 MG TAB"
	 rdfs:label="ZZZU/D GLIPIZIDE  10 MG TAB"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_263"
	 kb:Classification="ORAL HYPOGLYCEMIC AGENTS,ORAL"
	 kb:Code="HS502"
	 kb:NAT_ID="64001264"
	 kb:UNITS="TAB"
	 kb:VA_NAME="ZZZU/D GLIPIZIDE  5 MG TAB"
	 rdfs:label="ZZZU/D GLIPIZIDE  5 MG TAB"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_27"
	 kb:Classification="INSULIN"
	 kb:Code="HS501"
	 kb:GENERIC_NAME="INSULIN"
	 kb:NAT_ID="876"
	 kb:STRENGTH="100.0"
	 kb:UNITS="UNT/ML"
	 kb:VA_NAME="INSULIN NPH HUMAN 100 U/ML INJ PEN 1.5ML"
	 rdfs:label="INSULIN NPH HUMAN 100 U/ML INJ PEN 1.5ML"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_28"
	 kb:Classification="INSULIN"
	 kb:Code="HS501"
	 kb:NAT_ID="61206776"
	 kb:UNITS="VI"
	 kb:VA_NAME="INSULIN NPH HUMAN 100 U/ML INJ PEN 1.5ML"
	 rdfs:label="INSULIN NPH HUMAN 100 U/ML INJ PEN 1.5ML"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_29"
	 kb:Classification="INSULIN"
	 kb:Code="HS501"
	 kb:NAT_ID="66207336"
	 kb:UNITS="VI"
	 kb:VA_NAME="INSULIN NPH HUMAN 100 U/ML INJ PEN 1.5ML"
	 rdfs:label="INSULIN NPH HUMAN 100 U/ML INJ PEN 1.5ML"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_3"
	 kb:Classification="INSULIN"
	 kb:Code="HS501"
	 kb:GENERIC_NAME="INSULIN"
	 kb:NAT_ID="891"
	 kb:STRENGTH="100.0"
	 kb:UNITS="UNT/ML"
	 kb:VA_NAME="INSULIN HUMULIN 70/30 (NPH/REG) INJ CARTRIDGE,1.5ML"
	 rdfs:label="INSULIN HUMULIN 70/30 (NPH/REG) INJ CARTRIDGE,1.5ML"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_30"
	 kb:Classification="INSULIN"
	 kb:Code="HS501"
	 kb:GENERIC_NAME="INSULIN"
	 kb:NAT_ID="13352"
	 kb:STRENGTH="100.0"
	 kb:UNITS="UNT/ML"
	 kb:VA_NAME="INSULIN NPH HUMAN 100 U/ML INJ PEN 3ML"
	 rdfs:label="INSULIN NPH HUMAN 100 U/ML INJ PEN 3ML"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_31"
	 kb:Classification="INSULIN"
	 kb:Code="HS501"
	 kb:GENERIC_NAME="INSULIN"
	 kb:NAT_ID="16199"
	 kb:STRENGTH="100.0"
	 kb:UNITS="UNT/ML"
	 kb:VA_NAME="INSULIN NPH HUMAN 100 U/ML INJ SYRINGE 1.5ML"
	 rdfs:label="INSULIN NPH HUMAN 100 U/ML INJ SYRINGE 1.5ML"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_32"
	 kb:Classification="INSULIN"
	 kb:Code="HS501"
	 kb:GENERIC_NAME="INSULIN"
	 kb:NAT_ID="890"
	 kb:STRENGTH="100.0"
	 kb:UNITS="UNT/ML"
	 kb:VA_NAME="INSULIN NPH HUMULIN-N 100 U/ML INJ CARTRIDGE,1.5ML"
	 rdfs:label="INSULIN NPH HUMULIN-N 100 U/ML INJ CARTRIDGE,1.5ML"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_33"
	 kb:Classification="INSULIN"
	 kb:Code="HS501"
	 kb:GENERIC_NAME="INSULIN"
	 kb:NAT_ID="13484"
	 kb:STRENGTH="100.0"
	 kb:UNITS="UNT/ML"
	 kb:VA_NAME="INSULIN NPH HUMULIN-N 100 U/ML INJ PEN 3ML"
	 rdfs:label="INSULIN NPH HUMULIN-N 100 U/ML INJ PEN 3ML"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_34"
	 kb:Classification="INSULIN"
	 kb:Code="HS501"
	 kb:GENERIC_NAME="INSULIN"
	 kb:NAT_ID="13485"
	 kb:STRENGTH="100.0"
	 kb:UNITS="UNT/ML"
	 kb:VA_NAME="INSULIN NPH NOVOLIN-N 100 U/ML INJ PEN 3ML"
	 rdfs:label="INSULIN NPH NOVOLIN-N 100 U/ML INJ PEN 3ML"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_35"
	 kb:Classification="INSULIN"
	 kb:Code="HS501"
	 kb:GENERIC_NAME="INSULIN"
	 kb:NAT_ID="863"
	 kb:STRENGTH="100.0"
	 kb:UNITS="UNT/ML"
	 kb:VA_NAME="INSULIN NPH PURE PORK 100 U/ML INJ LILLY"
	 rdfs:label="INSULIN NPH PURE PORK 100 U/ML INJ LILLY"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_36"
	 kb:Classification="INSULIN"
	 kb:Code="HS501"
	 kb:NAT_ID="61200964"
	 kb:UNITS="VI"
	 kb:VA_NAME="INSULIN NPH PURE PORK 100 U/ML INJ LILLY"
	 rdfs:label="INSULIN NPH PURE PORK 100 U/ML INJ LILLY"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_37"
	 kb:Classification="INSULIN"
	 kb:Code="HS501"
	 kb:GENERIC_NAME="INSULIN"
	 kb:NAT_ID="882"
	 kb:STRENGTH="100.0"
	 kb:UNITS="UNT/ML"
	 kb:VA_NAME="INSULIN NPH PURE PORK 100 U/ML INJ NOVO"
	 rdfs:label="INSULIN NPH PURE PORK 100 U/ML INJ NOVO"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_38"
	 kb:Classification="INSULIN"
	 kb:Code="HS501"
	 kb:NAT_ID="64000888"
	 kb:UNITS="VI"
	 kb:VA_NAME="INSULIN NPH PURE PORK 100 UNIT/ML LILLY"
	 rdfs:label="INSULIN NPH PURE PORK 100 UNIT/ML LILLY"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_39"
	 kb:Classification="INSULIN"
	 kb:Code="HS501"
	 kb:NAT_ID="66200964"
	 kb:UNITS="VI"
	 kb:VA_NAME="INSULIN NPH PURE PORK 100 UNIT/ML LILLY"
	 rdfs:label="INSULIN NPH PURE PORK 100 UNIT/ML LILLY"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_4"
	 kb:Classification="INSULIN"
	 kb:Code="HS501"
	 kb:GENERIC_NAME="INSULIN"
	 kb:NAT_ID="869"
	 kb:VA_NAME="INSULIN HUMULIN 70/30 (NPH/REG) INJ LILY"
	 rdfs:label="INSULIN HUMULIN 70/30 (NPH/REG) INJ LILY"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_40"
	 kb:Classification="INSULIN"
	 kb:Code="HS501"
	 kb:NAT_ID="61200960"
	 kb:UNITS="VI"
	 kb:VA_NAME="INSULIN NPH U-100 BEEF 10ML"
	 rdfs:label="INSULIN NPH U-100 BEEF 10ML"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_41"
	 kb:Classification="INSULIN"
	 kb:Code="HS501"
	 kb:GENERIC_NAME="INSULIN"
	 kb:NAT_ID="858"
	 kb:STRENGTH="100.0"
	 kb:UNITS="UNT/ML"
	 kb:VA_NAME="INSULIN REG BEEF/PORK 100 U/ML INJ LILLY"
	 rdfs:label="INSULIN REG BEEF/PORK 100 U/ML INJ LILLY"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_42"
	 kb:Classification="INSULIN"
	 kb:Code="HS501"
	 kb:GENERIC_NAME="INSULIN"
	 kb:NAT_ID="860"
	 kb:STRENGTH="100.0"
	 kb:UNITS="UNT/ML"
	 kb:VA_NAME="INSULIN REG HUMAN 100 U/ML INJ HUMULIN R"
	 rdfs:label="INSULIN REG HUMAN 100 U/ML INJ HUMULIN R"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_43"
	 kb:Classification="INSULIN"
	 kb:Code="HS501"
	 kb:GENERIC_NAME="INSULIN"
	 kb:NAT_ID="16370"
	 kb:VA_NAME="INSULIN REG HUMAN 100 U/ML INJ INNOLET 3ML"
	 rdfs:label="INSULIN REG HUMAN 100 U/ML INJ INNOLET 3ML"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_44"
	 kb:Classification="INSULIN"
	 kb:Code="HS501"
	 kb:GENERIC_NAME="INSULIN"
	 kb:NAT_ID="873"
	 kb:STRENGTH="100.0"
	 kb:UNITS="UNT/ML"
	 kb:VA_NAME="INSULIN REG HUMAN 100 U/ML INJ NOVOLIN R"
	 rdfs:label="INSULIN REG HUMAN 100 U/ML INJ NOVOLIN R"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_45"
	 kb:Classification="INSULIN"
	 kb:Code="HS501"
	 kb:GENERIC_NAME="INSULIN"
	 kb:NAT_ID="874"
	 kb:STRENGTH="100.0"
	 kb:UNITS="UNT/ML"
	 kb:VA_NAME="INSULIN REG HUMAN 100 U/ML INJ PEN 1.5ML"
	 rdfs:label="INSULIN REG HUMAN 100 U/ML INJ PEN 1.5ML"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_46"
	 kb:Classification="INSULIN"
	 kb:Code="HS501"
	 kb:NAT_ID="61206776"
	 kb:UNITS="EA"
	 kb:VA_NAME="INSULIN REG HUMAN 100 U/ML INJ PEN 1.5ML"
	 rdfs:label="INSULIN REG HUMAN 100 U/ML INJ PEN 1.5ML"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_47"
	 kb:Classification="INSULIN"
	 kb:Code="HS501"
	 kb:NAT_ID="66207336"
	 kb:UNITS="EA"
	 kb:VA_NAME="INSULIN REG HUMAN 100 U/ML INJ PEN 1.5ML"
	 rdfs:label="INSULIN REG HUMAN 100 U/ML INJ PEN 1.5ML"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_48"
	 kb:Classification="INSULIN"
	 kb:Code="HS501"
	 kb:GENERIC_NAME="INSULIN"
	 kb:NAT_ID="872"
	 kb:STRENGTH="100.0"
	 kb:UNITS="UNT/ML"
	 kb:VA_NAME="INSULIN REG HUMAN 100 U/ML INJ VELOSULIN"
	 rdfs:label="INSULIN REG HUMAN 100 U/ML INJ VELOSULIN"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_49"
	 kb:Classification="INSULIN"
	 kb:Code="HS501"
	 kb:GENERIC_NAME="INSULIN"
	 kb:NAT_ID="861"
	 kb:STRENGTH="100.0"
	 kb:UNITS="UNT/ML"
	 kb:VA_NAME="INSULIN REG HUMULIN BUFFERED 100 U/ML INJ"
	 rdfs:label="INSULIN REG HUMULIN BUFFERED 100 U/ML INJ"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_5"
	 kb:Classification="INSULIN"
	 kb:Code="HS501"
	 kb:GENERIC_NAME="INSULIN"
	 kb:NAT_ID="13351"
	 kb:VA_NAME="INSULIN HUMULIN 70/30 (NPH/REG) INJ PEN,3ML"
	 rdfs:label="INSULIN HUMULIN 70/30 (NPH/REG) INJ PEN,3ML"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_50"
	 kb:Classification="INSULIN"
	 kb:Code="HS501"
	 kb:GENERIC_NAME="INSULIN"
	 kb:NAT_ID="889"
	 kb:STRENGTH="100.0"
	 kb:UNITS="UNT/ML"
	 kb:VA_NAME="INSULIN REG HUMULIN-R 100 U/ML CARTRIDGE,1.5ML"
	 rdfs:label="INSULIN REG HUMULIN-R 100 U/ML CARTRIDGE,1.5ML"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_51"
	 kb:Classification="INSULIN"
	 kb:Code="HS501"
	 kb:GENERIC_NAME="INSULIN"
	 kb:NAT_ID="859"
	 kb:STRENGTH="100.0"
	 kb:UNITS="UNT/ML"
	 kb:VA_NAME="INSULIN REG PURE PORK 100 U/ML INJ LILLY"
	 rdfs:label="INSULIN REG PURE PORK 100 U/ML INJ LILLY"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_52"
	 kb:Classification="INSULIN"
	 kb:Code="HS501"
	 kb:GENERIC_NAME="INSULIN"
	 kb:NAT_ID="880"
	 kb:STRENGTH="100.0"
	 kb:UNITS="UNT/ML"
	 kb:VA_NAME="INSULIN REG PURE PORK 100 U/ML INJ NOVO"
	 rdfs:label="INSULIN REG PURE PORK 100 U/ML INJ NOVO"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_53"
	 kb:Classification="INSULIN"
	 kb:Code="HS501"
	 kb:NAT_ID="66200968"
	 kb:UNITS="VI"
	 kb:VA_NAME="INSULIN REG PURE PORK 100 UNIT/ML LILLY"
	 rdfs:label="INSULIN REG PURE PORK 100 UNIT/ML LILLY"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_54"
	 kb:Classification="INSULIN"
	 kb:Code="HS501"
	 kb:GENERIC_NAME="INSULIN"
	 kb:NAT_ID="13486"
	 kb:STRENGTH="100.0"
	 kb:UNITS="UNT/ML"
	 kb:VA_NAME="INSULIN REGULAR NOVOLIN-R 100 U/ML PEN 3ML"
	 rdfs:label="INSULIN REGULAR NOVOLIN-R 100 U/ML PEN 3ML"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_55"
	 kb:Classification="INSULIN"
	 kb:Code="HS501"
	 kb:GENERIC_NAME="INSULIN"
	 kb:NAT_ID="883"
	 kb:STRENGTH="100.0"
	 kb:UNITS="UNT/ML"
	 kb:VA_NAME="INSULIN REGULAR PORK 100 U/ML INJ NOVO"
	 rdfs:label="INSULIN REGULAR PORK 100 U/ML INJ NOVO"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_56"
	 kb:Classification="INSULIN"
	 kb:Code="HS501"
	 kb:NAT_ID="61200968"
	 kb:UNITS="VI"
	 kb:VA_NAME="INSULIN REGULAR U-100 BEEF 10ML"
	 rdfs:label="INSULIN REGULAR U-100 BEEF 10ML"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_57"
	 kb:Classification="INSULIN"
	 kb:Code="HS501"
	 kb:NAT_ID="61200964"
	 kb:UNITS="VI"
	 kb:VA_NAME="INSULIN REGULAR U-100 PORK 10ML"
	 rdfs:label="INSULIN REGULAR U-100 PORK 10ML"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_58"
	 kb:Classification="INSULIN"
	 kb:Code="HS501"
	 kb:GENERIC_NAME="INSULIN"
	 kb:NAT_ID="886"
	 kb:STRENGTH="100.0"
	 kb:UNITS="UNT/ML"
	 kb:VA_NAME="INSULIN ULTRALENTE BEEF 100 U/ML IJ NOVO"
	 rdfs:label="INSULIN ULTRALENTE BEEF 100 U/ML IJ NOVO"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_59"
	 kb:Classification="INSULIN"
	 kb:Code="HS501"
	 kb:NAT_ID="61206172"
	 kb:UNITS="VI"
	 kb:VA_NAME="INSULIN ULTRALENTE HUMULIN U 100 U/ML IJ"
	 rdfs:label="INSULIN ULTRALENTE HUMULIN U 100 U/ML IJ"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_6"
	 kb:Classification="INSULIN"
	 kb:Code="HS501"
	 kb:GENERIC_NAME="INSULIN"
	 kb:NAT_ID="885"
	 kb:STRENGTH="100.0"
	 kb:UNITS="UNT/ML"
	 kb:VA_NAME="INSULIN LENTE BEEF 100 U/ML INJ NOVO"
	 rdfs:label="INSULIN LENTE BEEF 100 U/ML INJ NOVO"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_60"
	 kb:Classification="INSULIN"
	 kb:Code="HS501"
	 kb:NAT_ID="64025204"
	 kb:UNITS="VI"
	 kb:VA_NAME="INSULIN ULTRALENTE HUMULIN U 100 U/ML IJ"
	 rdfs:label="INSULIN ULTRALENTE HUMULIN U 100 U/ML IJ"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_61"
	 kb:Classification="INSULIN"
	 kb:Code="HS501"
	 kb:GENERIC_NAME="INSULIN"
	 kb:NAT_ID="868"
	 kb:STRENGTH="100.0"
	 kb:UNITS="UNT/ML"
	 kb:VA_NAME="INSULIN ULTRALENTE HUMULIN U 100 U/ML INJ"
	 rdfs:label="INSULIN ULTRALENTE HUMULIN U 100 U/ML INJ"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_62"
	 kb:Classification="INSULIN"
	 kb:Code="HS501"
	 kb:NAT_ID="66203432"
	 kb:UNITS="VI"
	 kb:VA_NAME="INSULIN ULTRALENTE HUMULIN U 100 UNIT/ML"
	 rdfs:label="INSULIN ULTRALENTE HUMULIN U 100 UNIT/ML"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_63"
	 kb:Classification="INSULIN"
	 kb:Code="HS501"
	 kb:NAT_ID="64026588"
	 kb:UNITS="VI"
	 kb:VA_NAME="INSULIN VELOS REG HUM 100U/ML INJ"
	 rdfs:label="INSULIN VELOS REG HUM 100U/ML INJ"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_64"
	 kb:Classification="INSULIN"
	 kb:Code="HS501"
	 kb:NAT_ID="64002016"
	 kb:UNITS="VI"
	 kb:VA_NAME="INSULIN, (NORDISK)NPH, U-100"
	 rdfs:label="INSULIN, (NORDISK)NPH, U-100"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_65"
	 kb:Classification="INSULIN"
	 kb:Code="HS501"
	 kb:NAT_ID="64002016"
	 kb:UNITS="VI"
	 kb:VA_NAME="INSULIN, (NORDISK)REGULAR, U-100"
	 rdfs:label="INSULIN, (NORDISK)REGULAR, U-100"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_66"
	 kb:Classification="INSULIN"
	 kb:Code="HS501"
	 kb:NAT_ID="64000896"
	 kb:UNITS="VI"
	 kb:VA_NAME="INSULIN, (PORK)REGULAR, U-100"
	 rdfs:label="INSULIN, (PORK)REGULAR, U-100"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_67"
	 kb:Classification="INSULIN"
	 kb:Code="HS501"
	 kb:GENERIC_NAME="INSULIN"
	 kb:NAT_ID="16665"
	 kb:STRENGTH="100.0"
	 kb:UNITS="UNT/ML"
	 kb:VA_NAME="INSULIN,ASPART,HUMAN 100 UNIT/ML INJ,PENFILL,3ML"
	 rdfs:label="INSULIN,ASPART,HUMAN 100 UNIT/ML INJ,PENFILL,3ML"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_68"
	 kb:Classification="INSULIN"
	 kb:Code="HS501"
	 kb:GENERIC_NAME="INSULIN"
	 kb:NAT_ID="14591"
	 kb:STRENGTH="100.0"
	 kb:UNITS="UNT/ML"
	 kb:VA_NAME="INSULIN,ASPART,HUMAN 100 UNT/ML INJ"
	 rdfs:label="INSULIN,ASPART,HUMAN 100 UNT/ML INJ"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_69"
	 kb:Classification="INSULIN"
	 kb:Code="HS501"
	 kb:GENERIC_NAME="INSULIN"
	 kb:NAT_ID="14592"
	 kb:STRENGTH="100.0"
	 kb:UNITS="UNT/ML"
	 kb:VA_NAME="INSULIN,ASPART,HUMAN 100 UNT/ML INJ,CARTRIDGE,3ML"
	 rdfs:label="INSULIN,ASPART,HUMAN 100 UNT/ML INJ,CARTRIDGE,3ML"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_7"
	 kb:Classification="INSULIN"
	 kb:Code="HS501"
	 kb:GENERIC_NAME="INSULIN"
	 kb:NAT_ID="865"
	 kb:STRENGTH="100.0"
	 kb:UNITS="UNT/ML"
	 kb:VA_NAME="INSULIN LENTE BEEF/PORK 100 U/ML INJ LIL"
	 rdfs:label="INSULIN LENTE BEEF/PORK 100 U/ML INJ LIL"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_70"
	 kb:Classification="INSULIN"
	 kb:Code="HS501"
	 kb:GENERIC_NAME="INSULIN"
	 kb:NAT_ID="16280"
	 kb:STRENGTH="100.0"
	 kb:UNITS="UNT/ML"
	 kb:VA_NAME="INSULIN,ASPART,HUMAN 100U/ML,NOVOLOG,FLEXPEN,3ML"
	 rdfs:label="INSULIN,ASPART,HUMAN 100U/ML,NOVOLOG,FLEXPEN,3ML"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_71"
	 kb:Classification="INSULIN"
	 kb:Code="HS501"
	 kb:GENERIC_NAME="INSULIN"
	 kb:NAT_ID="16263"
	 kb:VA_NAME="INSULIN,ASPART,HUMAN 70/30 INJ,NOVOLOG"
	 rdfs:label="INSULIN,ASPART,HUMAN 70/30 INJ,NOVOLOG"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_72"
	 kb:Classification="INSULIN"
	 kb:Code="HS501"
	 kb:GENERIC_NAME="INSULIN"
	 kb:NAT_ID="16265"
	 kb:VA_NAME="INSULIN,ASPART,HUMAN 70/30 INJ,NOVOLOG,FLEXPEN,3ML"
	 rdfs:label="INSULIN,ASPART,HUMAN 70/30 INJ,NOVOLOG,FLEXPEN,3ML"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_73"
	 kb:Classification="INSULIN"
	 kb:Code="HS501"
	 kb:GENERIC_NAME="INSULIN"
	 kb:NAT_ID="16264"
	 kb:VA_NAME="INSULIN,ASPART,HUMAN 70/30 INJ,NOVOLOG,PENFILL,3ML"
	 rdfs:label="INSULIN,ASPART,HUMAN 70/30 INJ,NOVOLOG,PENFILL,3ML"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_74"
	 kb:Classification="INSULIN"
	 kb:Code="HS501"
	 kb:GENERIC_NAME="INSULIN"
	 kb:NAT_ID="17587"
	 kb:STRENGTH="100.0"
	 kb:UNITS="UNT/ML"
	 kb:VA_NAME="INSULIN,DETEMIR,HUMAN 100 UNIT/ML INJ"
	 rdfs:label="INSULIN,DETEMIR,HUMAN 100 UNIT/ML INJ"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_75"
	 kb:Classification="INSULIN"
	 kb:Code="HS501"
	 kb:GENERIC_NAME="INSULIN"
	 kb:NAT_ID="17588"
	 kb:STRENGTH="100.0"
	 kb:UNITS="UNT/ML"
	 kb:VA_NAME="INSULIN,DETEMIR,HUMAN 100 UNIT/ML INJ,FLEXPEN,3ML"
	 rdfs:label="INSULIN,DETEMIR,HUMAN 100 UNIT/ML INJ,FLEXPEN,3ML"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_76"
	 kb:Classification="INSULIN"
	 kb:Code="HS501"
	 kb:GENERIC_NAME="INSULIN"
	 kb:NAT_ID="18590"
	 kb:STRENGTH="100.0"
	 kb:UNITS="UNT/ML"
	 kb:VA_NAME="INSULIN,GLARGINE,HUMAN 100 UNIT/ML INJ,SOLOSTAR,3ML"
	 rdfs:label="INSULIN,GLARGINE,HUMAN 100 UNIT/ML INJ,SOLOSTAR,3ML"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_77"
	 kb:Classification="INSULIN"
	 kb:Code="HS501"
	 kb:GENERIC_NAME="INSULIN"
	 kb:NAT_ID="14476"
	 kb:STRENGTH="100.0"
	 kb:UNITS="UNT/ML"
	 kb:VA_NAME="INSULIN,GLARGINE,HUMAN 100 UNT/ML INJ"
	 rdfs:label="INSULIN,GLARGINE,HUMAN 100 UNT/ML INJ"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_78"
	 kb:Classification="INSULIN"
	 kb:Code="HS501"
	 kb:GENERIC_NAME="INSULIN"
	 kb:NAT_ID="14477"
	 kb:STRENGTH="100.0"
	 kb:UNITS="UNT/ML"
	 kb:VA_NAME="INSULIN,GLARGINE,HUMAN 100 UNT/ML INJ,CARTRIDGE,3ML"
	 rdfs:label="INSULIN,GLARGINE,HUMAN 100 UNT/ML INJ,CARTRIDGE,3ML"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_79"
	 kb:Classification="INSULIN"
	 kb:Code="HS501"
	 kb:GENERIC_NAME="INSULIN"
	 kb:NAT_ID="16746"
	 kb:STRENGTH="100.0"
	 kb:UNITS="UNT/ML"
	 kb:VA_NAME="INSULIN,GLULISINE,HUMAN 100 UNIT/ML INJ"
	 rdfs:label="INSULIN,GLULISINE,HUMAN 100 UNIT/ML INJ"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_8"
	 kb:Classification="INSULIN"
	 kb:Code="HS501"
	 kb:GENERIC_NAME="INSULIN"
	 kb:NAT_ID="867"
	 kb:STRENGTH="100.0"
	 kb:UNITS="UNT/ML"
	 kb:VA_NAME="INSULIN LENTE HUMAN 100 U/ML IJ HUMULN L"
	 rdfs:label="INSULIN LENTE HUMAN 100 U/ML IJ HUMULN L"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_80"
	 kb:Classification="INSULIN"
	 kb:Code="HS501"
	 kb:GENERIC_NAME="INSULIN"
	 kb:NAT_ID="17849"
	 kb:VA_NAME="INSULIN,HUMAN 1MG X 180/3MG X 90 INHL,ORAL,BLISTER,KIT"
	 rdfs:label="INSULIN,HUMAN 1MG X 180/3MG X 90 INHL,ORAL,BLISTER,KIT"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_81"
	 kb:Classification="INSULIN"
	 kb:Code="HS501"
	 kb:GENERIC_NAME="INSULIN"
	 kb:NAT_ID="17851"
	 kb:VA_NAME="INSULIN,HUMAN 1MG X 180/3MG X 90 INHL,ORAL,BLISTER,PKT"
	 rdfs:label="INSULIN,HUMAN 1MG X 180/3MG X 90 INHL,ORAL,BLISTER,PKT"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_82"
	 kb:Classification="INSULIN"
	 kb:Code="HS501"
	 kb:GENERIC_NAME="INSULIN"
	 kb:NAT_ID="17850"
	 kb:VA_NAME="INSULIN,HUMAN 1MG X 90/3MG X 90 INHL,ORAL,BLISTER,PKT"
	 rdfs:label="INSULIN,HUMAN 1MG X 90/3MG X 90 INHL,ORAL,BLISTER,PKT"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_83"
	 kb:Classification="INSULIN"
	 kb:Code="HS501"
	 kb:GENERIC_NAME="INSULIN"
	 kb:NAT_ID="850"
	 kb:STRENGTH="100.0"
	 kb:UNITS="UNT/ML"
	 kb:VA_NAME="INSULIN,LENTE,BEEF 100UNT/ML INJ"
	 rdfs:label="INSULIN,LENTE,BEEF 100UNT/ML INJ"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_84"
	 kb:Classification="INSULIN"
	 kb:Code="HS501"
	 kb:GENERIC_NAME="INSULIN"
	 kb:NAT_ID="835"
	 kb:STRENGTH="100.0"
	 kb:UNITS="UNT/ML"
	 kb:VA_NAME="INSULIN,LENTE,BEEF/PORK 100UNT/ML INJ"
	 rdfs:label="INSULIN,LENTE,BEEF/PORK 100UNT/ML INJ"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_85"
	 kb:Classification="INSULIN"
	 kb:Code="HS501"
	 kb:GENERIC_NAME="INSULIN"
	 kb:NAT_ID="838"
	 kb:STRENGTH="40.0"
	 kb:UNITS="UNT/ML"
	 kb:VA_NAME="INSULIN,LENTE,BEEF/PORK 40UNT/ML INJ"
	 rdfs:label="INSULIN,LENTE,BEEF/PORK 40UNT/ML INJ"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_86"
	 kb:Classification="INSULIN"
	 kb:Code="HS501"
	 kb:NAT_ID="64000884"
	 kb:UNITS="VI"
	 kb:VA_NAME="INSULIN,LENTE,BEEF/PORK U-100 INJ"
	 rdfs:label="INSULIN,LENTE,BEEF/PORK U-100 INJ"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_87"
	 kb:Classification="INSULIN"
	 kb:Code="HS501"
	 kb:GENERIC_NAME="INSULIN"
	 kb:NAT_ID="837"
	 kb:STRENGTH="100.0"
	 kb:UNITS="UNT/ML"
	 kb:VA_NAME="INSULIN,LENTE,BEEF/PURIFIED 100UNT/ML INJ"
	 rdfs:label="INSULIN,LENTE,BEEF/PURIFIED 100UNT/ML INJ"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_88"
	 kb:Classification="INSULIN"
	 kb:Code="HS501"
	 kb:GENERIC_NAME="INSULIN"
	 kb:NAT_ID="844"
	 kb:STRENGTH="100.0"
	 kb:UNITS="UNT/ML"
	 kb:VA_NAME="INSULIN,LENTE,HUMAN 100UNT/ML INJ"
	 rdfs:label="INSULIN,LENTE,HUMAN 100UNT/ML INJ"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_89"
	 kb:Classification="INSULIN"
	 kb:Code="HS501"
	 kb:GENERIC_NAME="INSULIN"
	 kb:NAT_ID="836"
	 kb:STRENGTH="100.0"
	 kb:UNITS="UNT/ML"
	 kb:VA_NAME="INSULIN,LENTE,PORK/PURIFIED 100UNT/ML INJ"
	 rdfs:label="INSULIN,LENTE,PORK/PURIFIED 100UNT/ML INJ"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_9"
	 kb:Classification="INSULIN"
	 kb:Code="HS501"
	 kb:NAT_ID="64000888"
	 kb:UNITS="VI"
	 kb:VA_NAME="INSULIN LENTE HUMAN 100 U/ML IJ HUMULN L"
	 rdfs:label="INSULIN LENTE HUMAN 100 U/ML IJ HUMULN L"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_90"
	 kb:Classification="INSULIN"
	 kb:Code="HS501"
	 kb:GENERIC_NAME="INSULIN"
	 kb:NAT_ID="16467"
	 kb:UNITS="UNT/ML"
	 kb:VA_NAME="INSULIN,LISPRO,HUMAN 100 UNIT/ML INJ,CARTRIDGE,3ML"
	 rdfs:label="INSULIN,LISPRO,HUMAN 100 UNIT/ML INJ,CARTRIDGE,3ML"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_91"
	 kb:Classification="INSULIN"
	 kb:Code="HS501"
	 kb:GENERIC_NAME="INSULIN"
	 kb:NAT_ID="888"
	 kb:STRENGTH="100.0"
	 kb:UNITS="UNT/ML"
	 kb:VA_NAME="INSULIN,LISPRO,HUMAN 100 UNT/ML INJ,CARTRIDGE,1.5ML"
	 rdfs:label="INSULIN,LISPRO,HUMAN 100 UNT/ML INJ,CARTRIDGE,1.5ML"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_92"
	 kb:Classification="INSULIN"
	 kb:Code="HS501"
	 kb:GENERIC_NAME="INSULIN"
	 kb:NAT_ID="887"
	 kb:STRENGTH="100.0"
	 kb:UNITS="UNT/ML"
	 kb:VA_NAME="INSULIN,LISPRO,HUMAN 100 UNT/ML INJ,HUMALOG"
	 rdfs:label="INSULIN,LISPRO,HUMAN 100 UNT/ML INJ,HUMALOG"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_93"
	 kb:Classification="INSULIN"
	 kb:Code="HS501"
	 kb:GENERIC_NAME="INSULIN"
	 kb:NAT_ID="13353"
	 kb:STRENGTH="100.0"
	 kb:UNITS="UNT/ML"
	 kb:VA_NAME="INSULIN,LISPRO,HUMAN 100 UNT/ML INJ,PEN,3ML"
	 rdfs:label="INSULIN,LISPRO,HUMAN 100 UNT/ML INJ,PEN,3ML"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_94"
	 kb:Classification="INSULIN"
	 kb:Code="HS501"
	 kb:GENERIC_NAME="INSULIN"
	 kb:NAT_ID="17894"
	 kb:VA_NAME="INSULIN,LISPRO,HUMAN 50/50 INJ,PEN,3ML"
	 rdfs:label="INSULIN,LISPRO,HUMAN 50/50 INJ,PEN,3ML"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_95"
	 kb:Classification="INSULIN"
	 kb:Code="HS501"
	 kb:GENERIC_NAME="INSULIN"
	 kb:NAT_ID="14913"
	 kb:VA_NAME="INSULIN,LISPRO,HUMAN 75/25 INJ,HUMALOG"
	 rdfs:label="INSULIN,LISPRO,HUMAN 75/25 INJ,HUMALOG"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_96"
	 kb:Classification="INSULIN"
	 kb:Code="HS501"
	 kb:GENERIC_NAME="INSULIN"
	 kb:NAT_ID="14371"
	 kb:VA_NAME="INSULIN,LISPRO,HUMAN 75/25 INJ,PEN,3ML"
	 rdfs:label="INSULIN,LISPRO,HUMAN 75/25 INJ,PEN,3ML"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_97"
	 kb:Classification="INSULIN"
	 kb:Code="HS501"
	 kb:GENERIC_NAME="INSULIN"
	 kb:NAT_ID="857"
	 kb:VA_NAME="INSULIN,NPH 50UNT/REGULAR 50UNT/ML HUMAN INJ"
	 rdfs:label="INSULIN,NPH 50UNT/REGULAR 50UNT/ML HUMAN INJ"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_98"
	 kb:Classification="INSULIN"
	 kb:Code="HS501"
	 kb:GENERIC_NAME="INSULIN"
	 kb:NAT_ID="854"
	 kb:VA_NAME="INSULIN,NPH 70UNT/REGULAR 30UNT/ML HUMAN INJ"
	 rdfs:label="INSULIN,NPH 70UNT/REGULAR 30UNT/ML HUMAN INJ"/>
<kb:DiabetesDrugs rdf:about="&kb;DiabetesDrugs_Instance_99"
	 kb:Classification="INSULIN"
	 kb:Code="HS501"
	 kb:GENERIC_NAME="INSULIN"
	 kb:NAT_ID="853"
	 kb:VA_NAME="INSULIN,NPH 70UNT/REGULAR 30UNT/ML PORK/PURIFIED INJ"
	 rdfs:label="INSULIN,NPH 70UNT/REGULAR 30UNT/ML PORK/PURIFIED INJ"/>
<rdf:Description rdf:about="&kb;Jess_engine"
	 rdfs:label="Jess_engine">
	<rdf:type rdf:resource="&kb;:JESS-ENGINE"/>
</rdf:Description>
<rdf:Description rdf:about="&kb;Jess_engine_"
	 rdfs:label="Jess_engine_">
	<rdf:type rdf:resource="&kb;:JESS-ENGINE"/>
</rdf:Description>
<rdf:Description rdf:about="&kb;Jess_engine__"
	 rdfs:label="Jess_engine__">
	<rdf:type rdf:resource="&kb;:JESS-ENGINE"/>
</rdf:Description>
<rdf:Description rdf:about="&kb;Jess_engine___"
	 rdfs:label="Jess engine">
	<rdf:type rdf:resource="&kb;:JESS-ENGINE"/>
</rdf:Description>
<kb:Modules rdf:about="&kb;Modules_Instance_1"
	 kb:Module="E"
	 kb:ModuleID="1"
	 kb:Module_Name="Screening for Retinopathy"
	 rdfs:label="Modules_Instance_1"/>
<kb:Modules rdf:about="&kb;Modules_Instance_2"
	 kb:Module="F"
	 kb:ModuleID="2"
	 kb:Module_Name="FOOT CARE"
	 rdfs:label="Modules_Instance_2"/>
<kb:Modules rdf:about="&kb;Modules_Instance_3"
	 kb:Module="G"
	 kb:ModuleID="3"
	 kb:Module_Name="Glycemic Control"
	 rdfs:label="Modules_Instance_3"/>
<kb:RecID_ConceptID rdf:about="&kb;RecID_ConceptID_Instance_1"
	 kb:ConceptID="253"
	 kb:RecID="1"
	 rdfs:label="rec 1 uses 253"/>
<kb:RecID_ConceptID rdf:about="&kb;RecID_ConceptID_Instance_10"
	 kb:ConceptID="262"
	 kb:RecID="15"
	 rdfs:label="rec 15 uses 262"/>
<kb:RecID_ConceptID rdf:about="&kb;RecID_ConceptID_Instance_11"
	 kb:ConceptID="265"
	 kb:RecID="19"
	 rdfs:label="rec 19 uses 265"/>
<kb:RecID_ConceptID rdf:about="&kb;RecID_ConceptID_Instance_12"
	 kb:ConceptID="266"
	 kb:RecID="20"
	 rdfs:label="rec 20 uses 266"/>
<kb:RecID_ConceptID rdf:about="&kb;RecID_ConceptID_Instance_13"
	 kb:ConceptID="267"
	 kb:RecID="21"
	 rdfs:label="rec 21 uses 267"/>
<kb:RecID_ConceptID rdf:about="&kb;RecID_ConceptID_Instance_14"
	 kb:ConceptID="268"
	 kb:RecID="23"
	 rdfs:label="rec 23 uses 268"/>
<kb:RecID_ConceptID rdf:about="&kb;RecID_ConceptID_Instance_15"
	 kb:ConceptID="269"
	 kb:RecID="24"
	 rdfs:label="rec 24 uses 269"/>
<kb:RecID_ConceptID rdf:about="&kb;RecID_ConceptID_Instance_16"
	 kb:ConceptID="270"
	 kb:RecID="25"
	 rdfs:label="rec 25 uses 270"/>
<kb:RecID_ConceptID rdf:about="&kb;RecID_ConceptID_Instance_17"
	 kb:ConceptID="271"
	 kb:RecID="26"
	 rdfs:label="rec 26 uses 271"/>
<kb:RecID_ConceptID rdf:about="&kb;RecID_ConceptID_Instance_18"
	 kb:ConceptID="272"
	 kb:RecID="28"
	 rdfs:label="rec 28 uses 272"/>
<kb:RecID_ConceptID rdf:about="&kb;RecID_ConceptID_Instance_19"
	 kb:ConceptID="273"
	 kb:RecID="32"
	 rdfs:label="rec 32 uses 273"/>
<kb:RecID_ConceptID rdf:about="&kb;RecID_ConceptID_Instance_2"
	 kb:ConceptID="254"
	 kb:RecID="2"
	 rdfs:label="rec 2 uses 254"/>
<kb:RecID_ConceptID rdf:about="&kb;RecID_ConceptID_Instance_20"
	 kb:ConceptID="269"
	 kb:RecID="33"
	 rdfs:label="rec 33 uses 269"/>
<kb:RecID_ConceptID rdf:about="&kb;RecID_ConceptID_Instance_21"
	 kb:ConceptID="275"
	 kb:RecID="36"
	 rdfs:label="rec 36 uses 275"/>
<kb:RecID_ConceptID rdf:about="&kb;RecID_ConceptID_Instance_22"
	 kb:ConceptID="276"
	 kb:RecID="2"
	 rdfs:label="rec 2 uses 276"/>
<kb:RecID_ConceptID rdf:about="&kb;RecID_ConceptID_Instance_23"
	 kb:ConceptID="277"
	 kb:RecID="7"
	 rdfs:label="rec 7 uses 277"/>
<kb:RecID_ConceptID rdf:about="&kb;RecID_ConceptID_Instance_24"
	 kb:ConceptID="278"
	 kb:RecID="9"
	 rdfs:label="rec 9 uses 278"/>
<kb:RecID_ConceptID rdf:about="&kb;RecID_ConceptID_Instance_25"
	 kb:ConceptID="279"
	 kb:RecID="12"
	 rdfs:label="rec 12 uses 279"/>
<kb:RecID_ConceptID rdf:about="&kb;RecID_ConceptID_Instance_26"
	 kb:ConceptID="280"
	 kb:RecID="15"
	 rdfs:label="rec 15 uses 280"/>
<kb:RecID_ConceptID rdf:about="&kb;RecID_ConceptID_Instance_27"
	 kb:ConceptID="281"
	 kb:RecID="16"
	 rdfs:label="rec 16 uses 281"/>
<kb:RecID_ConceptID rdf:about="&kb;RecID_ConceptID_Instance_28"
	 kb:ConceptID="282"
	 kb:RecID="18"
	 rdfs:label="rec 18 uses 282"/>
<kb:RecID_ConceptID rdf:about="&kb;RecID_ConceptID_Instance_29"
	 kb:ConceptID="283"
	 kb:RecID="19"
	 rdfs:label="rec 19 uses 283"/>
<kb:RecID_ConceptID rdf:about="&kb;RecID_ConceptID_Instance_3"
	 kb:ConceptID="255"
	 kb:RecID="18"
	 rdfs:label="rec 18 uses 255"/>
<kb:RecID_ConceptID rdf:about="&kb;RecID_ConceptID_Instance_30"
	 kb:ConceptID="284"
	 kb:RecID="20"
	 rdfs:label="rec 20 uses 284"/>
<kb:RecID_ConceptID rdf:about="&kb;RecID_ConceptID_Instance_31"
	 kb:ConceptID="285"
	 kb:RecID="25"
	 rdfs:label="rec 25 uses 285"/>
<kb:RecID_ConceptID rdf:about="&kb;RecID_ConceptID_Instance_32"
	 kb:ConceptID="286"
	 kb:RecID="28"
	 rdfs:label="rec 28 uses 286"/>
<kb:RecID_ConceptID rdf:about="&kb;RecID_ConceptID_Instance_33"
	 kb:ConceptID="287"
	 kb:RecID="7"
	 rdfs:label="rec 7 uses 287"/>
<kb:RecID_ConceptID rdf:about="&kb;RecID_ConceptID_Instance_34"
	 kb:ConceptID="288"
	 kb:RecID="9"
	 rdfs:label="rec 9 uses 288"/>
<kb:RecID_ConceptID rdf:about="&kb;RecID_ConceptID_Instance_35"
	 kb:ConceptID="253"
	 kb:RecID="15"
	 rdfs:label="rec 15 uses 253"/>
<kb:RecID_ConceptID rdf:about="&kb;RecID_ConceptID_Instance_36"
	 kb:ConceptID="290"
	 kb:RecID="18"
	 rdfs:label="rec 18 uses 290"/>
<kb:RecID_ConceptID rdf:about="&kb;RecID_ConceptID_Instance_37"
	 kb:ConceptID="291"
	 kb:RecID="19"
	 rdfs:label="rec 19 uses 291"/>
<kb:RecID_ConceptID rdf:about="&kb;RecID_ConceptID_Instance_38"
	 kb:ConceptID="292"
	 kb:RecID="20"
	 rdfs:label="rec 20 uses 292"/>
<kb:RecID_ConceptID rdf:about="&kb;RecID_ConceptID_Instance_39"
	 kb:ConceptID="293"
	 kb:RecID="25"
	 rdfs:label="rec 25 uses 293"/>
<kb:RecID_ConceptID rdf:about="&kb;RecID_ConceptID_Instance_4"
	 kb:ConceptID="256"
	 kb:RecID="7"
	 rdfs:label="rec 7 uses 256"/>
<kb:RecID_ConceptID rdf:about="&kb;RecID_ConceptID_Instance_40"
	 kb:ConceptID="294"
	 kb:RecID="28"
	 rdfs:label="rec 28 uses 294"/>
<kb:RecID_ConceptID rdf:about="&kb;RecID_ConceptID_Instance_41"
	 kb:ConceptID="295"
	 kb:RecID="9"
	 rdfs:label="rec 9 uses 295"/>
<kb:RecID_ConceptID rdf:about="&kb;RecID_ConceptID_Instance_42"
	 kb:ConceptID="296"
	 kb:RecID="18"
	 rdfs:label="rec 18 uses 296"/>
<kb:RecID_ConceptID rdf:about="&kb;RecID_ConceptID_Instance_43"
	 kb:ConceptID="297"
	 kb:RecID="19"
	 rdfs:label="rec 19 uses 297"/>
<kb:RecID_ConceptID rdf:about="&kb;RecID_ConceptID_Instance_44"
	 kb:ConceptID="298"
	 kb:RecID="20"
	 rdfs:label="rec 20 uses 298"/>
<kb:RecID_ConceptID rdf:about="&kb;RecID_ConceptID_Instance_45"
	 kb:ConceptID="299"
	 kb:RecID="28"
	 rdfs:label="rec 28 uses 299"/>
<kb:RecID_ConceptID rdf:about="&kb;RecID_ConceptID_Instance_46"
	 kb:ConceptID="302"
	 kb:RecID="9"
	 rdfs:label="rec 9 uses 302"/>
<kb:RecID_ConceptID rdf:about="&kb;RecID_ConceptID_Instance_47"
	 kb:ConceptID="303"
	 kb:RecID="18"
	 rdfs:label="rec 18 uses 303"/>
<kb:RecID_ConceptID rdf:about="&kb;RecID_ConceptID_Instance_48"
	 kb:ConceptID="304"
	 kb:RecID="19"
	 rdfs:label="rec 19 uses 304"/>
<kb:RecID_ConceptID rdf:about="&kb;RecID_ConceptID_Instance_49"
	 kb:ConceptID="305"
	 kb:RecID="20"
	 rdfs:label="rec 20 uses 305"/>
<kb:RecID_ConceptID rdf:about="&kb;RecID_ConceptID_Instance_5"
	 kb:ConceptID="257"
	 kb:RecID="8"
	 rdfs:label="rec 8 uses 257"/>
<kb:RecID_ConceptID rdf:about="&kb;RecID_ConceptID_Instance_50"
	 kb:ConceptID="306"
	 kb:RecID="9"
	 rdfs:label="rec 9 uses 306"/>
<kb:RecID_ConceptID rdf:about="&kb;RecID_ConceptID_Instance_51"
	 kb:ConceptID="307"
	 kb:RecID="19"
	 rdfs:label="rec 19 uses 307"/>
<kb:RecID_ConceptID rdf:about="&kb;RecID_ConceptID_Instance_52"
	 kb:ConceptID="308"
	 kb:RecID="19"
	 rdfs:label="rec 19 uses 308"/>
<kb:RecID_ConceptID rdf:about="&kb;RecID_ConceptID_Instance_53"
	 kb:ConceptID="309"
	 kb:RecID="19"
	 rdfs:label="rec 19 uses 309"/>
<kb:RecID_ConceptID rdf:about="&kb;RecID_ConceptID_Instance_54"
	 kb:ConceptID="310"
	 kb:RecID="19"
	 rdfs:label="rec 19 uses 310"/>
<kb:RecID_ConceptID rdf:about="&kb;RecID_ConceptID_Instance_55"
	 kb:ConceptID="253"
	 kb:RecID="3"
	 rdfs:label="rec 3 uses 253"/>
<kb:RecID_ConceptID rdf:about="&kb;RecID_ConceptID_Instance_56"
	 kb:ConceptID="253"
	 kb:RecID="5"
	 rdfs:label="rec 5 uses 253"/>
<kb:RecID_ConceptID rdf:about="&kb;RecID_ConceptID_Instance_57"
	 kb:ConceptID="253"
	 kb:RecID="17"
	 rdfs:label="rec 17 uses 253"/>
<kb:RecID_ConceptID rdf:about="&kb;RecID_ConceptID_Instance_58"
	 kb:ConceptID="261"
	 kb:RecID="6"
	 rdfs:label="rec 6 uses 261"/>
<kb:RecID_ConceptID rdf:about="&kb;RecID_ConceptID_Instance_59"
	 kb:ConceptID="267"
	 kb:RecID="22"
	 rdfs:label="rec 22 uses 267"/>
<kb:RecID_ConceptID rdf:about="&kb;RecID_ConceptID_Instance_6"
	 kb:ConceptID="258"
	 kb:RecID="9"
	 rdfs:label="rec 9 uses 258"/>
<kb:RecID_ConceptID rdf:about="&kb;RecID_ConceptID_Instance_60"
	 kb:ConceptID="311"
	 kb:RecID="27"
	 rdfs:label="rec 27 uses 311"/>
<kb:RecID_ConceptID rdf:about="&kb;RecID_ConceptID_Instance_61"
	 kb:ConceptID="322"
	 kb:RecID="29"
	 rdfs:label="rec 29 uses 322"/>
<kb:RecID_ConceptID rdf:about="&kb;RecID_ConceptID_Instance_62"
	 kb:ConceptID="322"
	 kb:RecID="30"
	 rdfs:label="rec 30 uses 322"/>
<kb:RecID_ConceptID rdf:about="&kb;RecID_ConceptID_Instance_63"
	 kb:ConceptID="322"
	 kb:RecID="31"
	 rdfs:label="rec 31 uses 322"/>
<kb:RecID_ConceptID rdf:about="&kb;RecID_ConceptID_Instance_64"
	 kb:ConceptID="322"
	 kb:RecID="34"
	 rdfs:label="rec 34 uses 322"/>
<kb:RecID_ConceptID rdf:about="&kb;RecID_ConceptID_Instance_65"
	 kb:ConceptID="321"
	 kb:RecID="31"
	 rdfs:label="rec 31 uses 321"/>
<kb:RecID_ConceptID rdf:about="&kb;RecID_ConceptID_Instance_66"
	 kb:ConceptID="323"
	 kb:RecID="31"
	 rdfs:label="rec 31 uses 323"/>
<kb:RecID_ConceptID rdf:about="&kb;RecID_ConceptID_Instance_67"
	 kb:ConceptID="271"
	 kb:RecID="29"
	 rdfs:label="rec 29 uses 271"/>
<kb:RecID_ConceptID rdf:about="&kb;RecID_ConceptID_Instance_68"
	 kb:ConceptID="273"
	 kb:RecID="34"
	 rdfs:label="rec 34 uses 273"/>
<kb:RecID_ConceptID rdf:about="&kb;RecID_ConceptID_Instance_69"
	 kb:ConceptID="273"
	 kb:RecID="40"
	 rdfs:label="rec 40 uses 273"/>
<kb:RecID_ConceptID rdf:about="&kb;RecID_ConceptID_Instance_7"
	 kb:ConceptID="259"
	 kb:RecID="11"
	 rdfs:label="rec 11 uses 259"/>
<kb:RecID_ConceptID rdf:about="&kb;RecID_ConceptID_Instance_70"
	 kb:ConceptID="273"
	 kb:RecID="41"
	 rdfs:label="rec 41 uses 273"/>
<kb:RecID_ConceptID rdf:about="&kb;RecID_ConceptID_Instance_71"
	 kb:ConceptID="273"
	 kb:RecID="42"
	 rdfs:label="rec 42 uses 273"/>
<kb:RecID_ConceptID rdf:about="&kb;RecID_ConceptID_Instance_72"
	 kb:ConceptID="273"
	 kb:RecID="44"
	 rdfs:label="rec 44 uses 273"/>
<kb:RecID_ConceptID rdf:about="&kb;RecID_ConceptID_Instance_73"
	 kb:ConceptID="324"
	 kb:RecID="35"
	 rdfs:label="rec 35 uses 324"/>
<kb:RecID_ConceptID rdf:about="&kb;RecID_ConceptID_Instance_74"
	 kb:ConceptID="275"
	 kb:RecID="37"
	 rdfs:label="rec 37 uses 275"/>
<kb:RecID_ConceptID rdf:about="&kb;RecID_ConceptID_Instance_75"
	 kb:ConceptID="275"
	 kb:RecID="38"
	 rdfs:label="rec 38 uses 275"/>
<kb:RecID_ConceptID rdf:about="&kb;RecID_ConceptID_Instance_76"
	 kb:ConceptID="325"
	 kb:RecID="39"
	 rdfs:label="rec 39 uses 325"/>
<kb:RecID_ConceptID rdf:about="&kb;RecID_ConceptID_Instance_77"
	 kb:ConceptID="327"
	 kb:RecID="43"
	 rdfs:label="rec 43 uses 327"/>
<kb:RecID_ConceptID rdf:about="&kb;RecID_ConceptID_Instance_78"
	 kb:ConceptID="326"
	 kb:RecID="45"
	 rdfs:label="rec 45 uses 326"/>
<kb:RecID_ConceptID rdf:about="&kb;RecID_ConceptID_Instance_79"
	 kb:ConceptID="312"
	 kb:RecID="46"
	 rdfs:label="rec 46 uses 312"/>
<kb:RecID_ConceptID rdf:about="&kb;RecID_ConceptID_Instance_8"
	 kb:ConceptID="260"
	 kb:RecID="12"
	 rdfs:label="rec 12 uses 260"/>
<kb:RecID_ConceptID rdf:about="&kb;RecID_ConceptID_Instance_80"
	 kb:ConceptID="275"
	 kb:RecID="47"
	 rdfs:label="rec 47 uses 275"/>
<kb:RecID_ConceptID rdf:about="&kb;RecID_ConceptID_Instance_81"
	 kb:ConceptID="312"
	 kb:RecID="48"
	 rdfs:label="rec 48 uses 312"/>
<kb:RecID_ConceptID rdf:about="&kb;RecID_ConceptID_Instance_82"
	 kb:ConceptID="331"
	 kb:RecID="251"
	 rdfs:label="rec 251 uses 331"/>
<kb:RecID_ConceptID rdf:about="&kb;RecID_ConceptID_Instance_83"
	 kb:ConceptID="253"
	 kb:RecID="252"
	 rdfs:label="rec 252 uses 253"/>
<kb:RecID_ConceptID rdf:about="&kb;RecID_ConceptID_Instance_84"
	 kb:ConceptID="253"
	 kb:RecID="253"
	 rdfs:label="rec 253 uses 253"/>
<kb:RecID_ConceptID rdf:about="&kb;RecID_ConceptID_Instance_85"
	 kb:ConceptID="342"
	 kb:RecID="258"
	 rdfs:label="rec 258 uses 342"/>
<kb:RecID_ConceptID rdf:about="&kb;RecID_ConceptID_Instance_9"
	 kb:ConceptID="261"
	 kb:RecID="13"
	 rdfs:label="rec 13 uses 261"/>
<kb:Recommendation rdf:about="&kb;Recommendation1"
	 kb:RecID="1"
	 kb:overall_quality="Good"
	 kb:quality_of_evidence="B">
	<kb:Guideline_Recommendation>Retinopathy screening performed by a qualified professional using a dilated eye examination or a retinal image technique with proven accuracy, and interpreted by a trained reader or experienced eye care provider. </kb:Guideline_Recommendation>
	<rdfs:label>1: Retinopathy screening performed by a qualified professional using a dilated eye examination or a retinal image technique with proven accuracy, and interpreted by a trained reader or experienced eye care provider. </rdfs:label>
	<kb:uses_concepts rdf:resource="&kb;Concept253"/>
	<kb:guideline_reference rdf:resource="&kb;annotation_library_Class50000"/>
	<kb:module rdf:resource="&kb;annotation_library_Class80003"/>
</kb:Recommendation>
<kb:Recommendation rdf:about="&kb;Recommendation10"
	 kb:RecID="10"
	 kb:overall_quality="Poor"
	 kb:quality_of_evidence="C">
	<kb:Guideline_Recommendation>Existence of at least one of the listed risk factors is sufficient to define the patient as high-risk.  • DM for 15 years or more
• Any evidence of diabetic nephropathy (including microproteinuria)
• Type 2 DM and cardiovascular autonomic neuropathy
• Lower extremity amputation related to DM
• History of any diabetic retinopathy
• Pregnancy and pre-existing diabetes
</kb:Guideline_Recommendation>
	<rdfs:label>10: Existence of at least one of the listed risk factors is sufficient to define the patient as high-risk.  • DM for 15 years or more
• Any evidence of diabetic nephropathy (including microproteinuria)
• Type 2 DM and cardiovascular autonomic neuropathy
• Lower extremity amputation related to DM
• History of any diabetic retinopathy
• Pregnancy and pre-existing diabetes
</rdfs:label>
	<kb:guideline_reference rdf:resource="&kb;annotation_library_Class50000"/>
	<kb:module rdf:resource="&kb;annotation_library_Class80003"/>
</kb:Recommendation>
<kb:Recommendation rdf:about="&kb;Recommendation11"
	 kb:RecID="11"
	 kb:overall_quality="Fair"
	 kb:quality_of_evidence="C">
	<kb:Guideline_Recommendation>Patients at high-risk for ocular complications should receive a comprehensive dilated eye examination within three months of diagnosis by an ophthalmologist or optometrist knowledgeable and experienced in detecting diabetic eye disease.</kb:Guideline_Recommendation>
	<rdfs:label>11: Patients at high-risk for ocular complications should receive a comprehensive dilated eye examination within three months of diagnosis by an ophthalmologist or optometrist knowledgeable and experienced in detecting diabetic eye disease.</rdfs:label>
	<kb:uses_concepts rdf:resource="&kb;Concept259"/>
	<kb:guideline_reference rdf:resource="&kb;annotation_library_Class50000"/>
	<kb:module rdf:resource="&kb;annotation_library_Class80003"/>
</kb:Recommendation>
<kb:Recommendation rdf:about="&kb;Recommendation12"
	 kb:RecID="12"
	 kb:overall_quality="Good"
	 kb:quality_of_evidence="B">
	<kb:Guideline_Recommendation>A dilated fundus examination or validated fundus imaging technique should be used to detect retinopathy, with interpretation by a qualified, experienced reader.</kb:Guideline_Recommendation>
	<rdfs:label>12: A dilated fundus examination or validated fundus imaging technique should be used to detect retinopathy, with interpretation by a qualified, experienced reader.</rdfs:label>
	<kb:uses_concepts rdf:resource="&kb;Concept260"/>
	<kb:uses_concepts rdf:resource="&kb;Concept279"/>
	<kb:guideline_reference rdf:resource="&kb;annotation_library_Class50000"/>
	<kb:module rdf:resource="&kb;annotation_library_Class80003"/>
</kb:Recommendation>
<kb:Recommendation rdf:about="&kb;Recommendation13"
	 kb:RecID="13"
	 kb:overall_quality="Poor"
	 kb:quality_of_evidence="I">
	<kb:Guideline_Recommendation>Retinal imaging techniques cannot substitute for a comprehensive eye exam for other eye problems, when indicated. Periodic comprehensive eye examinations by a trained eye specialist should be scheduled based on the individual patient's risk factors for ocular disease, other than diabetic retinopathy.</kb:Guideline_Recommendation>
	<rdfs:label>13: Retinal imaging techniques cannot substitute for a comprehensive eye exam for other eye problems, when indicated. Periodic comprehensive eye examinations by a trained eye specialist should be scheduled based on the individual patient's risk factors for ocular disease, other than diabetic retinopathy.</rdfs:label>
	<kb:uses_concepts rdf:resource="&kb;Concept261"/>
	<kb:guideline_reference rdf:resource="&kb;annotation_library_Class50000"/>
	<kb:module rdf:resource="&kb;annotation_library_Class80003"/>
</kb:Recommendation>
<kb:Recommendation rdf:about="&kb;Recommendation14"
	 kb:RecID="14"
	 kb:overall_quality="Fair"
	 kb:quality_of_evidence="C">
	<kb:Guideline_Recommendation>Patients who have not had a dilated eye exam within the past 12 months and are newly diagnosed with type 2 DM or on insulin for established diabetes should have a dilated fundus examination performed within 3 months.</kb:Guideline_Recommendation>
	<rdfs:label>14: Patients who have not had a dilated eye exam within the past 12 months and are newly diagnosed with type 2 DM or on insulin for established diabetes should have a dilated fundus examination performed within 3 months.</rdfs:label>
	<kb:guideline_reference rdf:resource="&kb;annotation_library_Class50000"/>
	<kb:module rdf:resource="&kb;annotation_library_Class80003"/>
</kb:Recommendation>
<kb:Recommendation rdf:about="&kb;Recommendation15"
	 kb:RecID="15"
	 kb:overall_quality="Fair"
	 kb:quality_of_evidence="B">
	<kb:Guideline_Recommendation>Patients who have ocular risk factors, are on insulin, or who have had retinopathy detected on a previous examination should have a fundus examination at least yearly with the precise examination interval determined by the eye care specialist</kb:Guideline_Recommendation>
	<rdfs:label>15: Patients who have ocular risk factors, are on insulin, or who have had retinopathy detected on a previous examination should have a fundus examination at least yearly with the precise examination interval determined by the eye care specialist</rdfs:label>
	<kb:uses_concepts rdf:resource="&kb;Concept253"/>
	<kb:uses_concepts rdf:resource="&kb;Concept262"/>
	<kb:uses_concepts rdf:resource="&kb;Concept280"/>
	<kb:guideline_reference rdf:resource="&kb;annotation_library_Class50000"/>
	<kb:module rdf:resource="&kb;annotation_library_Class80003"/>
</kb:Recommendation>
<kb:Recommendation rdf:about="&kb;Recommendation16"
	 kb:RecID="16"
	 kb:overall_quality="none"
	 kb:quality_of_evidence="none">
	<kb:Guideline_Recommendation>Patients who have had retinopathy detected on previous examinations should be seen at least annually. The eye care provider should determine the optimal screening intervals based on the patient’s severity of retinopathy and risk factors associated with retinopathy progression.</kb:Guideline_Recommendation>
	<kb:expert_definition>step 10, Y in algorithm, MKG defined that pt should be seen by eye care provider wirthin 1 month of pcp referral</kb:expert_definition>
	<rdfs:label>16: Patients who have had retinopathy detected on previous examinations should be seen at least annually. The eye care provider should determine the optimal screening intervals based on the patient’s severity of retinopathy and risk factors associated with retinopathy progression.</rdfs:label>
	<kb:uses_concepts rdf:resource="&kb;Concept281"/>
	<kb:guideline_reference rdf:resource="&kb;annotation_library_Class50000"/>
	<kb:module rdf:resource="&kb;annotation_library_Class80003"/>
</kb:Recommendation>
<kb:Recommendation rdf:about="&kb;Recommendation17"
	 kb:RecID="17"
	 kb:overall_quality="Good"
	 kb:quality_of_evidence="B">
	<kb:Guideline_Recommendation>Patients who have had no retinopathy on all previous examinations should be screened for retinopathy at least every other year (biennial screening).</kb:Guideline_Recommendation>
	<rdfs:label>17: Patients who have had no retinopathy on all previous examinations should be screened for retinopathy at least every other year (biennial screening).</rdfs:label>
	<kb:uses_concepts rdf:resource="&kb;Concept253"/>
	<kb:guideline_reference rdf:resource="&kb;annotation_library_Class50000"/>
	<kb:module rdf:resource="&kb;annotation_library_Class80003"/>
</kb:Recommendation>
<kb:Recommendation rdf:about="&kb;Recommendation18"
	 kb:RecID="18"
	 kb:expert_definition="Step 12 in algorithm - MKG yearly follow up for these pts"
	 kb:overall_quality="Fair"
	 kb:quality_of_evidence="C">
	<kb:Guideline_Recommendation>More frequent screening should be considered in patients with clinical findings associated with an increased rate of progression or prevalence of retinopathy. These clinical findings include poorly controlled hypertension, chronic severe hyperglycemia, recent initiation or intensification of insulin therapy, or other known microvascular disease (albuminuria or neuropathy).</kb:Guideline_Recommendation>
	<rdfs:label>18: More frequent screening should be considered in patients with clinical findings associated with an increased rate of progression or prevalence of retinopathy. These clinical findings include poorly controlled hypertension, chronic severe hyperglycemia, recent initiation or intensification of insulin therapy, or other known microvascular disease (albuminuria or neuropathy).</rdfs:label>
	<kb:uses_concepts rdf:resource="&kb;Concept255"/>
	<kb:uses_concepts rdf:resource="&kb;Concept282"/>
	<kb:uses_concepts rdf:resource="&kb;Concept290"/>
	<kb:uses_concepts rdf:resource="&kb;Concept296"/>
	<kb:uses_concepts rdf:resource="&kb;Concept303"/>
	<kb:guideline_reference rdf:resource="&kb;annotation_library_Class50000"/>
	<kb:module rdf:resource="&kb;annotation_library_Class80003"/>
</kb:Recommendation>
<kb:Recommendation rdf:about="&kb;Recommendation19"
	 kb:RecID="19"
	 kb:overall_quality="Poor"
	 kb:quality_of_evidence="I">
	<kb:Guideline_Recommendation>Visual inspection of the feet at every routine primary care visit.</kb:Guideline_Recommendation>
	<rdfs:label>19: Visual inspection of the feet at every routine primary care visit.</rdfs:label>
	<kb:uses_concepts rdf:resource="&kb;Concept265"/>
	<kb:uses_concepts rdf:resource="&kb;Concept283"/>
	<kb:uses_concepts rdf:resource="&kb;Concept291"/>
	<kb:uses_concepts rdf:resource="&kb;Concept297"/>
	<kb:uses_concepts rdf:resource="&kb;Concept304"/>
	<kb:uses_concepts rdf:resource="&kb;Concept307"/>
	<kb:uses_concepts rdf:resource="&kb;Concept308"/>
	<kb:uses_concepts rdf:resource="&kb;Concept309"/>
	<kb:uses_concepts rdf:resource="&kb;Concept310"/>
	<kb:guideline_reference rdf:resource="&kb;annotation_library_Class50000"/>
	<kb:module rdf:resource="&kb;annotation_library_Class80002"/>
</kb:Recommendation>
<kb:Recommendation rdf:about="&kb;Recommendation2"
	 kb:RecID="2"
	 kb:overall_quality="Fair"
	 kb:quality_of_evidence="C">
	<kb:Guideline_Recommendation>Routine retinopathy screening for patients with type 1 diabetes within 3 years of the diagnosis and for patients with type 2 diabetes within 3 months of the diagnosis, at most. Patients with visual symptoms should be urgently referred. </kb:Guideline_Recommendation>
	<rdfs:label>2: Routine retinopathy screening for patients with type 1 diabetes within 3 years of the diagnosis and for patients with type 2 diabetes within 3 months of the diagnosis, at most. Patients with visual symptoms should be urgently referred. </rdfs:label>
	<kb:uses_concepts rdf:resource="&kb;Concept254"/>
	<kb:uses_concepts rdf:resource="&kb;Concept276"/>
	<kb:guideline_reference rdf:resource="&kb;annotation_library_Class50000"/>
	<kb:module rdf:resource="&kb;annotation_library_Class80003"/>
</kb:Recommendation>
<kb:Recommendation rdf:about="&kb;Recommendation20"
	 kb:RecID="20"
	 kb:overall_quality="Fair"
	 kb:quality_of_evidence="B">
	<kb:Guideline_Recommendation>foot risk assessment must be performed and documented at least once a year. A complete foot risk assessment includes:
• Evaluation of the skin for breakdown
• Assessment of protective sensation using the Semmes-Weinstein 5.07 monofilament
• Evaluation for LE arterial disease
• Evaluation for foot deformity
• Prior history of ulcers or amputations
In addition, the patient’s footwear should be evaluated.
</kb:Guideline_Recommendation>
	<rdfs:label>20: foot risk assessment must be performed and documented at least once a year. A complete foot risk assessment includes:
• Evaluation of the skin for breakdown
• Assessment of protective sensation using the Semmes-Weinstein 5.07 monofilament
• Evaluation for LE arterial disease
• Evaluation for foot deformity
• Prior history of ulcers or amputations
In addition, the patient’s footwear should be evaluated.
</rdfs:label>
	<kb:uses_concepts rdf:resource="&kb;Concept266"/>
	<kb:uses_concepts rdf:resource="&kb;Concept284"/>
	<kb:uses_concepts rdf:resource="&kb;Concept292"/>
	<kb:uses_concepts rdf:resource="&kb;Concept298"/>
	<kb:uses_concepts rdf:resource="&kb;Concept305"/>
	<kb:guideline_reference rdf:resource="&kb;annotation_library_Class50000"/>
	<kb:module rdf:resource="&kb;annotation_library_Class80002"/>
</kb:Recommendation>
<kb:Recommendation rdf:about="&kb;Recommendation21"
	 kb:Guideline_Recommendation="Assessment of peripheral vascular disease."
	 kb:RecID="21"
	 kb:overall_quality="Fair"
	 kb:quality_of_evidence="B"
	 rdfs:label="21: Assessment of peripheral vascular disease.">
	<kb:uses_concepts rdf:resource="&kb;Concept267"/>
	<kb:guideline_reference rdf:resource="&kb;annotation_library_Class50000"/>
	<kb:module rdf:resource="&kb;annotation_library_Class80002"/>
</kb:Recommendation>
<kb:Recommendation rdf:about="&kb;Recommendation22"
	 kb:Guideline_Recommendation="Evaluation for acute ischemia or rest pain."
	 kb:RecID="22"
	 kb:overall_quality="Poor"
	 kb:quality_of_evidence="I"
	 rdfs:label="22: Evaluation for acute ischemia or rest pain.">
	<kb:uses_concepts rdf:resource="&kb;Concept267"/>
	<kb:guideline_reference rdf:resource="&kb;annotation_library_Class50000"/>
	<kb:module rdf:resource="&kb;annotation_library_Class80002"/>
</kb:Recommendation>
<kb:Recommendation rdf:about="&kb;Recommendation23"
	 kb:Guideline_Recommendation="Evaluation for foot ulceration."
	 kb:RecID="23"
	 kb:overall_quality="Poor"
	 kb:quality_of_evidence="I"
	 rdfs:label="23: Evaluation for foot ulceration.">
	<kb:uses_concepts rdf:resource="&kb;Concept268"/>
	<kb:guideline_reference rdf:resource="&kb;annotation_library_Class50000"/>
	<kb:module rdf:resource="&kb;annotation_library_Class80002"/>
</kb:Recommendation>
<kb:Recommendation rdf:about="&kb;Recommendation24"
	 kb:Guideline_Recommendation="Evaluation for ingrown toenail."
	 kb:RecID="24"
	 kb:overall_quality="Fair"
	 kb:quality_of_evidence="B"
	 rdfs:label="24: Evaluation for ingrown toenail.">
	<kb:uses_concepts rdf:resource="&kb;Concept269"/>
	<kb:guideline_reference rdf:resource="&kb;annotation_library_Class50000"/>
	<kb:module rdf:resource="&kb;annotation_library_Class80002"/>
</kb:Recommendation>
<kb:Recommendation rdf:about="&kb;Recommendation25"
	 kb:RecID="25"
	 kb:overall_quality="na"
	 kb:quality_of_evidence="na">
	<kb:Guideline_Recommendation>Evaluation should be performed for limb-threatening conditions, such as systemic infection, acute ischemia/rest pain, foot ulceration, puncture wound, ingrown toenail, and hemorragic callus with or without cellulitis.</kb:Guideline_Recommendation>
	<rdfs:label>25: Evaluation should be performed for limb-threatening conditions, such as systemic infection, acute ischemia/rest pain, foot ulceration, puncture wound, ingrown toenail, and hemorragic callus with or without cellulitis.</rdfs:label>
	<kb:uses_concepts rdf:resource="&kb;Concept270"/>
	<kb:uses_concepts rdf:resource="&kb;Concept285"/>
	<kb:uses_concepts rdf:resource="&kb;Concept293"/>
	<kb:guideline_reference rdf:resource="&kb;annotation_library_Class50000"/>
	<kb:module rdf:resource="&kb;annotation_library_Class80002"/>
</kb:Recommendation>
<kb:Recommendation rdf:about="&kb;Recommendation251"
	 kb:RecID="251"
	 kb:overall_quality="Poor"
	 kb:quality_of_evidence="I">
	<kb:Guideline_Recommendation>Postprandial plasma glucose (PPG) level should be assessed in patients with:
o  Elevated HbA1c (not at target) but a normal fasting plasma glucose level
o  Frequent troublesome hypoglycemic symptoms during waking active hours</kb:Guideline_Recommendation>
	<rdfs:label>251: Postprandial plasma glucose (PPG) level should be assessed in patients with:
o  Elevated HbA1c (not at target) but a normal fasting plasma glucose level
o  Frequent troublesome hypoglycemic symptoms during waking active hours</rdfs:label>
	<kb:uses_concepts rdf:resource="&kb;Concept331"/>
	<kb:guideline_reference rdf:resource="&kb;annotation_library_Class50000"/>
	<kb:module rdf:resource="&kb;annotation_library_Class80001"/>
</kb:Recommendation>
<kb:Recommendation rdf:about="&kb;Recommendation252"
	 kb:Guideline_Recommendation="Progression to non-proliferative retinopathy."
	 kb:RecID="252"
	 kb:overall_quality="Good"
	 kb:quality_of_evidence="A"
	 rdfs:label="252: Progression to non-proliferative retinopathy.">
	<kb:uses_concepts rdf:resource="&kb;Concept253"/>
	<kb:guideline_reference rdf:resource="&kb;annotation_library_Class50000"/>
	<kb:module rdf:resource="&kb;annotation_library_Class80001"/>
</kb:Recommendation>
<kb:Recommendation rdf:about="&kb;Recommendation253"
	 kb:Guideline_Recommendation="Progression to proliferative retinopathy."
	 kb:RecID="253"
	 kb:overall_quality="Fair"
	 kb:quality_of_evidence="B"
	 rdfs:label="253: Progression to proliferative retinopathy.">
	<kb:uses_concepts rdf:resource="&kb;Concept253"/>
	<kb:guideline_reference rdf:resource="&kb;annotation_library_Class50000"/>
	<kb:module rdf:resource="&kb;annotation_library_Class80001"/>
</kb:Recommendation>
<kb:Recommendation rdf:about="&kb;Recommendation254"
	 kb:RecID="254"
	 kb:quality_of_evidence="G">
	<kb:Guideline_Recommendation>Each patient's glycemic target range must be individualized, based on the provider's appraisal of the risk-benefit ratio for that individual.</kb:Guideline_Recommendation>
	<rdfs:label>254: Each patient's glycemic target range must be individualized, based on the provider's appraisal of the risk-benefit ratio for that individual.</rdfs:label>
	<kb:guideline_reference rdf:resource="&kb;annotation_library_Class50000"/>
	<kb:module rdf:resource="&kb;annotation_library_Class80001"/>
</kb:Recommendation>
<kb:Recommendation rdf:about="&kb;Recommendation255"
	 kb:Guideline_Recommendation="Assess Glycemic Control"
	 kb:RecID="255"
	 kb:quality_of_evidence="B"
	 rdfs:label="255: Assess Glycemic Control">
	<kb:guideline_reference rdf:resource="&kb;annotation_library_Class50000"/>
	<kb:module rdf:resource="&kb;annotation_library_Class80001"/>
</kb:Recommendation>
<kb:Recommendation rdf:about="&kb;Recommendation256"
	 kb:RecID="256"
	 kb:quality_of_evidence="C">
	<kb:Guideline_Recommendation>Determine Recommended Glycemic Control Target Using Risk Stratification Criteria</kb:Guideline_Recommendation>
	<rdfs:label>256: Determine Recommended Glycemic Control Target Using Risk Stratification Criteria</rdfs:label>
	<kb:guideline_reference rdf:resource="&kb;annotation_library_Class50000"/>
	<kb:module rdf:resource="&kb;annotation_library_Class80001"/>
</kb:Recommendation>
<kb:Recommendation rdf:about="&kb;Recommendation257"
	 kb:RecID="257"
	 kb:overall_quality="na"
	 kb:quality_of_evidence="na">
	<kb:Guideline_Recommendation>Risks of a proposed therapy should be balanced against the potential benefits, based upon the patient's medical, social, and psychological status.</kb:Guideline_Recommendation>
	<rdfs:label>257: Risks of a proposed therapy should be balanced against the potential benefits, based upon the patient's medical, social, and psychological status.</rdfs:label>
	<kb:guideline_reference rdf:resource="&kb;annotation_library_Class50000"/>
	<kb:module rdf:resource="&kb;annotation_library_Class80001"/>
</kb:Recommendation>
<kb:Recommendation rdf:about="&kb;Recommendation258"
	 kb:RecID="258"
	 kb:quality_of_evidence="N">
	<kb:Guideline_Recommendation>1.	The patient should be scheduled for appropriate follow-up to evaluate response, tolerability to therapy, goal re-assessment, and management of acute and chronic problems.
2.	The frequency of primary care provider visits for the patient with diabetes who is meeting treatment goals and who has no unstable chronic complications should be individualized.
3.	When there is a sudden change in health status or when changes are made to the treatment regimen, follow-up within one month or sooner may be appropriate</kb:Guideline_Recommendation>
	<rdfs:label>258: 1.	The patient should be scheduled for appropriate follow-up to evaluate response, tolerability to therapy, goal re-assessment, and management of acute and chronic problems.
2.	The frequency of primary care provider visits for the patient with diabetes who is meeting treatment goals and who has no unstable chronic complications should be individualized.
3.	When there is a sudden change in health status or when changes are made to the treatment regimen, follow-up within one month or sooner may be appropriate</rdfs:label>
	<kb:uses_concepts rdf:resource="&kb;Concept342"/>
	<kb:guideline_reference rdf:resource="&kb;annotation_library_Class50000"/>
	<kb:module rdf:resource="&kb;annotation_library_Class80001"/>
</kb:Recommendation>
<kb:Recommendation rdf:about="&kb;Recommendation259"
	 kb:RecID="259"
	 kb:quality_of_evidence="M">
	<kb:Guideline_Recommendation>Treatment goals should be periodically reassessed based upon patient specific factors, including changes in the patient's health status, adverse drug reactions, adherence to therapy, and preferences.</kb:Guideline_Recommendation>
	<rdfs:label>259: Treatment goals should be periodically reassessed based upon patient specific factors, including changes in the patient's health status, adverse drug reactions, adherence to therapy, and preferences.</rdfs:label>
	<kb:guideline_reference rdf:resource="&kb;annotation_library_Class50000"/>
	<kb:module rdf:resource="&kb;annotation_library_Class80001"/>
</kb:Recommendation>
<kb:Recommendation rdf:about="&kb;Recommendation26"
	 kb:Guideline_Recommendation="Referral for life-threatening conditions"
	 kb:RecID="26"
	 kb:overall_quality="Poor"
	 kb:quality_of_evidence="I"
	 rdfs:label="26: Referral for life-threatening conditions">
	<kb:uses_concepts rdf:resource="&kb;Concept271"/>
	<kb:guideline_reference rdf:resource="&kb;annotation_library_Class50000"/>
	<kb:module rdf:resource="&kb;annotation_library_Class80002"/>
</kb:Recommendation>
<kb:Recommendation rdf:about="&kb;Recommendation260"
	 kb:RecID="260"
	 kb:quality_of_evidence="L">
	<kb:Guideline_Recommendation>1.If the patient does not achieve his/her target range, the provider should identify barriers to patient adherence to the treatment regimen (e.g., miscommunication, lack of education or understanding, financial/social/psychological barriers, and cultural beliefs).
2.If barriers are identified referral to a case manager or behavioral/financial counselor should be considered as appropriate.</kb:Guideline_Recommendation>
	<rdfs:label>260: 1.If the patient does not achieve his/her target range, the provider should identify barriers to patient adherence to the treatment regimen (e.g., miscommunication, lack of education or understanding, financial/social/psychological barriers, and cultural beliefs).
2.If barriers are identified referral to a case manager or behavioral/financial counselor should be considered as appropriate.</rdfs:label>
	<kb:guideline_reference rdf:resource="&kb;annotation_library_Class50000"/>
	<kb:module rdf:resource="&kb;annotation_library_Class80001"/>
</kb:Recommendation>
<kb:Recommendation rdf:about="&kb;Recommendation261"
	 kb:RecID="261"
	 kb:quality_of_evidence="K">
	<kb:Guideline_Recommendation>The patient with recurrent or severe hypoglycemia should be evaluated for precipitating factors that may be easily corrected (e.g., missed meals, exercise, incorrect administration of insulin-dosage or timing).</kb:Guideline_Recommendation>
	<rdfs:label>261: The patient with recurrent or severe hypoglycemia should be evaluated for precipitating factors that may be easily corrected (e.g., missed meals, exercise, incorrect administration of insulin-dosage or timing).</rdfs:label>
	<kb:guideline_reference rdf:resource="&kb;annotation_library_Class50000"/>
	<kb:module rdf:resource="&kb;annotation_library_Class80001"/>
</kb:Recommendation>
<kb:Recommendation rdf:about="&kb;Recommendation262"
	 kb:RecID="262"
	 kb:quality_of_evidence="J">
	<kb:Guideline_Recommendation>Individual treatment goals must be established with the patient based on the extent of the disease, comorbid conditions, and patient preferences.</kb:Guideline_Recommendation>
	<rdfs:label>262: Individual treatment goals must be established with the patient based on the extent of the disease, comorbid conditions, and patient preferences.</rdfs:label>
	<kb:guideline_reference rdf:resource="&kb;annotation_library_Class50000"/>
	<kb:module rdf:resource="&kb;annotation_library_Class80001"/>
</kb:Recommendation>
<kb:Recommendation rdf:about="&kb;Recommendation263"
	 kb:RecID="263"
	 kb:quality_of_evidence="J">
	<kb:Guideline_Recommendation>Institution of diet and exercise is usually the appropriate initial management in patients with new onset type 2 diabetes, depending upon severity of symptoms, pyschosocial evaluation, and overall health status. Encourage diet and exercise and lifestyle modification.</kb:Guideline_Recommendation>
	<rdfs:label>263: Institution of diet and exercise is usually the appropriate initial management in patients with new onset type 2 diabetes, depending upon severity of symptoms, pyschosocial evaluation, and overall health status. Encourage diet and exercise and lifestyle modification.</rdfs:label>
	<kb:guideline_reference rdf:resource="&kb;annotation_library_Class50000"/>
	<kb:module rdf:resource="&kb;annotation_library_Class80001"/>
</kb:Recommendation>
<kb:Recommendation rdf:about="&kb;Recommendation264"
	 kb:RecID="264"
	 kb:quality_of_evidence="J">
	<kb:Guideline_Recommendation>If treatment goals are not achieved with diet and exercise alone, drug therapy should be initiated.</kb:Guideline_Recommendation>
	<rdfs:label>264: If treatment goals are not achieved with diet and exercise alone, drug therapy should be initiated.</rdfs:label>
	<kb:guideline_reference rdf:resource="&kb;annotation_library_Class50000"/>
	<kb:module rdf:resource="&kb;annotation_library_Class80001"/>
</kb:Recommendation>
<kb:Recommendation rdf:about="&kb;Recommendation265"
	 kb:RecID="265"
	 kb:quality_of_evidence="J">
	<kb:Guideline_Recommendation>4.	There is no evidence that blood glucose monitoring in stable type 2 DM patients is of clinical benefit. If self-monitoring is to be done, a twice-weekly regimen is usually sufficient. Special situations, such as acute intercurrent illness, frequent hypo- or hyperglycemia, or changes in medication regimen, may justify more frequent monitoring on a temporary basis.</kb:Guideline_Recommendation>
	<rdfs:label>265: 4.	There is no evidence that blood glucose monitoring in stable type 2 DM patients is of clinical benefit. If self-monitoring is to be done, a twice-weekly regimen is usually sufficient. Special situations, such as acute intercurrent illness, frequent hypo- or hyperglycemia, or changes in medication regimen, may justify more frequent monitoring on a temporary basis.</rdfs:label>
	<kb:guideline_reference rdf:resource="&kb;annotation_library_Class50000"/>
	<kb:module rdf:resource="&kb;annotation_library_Class80001"/>
</kb:Recommendation>
<kb:Recommendation rdf:about="&kb;Recommendation266"
	 kb:Guideline_Recommendation="The PPG level should be used to modify the therapy"
	 kb:RecID="266"
	 kb:overall_quality="Poor"
	 kb:quality_of_evidence="I"
	 rdfs:label="266: The PPG level should be used to modify the therapy">
	<kb:guideline_reference rdf:resource="&kb;annotation_library_Class50000"/>
	<kb:module rdf:resource="&kb;annotation_library_Class80001"/>
</kb:Recommendation>
<kb:Recommendation rdf:about="&kb;Recommendation267"
	 kb:RecID="267"
	 kb:overall_quality="na"
	 kb:quality_of_evidence="na">
	<kb:Guideline_Recommendation>HbA1c should be measured periodically to assess glycemic control over time.</kb:Guideline_Recommendation>
	<rdfs:label>267: HbA1c should be measured periodically to assess glycemic control over time.</rdfs:label>
	<kb:guideline_reference rdf:resource="&kb;annotation_library_Class50000"/>
	<kb:module rdf:resource="&kb;annotation_library_Class80001"/>
</kb:Recommendation>
<kb:Recommendation rdf:about="&kb;Recommendation268"
	 kb:RecID="268"
	 kb:overall_quality="na"
	 kb:quality_of_evidence="na">
	<kb:Guideline_Recommendation xml:space='preserve'><![CDATA[HbA1c target for any patient with diabetes should be kept <9 percent to avoid symptoms of hyperglycemia.]]></kb:Guideline_Recommendation>
	<rdfs:label xml:space='preserve'><![CDATA[268: HbA1c target for any patient with diabetes should be kept <9 percent to avoid symptoms of hyperglycemia.]]></rdfs:label>
	<kb:guideline_reference rdf:resource="&kb;annotation_library_Class50000"/>
	<kb:module rdf:resource="&kb;annotation_library_Class80001"/>
</kb:Recommendation>
<kb:Recommendation rdf:about="&kb;Recommendation269"
	 kb:RecID="269"
	 kb:overall_quality="na"
	 kb:quality_of_evidence="na">
	<kb:Guideline_Recommendation xml:space='preserve'><![CDATA[The patient with very mild or no microvascular complications of diabetes, and who is free of major concurrent illnesses and with a reasonable life expectancy, should have an HbA1c target of <7 percent.]]></kb:Guideline_Recommendation>
	<rdfs:label xml:space='preserve'><![CDATA[269: The patient with very mild or no microvascular complications of diabetes, and who is free of major concurrent illnesses and with a reasonable life expectancy, should have an HbA1c target of <7 percent.]]></rdfs:label>
	<kb:guideline_reference rdf:resource="&kb;annotation_library_Class50000"/>
	<kb:module rdf:resource="&kb;annotation_library_Class80001"/>
</kb:Recommendation>
<kb:Recommendation rdf:about="&kb;Recommendation27"
	 kb:RecID="27"
	 kb:overall_quality="Poor"
	 kb:quality_of_evidence="I">
	<kb:Guideline_Recommendation>Referral to a vascular specialist for symptoms that limit lifestyle.</kb:Guideline_Recommendation>
	<rdfs:label>27: Referral to a vascular specialist for symptoms that limit lifestyle.</rdfs:label>
	<kb:uses_concepts rdf:resource="&kb;Concept311"/>
	<kb:guideline_reference rdf:resource="&kb;annotation_library_Class50000"/>
	<kb:module rdf:resource="&kb;annotation_library_Class80002"/>
</kb:Recommendation>
<kb:Recommendation rdf:about="&kb;Recommendation270"
	 kb:RecID="270"
	 kb:overall_quality="na"
	 kb:quality_of_evidence="na">
	<kb:Guideline_Recommendation>The patient with advanced microvascular complications and/or major comorbid illness, or short life expectancy is less likely to show survival benefit; therefore, aggressive glucose lowering may not be warranted.</kb:Guideline_Recommendation>
	<rdfs:label>270: The patient with advanced microvascular complications and/or major comorbid illness, or short life expectancy is less likely to show survival benefit; therefore, aggressive glucose lowering may not be warranted.</rdfs:label>
	<kb:guideline_reference rdf:resource="&kb;annotation_library_Class50000"/>
	<kb:module rdf:resource="&kb;annotation_library_Class80001"/>
</kb:Recommendation>
<kb:Recommendation rdf:about="&kb;Recommendation271"
	 kb:RecID="271"
	 kb:overall_quality="na"
	 kb:quality_of_evidence="na">
	<kb:Guideline_Recommendation>Risk of hypoglycemia should be considered in recommending a target goal.</kb:Guideline_Recommendation>
	<rdfs:label>271: Risk of hypoglycemia should be considered in recommending a target goal.</rdfs:label>
	<kb:guideline_reference rdf:resource="&kb;annotation_library_Class50000"/>
	<kb:module rdf:resource="&kb;annotation_library_Class80001"/>
</kb:Recommendation>
<kb:Recommendation rdf:about="&kb;Recommendation272"
	 kb:RecID="272"
	 kb:overall_quality="na"
	 kb:quality_of_evidence="na">
	<kb:Guideline_Recommendation>A specific target range of glycemic control should be negotiated by the patient and provider after discussing the risks and benefits of therapy.</kb:Guideline_Recommendation>
	<rdfs:label>272: A specific target range of glycemic control should be negotiated by the patient and provider after discussing the risks and benefits of therapy.</rdfs:label>
	<kb:guideline_reference rdf:resource="&kb;annotation_library_Class50000"/>
	<kb:module rdf:resource="&kb;annotation_library_Class80001"/>
</kb:Recommendation>
<kb:Recommendation rdf:about="&kb;Recommendation273"
	 kb:RecID="273"
	 kb:overall_quality="na"
	 kb:quality_of_evidence="na">
	<kb:Guideline_Recommendation>If necessary, the patient should be referred to an endocrine/diabetes clinic or a case manager to meet glycemic control target goals.</kb:Guideline_Recommendation>
	<rdfs:label>273: If necessary, the patient should be referred to an endocrine/diabetes clinic or a case manager to meet glycemic control target goals.</rdfs:label>
	<kb:guideline_reference rdf:resource="&kb;annotation_library_Class50000"/>
	<kb:module rdf:resource="&kb;annotation_library_Class80001"/>
</kb:Recommendation>
<kb:Recommendation rdf:about="&kb;Recommendation274"
	 kb:RecID="274"
	 kb:overall_quality="na"
	 kb:quality_of_evidence="na">
	<kb:Guideline_Recommendation>The patient with HbA1c >9.5 percent should be considered for aggressive management on an expedited basis.</kb:Guideline_Recommendation>
	<rdfs:label>274: The patient with HbA1c >9.5 percent should be considered for aggressive management on an expedited basis.</rdfs:label>
	<kb:guideline_reference rdf:resource="&kb;annotation_library_Class50000"/>
	<kb:module rdf:resource="&kb;annotation_library_Class80001"/>
</kb:Recommendation>
<kb:Recommendation rdf:about="&kb;Recommendation275"
	 kb:RecID="275"
	 kb:overall_quality="na"
	 kb:quality_of_evidence="na">
	<kb:Guideline_Recommendation>The patient who is on high-dose multiple agents should be considered for referral.</kb:Guideline_Recommendation>
	<kb:expert_definition>need to define high dose of multiple agents:
MM talked to Kristen To on 10/24/08
KT says the high dosage in her spreadsheet should suffice, and that 2 or more agents would be considered multiple agents.  Also most of the referrals should go to diabetes care (the clinic where she works), not endo.  Endo deals with very complicated cases and she would hate to have us
over refer to endo.  So what we decided was the first 3 bullet points on the guideline under high risk (p 8 (for me) module G annotation f) should
be referred to endo, the last 2 referred to diabetes care.</kb:expert_definition>
	<rdfs:label>275: The patient who is on high-dose multiple agents should be considered for referral.</rdfs:label>
	<kb:guideline_reference rdf:resource="&kb;annotation_library_Class50000"/>
	<kb:module rdf:resource="&kb;annotation_library_Class80001"/>
</kb:Recommendation>
<kb:Recommendation rdf:about="&kb;Recommendation276"
	 kb:RecID="276"
	 kb:quality_of_evidence="G">
	<kb:Guideline_Recommendation>The patient with type 1 DM should receive insulin replacement therapy.</kb:Guideline_Recommendation>
	<rdfs:label>276: The patient with type 1 DM should receive insulin replacement therapy.</rdfs:label>
	<kb:guideline_reference rdf:resource="&kb;annotation_library_Class50000"/>
	<kb:module rdf:resource="&kb;annotation_library_Class80001"/>
</kb:Recommendation>
<kb:Recommendation rdf:about="&kb;Recommendation277"
	 kb:RecID="277"
	 kb:overall_quality="na"
	 kb:quality_of_evidence="na">
	<kb:Guideline_Recommendation>The patient with type 2 DM or DM of undetermined cause who exhibits significant or rapid weight loss and/or persistent non-fasting ketonuria has at least severe relative insulin deficiency and will likely require insulin therapy on an indefinite basis.</kb:Guideline_Recommendation>
	<rdfs:label>277: The patient with type 2 DM or DM of undetermined cause who exhibits significant or rapid weight loss and/or persistent non-fasting ketonuria has at least severe relative insulin deficiency and will likely require insulin therapy on an indefinite basis.</rdfs:label>
	<kb:guideline_reference rdf:resource="&kb;annotation_library_Class50000"/>
	<kb:module rdf:resource="&kb;annotation_library_Class80001"/>
</kb:Recommendation>
<kb:Recommendation rdf:about="&kb;Recommendation278"
	 kb:RecID="278"
	 kb:overall_quality="na"
	 kb:quality_of_evidence="na">
	<kb:Guideline_Recommendation>All patients with type 1 DM should be referred to a diabetic clinic with multidisciplinary resources (e.g., diabetologist, diabetic nurse, educator/manager, and registered dietitian) for institution and adjustment of insulin therapy.</kb:Guideline_Recommendation>
	<rdfs:label>278: All patients with type 1 DM should be referred to a diabetic clinic with multidisciplinary resources (e.g., diabetologist, diabetic nurse, educator/manager, and registered dietitian) for institution and adjustment of insulin therapy.</rdfs:label>
	<kb:guideline_reference rdf:resource="&kb;annotation_library_Class50000"/>
	<kb:module rdf:resource="&kb;annotation_library_Class80001"/>
</kb:Recommendation>
<kb:Recommendation rdf:about="&kb;Recommendation279"
	 kb:RecID="279"
	 kb:overall_quality="na"
	 kb:quality_of_evidence="na">
	<kb:Guideline_Recommendation>1.If expeditious referral is not possible, the primary care provider should institute "survival" insulin therapy.
-- Calculate total daily dose (TDD) of 0.5 units/kg body weight/day.
-- Two-thirds of the TDD administered 30 minutes prior to breakfast as two-parts human neutral protamine Hagedorn insulin (NPH) insulin and one-part human regular insulin.
-- The remaining third of the TDD can be split equally, as human regular insulin 30 minutes before supper and as human NPH insulin at bedtime.</kb:Guideline_Recommendation>
	<rdfs:label>279: 1.If expeditious referral is not possible, the primary care provider should institute "survival" insulin therapy.
-- Calculate total daily dose (TDD) of 0.5 units/kg body weight/day.
-- Two-thirds of the TDD administered 30 minutes prior to breakfast as two-parts human neutral protamine Hagedorn insulin (NPH) insulin and one-part human regular insulin.
-- The remaining third of the TDD can be split equally, as human regular insulin 30 minutes before supper and as human NPH insulin at bedtime.</rdfs:label>
	<kb:guideline_reference rdf:resource="&kb;annotation_library_Class50000"/>
	<kb:module rdf:resource="&kb;annotation_library_Class80001"/>
</kb:Recommendation>
<kb:Recommendation rdf:about="&kb;Recommendation28"
	 kb:Guideline_Recommendation="Identification of risk factors in the diabetic foot."
	 kb:RecID="28"
	 kb:overall_quality="Fair"
	 kb:quality_of_evidence="B"
	 rdfs:label="28: Identification of risk factors in the diabetic foot.">
	<kb:uses_concepts rdf:resource="&kb;Concept272"/>
	<kb:uses_concepts rdf:resource="&kb;Concept286"/>
	<kb:uses_concepts rdf:resource="&kb;Concept294"/>
	<kb:uses_concepts rdf:resource="&kb;Concept299"/>
	<kb:guideline_reference rdf:resource="&kb;annotation_library_Class50000"/>
	<kb:module rdf:resource="&kb;annotation_library_Class80002"/>
</kb:Recommendation>
<kb:Recommendation rdf:about="&kb;Recommendation280"
	 kb:RecID="280"
	 kb:overall_quality="na"
	 kb:quality_of_evidence="na">
	<kb:Guideline_Recommendation>Patients with diabetes should be assessed for knowledge, performance skills, and barriers to full compliance.</kb:Guideline_Recommendation>
	<rdfs:label>280: Patients with diabetes should be assessed for knowledge, performance skills, and barriers to full compliance.</rdfs:label>
	<kb:guideline_reference rdf:resource="&kb;annotation_library_Class50000"/>
	<kb:module rdf:resource="&kb;annotation_library_Class80001"/>
</kb:Recommendation>
<kb:Recommendation rdf:about="&kb;Recommendation281"
	 kb:RecID="281"
	 kb:overall_quality="na"
	 kb:quality_of_evidence="na">
	<kb:Guideline_Recommendation>If psychosocial, personal, or financial barriers are identified, additional resources should be consulted, as applicable (e.g., mental health, medical social work, or financial counselors).</kb:Guideline_Recommendation>
	<rdfs:label>281: If psychosocial, personal, or financial barriers are identified, additional resources should be consulted, as applicable (e.g., mental health, medical social work, or financial counselors).</rdfs:label>
	<kb:guideline_reference rdf:resource="&kb;annotation_library_Class50000"/>
	<kb:module rdf:resource="&kb;annotation_library_Class80001"/>
</kb:Recommendation>
<kb:Recommendation rdf:about="&kb;Recommendation282"
	 kb:RecID="282"
	 kb:overall_quality="na"
	 kb:quality_of_evidence="na">
	<kb:Guideline_Recommendation>Individual treatment goals must be established with the patient based on the extent of the disease, comorbid conditions, and patient preferences.</kb:Guideline_Recommendation>
	<rdfs:label>282: Individual treatment goals must be established with the patient based on the extent of the disease, comorbid conditions, and patient preferences.</rdfs:label>
	<kb:guideline_reference rdf:resource="&kb;annotation_library_Class50000"/>
	<kb:module rdf:resource="&kb;annotation_library_Class80001"/>
</kb:Recommendation>
<kb:Recommendation rdf:about="&kb;Recommendation283"
	 kb:RecID="283"
	 kb:overall_quality="na"
	 kb:quality_of_evidence="na">
	<kb:Guideline_Recommendation>Institution of diet and exercise is usually the appropriate initial management in patients with new onset type 2 diabetes, depending upon severity of symptoms, pyschosocial evaluation, and overall health status. Encourage diet and exercise and lifestyle modification.</kb:Guideline_Recommendation>
	<rdfs:label>283: Institution of diet and exercise is usually the appropriate initial management in patients with new onset type 2 diabetes, depending upon severity of symptoms, pyschosocial evaluation, and overall health status. Encourage diet and exercise and lifestyle modification.</rdfs:label>
	<kb:guideline_reference rdf:resource="&kb;annotation_library_Class50000"/>
	<kb:module rdf:resource="&kb;annotation_library_Class80001"/>
</kb:Recommendation>
<kb:Recommendation rdf:about="&kb;Recommendation284"
	 kb:RecID="284"
	 kb:overall_quality="na"
	 kb:quality_of_evidence="na">
	<kb:Guideline_Recommendation>If treatment goals are not achieved with diet and exercise alone, drug therapy should be initiated.</kb:Guideline_Recommendation>
	<rdfs:label>284: If treatment goals are not achieved with diet and exercise alone, drug therapy should be initiated.</rdfs:label>
	<kb:guideline_reference rdf:resource="&kb;annotation_library_Class50000"/>
	<kb:module rdf:resource="&kb;annotation_library_Class80001"/>
</kb:Recommendation>
<kb:Recommendation rdf:about="&kb;Recommendation285"
	 kb:RecID="285"
	 kb:overall_quality="na"
	 kb:quality_of_evidence="na">
	<kb:Guideline_Recommendation>There is no evidence that blood glucose monitoring in stable type 2 DM patients is of clinical benefit. If self-monitoring is to be done, a twice-weekly regimen is usually sufficient. Special situations, such as acute intercurrent illness, frequent hypo- or hyperglycemia, or changes in medication regimen, may justify more frequent monitoring on a temporary basis.</kb:Guideline_Recommendation>
	<rdfs:label>285: There is no evidence that blood glucose monitoring in stable type 2 DM patients is of clinical benefit. If self-monitoring is to be done, a twice-weekly regimen is usually sufficient. Special situations, such as acute intercurrent illness, frequent hypo- or hyperglycemia, or changes in medication regimen, may justify more frequent monitoring on a temporary basis.</rdfs:label>
	<kb:guideline_reference rdf:resource="&kb;annotation_library_Class50000"/>
	<kb:module rdf:resource="&kb;annotation_library_Class80001"/>
</kb:Recommendation>
<kb:Recommendation rdf:about="&kb;Recommendation286"
	 kb:RecID="286"
	 kb:overall_quality="na"
	 kb:quality_of_evidence="na">
	<kb:Guideline_Recommendation>J-1. MONOTHERAPY
•	Both metformin and sulfonylureas decrease HbA1c to a similar degree.
•	There is a greater weight gain associated with the use of sulfonylurea versus metformin.
•	Studies indicate that weight loss is an important factor in the control of HbA1c.
•	In overweight patients, treatment with metformin may result in reduced diabetes endpoints for all causes of mortality and stroke.
•	Other oral agents, while less effective, are still appropriate first line agents if the desired increase in HbA1c is proportionally less or if there are additional contraindications to the other first line medications.</kb:Guideline_Recommendation>
	<rdfs:label>286: J-1. MONOTHERAPY
•	Both metformin and sulfonylureas decrease HbA1c to a similar degree.
•	There is a greater weight gain associated with the use of sulfonylurea versus metformin.
•	Studies indicate that weight loss is an important factor in the control of HbA1c.
•	In overweight patients, treatment with metformin may result in reduced diabetes endpoints for all causes of mortality and stroke.
•	Other oral agents, while less effective, are still appropriate first line agents if the desired increase in HbA1c is proportionally less or if there are additional contraindications to the other first line medications.</rdfs:label>
	<kb:guideline_reference rdf:resource="&kb;annotation_library_Class50000"/>
	<kb:module rdf:resource="&kb;annotation_library_Class80001"/>
</kb:Recommendation>
<kb:Recommendation rdf:about="&kb;Recommendation287"
	 kb:RecID="287"
	 kb:overall_quality="Fair"
	 kb:quality_of_evidence="B">
	<kb:Guideline_Recommendation>J1. MONOTHERAPY

Sulfonylurea as first line for most patients.</kb:Guideline_Recommendation>
	<rdfs:label>287: J1. MONOTHERAPY

Sulfonylurea as first line for most patients.</rdfs:label>
	<kb:guideline_reference rdf:resource="&kb;annotation_library_Class50000"/>
	<kb:module rdf:resource="&kb;annotation_library_Class80001"/>
</kb:Recommendation>
<kb:Recommendation rdf:about="&kb;Recommendation288"
	 kb:RecID="288"
	 kb:overall_quality="Good"
	 kb:quality_of_evidence="A">
	<kb:Guideline_Recommendation>J1 MONOTHERAPY

Metformin as first line for overweight patients.</kb:Guideline_Recommendation>
	<rdfs:label>288: J1 MONOTHERAPY

Metformin as first line for overweight patients.</rdfs:label>
	<kb:guideline_reference rdf:resource="&kb;annotation_library_Class50000"/>
	<kb:module rdf:resource="&kb;annotation_library_Class80001"/>
</kb:Recommendation>
<kb:Recommendation rdf:about="&kb;Recommendation289"
	 kb:RecID="289"
	 kb:overall_quality="Fair"
	 kb:quality_of_evidence="B">
	<kb:Guideline_Recommendation>J1 MONOTHERAPY

Glitazones not preferred as monotherapy.</kb:Guideline_Recommendation>
	<rdfs:label>289: J1 MONOTHERAPY

Glitazones not preferred as monotherapy.</rdfs:label>
	<kb:guideline_reference rdf:resource="&kb;annotation_library_Class50000"/>
	<kb:module rdf:resource="&kb;annotation_library_Class80001"/>
</kb:Recommendation>
<kb:Recommendation rdf:about="&kb;Recommendation29"
	 kb:RecID="29"
	 kb:overall_quality="na"
	 kb:quality_of_evidence="na">
	<kb:Guideline_Recommendation>The patient at high-risk should be referred to a foot care specialist for a more comprehensive evaluation and intensive treatment plan including patient education concerning foot care practices, hygiene, and footwear.</kb:Guideline_Recommendation>
	<rdfs:label>29: The patient at high-risk should be referred to a foot care specialist for a more comprehensive evaluation and intensive treatment plan including patient education concerning foot care practices, hygiene, and footwear.</rdfs:label>
	<kb:uses_concepts rdf:resource="&kb;Concept271"/>
	<kb:uses_concepts rdf:resource="&kb;Concept322"/>
	<kb:guideline_reference rdf:resource="&kb;annotation_library_Class50000"/>
	<kb:module rdf:resource="&kb;annotation_library_Class80002"/>
</kb:Recommendation>
<kb:Recommendation rdf:about="&kb;Recommendation290"
	 kb:RecID="290"
	 kb:overall_quality="na"
	 kb:quality_of_evidence="na">
	<kb:Guideline_Recommendation>J-2. COMBINATION THERAPY

Use of Metformin or Glitazones in Combination with Insulin</kb:Guideline_Recommendation>
	<rdfs:label>290: J-2. COMBINATION THERAPY

Use of Metformin or Glitazones in Combination with Insulin</rdfs:label>
	<kb:guideline_reference rdf:resource="&kb;annotation_library_Class50000"/>
	<kb:module rdf:resource="&kb;annotation_library_Class80001"/>
</kb:Recommendation>
<kb:Recommendation rdf:about="&kb;Recommendation291"
	 kb:RecID="291"
	 kb:quality_of_evidence="J">
	<kb:Guideline_Recommendation>J2- COMBINATION THERAPY

Glitazones In Combination With Other Agents</kb:Guideline_Recommendation>
	<rdfs:label>291: J2- COMBINATION THERAPY

Glitazones In Combination With Other Agents</rdfs:label>
	<kb:guideline_reference rdf:resource="&kb;annotation_library_Class50000"/>
	<kb:module rdf:resource="&kb;annotation_library_Class80001"/>
</kb:Recommendation>
<kb:Recommendation rdf:about="&kb;Recommendation292"
	 kb:RecID="292"
	 kb:overall_quality="Fair"
	 kb:quality_of_evidence="B">
	<kb:Guideline_Recommendation>J2  COMBINATION THERAPY

Metformin as add-on therapy to SFU for failed sulfonylurea treatment, if not contraindicated.</kb:Guideline_Recommendation>
	<rdfs:label>292: J2  COMBINATION THERAPY

Metformin as add-on therapy to SFU for failed sulfonylurea treatment, if not contraindicated.</rdfs:label>
	<kb:guideline_reference rdf:resource="&kb;annotation_library_Class50000"/>
	<kb:module rdf:resource="&kb;annotation_library_Class80001"/>
</kb:Recommendation>
<kb:Recommendation rdf:about="&kb;Recommendation293"
	 kb:RecID="293"
	 kb:overall_quality="Fair"
	 kb:quality_of_evidence="B">
	<kb:Guideline_Recommendation>J2 COMBINATION THERAPY

Insulin as add-on therapy, if the patient is not within 1.5 percent of the target range.</kb:Guideline_Recommendation>
	<rdfs:label>293: J2 COMBINATION THERAPY

Insulin as add-on therapy, if the patient is not within 1.5 percent of the target range.</rdfs:label>
	<kb:guideline_reference rdf:resource="&kb;annotation_library_Class50000"/>
	<kb:module rdf:resource="&kb;annotation_library_Class80001"/>
</kb:Recommendation>
<kb:Recommendation rdf:about="&kb;Recommendation294"
	 kb:Guideline_Recommendation="J-3. INSULIN THERAPY"
	 kb:RecID="294"
	 kb:quality_of_evidence="J"
	 rdfs:label="294: J-3. INSULIN THERAPY">
	<kb:guideline_reference rdf:resource="&kb;annotation_library_Class50000"/>
	<kb:module rdf:resource="&kb;annotation_library_Class80001"/>
</kb:Recommendation>
<kb:Recommendation rdf:about="&kb;Recommendation296"
	 kb:RecID="296"
	 kb:quality_of_evidence="K">
	<kb:Guideline_Recommendation>The patient with recurrent or severe hypoglycemia should be evaluated for precipitating factors that may be easily corrected (e.g., missed meals, exercise, incorrect administration of insulin-dosage or timing).</kb:Guideline_Recommendation>
	<rdfs:label>296: The patient with recurrent or severe hypoglycemia should be evaluated for precipitating factors that may be easily corrected (e.g., missed meals, exercise, incorrect administration of insulin-dosage or timing).</rdfs:label>
	<kb:guideline_reference rdf:resource="&kb;annotation_library_Class50000"/>
	<kb:module rdf:resource="&kb;annotation_library_Class80001"/>
</kb:Recommendation>
<kb:Recommendation rdf:about="&kb;Recommendation297"
	 kb:RecID="297"
	 kb:quality_of_evidence="L">
	<kb:Guideline_Recommendation>If the patient does not achieve his/her target range, the provider should identify barriers to patient adherence to the treatment regimen (e.g., miscommunication, lack of education or understanding, financial/social/psychological barriers, and cultural beliefs).</kb:Guideline_Recommendation>
	<rdfs:label>297: If the patient does not achieve his/her target range, the provider should identify barriers to patient adherence to the treatment regimen (e.g., miscommunication, lack of education or understanding, financial/social/psychological barriers, and cultural beliefs).</rdfs:label>
	<kb:guideline_reference rdf:resource="&kb;annotation_library_Class50000"/>
	<kb:module rdf:resource="&kb;annotation_library_Class80001"/>
</kb:Recommendation>
<kb:Recommendation rdf:about="&kb;Recommendation298"
	 kb:RecID="298"
	 kb:quality_of_evidence="L">
	<kb:Guideline_Recommendation>If barriers are identified referral to a case manager or behavioral/financial counselor should be considered as appropriate.</kb:Guideline_Recommendation>
	<rdfs:label>298: If barriers are identified referral to a case manager or behavioral/financial counselor should be considered as appropriate.</rdfs:label>
	<kb:guideline_reference rdf:resource="&kb;annotation_library_Class50000"/>
	<kb:module rdf:resource="&kb;annotation_library_Class80001"/>
</kb:Recommendation>
<kb:Recommendation rdf:about="&kb;Recommendation299"
	 kb:RecID="299"
	 kb:quality_of_evidence="M">
	<kb:Guideline_Recommendation>Treatment goals should be periodically reassessed based upon patient specific factors, including changes in the patient's health status, adverse drug reactions, adherence to therapy, and preferences.</kb:Guideline_Recommendation>
	<rdfs:label>299: Treatment goals should be periodically reassessed based upon patient specific factors, including changes in the patient's health status, adverse drug reactions, adherence to therapy, and preferences.</rdfs:label>
	<kb:guideline_reference rdf:resource="&kb;annotation_library_Class50000"/>
	<kb:module rdf:resource="&kb;annotation_library_Class80001"/>
</kb:Recommendation>
<kb:Recommendation rdf:about="&kb;Recommendation3"
	 kb:RecID="3"
	 kb:overall_quality="Good"
	 kb:quality_of_evidence="B">
	<kb:Guideline_Recommendation>Biennial screening (every other year) for retinopathy for patients with no retinopathy on all previous examinations. </kb:Guideline_Recommendation>
	<rdfs:label>3: Biennial screening (every other year) for retinopathy for patients with no retinopathy on all previous examinations. </rdfs:label>
	<kb:uses_concepts rdf:resource="&kb;Concept253"/>
	<kb:guideline_reference rdf:resource="&kb;annotation_library_Class50000"/>
	<kb:module rdf:resource="&kb;annotation_library_Class80003"/>
</kb:Recommendation>
<kb:Recommendation rdf:about="&kb;Recommendation30"
	 kb:RecID="30"
	 kb:overall_quality="na"
	 kb:quality_of_evidence="na">
	<kb:Guideline_Recommendation>The existence of one of the following characteristics is sufficient to define the patient as high-risk for foot problem.
o Lack of sensation to Semmes-Weinstein 5.07 monofilament at one or more noncallused plantar sites
o Evidence of LE arterial disease (absence of both dorsalis pedis and tibialis posterior pulses, dependent rubor with pallor on elevation, history of rest pain or claudication, and prior history of LE bypass surgery)
o Foot deformities (specifically hammer toes, claw toe, Charcot's arthropathy, bunions, and metatarsal head deformities)
o History of foot ulcer or non-traumatic LEA at any level</kb:Guideline_Recommendation>
	<rdfs:label>30: The existence of one of the following characteristics is sufficient to define the patient as high-risk for foot problem.
o Lack of sensation to Semmes-Weinstein 5.07 monofilament at one or more noncallused plantar sites
o Evidence of LE arterial disease (absence of both dorsalis pedis and tibialis posterior pulses, dependent rubor with pallor on elevation, history of rest pain or claudication, and prior history of LE bypass surgery)
o Foot deformities (specifically hammer toes, claw toe, Charcot's arthropathy, bunions, and metatarsal head deformities)
o History of foot ulcer or non-traumatic LEA at any level</rdfs:label>
	<kb:uses_concepts rdf:resource="&kb;Concept322"/>
	<kb:guideline_reference rdf:resource="&kb;annotation_library_Class50000"/>
	<kb:module rdf:resource="&kb;annotation_library_Class80002"/>
</kb:Recommendation>
<kb:Recommendation rdf:about="&kb;Recommendation300"
	 kb:RecID="300"
	 kb:overall_quality="na"
	 kb:quality_of_evidence="na">
	<kb:Guideline_Recommendation>FOLLOW UP

The patient should be scheduled for appropriate follow-up to evaluate response, tolerability to therapy, goal re-assessment, and management of acute and chronic problems.</kb:Guideline_Recommendation>
	<rdfs:label>300: FOLLOW UP

The patient should be scheduled for appropriate follow-up to evaluate response, tolerability to therapy, goal re-assessment, and management of acute and chronic problems.</rdfs:label>
	<kb:guideline_reference rdf:resource="&kb;annotation_library_Class50000"/>
	<kb:module rdf:resource="&kb;annotation_library_Class80001"/>
</kb:Recommendation>
<kb:Recommendation rdf:about="&kb;Recommendation301"
	 kb:RecID="301"
	 kb:overall_quality="na"
	 kb:quality_of_evidence="na">
	<kb:Guideline_Recommendation>FOLLOW UP

The frequency of primary care provider visits for the patient with diabetes who is meeting treatment goals and who has no unstable chronic complications should be individualized.</kb:Guideline_Recommendation>
	<rdfs:label>301: FOLLOW UP

The frequency of primary care provider visits for the patient with diabetes who is meeting treatment goals and who has no unstable chronic complications should be individualized.</rdfs:label>
	<kb:guideline_reference rdf:resource="&kb;annotation_library_Class50000"/>
	<kb:module rdf:resource="&kb;annotation_library_Class80001"/>
</kb:Recommendation>
<kb:Recommendation rdf:about="&kb;Recommendation302"
	 kb:RecID="302"
	 kb:overall_quality="na"
	 kb:quality_of_evidence="na">
	<kb:Guideline_Recommendation>FOLLOW UP

When there is a sudden change in health status or when changes are made to the treatment regimen, follow-up within one month or sooner may be appropriate.</kb:Guideline_Recommendation>
	<rdfs:label>302: FOLLOW UP

When there is a sudden change in health status or when changes are made to the treatment regimen, follow-up within one month or sooner may be appropriate.</rdfs:label>
	<kb:guideline_reference rdf:resource="&kb;annotation_library_Class50000"/>
	<kb:module rdf:resource="&kb;annotation_library_Class80001"/>
</kb:Recommendation>
<kb:Recommendation rdf:about="&kb;Recommendation31"
	 kb:RecID="31"
	 kb:overall_quality="na"
	 kb:quality_of_evidence="na">
	<kb:Guideline_Recommendation>Patients without limb-threatening conditions should be evaluated for their level of risk for LE foot ulcers and amputations.</kb:Guideline_Recommendation>
	<rdfs:label>31: Patients without limb-threatening conditions should be evaluated for their level of risk for LE foot ulcers and amputations.</rdfs:label>
	<kb:uses_concepts rdf:resource="&kb;Concept321"/>
	<kb:uses_concepts rdf:resource="&kb;Concept322"/>
	<kb:uses_concepts rdf:resource="&kb;Concept323"/>
	<kb:guideline_reference rdf:resource="&kb;annotation_library_Class50000"/>
	<kb:module rdf:resource="&kb;annotation_library_Class80002"/>
</kb:Recommendation>
<kb:Recommendation rdf:about="&kb;Recommendation32"
	 kb:RecID="32"
	 kb:quality_of_evidence="F">
	<kb:Guideline_Recommendation>Minor lesions or wounds that could possibly be treated by the primary care provider are blisters, erosions, and/or minor cuts that do not extend beyond subcutaneous tissue. Pulses are present, there are no signs of acute infection, and there is no severe lower limb pain and no sign of a worsening lesion.</kb:Guideline_Recommendation>
	<rdfs:label>32: Minor lesions or wounds that could possibly be treated by the primary care provider are blisters, erosions, and/or minor cuts that do not extend beyond subcutaneous tissue. Pulses are present, there are no signs of acute infection, and there is no severe lower limb pain and no sign of a worsening lesion.</rdfs:label>
	<kb:uses_concepts rdf:resource="&kb;Concept273"/>
	<kb:guideline_reference rdf:resource="&kb;annotation_library_Class50000"/>
	<kb:module rdf:resource="&kb;annotation_library_Class80002"/>
</kb:Recommendation>
<kb:Recommendation rdf:about="&kb;Recommendation33"
	 kb:RecID="33"
	 kb:quality_of_evidence="F">
	<kb:Guideline_Recommendation>Patients with an ingrown toenail should be referred to a foot specialist for evaluation and treatment </kb:Guideline_Recommendation>
	<rdfs:label>33: Patients with an ingrown toenail should be referred to a foot specialist for evaluation and treatment </rdfs:label>
	<kb:uses_concepts rdf:resource="&kb;Concept269"/>
	<kb:guideline_reference rdf:resource="&kb;annotation_library_Class50000"/>
	<kb:module rdf:resource="&kb;annotation_library_Class80002"/>
</kb:Recommendation>
<kb:Recommendation rdf:about="&kb;Recommendation34"
	 kb:RecID="34"
	 kb:overall_quality="Poor"
	 kb:quality_of_evidence="I">
	<kb:Guideline_Recommendation>High-risk patients with a minor foot wound or lesion should be promptly referred to a foot care specialist (i.e., podiatrist, vascular surgeon, orthopedic surgeon, and other healthcare providers with demonstrated training, competence, and licensure in foot care) for evaluation and treatment.</kb:Guideline_Recommendation>
	<rdfs:label>34: High-risk patients with a minor foot wound or lesion should be promptly referred to a foot care specialist (i.e., podiatrist, vascular surgeon, orthopedic surgeon, and other healthcare providers with demonstrated training, competence, and licensure in foot care) for evaluation and treatment.</rdfs:label>
	<kb:uses_concepts rdf:resource="&kb;Concept273"/>
	<kb:uses_concepts rdf:resource="&kb;Concept322"/>
	<kb:guideline_reference rdf:resource="&kb;annotation_library_Class50000"/>
	<kb:module rdf:resource="&kb;annotation_library_Class80002"/>
</kb:Recommendation>
<kb:Recommendation rdf:about="&kb;Recommendation35"
	 kb:RecID="35"
	 kb:overall_quality="Poor"
	 kb:quality_of_evidence="I">
	<kb:Guideline_Recommendation>Footwear prescriptions should be based upon individual characteristics of foot structure and function.</kb:Guideline_Recommendation>
	<rdfs:label>35: Footwear prescriptions should be based upon individual characteristics of foot structure and function.</rdfs:label>
	<kb:uses_concepts rdf:resource="&kb;Concept324"/>
	<kb:guideline_reference rdf:resource="&kb;annotation_library_Class50000"/>
	<kb:module rdf:resource="&kb;annotation_library_Class80002"/>
</kb:Recommendation>
<kb:Recommendation rdf:about="&kb;Recommendation36"
	 kb:RecID="36"
	 kb:quality_of_evidence="H">
	<kb:Guideline_Recommendation>All patients and their families should receive self-management education for preventive foot care and selection of footwear. Instruction should include recommendations for daily foot inspection and preventive foot care, skin care, and use of emollients, nail care, and treatment for callus.</kb:Guideline_Recommendation>
	<rdfs:label>36: All patients and their families should receive self-management education for preventive foot care and selection of footwear. Instruction should include recommendations for daily foot inspection and preventive foot care, skin care, and use of emollients, nail care, and treatment for callus.</rdfs:label>
	<kb:uses_concepts rdf:resource="&kb;Concept275"/>
	<kb:guideline_reference rdf:resource="&kb;annotation_library_Class50000"/>
	<kb:module rdf:resource="&kb;annotation_library_Class80002"/>
</kb:Recommendation>
<kb:Recommendation rdf:about="&kb;Recommendation37"
	 kb:Guideline_Recommendation="Patient education on specific aspects of care."
	 kb:RecID="37"
	 kb:overall_quality="Fair"
	 kb:quality_of_evidence="B"
	 rdfs:label="37: Patient education on specific aspects of care.">
	<kb:uses_concepts rdf:resource="&kb;Concept275"/>
	<kb:guideline_reference rdf:resource="&kb;annotation_library_Class50000"/>
	<kb:module rdf:resource="&kb;annotation_library_Class80002"/>
</kb:Recommendation>
<kb:Recommendation rdf:about="&kb;Recommendation38"
	 kb:Guideline_Recommendation="Patient instruction on self-foot care."
	 kb:RecID="38"
	 kb:overall_quality="Fair"
	 kb:quality_of_evidence="B"
	 rdfs:label="38: Patient instruction on self-foot care.">
	<kb:uses_concepts rdf:resource="&kb;Concept275"/>
	<kb:guideline_reference rdf:resource="&kb;annotation_library_Class50000"/>
	<kb:module rdf:resource="&kb;annotation_library_Class80002"/>
</kb:Recommendation>
<kb:Recommendation rdf:about="&kb;Recommendation39"
	 kb:RecID="39"
	 kb:overall_quality="na"
	 kb:quality_of_evidence="na">
	<kb:Guideline_Recommendation>Visual inspection and peripheral sensation testing should be performed at each routine primary care visit for all patients </kb:Guideline_Recommendation>
	<rdfs:label>39: Visual inspection and peripheral sensation testing should be performed at each routine primary care visit for all patients </rdfs:label>
	<kb:uses_concepts rdf:resource="&kb;Concept325"/>
	<kb:guideline_reference rdf:resource="&kb;annotation_library_Class50000"/>
	<kb:module rdf:resource="&kb;annotation_library_Class80002"/>
</kb:Recommendation>
<kb:Recommendation rdf:about="&kb;Recommendation40"
	 kb:RecID="40"
	 kb:quality_of_evidence="J">
	<kb:Guideline_Recommendation>Patients with diabetes with minor wounds or foot lesions should have a wound assessment.</kb:Guideline_Recommendation>
	<rdfs:label>40: Patients with diabetes with minor wounds or foot lesions should have a wound assessment.</rdfs:label>
	<kb:uses_concepts rdf:resource="&kb;Concept273"/>
	<kb:guideline_reference rdf:resource="&kb;annotation_library_Class50000"/>
	<kb:module rdf:resource="&kb;annotation_library_Class80002"/>
</kb:Recommendation>
<kb:Recommendation rdf:about="&kb;Recommendation41"
	 kb:RecID="41"
	 kb:quality_of_evidence="K">
	<kb:Guideline_Recommendation>Patients with diabetes with uncomplicated minor lesions should receive local wound care. Primary care providers should attempt to offload weight-bearing on the affected extremity.</kb:Guideline_Recommendation>
	<rdfs:label>41: Patients with diabetes with uncomplicated minor lesions should receive local wound care. Primary care providers should attempt to offload weight-bearing on the affected extremity.</rdfs:label>
	<kb:uses_concepts rdf:resource="&kb;Concept273"/>
	<kb:guideline_reference rdf:resource="&kb;annotation_library_Class50000"/>
	<kb:module rdf:resource="&kb;annotation_library_Class80002"/>
</kb:Recommendation>
<kb:Recommendation rdf:about="&kb;Recommendation42"
	 kb:RecID="42"
	 kb:quality_of_evidence="K">
	<kb:Guideline_Recommendation>Patients with diabetes with uncomplicated minor lesions must be followed at least monthly.</kb:Guideline_Recommendation>
	<rdfs:label>42: Patients with diabetes with uncomplicated minor lesions must be followed at least monthly.</rdfs:label>
	<kb:uses_concepts rdf:resource="&kb;Concept273"/>
	<kb:guideline_reference rdf:resource="&kb;annotation_library_Class50000"/>
	<kb:module rdf:resource="&kb;annotation_library_Class80002"/>
</kb:Recommendation>
<kb:Recommendation rdf:about="&kb;Recommendation43"
	 kb:Guideline_Recommendation="Local wound care."
	 kb:RecID="43"
	 kb:overall_quality="Poor"
	 kb:quality_of_evidence="I"
	 rdfs:label="43: Local wound care.">
	<kb:uses_concepts rdf:resource="&kb;Concept327"/>
	<kb:guideline_reference rdf:resource="&kb;annotation_library_Class50000"/>
	<kb:module rdf:resource="&kb;annotation_library_Class80002"/>
</kb:Recommendation>
<kb:Recommendation rdf:about="&kb;Recommendation44"
	 kb:RecID="44"
	 kb:quality_of_evidence="L">
	<kb:Guideline_Recommendation>Patients with diabetes treated for an uncomplicated wound should be assessed within four weeks from the initial wound assessment for appropriate reduction in lesion size and depth and appearance of healthy granulating tissue with no evidence of infection.</kb:Guideline_Recommendation>
	<rdfs:label>44: Patients with diabetes treated for an uncomplicated wound should be assessed within four weeks from the initial wound assessment for appropriate reduction in lesion size and depth and appearance of healthy granulating tissue with no evidence of infection.</rdfs:label>
	<kb:uses_concepts rdf:resource="&kb;Concept273"/>
	<kb:guideline_reference rdf:resource="&kb;annotation_library_Class50000"/>
	<kb:module rdf:resource="&kb;annotation_library_Class80002"/>
</kb:Recommendation>
<kb:Recommendation rdf:about="&kb;Recommendation45"
	 kb:Guideline_Recommendation="Assessment of wound healing progress within 4 weeks."
	 kb:RecID="45"
	 kb:overall_quality="Poor"
	 kb:quality_of_evidence="I"
	 rdfs:label="45: Assessment of wound healing progress within 4 weeks.">
	<kb:uses_concepts rdf:resource="&kb;Concept326"/>
	<kb:guideline_reference rdf:resource="&kb;annotation_library_Class50000"/>
	<kb:module rdf:resource="&kb;annotation_library_Class80002"/>
</kb:Recommendation>
<kb:Recommendation rdf:about="&kb;Recommendation46"
	 kb:RecID="46"
	 kb:overall_quality="na"
	 kb:quality_of_evidence="na">
	<kb:Guideline_Recommendation>Patients with diabetes with minor foot problems (e.g., onychomycosis, painful corn, dry skin, athlete’s foot, minor calluses, uncomplicated nail trimming and improper foot hygiene) may be treated by a primary care provider in the office or by the patient or family members at home </kb:Guideline_Recommendation>
	<rdfs:label>46: Patients with diabetes with minor foot problems (e.g., onychomycosis, painful corn, dry skin, athlete’s foot, minor calluses, uncomplicated nail trimming and improper foot hygiene) may be treated by a primary care provider in the office or by the patient or family members at home </rdfs:label>
	<kb:uses_concepts rdf:resource="&kb;Concept312"/>
	<kb:guideline_reference rdf:resource="&kb;annotation_library_Class50000"/>
	<kb:module rdf:resource="&kb;annotation_library_Class80002"/>
</kb:Recommendation>
<kb:Recommendation rdf:about="&kb;Recommendation47"
	 kb:RecID="47"
	 kb:quality_of_evidence="N">
	<kb:Guideline_Recommendation>Assure that patient and family members have received appropriate education regarding preventive foot care.</kb:Guideline_Recommendation>
	<rdfs:label>47: Assure that patient and family members have received appropriate education regarding preventive foot care.</rdfs:label>
	<kb:uses_concepts rdf:resource="&kb;Concept275"/>
	<kb:guideline_reference rdf:resource="&kb;annotation_library_Class50000"/>
	<kb:module rdf:resource="&kb;annotation_library_Class80002"/>
</kb:Recommendation>
<kb:Recommendation rdf:about="&kb;Recommendation48"
	 kb:Guideline_Recommendation="Treat minor foot problems, as appropriate"
	 kb:RecID="48"
	 kb:overall_quality="Poor"
	 kb:quality_of_evidence="I"
	 rdfs:label="48: Treat minor foot problems, as appropriate">
	<kb:uses_concepts rdf:resource="&kb;Concept312"/>
	<kb:guideline_reference rdf:resource="&kb;annotation_library_Class50000"/>
	<kb:module rdf:resource="&kb;annotation_library_Class80002"/>
</kb:Recommendation>
<kb:Recommendation rdf:about="&kb;Recommendation5"
	 kb:RecID="5"
	 kb:overall_quality="Fair"
	 kb:quality_of_evidence="B">
	<kb:Guideline_Recommendation>At least annual screening for patients who had retinopathy detected on previous examinations. Optimal screening intervals should be based on the patient’s severity of retinopathy and risk factors associated with retinopathy progression. </kb:Guideline_Recommendation>
	<rdfs:label>5: At least annual screening for patients who had retinopathy detected on previous examinations. Optimal screening intervals should be based on the patient’s severity of retinopathy and risk factors associated with retinopathy progression. </rdfs:label>
	<kb:uses_concepts rdf:resource="&kb;Concept253"/>
	<kb:guideline_reference rdf:resource="&kb;annotation_library_Class50000"/>
	<kb:module rdf:resource="&kb;annotation_library_Class80003"/>
</kb:Recommendation>
<kb:Recommendation rdf:about="&kb;Recommendation6"
	 kb:RecID="6"
	 kb:overall_quality="Poor"
	 kb:quality_of_evidence="I">
	<kb:Guideline_Recommendation>Periodic comprehensive eye examinations by a trained eye specialist based on the individual patient's risk factors for ocular disease, other than diabetic retinopathy.</kb:Guideline_Recommendation>
	<rdfs:label>6: Periodic comprehensive eye examinations by a trained eye specialist based on the individual patient's risk factors for ocular disease, other than diabetic retinopathy.</rdfs:label>
	<kb:uses_concepts rdf:resource="&kb;Concept261"/>
	<kb:guideline_reference rdf:resource="&kb;annotation_library_Class50000"/>
	<kb:module rdf:resource="&kb;annotation_library_Class80003"/>
</kb:Recommendation>
<kb:Recommendation rdf:about="&kb;Recommendation7"
	 kb:RecID="7"
	 kb:overall_quality="na"
	 kb:quality_of_evidence="na">
	<kb:Guideline_Recommendation>Patients with an acute change in vision (i.e., occurring within a 48 – 72 hours period) or change in ocular function should be urgently referred to an eye care provider.</kb:Guideline_Recommendation>
	<rdfs:label>7: Patients with an acute change in vision (i.e., occurring within a 48 – 72 hours period) or change in ocular function should be urgently referred to an eye care provider.</rdfs:label>
	<kb:uses_concepts rdf:resource="&kb;Concept256"/>
	<kb:uses_concepts rdf:resource="&kb;Concept277"/>
	<kb:uses_concepts rdf:resource="&kb;Concept287"/>
	<kb:guideline_reference rdf:resource="&kb;annotation_library_Class50000"/>
	<kb:module rdf:resource="&kb;annotation_library_Class80003"/>
</kb:Recommendation>
<kb:Recommendation rdf:about="&kb;Recommendation8"
	 kb:RecID="8"
	 kb:overall_quality="Fair"
	 kb:quality_of_evidence="B">
	<kb:Guideline_Recommendation xml:space='preserve'><![CDATA[Diabetic patients (type 1) with early onset (age <30 years) should begin annual evaluations when the duration of the diabetes diagnosis is greater than 3 years.]]></kb:Guideline_Recommendation>
	<kb:expert_definition>step 5 in algorithm   MKG- 1st exam should be within 3 months of pcp visit referral to eye care provider</kb:expert_definition>
	<rdfs:label xml:space='preserve'><![CDATA[8: Diabetic patients (type 1) with early onset (age <30 years) should begin annual evaluations when the duration of the diabetes diagnosis is greater than 3 years.]]></rdfs:label>
	<kb:uses_concepts rdf:resource="&kb;Concept257"/>
	<kb:guideline_reference rdf:resource="&kb;annotation_library_Class50000"/>
	<kb:module rdf:resource="&kb;annotation_library_Class80003"/>
</kb:Recommendation>
<kb:Recommendations rdf:about="&kb;Recommendations_Instance_1"
	 kb:ModuleName="1"
	 kb:Overall_Quality="Good"
	 kb:Quality_of_Evidence="I"
	 kb:RecID="1"
	 kb:recommendation="B">
	<kb:Guideline_Recommendation>Retinopathy screening performed by a qualified professional using a dilated eye examination or a retinal image technique with proven accuracy, and interpreted by a trained reader or experienced eye care provider. </kb:Guideline_Recommendation>
	<rdfs:label>1: Retinopathy screening performed by a qualified professional using a dilated eye examination or a retinal image technique with proven accuracy, and interpreted by a trained reader or experienced eye care provider. </rdfs:label>
</kb:Recommendations>
<kb:Recommendations rdf:about="&kb;Recommendations_Instance_10"
	 kb:ModuleName="1"
	 kb:Overall_Quality="Poor"
	 kb:Quality_of_Evidence="III"
	 kb:RecID="10"
	 kb:Recommendation_Annotation="C"
	 kb:recommendation="C">
	<kb:Guideline_Recommendation>Existence of at least one of the listed risk factors is sufficient to define the patient as high-risk.  • DM for 15 years or more
• Any evidence of diabetic nephropathy (including microproteinuria)
• Type 2 DM and cardiovascular autonomic neuropathy
• Lower extremity amputation related to DM
• History of any diabetic retinopathy
• Pregnancy and pre-existing diabetes
</kb:Guideline_Recommendation>
	<rdfs:label>10: Existence of at least one of the listed risk factors is sufficient to define the patient as high-risk.  • DM for 15 years or more
• Any evidence of diabetic nephropathy (including microproteinuria)
• Type 2 DM and cardiovascular autonomic neuropathy
• Lower extremity amputation related to DM
• History of any diabetic retinopathy
• Pregnancy and pre-existing diabetes
</rdfs:label>
</kb:Recommendations>
<kb:Recommendations rdf:about="&kb;Recommendations_Instance_11"
	 kb:ModuleName="1"
	 kb:Overall_Quality="Fair"
	 kb:Quality_of_Evidence="II-1"
	 kb:RecID="11"
	 kb:Recommendation_Annotation="D"
	 kb:recommendation="C">
	<kb:Guideline_Recommendation>Patients at high-risk for ocular complications should receive a comprehensive dilated eye examination within three months of diagnosis by an ophthalmologist or optometrist knowledgeable and experienced in detecting diabetic eye disease.</kb:Guideline_Recommendation>
	<rdfs:label>11: Patients at high-risk for ocular complications should receive a comprehensive dilated eye examination within three months of diagnosis by an ophthalmologist or optometrist knowledgeable and experienced in detecting diabetic eye disease.</rdfs:label>
</kb:Recommendations>
<kb:Recommendations rdf:about="&kb;Recommendations_Instance_12"
	 kb:ModuleName="1"
	 kb:Overall_Quality="Good"
	 kb:Quality_of_Evidence="I"
	 kb:RecID="12"
	 kb:Recommendation_Annotation="D"
	 kb:recommendation="B">
	<kb:Guideline_Recommendation>A dilated fundus examination or validated fundus imaging technique should be used to detect retinopathy, with interpretation by a qualified, experienced reader.</kb:Guideline_Recommendation>
	<rdfs:label>12: A dilated fundus examination or validated fundus imaging technique should be used to detect retinopathy, with interpretation by a qualified, experienced reader.</rdfs:label>
</kb:Recommendations>
<kb:Recommendations rdf:about="&kb;Recommendations_Instance_13"
	 kb:ModuleName="1"
	 kb:Overall_Quality="Poor"
	 kb:Quality_of_Evidence="II"
	 kb:RecID="13"
	 kb:Recommendation_Annotation="D"
	 kb:recommendation="I">
	<kb:Guideline_Recommendation>Retinal imaging techniques cannot substitute for a comprehensive eye exam for other eye problems, when indicated. Periodic comprehensive eye examinations by a trained eye specialist should be scheduled based on the individual patient's risk factors for ocular disease, other than diabetic retinopathy.</kb:Guideline_Recommendation>
	<rdfs:label>13: Retinal imaging techniques cannot substitute for a comprehensive eye exam for other eye problems, when indicated. Periodic comprehensive eye examinations by a trained eye specialist should be scheduled based on the individual patient's risk factors for ocular disease, other than diabetic retinopathy.</rdfs:label>
</kb:Recommendations>
<kb:Recommendations rdf:about="&kb;Recommendations_Instance_14"
	 kb:ModuleName="1"
	 kb:Overall_Quality="Fair"
	 kb:Quality_of_Evidence="II-1"
	 kb:RecID="14"
	 kb:Recommendation_Annotation="E"
	 kb:recommendation="C">
	<kb:Guideline_Recommendation>Patients who have not had a dilated eye exam within the past 12 months and are newly diagnosed with type 2 DM or on insulin for established diabetes should have a dilated fundus examination performed within 3 months.</kb:Guideline_Recommendation>
	<rdfs:label>14: Patients who have not had a dilated eye exam within the past 12 months and are newly diagnosed with type 2 DM or on insulin for established diabetes should have a dilated fundus examination performed within 3 months.</rdfs:label>
</kb:Recommendations>
<kb:Recommendations rdf:about="&kb;Recommendations_Instance_15"
	 kb:ModuleName="1"
	 kb:Overall_Quality="Fair"
	 kb:Quality_of_Evidence="I"
	 kb:RecID="15"
	 kb:Recommendation_Annotation="F"
	 kb:recommendation="B">
	<kb:Guideline_Recommendation>Patients who have ocular risk factors, are on insulin, or who have had retinopathy detected on a previous examination should have a fundus examination at least yearly with the precise examination interval determined by the eye care specialist</kb:Guideline_Recommendation>
	<rdfs:label>15: Patients who have ocular risk factors, are on insulin, or who have had retinopathy detected on a previous examination should have a fundus examination at least yearly with the precise examination interval determined by the eye care specialist</rdfs:label>
</kb:Recommendations>
<kb:Recommendations rdf:about="&kb;Recommendations_Instance_16"
	 kb:ModuleName="1"
	 kb:Overall_Quality="none"
	 kb:Quality_of_Evidence="none"
	 kb:RecID="16"
	 kb:Recommendation_Annotation="G"
	 kb:recommendation="none">
	<kb:Guideline_Recommendation>Patients who have had retinopathy detected on previous examinations should be seen at least annually. The eye care provider should determine the optimal screening intervals based on the patient’s severity of retinopathy and risk factors associated with retinopathy progression.</kb:Guideline_Recommendation>
	<kb:expert_definition>step 10, Y in algorithm, MKG defined that pt should be seen by eye care provider wirthin 1 month of pcp referral</kb:expert_definition>
	<rdfs:label>16: Patients who have had retinopathy detected on previous examinations should be seen at least annually. The eye care provider should determine the optimal screening intervals based on the patient’s severity of retinopathy and risk factors associated with retinopathy progression.</rdfs:label>
</kb:Recommendations>
<kb:Recommendations rdf:about="&kb;Recommendations_Instance_17"
	 kb:ModuleName="1"
	 kb:Overall_Quality="Good"
	 kb:Quality_of_Evidence="II-1"
	 kb:RecID="17"
	 kb:recommendation="B">
	<kb:Guideline_Recommendation>Patients who have had no retinopathy on all previous examinations should be screened for retinopathy at least every other year (biennial screening).</kb:Guideline_Recommendation>
	<rdfs:label>17: Patients who have had no retinopathy on all previous examinations should be screened for retinopathy at least every other year (biennial screening).</rdfs:label>
</kb:Recommendations>
<kb:Recommendations rdf:about="&kb;Recommendations_Instance_18"
	 kb:ModuleName="1"
	 kb:Overall_Quality="Fair"
	 kb:Quality_of_Evidence="I"
	 kb:RecID="18"
	 kb:expert_definition="Step 12 in algorithm - MKG yearly follow up for these pts"
	 kb:recommendation="C">
	<kb:Guideline_Recommendation>More frequent screening should be considered in patients with clinical findings associated with an increased rate of progression or prevalence of retinopathy. These clinical findings include poorly controlled hypertension, chronic severe hyperglycemia, recent initiation or intensification of insulin therapy, or other known microvascular disease (albuminuria or neuropathy).</kb:Guideline_Recommendation>
	<rdfs:label>18: More frequent screening should be considered in patients with clinical findings associated with an increased rate of progression or prevalence of retinopathy. These clinical findings include poorly controlled hypertension, chronic severe hyperglycemia, recent initiation or intensification of insulin therapy, or other known microvascular disease (albuminuria or neuropathy).</rdfs:label>
</kb:Recommendations>
<kb:Recommendations rdf:about="&kb;Recommendations_Instance_19"
	 kb:ModuleName="2"
	 kb:Overall_Quality="Poor"
	 kb:Quality_of_Evidence="III"
	 kb:RecID="19"
	 kb:Recommendation_Annotation="A"
	 kb:recommendation="I">
	<kb:Guideline_Recommendation>Visual inspection of the feet at every routine primary care visit.</kb:Guideline_Recommendation>
	<rdfs:label>19: Visual inspection of the feet at every routine primary care visit.</rdfs:label>
</kb:Recommendations>
<kb:Recommendations rdf:about="&kb;Recommendations_Instance_2"
	 kb:ModuleName="1"
	 kb:Overall_Quality="Fair"
	 kb:Quality_of_Evidence="II-1"
	 kb:RecID="2"
	 kb:recommendation="C">
	<kb:Guideline_Recommendation>Routine retinopathy screening for patients with type 1 diabetes within 3 years of the diagnosis and for patients with type 2 diabetes within 3 months of the diagnosis, at most. Patients with visual symptoms should be urgently referred. </kb:Guideline_Recommendation>
	<rdfs:label>2: Routine retinopathy screening for patients with type 1 diabetes within 3 years of the diagnosis and for patients with type 2 diabetes within 3 months of the diagnosis, at most. Patients with visual symptoms should be urgently referred. </rdfs:label>
</kb:Recommendations>
<kb:Recommendations rdf:about="&kb;Recommendations_Instance_20"
	 kb:ModuleName="2"
	 kb:Overall_Quality="Fair"
	 kb:Quality_of_Evidence="III II II"
	 kb:RecID="20"
	 kb:Recommendation_Annotation="B"
	 kb:recommendation="B">
	<kb:Guideline_Recommendation>foot risk assessment must be performed and documented at least once a year. A complete foot risk assessment includes:
• Evaluation of the skin for breakdown
• Assessment of protective sensation using the Semmes-Weinstein 5.07 monofilament
• Evaluation for LE arterial disease
• Evaluation for foot deformity
• Prior history of ulcers or amputations
In addition, the patient’s footwear should be evaluated.
</kb:Guideline_Recommendation>
	<rdfs:label>20: foot risk assessment must be performed and documented at least once a year. A complete foot risk assessment includes:
• Evaluation of the skin for breakdown
• Assessment of protective sensation using the Semmes-Weinstein 5.07 monofilament
• Evaluation for LE arterial disease
• Evaluation for foot deformity
• Prior history of ulcers or amputations
In addition, the patient’s footwear should be evaluated.
</rdfs:label>
</kb:Recommendations>
<kb:Recommendations rdf:about="&kb;Recommendations_Instance_21"
	 kb:Guideline_Recommendation="Assessment of peripheral vascular disease."
	 kb:ModuleName="2"
	 kb:Overall_Quality="Fair"
	 kb:Quality_of_Evidence="II-1"
	 kb:RecID="21"
	 kb:Recommendation_Annotation="C"
	 kb:recommendation="B"
	 rdfs:label="21: Assessment of peripheral vascular disease."/>
<kb:Recommendations rdf:about="&kb;Recommendations_Instance_22"
	 kb:Guideline_Recommendation="Evaluation for acute ischemia or rest pain."
	 kb:ModuleName="2"
	 kb:Overall_Quality="Poor"
	 kb:Quality_of_Evidence="III"
	 kb:RecID="22"
	 kb:Recommendation_Annotation="C"
	 kb:recommendation="I"
	 rdfs:label="22: Evaluation for acute ischemia or rest pain."/>
<kb:Recommendations rdf:about="&kb;Recommendations_Instance_23"
	 kb:Guideline_Recommendation="Evaluation for foot ulceration."
	 kb:ModuleName="2"
	 kb:Overall_Quality="Poor"
	 kb:Quality_of_Evidence="III"
	 kb:RecID="23"
	 kb:Recommendation_Annotation="C"
	 kb:recommendation="I"
	 rdfs:label="23: Evaluation for foot ulceration."/>
<kb:Recommendations rdf:about="&kb;Recommendations_Instance_24"
	 kb:Guideline_Recommendation="Evaluation for ingrown toenail."
	 kb:ModuleName="2"
	 kb:Overall_Quality="Fair"
	 kb:Quality_of_Evidence="II-1"
	 kb:RecID="24"
	 kb:Recommendation_Annotation="C"
	 kb:recommendation="B"
	 rdfs:label="24: Evaluation for ingrown toenail."/>
<kb:Recommendations rdf:about="&kb;Recommendations_Instance_25"
	 kb:ModuleName="2"
	 kb:Overall_Quality="na"
	 kb:Quality_of_Evidence="na"
	 kb:RecID="25"
	 kb:Recommendation_Annotation="C"
	 kb:recommendation="na">
	<kb:Guideline_Recommendation>Evaluation should be performed for limb-threatening conditions, such as systemic infection, acute ischemia/rest pain, foot ulceration, puncture wound, ingrown toenail, and hemorragic callus with or without cellulitis.</kb:Guideline_Recommendation>
	<rdfs:label>25: Evaluation should be performed for limb-threatening conditions, such as systemic infection, acute ischemia/rest pain, foot ulceration, puncture wound, ingrown toenail, and hemorragic callus with or without cellulitis.</rdfs:label>
</kb:Recommendations>
<kb:Recommendations rdf:about="&kb;Recommendations_Instance_26"
	 kb:Guideline_Recommendation="Referral for life-threatening conditions"
	 kb:ModuleName="2"
	 kb:Overall_Quality="Poor"
	 kb:Quality_of_Evidence="III"
	 kb:RecID="26"
	 kb:Recommendation_Annotation="D"
	 kb:recommendation="I"
	 rdfs:label="26: Referral for life-threatening conditions"/>
<kb:Recommendations rdf:about="&kb;Recommendations_Instance_27"
	 kb:ModuleName="2"
	 kb:Overall_Quality="Poor"
	 kb:Quality_of_Evidence="III, II, III"
	 kb:RecID="27"
	 kb:Recommendation_Annotation="D"
	 kb:recommendation="I">
	<kb:Guideline_Recommendation>Referral to a vascular specialist for symptoms that limit lifestyle.</kb:Guideline_Recommendation>
	<rdfs:label>27: Referral to a vascular specialist for symptoms that limit lifestyle.</rdfs:label>
</kb:Recommendations>
<kb:Recommendations rdf:about="&kb;Recommendations_Instance_28"
	 kb:Guideline_Recommendation="Identification of risk factors in the diabetic foot."
	 kb:ModuleName="2"
	 kb:Overall_Quality="Fair"
	 kb:RecID="28"
	 kb:recommendation="B"
	 rdfs:label="28: Identification of risk factors in the diabetic foot.">
	<kb:Quality_of_Evidence>III, III, III, III, II-2, II, III, II, II, III, II
</kb:Quality_of_Evidence>
</kb:Recommendations>
<kb:Recommendations rdf:about="&kb;Recommendations_Instance_29"
	 kb:ModuleName="2"
	 kb:Overall_Quality="na"
	 kb:Quality_of_Evidence="na"
	 kb:RecID="29"
	 kb:Recommendation_Annotation="E"
	 kb:recommendation="na">
	<kb:Guideline_Recommendation>The patient at high-risk should be referred to a foot care specialist for a more comprehensive evaluation and intensive treatment plan including patient education concerning foot care practices, hygiene, and footwear.</kb:Guideline_Recommendation>
	<rdfs:label>29: The patient at high-risk should be referred to a foot care specialist for a more comprehensive evaluation and intensive treatment plan including patient education concerning foot care practices, hygiene, and footwear.</rdfs:label>
</kb:Recommendations>
<kb:Recommendations rdf:about="&kb;Recommendations_Instance_3"
	 kb:ModuleName="1"
	 kb:Overall_Quality="Good"
	 kb:Quality_of_Evidence="II-2"
	 kb:RecID="3"
	 kb:recommendation="B">
	<kb:Guideline_Recommendation>Biennial screening (every other year) for retinopathy for patients with no retinopathy on all previous examinations. </kb:Guideline_Recommendation>
	<rdfs:label>3: Biennial screening (every other year) for retinopathy for patients with no retinopathy on all previous examinations. </rdfs:label>
</kb:Recommendations>
<kb:Recommendations rdf:about="&kb;Recommendations_Instance_30"
	 kb:ModuleName="2"
	 kb:Overall_Quality="na"
	 kb:Quality_of_Evidence="na"
	 kb:RecID="30"
	 kb:Recommendation_Annotation="E"
	 kb:recommendation="na">
	<kb:Guideline_Recommendation>The existence of one of the following characteristics is sufficient to define the patient as high-risk for foot problem.
o Lack of sensation to Semmes-Weinstein 5.07 monofilament at one or more noncallused plantar sites
o Evidence of LE arterial disease (absence of both dorsalis pedis and tibialis posterior pulses, dependent rubor with pallor on elevation, history of rest pain or claudication, and prior history of LE bypass surgery)
o Foot deformities (specifically hammer toes, claw toe, Charcot's arthropathy, bunions, and metatarsal head deformities)
o History of foot ulcer or non-traumatic LEA at any level</kb:Guideline_Recommendation>
	<rdfs:label>30: The existence of one of the following characteristics is sufficient to define the patient as high-risk for foot problem.
o Lack of sensation to Semmes-Weinstein 5.07 monofilament at one or more noncallused plantar sites
o Evidence of LE arterial disease (absence of both dorsalis pedis and tibialis posterior pulses, dependent rubor with pallor on elevation, history of rest pain or claudication, and prior history of LE bypass surgery)
o Foot deformities (specifically hammer toes, claw toe, Charcot's arthropathy, bunions, and metatarsal head deformities)
o History of foot ulcer or non-traumatic LEA at any level</rdfs:label>
</kb:Recommendations>
<kb:Recommendations rdf:about="&kb;Recommendations_Instance_31"
	 kb:ModuleName="2"
	 kb:Overall_Quality="na"
	 kb:Quality_of_Evidence="na"
	 kb:RecID="31"
	 kb:Recommendation_Annotation="E"
	 kb:recommendation="na">
	<kb:Guideline_Recommendation>Patients without limb-threatening conditions should be evaluated for their level of risk for LE foot ulcers and amputations.</kb:Guideline_Recommendation>
	<rdfs:label>31: Patients without limb-threatening conditions should be evaluated for their level of risk for LE foot ulcers and amputations.</rdfs:label>
</kb:Recommendations>
<kb:Recommendations rdf:about="&kb;Recommendations_Instance_32"
	 kb:ModuleName="2"
	 kb:RecID="32"
	 kb:Recommendation_Annotation="F">
	<kb:Guideline_Recommendation>Minor lesions or wounds that could possibly be treated by the primary care provider are blisters, erosions, and/or minor cuts that do not extend beyond subcutaneous tissue. Pulses are present, there are no signs of acute infection, and there is no severe lower limb pain and no sign of a worsening lesion.</kb:Guideline_Recommendation>
	<rdfs:label>32: Minor lesions or wounds that could possibly be treated by the primary care provider are blisters, erosions, and/or minor cuts that do not extend beyond subcutaneous tissue. Pulses are present, there are no signs of acute infection, and there is no severe lower limb pain and no sign of a worsening lesion.</rdfs:label>
</kb:Recommendations>
<kb:Recommendations rdf:about="&kb;Recommendations_Instance_33"
	 kb:ModuleName="2"
	 kb:RecID="33"
	 kb:Recommendation_Annotation="F">
	<kb:Guideline_Recommendation>Patients with an ingrown toenail should be referred to a foot specialist for evaluation and treatment </kb:Guideline_Recommendation>
	<rdfs:label>33: Patients with an ingrown toenail should be referred to a foot specialist for evaluation and treatment </rdfs:label>
</kb:Recommendations>
<kb:Recommendations rdf:about="&kb;Recommendations_Instance_34"
	 kb:ModuleName="2"
	 kb:Overall_Quality="Poor"
	 kb:Quality_of_Evidence="III"
	 kb:RecID="34"
	 kb:Recommendation_Annotation="G"
	 kb:recommendation="I">
	<kb:Guideline_Recommendation>High-risk patients with a minor foot wound or lesion should be promptly referred to a foot care specialist (i.e., podiatrist, vascular surgeon, orthopedic surgeon, and other healthcare providers with demonstrated training, competence, and licensure in foot care) for evaluation and treatment.</kb:Guideline_Recommendation>
	<rdfs:label>34: High-risk patients with a minor foot wound or lesion should be promptly referred to a foot care specialist (i.e., podiatrist, vascular surgeon, orthopedic surgeon, and other healthcare providers with demonstrated training, competence, and licensure in foot care) for evaluation and treatment.</rdfs:label>
</kb:Recommendations>
<kb:Recommendations rdf:about="&kb;Recommendations_Instance_35"
	 kb:ModuleName="2"
	 kb:Overall_Quality="Poor"
	 kb:Quality_of_Evidence="III"
	 kb:RecID="35"
	 kb:Recommendation_Annotation="G"
	 kb:recommendation="I">
	<kb:Guideline_Recommendation>Footwear prescriptions should be based upon individual characteristics of foot structure and function.</kb:Guideline_Recommendation>
	<rdfs:label>35: Footwear prescriptions should be based upon individual characteristics of foot structure and function.</rdfs:label>
</kb:Recommendations>
<kb:Recommendations rdf:about="&kb;Recommendations_Instance_36"
	 kb:ModuleName="2"
	 kb:RecID="36"
	 kb:Recommendation_Annotation="H">
	<kb:Guideline_Recommendation>All patients and their families should receive self-management education for preventive foot care and selection of footwear. Instruction should include recommendations for daily foot inspection and preventive foot care, skin care, and use of emollients, nail care, and treatment for callus.</kb:Guideline_Recommendation>
	<rdfs:label>36: All patients and their families should receive self-management education for preventive foot care and selection of footwear. Instruction should include recommendations for daily foot inspection and preventive foot care, skin care, and use of emollients, nail care, and treatment for callus.</rdfs:label>
</kb:Recommendations>
<kb:Recommendations rdf:about="&kb;Recommendations_Instance_37"
	 kb:Guideline_Recommendation="Patient education on specific aspects of care."
	 kb:ModuleName="2"
	 kb:Overall_Quality="Fair"
	 kb:Quality_of_Evidence="III, I, III"
	 kb:RecID="37"
	 kb:Recommendation_Annotation="H"
	 kb:recommendation="B"
	 rdfs:label="37: Patient education on specific aspects of care."/>
<kb:Recommendations rdf:about="&kb;Recommendations_Instance_38"
	 kb:Guideline_Recommendation="Patient instruction on self-foot care."
	 kb:ModuleName="2"
	 kb:Overall_Quality="Fair"
	 kb:Quality_of_Evidence="III, II, II, III, II, III"
	 kb:RecID="38"
	 kb:Recommendation_Annotation="H"
	 kb:recommendation="B"
	 rdfs:label="38: Patient instruction on self-foot care."/>
<kb:Recommendations rdf:about="&kb;Recommendations_Instance_39"
	 kb:ModuleName="2"
	 kb:Overall_Quality="na"
	 kb:Quality_of_Evidence="na"
	 kb:RecID="39"
	 kb:Recommendation_Annotation="I"
	 kb:recommendation="na">
	<kb:Guideline_Recommendation>Visual inspection and peripheral sensation testing should be performed at each routine primary care visit for all patients </kb:Guideline_Recommendation>
	<rdfs:label>39: Visual inspection and peripheral sensation testing should be performed at each routine primary care visit for all patients </rdfs:label>
</kb:Recommendations>
<kb:Recommendations rdf:about="&kb;Recommendations_Instance_4"
	 kb:ModuleName="1"
	 kb:Overall_Quality="Fair"
	 kb:Quality_of_Evidence="I"
	 kb:RecID="5"
	 kb:recommendation="B">
	<kb:Guideline_Recommendation>At least annual screening for patients who had retinopathy detected on previous examinations. Optimal screening intervals should be based on the patient’s severity of retinopathy and risk factors associated with retinopathy progression. </kb:Guideline_Recommendation>
	<rdfs:label>5: At least annual screening for patients who had retinopathy detected on previous examinations. Optimal screening intervals should be based on the patient’s severity of retinopathy and risk factors associated with retinopathy progression. </rdfs:label>
</kb:Recommendations>
<kb:Recommendations rdf:about="&kb;Recommendations_Instance_40"
	 kb:ModuleName="2"
	 kb:RecID="40"
	 kb:Recommendation_Annotation="J">
	<kb:Guideline_Recommendation>Patients with diabetes with minor wounds or foot lesions should have a wound assessment.</kb:Guideline_Recommendation>
	<rdfs:label>40: Patients with diabetes with minor wounds or foot lesions should have a wound assessment.</rdfs:label>
</kb:Recommendations>
<kb:Recommendations rdf:about="&kb;Recommendations_Instance_41"
	 kb:ModuleName="2"
	 kb:RecID="41"
	 kb:Recommendation_Annotation="K">
	<kb:Guideline_Recommendation>Patients with diabetes with uncomplicated minor lesions should receive local wound care. Primary care providers should attempt to offload weight-bearing on the affected extremity.</kb:Guideline_Recommendation>
	<rdfs:label>41: Patients with diabetes with uncomplicated minor lesions should receive local wound care. Primary care providers should attempt to offload weight-bearing on the affected extremity.</rdfs:label>
</kb:Recommendations>
<kb:Recommendations rdf:about="&kb;Recommendations_Instance_42"
	 kb:ModuleName="2"
	 kb:RecID="42"
	 kb:Recommendation_Annotation="K">
	<kb:Guideline_Recommendation>Patients with diabetes with uncomplicated minor lesions must be followed at least monthly.</kb:Guideline_Recommendation>
	<rdfs:label>42: Patients with diabetes with uncomplicated minor lesions must be followed at least monthly.</rdfs:label>
</kb:Recommendations>
<kb:Recommendations rdf:about="&kb;Recommendations_Instance_43"
	 kb:Guideline_Recommendation="Local wound care."
	 kb:ModuleName="2"
	 kb:Overall_Quality="Poor"
	 kb:Quality_of_Evidence="III"
	 kb:RecID="43"
	 kb:Recommendation_Annotation="K"
	 kb:recommendation="I"
	 rdfs:label="43: Local wound care."/>
<kb:Recommendations rdf:about="&kb;Recommendations_Instance_44"
	 kb:ModuleName="2"
	 kb:RecID="44"
	 kb:Recommendation_Annotation="L">
	<kb:Guideline_Recommendation>Patients with diabetes treated for an uncomplicated wound should be assessed within four weeks from the initial wound assessment for appropriate reduction in lesion size and depth and appearance of healthy granulating tissue with no evidence of infection.</kb:Guideline_Recommendation>
	<rdfs:label>44: Patients with diabetes treated for an uncomplicated wound should be assessed within four weeks from the initial wound assessment for appropriate reduction in lesion size and depth and appearance of healthy granulating tissue with no evidence of infection.</rdfs:label>
</kb:Recommendations>
<kb:Recommendations rdf:about="&kb;Recommendations_Instance_45"
	 kb:Guideline_Recommendation="Assessment of wound healing progress within 4 weeks."
	 kb:ModuleName="2"
	 kb:Overall_Quality="Poor"
	 kb:Quality_of_Evidence="III"
	 kb:RecID="45"
	 kb:Recommendation_Annotation="L"
	 kb:recommendation="I"
	 rdfs:label="45: Assessment of wound healing progress within 4 weeks."/>
<kb:Recommendations rdf:about="&kb;Recommendations_Instance_46"
	 kb:ModuleName="2"
	 kb:Overall_Quality="na"
	 kb:Quality_of_Evidence="na"
	 kb:RecID="46"
	 kb:Recommendation_Annotation="M"
	 kb:recommendation="na">
	<kb:Guideline_Recommendation>Patients with diabetes with minor foot problems (e.g., onychomycosis, painful corn, dry skin, athlete’s foot, minor calluses, uncomplicated nail trimming and improper foot hygiene) may be treated by a primary care provider in the office or by the patient or family members at home </kb:Guideline_Recommendation>
	<rdfs:label>46: Patients with diabetes with minor foot problems (e.g., onychomycosis, painful corn, dry skin, athlete’s foot, minor calluses, uncomplicated nail trimming and improper foot hygiene) may be treated by a primary care provider in the office or by the patient or family members at home </rdfs:label>
</kb:Recommendations>
<kb:Recommendations rdf:about="&kb;Recommendations_Instance_47"
	 kb:ModuleName="2"
	 kb:RecID="47"
	 kb:Recommendation_Annotation="N">
	<kb:Guideline_Recommendation>Assure that patient and family members have received appropriate education regarding preventive foot care.</kb:Guideline_Recommendation>
	<rdfs:label>47: Assure that patient and family members have received appropriate education regarding preventive foot care.</rdfs:label>
</kb:Recommendations>
<kb:Recommendations rdf:about="&kb;Recommendations_Instance_48"
	 kb:Guideline_Recommendation="Treat minor foot problems, as appropriate"
	 kb:ModuleName="2"
	 kb:Overall_Quality="Poor"
	 kb:Quality_of_Evidence="III, II, III, III, III"
	 kb:RecID="48"
	 kb:Recommendation_Annotation="N"
	 kb:recommendation="I"
	 rdfs:label="48: Treat minor foot problems, as appropriate"/>
<kb:Recommendations rdf:about="&kb;Recommendations_Instance_49"
	 kb:Guideline_Recommendation="Progression to proliferative retinopathy."
	 kb:ModuleName="3"
	 kb:Overall_Quality="Fair"
	 kb:Quality_of_Evidence="I"
	 kb:RecID="253"
	 kb:Recommendation_Annotation="B"
	 kb:recommendation="B"
	 rdfs:label="253: Progression to proliferative retinopathy."/>
<kb:Recommendations rdf:about="&kb;Recommendations_Instance_5"
	 kb:ModuleName="1"
	 kb:Overall_Quality="Poor"
	 kb:Quality_of_Evidence="III"
	 kb:RecID="6"
	 kb:recommendation="I">
	<kb:Guideline_Recommendation>Periodic comprehensive eye examinations by a trained eye specialist based on the individual patient's risk factors for ocular disease, other than diabetic retinopathy.</kb:Guideline_Recommendation>
	<rdfs:label>6: Periodic comprehensive eye examinations by a trained eye specialist based on the individual patient's risk factors for ocular disease, other than diabetic retinopathy.</rdfs:label>
</kb:Recommendations>
<kb:Recommendations rdf:about="&kb;Recommendations_Instance_50"
	 kb:ModuleName="3"
	 kb:RecID="254"
	 kb:Recommendation_Annotation="G">
	<kb:Guideline_Recommendation>Each patient's glycemic target range must be individualized, based on the provider's appraisal of the risk-benefit ratio for that individual.</kb:Guideline_Recommendation>
	<rdfs:label>254: Each patient's glycemic target range must be individualized, based on the provider's appraisal of the risk-benefit ratio for that individual.</rdfs:label>
</kb:Recommendations>
<kb:Recommendations rdf:about="&kb;Recommendations_Instance_51"
	 kb:Guideline_Recommendation="Assess Glycemic Control"
	 kb:ModuleName="3"
	 kb:RecID="255"
	 kb:Recommendation_Annotation="B"
	 rdfs:label="255: Assess Glycemic Control"/>
<kb:Recommendations rdf:about="&kb;Recommendations_Instance_52"
	 kb:ModuleName="3"
	 kb:RecID="256"
	 kb:Recommendation_Annotation="C">
	<kb:Guideline_Recommendation>Determine Recommended Glycemic Control Target Using Risk Stratification Criteria</kb:Guideline_Recommendation>
	<rdfs:label>256: Determine Recommended Glycemic Control Target Using Risk Stratification Criteria</rdfs:label>
</kb:Recommendations>
<kb:Recommendations rdf:about="&kb;Recommendations_Instance_53"
	 kb:ModuleName="3"
	 kb:Overall_Quality="na"
	 kb:Quality_of_Evidence="na"
	 kb:RecID="257"
	 kb:Recommendation_Annotation="D"
	 kb:recommendation="na">
	<kb:Guideline_Recommendation>Risks of a proposed therapy should be balanced against the potential benefits, based upon the patient's medical, social, and psychological status.</kb:Guideline_Recommendation>
	<rdfs:label>257: Risks of a proposed therapy should be balanced against the potential benefits, based upon the patient's medical, social, and psychological status.</rdfs:label>
</kb:Recommendations>
<kb:Recommendations rdf:about="&kb;Recommendations_Instance_54"
	 kb:ModuleName="3"
	 kb:RecID="258"
	 kb:Recommendation_Annotation="N">
	<kb:Guideline_Recommendation>1.	The patient should be scheduled for appropriate follow-up to evaluate response, tolerability to therapy, goal re-assessment, and management of acute and chronic problems.
2.	The frequency of primary care provider visits for the patient with diabetes who is meeting treatment goals and who has no unstable chronic complications should be individualized.
3.	When there is a sudden change in health status or when changes are made to the treatment regimen, follow-up within one month or sooner may be appropriate</kb:Guideline_Recommendation>
	<rdfs:label>258: 1.	The patient should be scheduled for appropriate follow-up to evaluate response, tolerability to therapy, goal re-assessment, and management of acute and chronic problems.
2.	The frequency of primary care provider visits for the patient with diabetes who is meeting treatment goals and who has no unstable chronic complications should be individualized.
3.	When there is a sudden change in health status or when changes are made to the treatment regimen, follow-up within one month or sooner may be appropriate</rdfs:label>
</kb:Recommendations>
<kb:Recommendations rdf:about="&kb;Recommendations_Instance_55"
	 kb:ModuleName="3"
	 kb:RecID="259"
	 kb:Recommendation_Annotation="M">
	<kb:Guideline_Recommendation>Treatment goals should be periodically reassessed based upon patient specific factors, including changes in the patient's health status, adverse drug reactions, adherence to therapy, and preferences.</kb:Guideline_Recommendation>
	<rdfs:label>259: Treatment goals should be periodically reassessed based upon patient specific factors, including changes in the patient's health status, adverse drug reactions, adherence to therapy, and preferences.</rdfs:label>
</kb:Recommendations>
<kb:Recommendations rdf:about="&kb;Recommendations_Instance_56"
	 kb:ModuleName="3"
	 kb:RecID="260"
	 kb:Recommendation_Annotation="L">
	<kb:Guideline_Recommendation>1.If the patient does not achieve his/her target range, the provider should identify barriers to patient adherence to the treatment regimen (e.g., miscommunication, lack of education or understanding, financial/social/psychological barriers, and cultural beliefs).
2.If barriers are identified referral to a case manager or behavioral/financial counselor should be considered as appropriate.</kb:Guideline_Recommendation>
	<rdfs:label>260: 1.If the patient does not achieve his/her target range, the provider should identify barriers to patient adherence to the treatment regimen (e.g., miscommunication, lack of education or understanding, financial/social/psychological barriers, and cultural beliefs).
2.If barriers are identified referral to a case manager or behavioral/financial counselor should be considered as appropriate.</rdfs:label>
</kb:Recommendations>
<kb:Recommendations rdf:about="&kb;Recommendations_Instance_57"
	 kb:ModuleName="3"
	 kb:RecID="261"
	 kb:Recommendation_Annotation="K">
	<kb:Guideline_Recommendation>The patient with recurrent or severe hypoglycemia should be evaluated for precipitating factors that may be easily corrected (e.g., missed meals, exercise, incorrect administration of insulin-dosage or timing).</kb:Guideline_Recommendation>
	<rdfs:label>261: The patient with recurrent or severe hypoglycemia should be evaluated for precipitating factors that may be easily corrected (e.g., missed meals, exercise, incorrect administration of insulin-dosage or timing).</rdfs:label>
</kb:Recommendations>
<kb:Recommendations rdf:about="&kb;Recommendations_Instance_58"
	 kb:ModuleName="3"
	 kb:RecID="262"
	 kb:Recommendation_Annotation="J">
	<kb:Guideline_Recommendation>Individual treatment goals must be established with the patient based on the extent of the disease, comorbid conditions, and patient preferences.</kb:Guideline_Recommendation>
	<rdfs:label>262: Individual treatment goals must be established with the patient based on the extent of the disease, comorbid conditions, and patient preferences.</rdfs:label>
</kb:Recommendations>
<kb:Recommendations rdf:about="&kb;Recommendations_Instance_59"
	 kb:ModuleName="3"
	 kb:RecID="263"
	 kb:Recommendation_Annotation="J">
	<kb:Guideline_Recommendation>Institution of diet and exercise is usually the appropriate initial management in patients with new onset type 2 diabetes, depending upon severity of symptoms, pyschosocial evaluation, and overall health status. Encourage diet and exercise and lifestyle modification.</kb:Guideline_Recommendation>
	<rdfs:label>263: Institution of diet and exercise is usually the appropriate initial management in patients with new onset type 2 diabetes, depending upon severity of symptoms, pyschosocial evaluation, and overall health status. Encourage diet and exercise and lifestyle modification.</rdfs:label>
</kb:Recommendations>
<kb:Recommendations rdf:about="&kb;Recommendations_Instance_6"
	 kb:ModuleName="1"
	 kb:Overall_Quality="na"
	 kb:Quality_of_Evidence="na"
	 kb:RecID="7"
	 kb:Recommendation_Annotation="A"
	 kb:recommendation="na">
	<kb:Guideline_Recommendation>Patients with an acute change in vision (i.e., occurring within a 48 – 72 hours period) or change in ocular function should be urgently referred to an eye care provider.</kb:Guideline_Recommendation>
	<rdfs:label>7: Patients with an acute change in vision (i.e., occurring within a 48 – 72 hours period) or change in ocular function should be urgently referred to an eye care provider.</rdfs:label>
</kb:Recommendations>
<kb:Recommendations rdf:about="&kb;Recommendations_Instance_60"
	 kb:ModuleName="3"
	 kb:RecID="264"
	 kb:Recommendation_Annotation="J">
	<kb:Guideline_Recommendation>If treatment goals are not achieved with diet and exercise alone, drug therapy should be initiated.</kb:Guideline_Recommendation>
	<rdfs:label>264: If treatment goals are not achieved with diet and exercise alone, drug therapy should be initiated.</rdfs:label>
</kb:Recommendations>
<kb:Recommendations rdf:about="&kb;Recommendations_Instance_61"
	 kb:ModuleName="3"
	 kb:RecID="265"
	 kb:Recommendation_Annotation="J">
	<kb:Guideline_Recommendation>4.	There is no evidence that blood glucose monitoring in stable type 2 DM patients is of clinical benefit. If self-monitoring is to be done, a twice-weekly regimen is usually sufficient. Special situations, such as acute intercurrent illness, frequent hypo- or hyperglycemia, or changes in medication regimen, may justify more frequent monitoring on a temporary basis.</kb:Guideline_Recommendation>
	<rdfs:label>265: 4.	There is no evidence that blood glucose monitoring in stable type 2 DM patients is of clinical benefit. If self-monitoring is to be done, a twice-weekly regimen is usually sufficient. Special situations, such as acute intercurrent illness, frequent hypo- or hyperglycemia, or changes in medication regimen, may justify more frequent monitoring on a temporary basis.</rdfs:label>
</kb:Recommendations>
<kb:Recommendations rdf:about="&kb;Recommendations_Instance_62"
	 kb:Guideline_Recommendation="The PPG level should be used to modify the therapy"
	 kb:ModuleName="3"
	 kb:Overall_Quality="Poor"
	 kb:Quality_of_Evidence="III"
	 kb:RecID="266"
	 kb:Recommendation_Annotation="B"
	 kb:recommendation="I"
	 rdfs:label="266: The PPG level should be used to modify the therapy"/>
<kb:Recommendations rdf:about="&kb;Recommendations_Instance_63"
	 kb:ModuleName="3"
	 kb:Overall_Quality="na"
	 kb:Quality_of_Evidence="na"
	 kb:RecID="267"
	 kb:Recommendation_Annotation="B"
	 kb:recommendation="na">
	<kb:Guideline_Recommendation>HbA1c should be measured periodically to assess glycemic control over time.</kb:Guideline_Recommendation>
	<rdfs:label>267: HbA1c should be measured periodically to assess glycemic control over time.</rdfs:label>
</kb:Recommendations>
<kb:Recommendations rdf:about="&kb;Recommendations_Instance_64"
	 kb:ModuleName="3"
	 kb:Overall_Quality="na"
	 kb:Quality_of_Evidence="na"
	 kb:RecID="268"
	 kb:Recommendation_Annotation="C"
	 kb:recommendation="na">
	<kb:Guideline_Recommendation xml:space='preserve'><![CDATA[HbA1c target for any patient with diabetes should be kept <9 percent to avoid symptoms of hyperglycemia.]]></kb:Guideline_Recommendation>
	<rdfs:label xml:space='preserve'><![CDATA[268: HbA1c target for any patient with diabetes should be kept <9 percent to avoid symptoms of hyperglycemia.]]></rdfs:label>
</kb:Recommendations>
<kb:Recommendations rdf:about="&kb;Recommendations_Instance_65"
	 kb:ModuleName="3"
	 kb:Overall_Quality="na"
	 kb:Quality_of_Evidence="na"
	 kb:RecID="270"
	 kb:Recommendation_Annotation="C"
	 kb:recommendation="na">
	<kb:Guideline_Recommendation>The patient with advanced microvascular complications and/or major comorbid illness, or short life expectancy is less likely to show survival benefit; therefore, aggressive glucose lowering may not be warranted.</kb:Guideline_Recommendation>
	<rdfs:label>270: The patient with advanced microvascular complications and/or major comorbid illness, or short life expectancy is less likely to show survival benefit; therefore, aggressive glucose lowering may not be warranted.</rdfs:label>
</kb:Recommendations>
<kb:Recommendations rdf:about="&kb;Recommendations_Instance_66"
	 kb:ModuleName="3"
	 kb:Overall_Quality="na"
	 kb:Quality_of_Evidence="na"
	 kb:RecID="271"
	 kb:Recommendation_Annotation="C"
	 kb:recommendation="na">
	<kb:Guideline_Recommendation>Risk of hypoglycemia should be considered in recommending a target goal.</kb:Guideline_Recommendation>
	<rdfs:label>271: Risk of hypoglycemia should be considered in recommending a target goal.</rdfs:label>
</kb:Recommendations>
<kb:Recommendations rdf:about="&kb;Recommendations_Instance_67"
	 kb:ModuleName="3"
	 kb:Overall_Quality="na"
	 kb:Quality_of_Evidence="na"
	 kb:RecID="272"
	 kb:Recommendation_Annotation="E"
	 kb:recommendation="na">
	<kb:Guideline_Recommendation>A specific target range of glycemic control should be negotiated by the patient and provider after discussing the risks and benefits of therapy.</kb:Guideline_Recommendation>
	<rdfs:label>272: A specific target range of glycemic control should be negotiated by the patient and provider after discussing the risks and benefits of therapy.</rdfs:label>
</kb:Recommendations>
<kb:Recommendations rdf:about="&kb;Recommendations_Instance_68"
	 kb:ModuleName="3"
	 kb:Overall_Quality="na"
	 kb:Quality_of_Evidence="na"
	 kb:RecID="273"
	 kb:Recommendation_Annotation="E"
	 kb:recommendation="na">
	<kb:Guideline_Recommendation>If necessary, the patient should be referred to an endocrine/diabetes clinic or a case manager to meet glycemic control target goals.</kb:Guideline_Recommendation>
	<rdfs:label>273: If necessary, the patient should be referred to an endocrine/diabetes clinic or a case manager to meet glycemic control target goals.</rdfs:label>
</kb:Recommendations>
<kb:Recommendations rdf:about="&kb;Recommendations_Instance_69"
	 kb:ModuleName="3"
	 kb:Overall_Quality="na"
	 kb:Quality_of_Evidence="na"
	 kb:RecID="274"
	 kb:Recommendation_Annotation="F"
	 kb:recommendation="na">
	<kb:Guideline_Recommendation>The patient with HbA1c >9.5 percent should be considered for aggressive management on an expedited basis.</kb:Guideline_Recommendation>
	<rdfs:label>274: The patient with HbA1c >9.5 percent should be considered for aggressive management on an expedited basis.</rdfs:label>
</kb:Recommendations>
<kb:Recommendations rdf:about="&kb;Recommendations_Instance_7"
	 kb:ModuleName="3"
	 kb:Overall_Quality="Poor"
	 kb:Quality_of_Evidence="III"
	 kb:RecID="251"
	 kb:Recommendation_Annotation="B"
	 kb:recommendation="I">
	<kb:Guideline_Recommendation>Postprandial plasma glucose (PPG) level should be assessed in patients with:
o  Elevated HbA1c (not at target) but a normal fasting plasma glucose level
o  Frequent troublesome hypoglycemic symptoms during waking active hours</kb:Guideline_Recommendation>
	<rdfs:label>251: Postprandial plasma glucose (PPG) level should be assessed in patients with:
o  Elevated HbA1c (not at target) but a normal fasting plasma glucose level
o  Frequent troublesome hypoglycemic symptoms during waking active hours</rdfs:label>
</kb:Recommendations>
<kb:Recommendations rdf:about="&kb;Recommendations_Instance_70"
	 kb:ModuleName="3"
	 kb:Overall_Quality="na"
	 kb:Quality_of_Evidence="na"
	 kb:RecID="275"
	 kb:Recommendation_Annotation="F"
	 kb:recommendation="na">
	<kb:Guideline_Recommendation>The patient who is on high-dose multiple agents should be considered for referral.</kb:Guideline_Recommendation>
	<kb:expert_definition>need to define high dose of multiple agents:
MM talked to Kristen To on 10/24/08
KT says the high dosage in her spreadsheet should suffice, and that 2 or more agents would be considered multiple agents.  Also most of the referrals should go to diabetes care (the clinic where she works), not endo.  Endo deals with very complicated cases and she would hate to have us
over refer to endo.  So what we decided was the first 3 bullet points on the guideline under high risk (p 8 (for me) module G annotation f) should
be referred to endo, the last 2 referred to diabetes care.</kb:expert_definition>
	<rdfs:label>275: The patient who is on high-dose multiple agents should be considered for referral.</rdfs:label>
</kb:Recommendations>
<kb:Recommendations rdf:about="&kb;Recommendations_Instance_71"
	 kb:ModuleName="3"
	 kb:RecID="276"
	 kb:Recommendation_Annotation="G">
	<kb:Guideline_Recommendation>The patient with type 1 DM should receive insulin replacement therapy.</kb:Guideline_Recommendation>
	<rdfs:label>276: The patient with type 1 DM should receive insulin replacement therapy.</rdfs:label>
</kb:Recommendations>
<kb:Recommendations rdf:about="&kb;Recommendations_Instance_72"
	 kb:ModuleName="3"
	 kb:Overall_Quality="na"
	 kb:Quality_of_Evidence="na"
	 kb:RecID="277"
	 kb:Recommendation_Annotation="G"
	 kb:recommendation="na">
	<kb:Guideline_Recommendation>The patient with type 2 DM or DM of undetermined cause who exhibits significant or rapid weight loss and/or persistent non-fasting ketonuria has at least severe relative insulin deficiency and will likely require insulin therapy on an indefinite basis.</kb:Guideline_Recommendation>
	<rdfs:label>277: The patient with type 2 DM or DM of undetermined cause who exhibits significant or rapid weight loss and/or persistent non-fasting ketonuria has at least severe relative insulin deficiency and will likely require insulin therapy on an indefinite basis.</rdfs:label>
</kb:Recommendations>
<kb:Recommendations rdf:about="&kb;Recommendations_Instance_73"
	 kb:ModuleName="3"
	 kb:Overall_Quality="na"
	 kb:Quality_of_Evidence="na"
	 kb:RecID="278"
	 kb:Recommendation_Annotation="H"
	 kb:recommendation="na">
	<kb:Guideline_Recommendation>All patients with type 1 DM should be referred to a diabetic clinic with multidisciplinary resources (e.g., diabetologist, diabetic nurse, educator/manager, and registered dietitian) for institution and adjustment of insulin therapy.</kb:Guideline_Recommendation>
	<rdfs:label>278: All patients with type 1 DM should be referred to a diabetic clinic with multidisciplinary resources (e.g., diabetologist, diabetic nurse, educator/manager, and registered dietitian) for institution and adjustment of insulin therapy.</rdfs:label>
</kb:Recommendations>
<kb:Recommendations rdf:about="&kb;Recommendations_Instance_74"
	 kb:ModuleName="3"
	 kb:Overall_Quality="na"
	 kb:Quality_of_Evidence="na"
	 kb:RecID="279"
	 kb:Recommendation_Annotation="H"
	 kb:recommendation="na">
	<kb:Guideline_Recommendation>1.If expeditious referral is not possible, the primary care provider should institute "survival" insulin therapy.
-- Calculate total daily dose (TDD) of 0.5 units/kg body weight/day.
-- Two-thirds of the TDD administered 30 minutes prior to breakfast as two-parts human neutral protamine Hagedorn insulin (NPH) insulin and one-part human regular insulin.
-- The remaining third of the TDD can be split equally, as human regular insulin 30 minutes before supper and as human NPH insulin at bedtime.</kb:Guideline_Recommendation>
	<rdfs:label>279: 1.If expeditious referral is not possible, the primary care provider should institute "survival" insulin therapy.
-- Calculate total daily dose (TDD) of 0.5 units/kg body weight/day.
-- Two-thirds of the TDD administered 30 minutes prior to breakfast as two-parts human neutral protamine Hagedorn insulin (NPH) insulin and one-part human regular insulin.
-- The remaining third of the TDD can be split equally, as human regular insulin 30 minutes before supper and as human NPH insulin at bedtime.</rdfs:label>
</kb:Recommendations>
<kb:Recommendations rdf:about="&kb;Recommendations_Instance_75"
	 kb:ModuleName="3"
	 kb:Overall_Quality="na"
	 kb:Quality_of_Evidence="na"
	 kb:RecID="280"
	 kb:Recommendation_Annotation="I"
	 kb:recommendation="na">
	<kb:Guideline_Recommendation>Patients with diabetes should be assessed for knowledge, performance skills, and barriers to full compliance.</kb:Guideline_Recommendation>
	<rdfs:label>280: Patients with diabetes should be assessed for knowledge, performance skills, and barriers to full compliance.</rdfs:label>
</kb:Recommendations>
<kb:Recommendations rdf:about="&kb;Recommendations_Instance_76"
	 kb:ModuleName="3"
	 kb:Overall_Quality="na"
	 kb:Quality_of_Evidence="na"
	 kb:RecID="281"
	 kb:Recommendation_Annotation="I"
	 kb:recommendation="na">
	<kb:Guideline_Recommendation>If psychosocial, personal, or financial barriers are identified, additional resources should be consulted, as applicable (e.g., mental health, medical social work, or financial counselors).</kb:Guideline_Recommendation>
	<rdfs:label>281: If psychosocial, personal, or financial barriers are identified, additional resources should be consulted, as applicable (e.g., mental health, medical social work, or financial counselors).</rdfs:label>
</kb:Recommendations>
<kb:Recommendations rdf:about="&kb;Recommendations_Instance_77"
	 kb:ModuleName="3"
	 kb:Overall_Quality="na"
	 kb:Quality_of_Evidence="na"
	 kb:RecID="282"
	 kb:Recommendation_Annotation="J"
	 kb:recommendation="na">
	<kb:Guideline_Recommendation>Individual treatment goals must be established with the patient based on the extent of the disease, comorbid conditions, and patient preferences.</kb:Guideline_Recommendation>
	<rdfs:label>282: Individual treatment goals must be established with the patient based on the extent of the disease, comorbid conditions, and patient preferences.</rdfs:label>
</kb:Recommendations>
<kb:Recommendations rdf:about="&kb;Recommendations_Instance_78"
	 kb:ModuleName="3"
	 kb:Overall_Quality="na"
	 kb:Quality_of_Evidence="na"
	 kb:RecID="283"
	 kb:Recommendation_Annotation="J"
	 kb:recommendation="na">
	<kb:Guideline_Recommendation>Institution of diet and exercise is usually the appropriate initial management in patients with new onset type 2 diabetes, depending upon severity of symptoms, pyschosocial evaluation, and overall health status. Encourage diet and exercise and lifestyle modification.</kb:Guideline_Recommendation>
	<rdfs:label>283: Institution of diet and exercise is usually the appropriate initial management in patients with new onset type 2 diabetes, depending upon severity of symptoms, pyschosocial evaluation, and overall health status. Encourage diet and exercise and lifestyle modification.</rdfs:label>
</kb:Recommendations>
<kb:Recommendations rdf:about="&kb;Recommendations_Instance_79"
	 kb:ModuleName="3"
	 kb:Overall_Quality="na"
	 kb:Quality_of_Evidence="na"
	 kb:RecID="284"
	 kb:Recommendation_Annotation="J"
	 kb:recommendation="na">
	<kb:Guideline_Recommendation>If treatment goals are not achieved with diet and exercise alone, drug therapy should be initiated.</kb:Guideline_Recommendation>
	<rdfs:label>284: If treatment goals are not achieved with diet and exercise alone, drug therapy should be initiated.</rdfs:label>
</kb:Recommendations>
<kb:Recommendations rdf:about="&kb;Recommendations_Instance_8"
	 kb:Guideline_Recommendation="Progression to non-proliferative retinopathy."
	 kb:ModuleName="3"
	 kb:Overall_Quality="Good"
	 kb:Quality_of_Evidence="I"
	 kb:RecID="252"
	 kb:Recommendation_Annotation="C"
	 kb:recommendation="A"
	 rdfs:label="252: Progression to non-proliferative retinopathy."/>
<kb:Recommendations rdf:about="&kb;Recommendations_Instance_80"
	 kb:ModuleName="3"
	 kb:Overall_Quality="na"
	 kb:Quality_of_Evidence="na"
	 kb:RecID="285"
	 kb:Recommendation_Annotation="J"
	 kb:recommendation="na">
	<kb:Guideline_Recommendation>There is no evidence that blood glucose monitoring in stable type 2 DM patients is of clinical benefit. If self-monitoring is to be done, a twice-weekly regimen is usually sufficient. Special situations, such as acute intercurrent illness, frequent hypo- or hyperglycemia, or changes in medication regimen, may justify more frequent monitoring on a temporary basis.</kb:Guideline_Recommendation>
	<rdfs:label>285: There is no evidence that blood glucose monitoring in stable type 2 DM patients is of clinical benefit. If self-monitoring is to be done, a twice-weekly regimen is usually sufficient. Special situations, such as acute intercurrent illness, frequent hypo- or hyperglycemia, or changes in medication regimen, may justify more frequent monitoring on a temporary basis.</rdfs:label>
</kb:Recommendations>
<kb:Recommendations rdf:about="&kb;Recommendations_Instance_81"
	 kb:ModuleName="3"
	 kb:Overall_Quality="na"
	 kb:Quality_of_Evidence="na"
	 kb:RecID="286"
	 kb:Recommendation_Annotation="J"
	 kb:recommendation="na">
	<kb:Guideline_Recommendation>J-1. MONOTHERAPY
•	Both metformin and sulfonylureas decrease HbA1c to a similar degree.
•	There is a greater weight gain associated with the use of sulfonylurea versus metformin.
•	Studies indicate that weight loss is an important factor in the control of HbA1c.
•	In overweight patients, treatment with metformin may result in reduced diabetes endpoints for all causes of mortality and stroke.
•	Other oral agents, while less effective, are still appropriate first line agents if the desired increase in HbA1c is proportionally less or if there are additional contraindications to the other first line medications.</kb:Guideline_Recommendation>
	<rdfs:label>286: J-1. MONOTHERAPY
•	Both metformin and sulfonylureas decrease HbA1c to a similar degree.
•	There is a greater weight gain associated with the use of sulfonylurea versus metformin.
•	Studies indicate that weight loss is an important factor in the control of HbA1c.
•	In overweight patients, treatment with metformin may result in reduced diabetes endpoints for all causes of mortality and stroke.
•	Other oral agents, while less effective, are still appropriate first line agents if the desired increase in HbA1c is proportionally less or if there are additional contraindications to the other first line medications.</rdfs:label>
</kb:Recommendations>
<kb:Recommendations rdf:about="&kb;Recommendations_Instance_82"
	 kb:ModuleName="3"
	 kb:Overall_Quality="Fair"
	 kb:Quality_of_Evidence="I"
	 kb:RecID="287"
	 kb:Recommendation_Annotation="J"
	 kb:recommendation="B">
	<kb:Guideline_Recommendation>J1. MONOTHERAPY

Sulfonylurea as first line for most patients.</kb:Guideline_Recommendation>
	<rdfs:label>287: J1. MONOTHERAPY

Sulfonylurea as first line for most patients.</rdfs:label>
</kb:Recommendations>
<kb:Recommendations rdf:about="&kb;Recommendations_Instance_83"
	 kb:ModuleName="3"
	 kb:Overall_Quality="Good"
	 kb:Quality_of_Evidence="I"
	 kb:RecID="288"
	 kb:Recommendation_Annotation="J"
	 kb:recommendation="A">
	<kb:Guideline_Recommendation>J1 MONOTHERAPY

Metformin as first line for overweight patients.</kb:Guideline_Recommendation>
	<rdfs:label>288: J1 MONOTHERAPY

Metformin as first line for overweight patients.</rdfs:label>
</kb:Recommendations>
<kb:Recommendations rdf:about="&kb;Recommendations_Instance_84"
	 kb:ModuleName="3"
	 kb:Overall_Quality="Fair"
	 kb:Quality_of_Evidence="I,I,II-1,II-1"
	 kb:RecID="289"
	 kb:Recommendation_Annotation="J"
	 kb:recommendation="B">
	<kb:Guideline_Recommendation>J1 MONOTHERAPY

Glitazones not preferred as monotherapy.</kb:Guideline_Recommendation>
	<rdfs:label>289: J1 MONOTHERAPY

Glitazones not preferred as monotherapy.</rdfs:label>
</kb:Recommendations>
<kb:Recommendations rdf:about="&kb;Recommendations_Instance_85"
	 kb:ModuleName="3"
	 kb:Overall_Quality="na"
	 kb:Quality_of_Evidence="na"
	 kb:RecID="290"
	 kb:Recommendation_Annotation="J"
	 kb:recommendation="na">
	<kb:Guideline_Recommendation>J-2. COMBINATION THERAPY

Use of Metformin or Glitazones in Combination with Insulin</kb:Guideline_Recommendation>
	<rdfs:label>290: J-2. COMBINATION THERAPY

Use of Metformin or Glitazones in Combination with Insulin</rdfs:label>
</kb:Recommendations>
<kb:Recommendations rdf:about="&kb;Recommendations_Instance_86"
	 kb:ModuleName="3"
	 kb:Overall_Quality="na"
	 kb:Quality_of_Evidence="na"
	 kb:RecID="269"
	 kb:Recommendation_Annotation="C"
	 kb:recommendation="na">
	<kb:Guideline_Recommendation xml:space='preserve'><![CDATA[The patient with very mild or no microvascular complications of diabetes, and who is free of major concurrent illnesses and with a reasonable life expectancy, should have an HbA1c target of <7 percent.]]></kb:Guideline_Recommendation>
	<rdfs:label xml:space='preserve'><![CDATA[269: The patient with very mild or no microvascular complications of diabetes, and who is free of major concurrent illnesses and with a reasonable life expectancy, should have an HbA1c target of <7 percent.]]></rdfs:label>
</kb:Recommendations>
<kb:Recommendations rdf:about="&kb;Recommendations_Instance_87"
	 kb:ModuleName="3"
	 kb:RecID="291"
	 kb:Recommendation_Annotation="J">
	<kb:Guideline_Recommendation>J2- COMBINATION THERAPY

Glitazones In Combination With Other Agents</kb:Guideline_Recommendation>
	<rdfs:label>291: J2- COMBINATION THERAPY

Glitazones In Combination With Other Agents</rdfs:label>
</kb:Recommendations>
<kb:Recommendations rdf:about="&kb;Recommendations_Instance_88"
	 kb:ModuleName="3"
	 kb:Overall_Quality="Fair"
	 kb:Quality_of_Evidence="I"
	 kb:RecID="292"
	 kb:Recommendation_Annotation="J"
	 kb:recommendation="B">
	<kb:Guideline_Recommendation>J2  COMBINATION THERAPY

Metformin as add-on therapy to SFU for failed sulfonylurea treatment, if not contraindicated.</kb:Guideline_Recommendation>
	<rdfs:label>292: J2  COMBINATION THERAPY

Metformin as add-on therapy to SFU for failed sulfonylurea treatment, if not contraindicated.</rdfs:label>
</kb:Recommendations>
<kb:Recommendations rdf:about="&kb;Recommendations_Instance_89"
	 kb:ModuleName="3"
	 kb:Overall_Quality="Fair"
	 kb:Quality_of_Evidence="I"
	 kb:RecID="293"
	 kb:Recommendation_Annotation="J"
	 kb:recommendation="B">
	<kb:Guideline_Recommendation>J2 COMBINATION THERAPY

Insulin as add-on therapy, if the patient is not within 1.5 percent of the target range.</kb:Guideline_Recommendation>
	<rdfs:label>293: J2 COMBINATION THERAPY

Insulin as add-on therapy, if the patient is not within 1.5 percent of the target range.</rdfs:label>
</kb:Recommendations>
<kb:Recommendations rdf:about="&kb;Recommendations_Instance_9"
	 kb:ModuleName="1"
	 kb:Overall_Quality="Fair"
	 kb:Quality_of_Evidence="I"
	 kb:RecID="8"
	 kb:Recommendation_Annotation="B"
	 kb:recommendation="B">
	<kb:Guideline_Recommendation xml:space='preserve'><![CDATA[Diabetic patients (type 1) with early onset (age <30 years) should begin annual evaluations when the duration of the diabetes diagnosis is greater than 3 years.]]></kb:Guideline_Recommendation>
	<kb:expert_definition>step 5 in algorithm   MKG- 1st exam should be within 3 months of pcp visit referral to eye care provider</kb:expert_definition>
	<rdfs:label xml:space='preserve'><![CDATA[8: Diabetic patients (type 1) with early onset (age <30 years) should begin annual evaluations when the duration of the diabetes diagnosis is greater than 3 years.]]></rdfs:label>
</kb:Recommendations>
<kb:Recommendations rdf:about="&kb;Recommendations_Instance_90"
	 kb:Guideline_Recommendation="J-3. INSULIN THERAPY"
	 kb:ModuleName="3"
	 kb:RecID="294"
	 kb:Recommendation_Annotation="J"
	 rdfs:label="294: J-3. INSULIN THERAPY"/>
<kb:Recommendations rdf:about="&kb;Recommendations_Instance_91"
	 kb:ModuleName="3"
	 kb:RecID="296"
	 kb:Recommendation_Annotation="K">
	<kb:Guideline_Recommendation>The patient with recurrent or severe hypoglycemia should be evaluated for precipitating factors that may be easily corrected (e.g., missed meals, exercise, incorrect administration of insulin-dosage or timing).</kb:Guideline_Recommendation>
	<rdfs:label>296: The patient with recurrent or severe hypoglycemia should be evaluated for precipitating factors that may be easily corrected (e.g., missed meals, exercise, incorrect administration of insulin-dosage or timing).</rdfs:label>
</kb:Recommendations>
<kb:Recommendations rdf:about="&kb;Recommendations_Instance_92"
	 kb:ModuleName="3"
	 kb:RecID="297"
	 kb:Recommendation_Annotation="L">
	<kb:Guideline_Recommendation>If the patient does not achieve his/her target range, the provider should identify barriers to patient adherence to the treatment regimen (e.g., miscommunication, lack of education or understanding, financial/social/psychological barriers, and cultural beliefs).</kb:Guideline_Recommendation>
	<rdfs:label>297: If the patient does not achieve his/her target range, the provider should identify barriers to patient adherence to the treatment regimen (e.g., miscommunication, lack of education or understanding, financial/social/psychological barriers, and cultural beliefs).</rdfs:label>
</kb:Recommendations>
<kb:Recommendations rdf:about="&kb;Recommendations_Instance_93"
	 kb:ModuleName="3"
	 kb:RecID="298"
	 kb:Recommendation_Annotation="L">
	<kb:Guideline_Recommendation>If barriers are identified referral to a case manager or behavioral/financial counselor should be considered as appropriate.</kb:Guideline_Recommendation>
	<rdfs:label>298: If barriers are identified referral to a case manager or behavioral/financial counselor should be considered as appropriate.</rdfs:label>
</kb:Recommendations>
<kb:Recommendations rdf:about="&kb;Recommendations_Instance_94"
	 kb:ModuleName="3"
	 kb:RecID="299"
	 kb:Recommendation_Annotation="M">
	<kb:Guideline_Recommendation>Treatment goals should be periodically reassessed based upon patient specific factors, including changes in the patient's health status, adverse drug reactions, adherence to therapy, and preferences.</kb:Guideline_Recommendation>
	<rdfs:label>299: Treatment goals should be periodically reassessed based upon patient specific factors, including changes in the patient's health status, adverse drug reactions, adherence to therapy, and preferences.</rdfs:label>
</kb:Recommendations>
<kb:Recommendations rdf:about="&kb;Recommendations_Instance_95"
	 kb:ModuleName="3"
	 kb:Overall_Quality="na"
	 kb:Quality_of_Evidence="na"
	 kb:RecID="300"
	 kb:Recommendation_Annotation="N"
	 kb:recommendation="na">
	<kb:Guideline_Recommendation>FOLLOW UP

The patient should be scheduled for appropriate follow-up to evaluate response, tolerability to therapy, goal re-assessment, and management of acute and chronic problems.</kb:Guideline_Recommendation>
	<rdfs:label>300: FOLLOW UP

The patient should be scheduled for appropriate follow-up to evaluate response, tolerability to therapy, goal re-assessment, and management of acute and chronic problems.</rdfs:label>
</kb:Recommendations>
<kb:Recommendations rdf:about="&kb;Recommendations_Instance_96"
	 kb:ModuleName="3"
	 kb:Overall_Quality="na"
	 kb:Quality_of_Evidence="na"
	 kb:RecID="301"
	 kb:Recommendation_Annotation="N"
	 kb:recommendation="na">
	<kb:Guideline_Recommendation>FOLLOW UP

The frequency of primary care provider visits for the patient with diabetes who is meeting treatment goals and who has no unstable chronic complications should be individualized.</kb:Guideline_Recommendation>
	<rdfs:label>301: FOLLOW UP

The frequency of primary care provider visits for the patient with diabetes who is meeting treatment goals and who has no unstable chronic complications should be individualized.</rdfs:label>
</kb:Recommendations>
<kb:Recommendations rdf:about="&kb;Recommendations_Instance_97"
	 kb:ModuleName="3"
	 kb:Overall_Quality="na"
	 kb:Quality_of_Evidence="na"
	 kb:RecID="302"
	 kb:Recommendation_Annotation="N"
	 kb:recommendation="na">
	<kb:Guideline_Recommendation>FOLLOW UP

When there is a sudden change in health status or when changes are made to the treatment regimen, follow-up within one month or sooner may be appropriate.</kb:Guideline_Recommendation>
	<rdfs:label>302: FOLLOW UP

When there is a sudden change in health status or when changes are made to the treatment regimen, follow-up within one month or sooner may be appropriate.</rdfs:label>
</kb:Recommendations>
<kb:Ontology_Class rdf:about="&kb;annotation_ATHENA_GlycemicControl_Instance_230700"
	 kb:currentName="Moderate microvascular disease"
	 rdfs:label="Moderate microvascular disease">
	<kb:associatedAnnotations rdf:resource="&kb;Concept335"/>
</kb:Ontology_Class>
<kb:Ontology_Class rdf:about="&kb;annotation_ATHENA_GlycemicControl_Instance_230835"
	 kb:currentName="hyperglycemia"
	 rdfs:label="hyperglycemia"/>
<kb:Ontology_Class rdf:about="&kb;annotation_ATHENA_GlycemicControl_Instance_270093"
	 kb:currentName="Allergy to Sufonylureas"
	 rdfs:label="Allergy to Sufonylureas"/>
<kb:Ontology_Class rdf:about="&kb;annotation_ATHENA_GlycemicControl_Instance_270149"
	 kb:currentName="Weight gain"
	 rdfs:label="Weight gain"/>
<kb:Ontology_Class rdf:about="&kb;annotation_ATHENA_GlycemicControl_Instance_270165"
	 kb:currentName="Hypersensitivity"
	 rdfs:label="Hypersensitivity"/>
<kb:Ontology_Class rdf:about="&kb;annotation_ATHENA_GlycemicControl_Instance_270377"
	 kb:currentName="ATHENA_GlycemicControl_Class_50025"
	 rdfs:label="ATHENA_GlycemicControl_Class_50025"/>
<kb:Ontology_Class rdf:about="&kb;annotation_ATHENA_GlycemicControl_Instance_270512"
	 kb:currentName="history of severe hypoglycemic reactions"
	 rdfs:label="history of severe hypoglycemic reactions"/>
<kb:Ontology_Class rdf:about="&kb;annotation_collaborativeNewspaper_Instance_10000"
	 kb:currentName="MyNewClass"
	 rdfs:label="MyNewClass"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class0"
	 rdfs:label="annotation_library_Class0"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class100001"
	 kb:currentName="foot ulcer"
	 rdfs:label="foot ulcer"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class100010">
	<kb:currentName>Assessment of protective sensation using the Semmes-Weinstein 5.07 monofilament</kb:currentName>
	<rdfs:label>Assessment of protective sensation using the Semmes-Weinstein 5.07 monofilament</rdfs:label>
</kb:Ontology_Class>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class100019"
	 kb:currentName="trauma"
	 rdfs:label="trauma"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class100028">
	<kb:currentName>other known microvascular disease (albuminuria or neuropathy)</kb:currentName>
	<rdfs:label>other known microvascular disease (albuminuria or neuropathy)</rdfs:label>
</kb:Ontology_Class>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class100036"
	 kb:currentName="circulatory symptoms that limit patient's lifestyle"
	 rdfs:label="circulatory symptoms that limit patient's lifestyle"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class100042"
	 kb:currentName="circulatory symptoms that limit patients lifestyle"
	 rdfs:label="circulatory symptoms that limit patients lifestyle"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class1016"
	 rdfs:label="annotation_library_Class1016"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class1039"
	 rdfs:label="annotation_library_Class1039"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class1062"
	 rdfs:label="annotation_library_Class1062"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class1085"
	 rdfs:label="annotation_library_Class1085"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class110001"
	 kb:currentName="foot ulcer"
	 rdfs:label="foot ulcer">
	<kb:associatedAnnotations rdf:resource="&kb;Concept268"/>
</kb:Ontology_Class>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class110002"
	 kb:currentName="circulatory symptoms that limit patient's lifestyle"
	 rdfs:label="circulatory symptoms that limit patient's lifestyle">
	<kb:associatedAnnotations rdf:resource="&kb;Concept311"/>
</kb:Ontology_Class>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class110003">
	<kb:currentName>other known microvascular disease (albuminuria or neuropathy)</kb:currentName>
	<rdfs:label>other known microvascular disease (albuminuria or neuropathy)</rdfs:label>
	<kb:associatedAnnotations rdf:resource="&kb;Concept303"/>
</kb:Ontology_Class>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class1108"
	 rdfs:label="annotation_library_Class1108"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class1131"
	 rdfs:label="annotation_library_Class1131"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class1154"
	 kb:currentName="High_Risk_Psych_Diseases"
	 rdfs:label="High_Risk_Psych_Diseases"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class1177"
	 kb:currentName="Anxiety"
	 rdfs:label="Anxiety"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class119"
	 rdfs:label="annotation_library_Class119"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class1200"
	 kb:currentName="Drug Induced Mental Disorder"
	 rdfs:label="Drug Induced Mental Disorder"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class1223"
	 kb:currentName="Personality_Disorder"
	 rdfs:label="Personality_Disorder"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class1246"
	 kb:currentName="Suicidality"
	 rdfs:label="Suicidality"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class1269"
	 kb:currentName="E950.0"
	 rdfs:label="E950.0"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class1292"
	 kb:currentName="E950.01"
	 rdfs:label="E950.01"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class1315"
	 kb:currentName="E950.02"
	 rdfs:label="E950.02"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class1338"
	 kb:currentName="E950.1"
	 rdfs:label="E950.1"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class1361"
	 kb:currentName="E950.11"
	 rdfs:label="E950.11"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class1384"
	 kb:currentName="E950.12"
	 rdfs:label="E950.12"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class1407"
	 kb:currentName="E950.2"
	 rdfs:label="E950.2"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class142"
	 rdfs:label="annotation_library_Class142"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class1430"
	 kb:currentName="E950.21"
	 rdfs:label="E950.21"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class1453"
	 kb:currentName="E950.22"
	 rdfs:label="E950.22"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class1476"
	 kb:currentName="E950.3"
	 rdfs:label="E950.3"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class1499"
	 kb:currentName="E950.31"
	 rdfs:label="E950.31"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class1522"
	 kb:currentName="E950.32"
	 rdfs:label="E950.32"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class1545"
	 kb:currentName="E950.4"
	 rdfs:label="E950.4"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class1568"
	 kb:currentName="E950.41"
	 rdfs:label="E950.41"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class1591"
	 kb:currentName="E950.42"
	 rdfs:label="E950.42"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class1614"
	 kb:currentName="E950.5"
	 rdfs:label="E950.5"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class1637"
	 kb:currentName="E950.51"
	 rdfs:label="E950.51"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class165"
	 rdfs:label="annotation_library_Class165"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class1660"
	 kb:currentName="E950.52"
	 rdfs:label="E950.52"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class1683"
	 kb:currentName="E950.6"
	 rdfs:label="E950.6"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class1706"
	 kb:currentName="E950.61"
	 rdfs:label="E950.61"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class1729"
	 kb:currentName="E950.62"
	 rdfs:label="E950.62"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class1752"
	 kb:currentName="E950.7"
	 rdfs:label="E950.7"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class1775"
	 kb:currentName="E950.71"
	 rdfs:label="E950.71"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class1798"
	 kb:currentName="E950.72"
	 rdfs:label="E950.72"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class1821"
	 kb:currentName="E950.8"
	 rdfs:label="E950.8"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class1844"
	 kb:currentName="E950.81"
	 rdfs:label="E950.81"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class1867"
	 kb:currentName="E950.82"
	 rdfs:label="E950.82"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class188"
	 rdfs:label="annotation_library_Class188"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class1890"
	 kb:currentName="E950.9"
	 rdfs:label="E950.9"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class19"
	 kb:currentName="Psychiatric_Diseases"
	 rdfs:label="Psychiatric_Diseases"/>
<kb:Comment rdf:about="&kb;annotation_library_Class190004"
	 kb:author="vhapalmartins"
	 kb:subject="ci specific to gliburide"
	 rdfs:label="ci specific to gliburide">
	<kb:body>need to add specific contraindications to glyburide: glyburide, especially in patients with renal insufficiency or decreased renal function due to age. Each VISN received a list of patients aged 65 years and older with an active prescription for glyburide and a serum creatinine ≥ 2 mg/dl so that appropriate intervention, such as a switch to glipizide, could be taken.  (July 9/2009:  On September 4, 2007, VA MedSAFE )</kb:body>
	<kb:created rdf:resource="&kb;annotation_library_Class190005"/>
</kb:Comment>
<kb:Timestamp rdf:about="&kb;annotation_library_Class190005"
	 kb:date="09/17/2009 12:03:34 PDT"
	 kb:sequence="2"
	 rdfs:label="09/17/2009 12:03:34 PDT"/>
<kb:Comment rdf:about="&kb;annotation_library_Class190006"
	 kb:author="vhapalmartins"
	 kb:subject="specific bad drug partner"
	 rdfs:label="specific bad drug partner">
	<kb:body>FDA  Recommendations and Considerations for Healthcare Professionals
•	Rosiglitazone may cause myocardial ischemia in some patients. 
•	Co-administration of rosiglitazone and insulin is not recommended.   A higher risk of myocardial ischemia was observed in controlled, double-blind clinical trials where rosiglitazone was added on to established insulin therapy. 
•	Rosiglitazone is not recommended for patients with heart disease who are taking nitrates.  A subgroup analysis of 42 clinical studies identified that patients with heart disease who are taking nitrates are at an increased risk of myocardial ischemia</kb:body>
	<kb:created rdf:resource="&kb;annotation_library_Class190007"/>
</kb:Comment>
<kb:Timestamp rdf:about="&kb;annotation_library_Class190007"
	 kb:date="09/17/2009 13:46:25 PDT"
	 kb:sequence="3"
	 rdfs:label="09/17/2009 13:46:25 PDT"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class190009"
	 kb:currentName="Aspirin"
	 rdfs:label="Aspirin"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class190022"
	 kb:currentName="ACE_inhibitor"
	 rdfs:label="ACE_inhibitor"/>
<kb:Comment rdf:about="&kb;annotation_library_Class190130"
	 kb:author="vhapalmartins"
	 kb:subject="consultation template"
	 rdfs:label="consultation template">
	<kb:body>what is the difference between the 2 different arrows to connect branches adn actions: followed by and consultation selection? Which should I use?</kb:body>
	<kb:created rdf:resource="&kb;annotation_library_Class190131"/>
</kb:Comment>
<kb:Timestamp rdf:about="&kb;annotation_library_Class190131"
	 kb:date="09/17/2009 14:18:50 PDT"
	 kb:sequence="60"
	 rdfs:label="09/17/2009 14:18:50 PDT"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class190196"
	 kb:currentName="B 12"
	 rdfs:label="B 12"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class190319"
	 rdfs:label="annotation_library_Class190319"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class190322"
	 kb:currentName="ATHENA_GlycemicControl_Class_0"
	 rdfs:label="ATHENA_GlycemicControl_Class_0"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class190329"
	 rdfs:label="annotation_library_Class190329"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class190338"
	 rdfs:label="annotation_library_Class190338"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class190349"
	 kb:currentName="ATHENA_GlycemicControl_Class80021"
	 rdfs:label="ATHENA_GlycemicControl_Class80021"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class190358"
	 kb:currentName="ATHENA_GlycemicControl_Class80020"
	 rdfs:label="ATHENA_GlycemicControl_Class80020"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class190365"
	 rdfs:label="annotation_library_Class190365"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class190368"
	 kb:currentName="ATHENA_GlycemicControl_Class_10005"
	 rdfs:label="ATHENA_GlycemicControl_Class_10005"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class190375"
	 rdfs:label="annotation_library_Class190375"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class190378"
	 kb:currentName="ATHENA_GlycemicControl_Class_10006"
	 rdfs:label="ATHENA_GlycemicControl_Class_10006"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class190385">
	<kb:currentName xml:space='preserve'><![CDATA[eGFR < 30]]></kb:currentName>
	<rdfs:label xml:space='preserve'><![CDATA[eGFR < 30]]></rdfs:label>
</kb:Ontology_Class>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class1913"
	 kb:currentName="E950.91"
	 rdfs:label="E950.91"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class1936"
	 kb:currentName="E950.92"
	 rdfs:label="E950.92"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class1959"
	 kb:currentName="E951.0"
	 rdfs:label="E951.0"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class1982"
	 kb:currentName="E951.01"
	 rdfs:label="E951.01"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class20001"
	 kb:currentName="Blood_Chemistry"
	 rdfs:label="Blood_Chemistry"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class20004"
	 kb:currentName="eGFR"
	 rdfs:label="eGFR"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class20007"
	 rdfs:label="annotation_library_Class20007"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class2005"
	 kb:currentName="E951.02"
	 rdfs:label="E951.02"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class2028"
	 kb:currentName="E951.1"
	 rdfs:label="E951.1"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class2051"
	 kb:currentName="E951.11"
	 rdfs:label="E951.11"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class2074"
	 kb:currentName="E951.12"
	 rdfs:label="E951.12"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class2097"
	 kb:currentName="E951.8"
	 rdfs:label="E951.8"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class211"
	 rdfs:label="annotation_library_Class211"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class2120"
	 kb:currentName="E951.81"
	 rdfs:label="E951.81"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class2143"
	 kb:currentName="E951.82"
	 rdfs:label="E951.82"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class2166"
	 kb:currentName="E952.0"
	 rdfs:label="E952.0"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class2189"
	 kb:currentName="E952.01"
	 rdfs:label="E952.01"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class2212"
	 kb:currentName="E952.02"
	 rdfs:label="E952.02"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class2235"
	 kb:currentName="E952.1"
	 rdfs:label="E952.1"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class2258"
	 kb:currentName="E952.11"
	 rdfs:label="E952.11"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class2281"
	 kb:currentName="E952.12"
	 rdfs:label="E952.12"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class2304"
	 kb:currentName="E952.8"
	 rdfs:label="E952.8"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class2327"
	 kb:currentName="E952.81"
	 rdfs:label="E952.81"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class234"
	 rdfs:label="annotation_library_Class234"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class2350"
	 kb:currentName="E952.82"
	 rdfs:label="E952.82"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class2373"
	 kb:currentName="E952.9"
	 rdfs:label="E952.9"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class2396"
	 kb:currentName="E952.91"
	 rdfs:label="E952.91"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class2419"
	 kb:currentName="E952.92"
	 rdfs:label="E952.92"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class2442"
	 kb:currentName="E953.0"
	 rdfs:label="E953.0"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class2465"
	 kb:currentName="E953.01"
	 rdfs:label="E953.01"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class2488"
	 kb:currentName="E953.02"
	 rdfs:label="E953.02"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class2511"
	 kb:currentName="E953.1"
	 rdfs:label="E953.1"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class2534"
	 kb:currentName="E953.11"
	 rdfs:label="E953.11"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class2557"
	 kb:currentName="E953.12"
	 rdfs:label="E953.12"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class257"
	 rdfs:label="annotation_library_Class257"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class2580"
	 kb:currentName="E953.8"
	 rdfs:label="E953.8"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class260001"
	 kb:currentName="CCS-9"
	 rdfs:label="CCS-9"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class260004"
	 kb:currentName="Hepatobiliary_Diseases"
	 rdfs:label="Hepatobiliary_Diseases"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class260015"
	 kb:currentName="CCS-9.8"
	 rdfs:label="CCS-9.8"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class260026"
	 kb:currentName="Immunological_Diseases"
	 rdfs:label="Immunological_Diseases"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class260035"
	 kb:currentName="CCS-10"
	 rdfs:label="CCS-10"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class260038"
	 kb:currentName="Renal-Urinary_Diseases"
	 rdfs:label="Renal-Urinary_Diseases"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class260047"
	 kb:currentName="Diseases of the respiratory system"
	 rdfs:label="Diseases of the respiratory system"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class260062"
	 kb:currentName="Respiratory_Diseases"
	 rdfs:label="Respiratory_Diseases"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class260073">
	<kb:currentName xml:space='preserve'><![CDATA[Obstetric&Gynecological_Diseases]]></kb:currentName>
	<rdfs:label xml:space='preserve'><![CDATA[Obstetric&Gynecological_Diseases]]></rdfs:label>
</kb:Ontology_Class>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class2603"
	 kb:currentName="E953.81"
	 rdfs:label="E953.81"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class2626"
	 kb:currentName="E953.82"
	 rdfs:label="E953.82"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class2649"
	 kb:currentName="E953.9"
	 rdfs:label="E953.9"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class2672"
	 kb:currentName="E954"
	 rdfs:label="E954"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class2695"
	 kb:currentName="E954.1"
	 rdfs:label="E954.1"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class270001"
	 kb:currentName="CCS-6.7"
	 rdfs:label="CCS-6.7"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class270004"
	 kb:currentName="Cataracts"
	 rdfs:label="Cataracts"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class270007"
	 rdfs:label="annotation_library_Class270007"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class270016"
	 kb:currentName="Visual_disturbance"
	 rdfs:label="Visual_disturbance"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class2718"
	 kb:currentName="E954.2"
	 rdfs:label="E954.2"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class2741"
	 kb:currentName="E955.0"
	 rdfs:label="E955.0"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class2764"
	 kb:currentName="E955.01"
	 rdfs:label="E955.01"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class2787"
	 kb:currentName="E955.02"
	 rdfs:label="E955.02"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class280"
	 rdfs:label="annotation_library_Class280"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class280001"
	 rdfs:label="annotation_library_Class280001"/>
<kb:Ontology_Property rdf:about="&kb;annotation_library_Class280002"
	 kb:currentName=":DEFINITION"
	 rdfs:label=":DEFINITION"/>
<kb:Ontology_Property rdf:about="&kb;annotation_library_Class280005"
	 kb:currentName=":DEFINITION-NAME"
	 rdfs:label=":DEFINITION-NAME"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class280016"
	 rdfs:label="annotation_library_Class280016"/>
<kb:Ontology_Property rdf:about="&kb;annotation_library_Class280017"
	 kb:currentName=":DOCUMENTATION"
	 rdfs:label=":DOCUMENTATION"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class280024"
	 rdfs:label="annotation_library_Class280024"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class280029"
	 rdfs:label="annotation_library_Class280029"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class280036"
	 rdfs:label="annotation_library_Class280036"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class280043"
	 rdfs:label="annotation_library_Class280043"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class280050"
	 rdfs:label="annotation_library_Class280050"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class280057"
	 rdfs:label="annotation_library_Class280057"/>
<kb:Ontology_Property rdf:about="&kb;annotation_library_Class280060"
	 kb:currentName=":KB-SAVE"
	 rdfs:label=":KB-SAVE"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class280080"
	 rdfs:label="annotation_library_Class280080"/>
<kb:Ontology_Property rdf:about="&kb;annotation_library_Class280081"
	 kb:currentName=":STARTUP-FILE"
	 rdfs:label=":STARTUP-FILE"/>
<kb:Ontology_Property rdf:about="&kb;annotation_library_Class280084"
	 kb:currentName=":STARTUP-EXPRESSION"
	 rdfs:label=":STARTUP-EXPRESSION"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class280105"
	 rdfs:label="annotation_library_Class280105"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class280116"
	 rdfs:label="annotation_library_Class280116"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class2810"
	 kb:currentName="E955.1"
	 rdfs:label="E955.1"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class2833"
	 kb:currentName="E955.11"
	 rdfs:label="E955.11"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class2856"
	 kb:currentName="E955.12"
	 rdfs:label="E955.12"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class2879"
	 kb:currentName="E955.2"
	 rdfs:label="E955.2"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class290001"
	 kb:currentName="Antihypertensive_Agents"
	 rdfs:label="Antihypertensive_Agents"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class290010"
	 kb:currentName="ACE_Inhibitors"
	 rdfs:label="ACE_Inhibitors"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class290019"
	 kb:currentName="benazepril"
	 rdfs:label="benazepril"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class290028"
	 kb:currentName="captopril"
	 rdfs:label="captopril"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class290037"
	 kb:currentName="enalapril"
	 rdfs:label="enalapril"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class290046"
	 kb:currentName="fosinopril"
	 rdfs:label="fosinopril"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class290055"
	 kb:currentName="fosinopril NA"
	 rdfs:label="fosinopril NA"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class290064"
	 kb:currentName="lisinopril"
	 rdfs:label="lisinopril"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class290073"
	 kb:currentName="moexipril"
	 rdfs:label="moexipril"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class290082"
	 kb:currentName="perindopril"
	 rdfs:label="perindopril"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class290091"
	 kb:currentName="quinapril"
	 rdfs:label="quinapril"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class290100"
	 kb:currentName="ramipril"
	 rdfs:label="ramipril"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class290109"
	 kb:currentName="trandolapril"
	 rdfs:label="trandolapril"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class290118"
	 kb:currentName="Angiotensin_II_receptor_blockers"
	 rdfs:label="Angiotensin_II_receptor_blockers"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class290127"
	 kb:currentName="candesartan"
	 rdfs:label="candesartan"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class290136"
	 kb:currentName="eprosartan"
	 rdfs:label="eprosartan"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class290145"
	 kb:currentName="irbesartan"
	 rdfs:label="irbesartan"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class290154"
	 kb:currentName="losartan"
	 rdfs:label="losartan"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class290163"
	 kb:currentName="telmisartan"
	 rdfs:label="telmisartan"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class290172"
	 kb:currentName="valsartan"
	 rdfs:label="valsartan"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class290181"
	 kb:currentName="Potassium-Sparing_Diuretics"
	 rdfs:label="Potassium-Sparing_Diuretics"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class290190"
	 kb:currentName="amiloride"
	 rdfs:label="amiloride"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class290199"
	 kb:currentName="spironolactone"
	 rdfs:label="spironolactone"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class2902"
	 kb:currentName="E955.21"
	 rdfs:label="E955.21"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class290208"
	 kb:currentName="triamterene"
	 rdfs:label="triamterene"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class290217"
	 kb:currentName="eplerenone"
	 rdfs:label="eplerenone"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class290226"
	 kb:currentName="Alpha_beta_blockers"
	 rdfs:label="Alpha_beta_blockers"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class290235"
	 kb:currentName="carvedilol"
	 rdfs:label="carvedilol"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class290244"
	 kb:currentName="labetalol"
	 rdfs:label="labetalol"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class290253"
	 kb:currentName="Beta-Blockers"
	 rdfs:label="Beta-Blockers"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class290262"
	 kb:currentName="Beta-Blockers-Cardioselective"
	 rdfs:label="Beta-Blockers-Cardioselective"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class290271"
	 kb:currentName="acebutolol"
	 rdfs:label="acebutolol"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class290280"
	 kb:currentName="atenolol"
	 rdfs:label="atenolol"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class290289"
	 kb:currentName="betaxolol"
	 rdfs:label="betaxolol"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class290298"
	 kb:currentName="bisoprolol"
	 rdfs:label="bisoprolol"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class290307"
	 kb:currentName="metoprolol"
	 rdfs:label="metoprolol"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class290316"
	 kb:currentName="metoprolol_SA"
	 rdfs:label="metoprolol_SA"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class290325"
	 kb:currentName="beta-blockers-ISA"
	 rdfs:label="beta-blockers-ISA"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class290334"
	 kb:currentName="pindolol"
	 rdfs:label="pindolol"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class290343"
	 kb:currentName="Beta-Blockers-non-cardioselective"
	 rdfs:label="Beta-Blockers-non-cardioselective"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class290352"
	 kb:currentName="carteolol"
	 rdfs:label="carteolol"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class290361"
	 kb:currentName="nadolol"
	 rdfs:label="nadolol"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class290370"
	 kb:currentName="penbutolol"
	 rdfs:label="penbutolol"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class290379"
	 kb:currentName="propranolol"
	 rdfs:label="propranolol"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class290388"
	 kb:currentName="propranolol_SA"
	 rdfs:label="propranolol_SA"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class290397"
	 kb:currentName="timolol"
	 rdfs:label="timolol"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class290406"
	 kb:currentName="Adrenergic_inhibitors_central"
	 rdfs:label="Adrenergic_inhibitors_central"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class290415"
	 kb:currentName="clonidine"
	 rdfs:label="clonidine"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class290424"
	 kb:currentName="guanabenz"
	 rdfs:label="guanabenz"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class290433"
	 kb:currentName="guanfacine"
	 rdfs:label="guanfacine"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class290442"
	 kb:currentName="methyldopa"
	 rdfs:label="methyldopa"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class290451"
	 kb:currentName="methyldopa_SA"
	 rdfs:label="methyldopa_SA"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class290460"
	 kb:currentName="Adrenergic_inhibitors_peripheral"
	 rdfs:label="Adrenergic_inhibitors_peripheral"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class290469"
	 kb:currentName="alseroxylon"
	 rdfs:label="alseroxylon"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class290478"
	 kb:currentName="cryptenamine"
	 rdfs:label="cryptenamine"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class290487"
	 kb:currentName="deserpidine"
	 rdfs:label="deserpidine"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class290496"
	 kb:currentName="guanadrel"
	 rdfs:label="guanadrel"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class290505"
	 kb:currentName="guanethidine"
	 rdfs:label="guanethidine"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class290514"
	 kb:currentName="rauwolfia"
	 rdfs:label="rauwolfia"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class290523"
	 kb:currentName="rauwolfia serpentina"
	 rdfs:label="rauwolfia serpentina"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class290532"
	 kb:currentName="rescinnamine"
	 rdfs:label="rescinnamine"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class290541"
	 kb:currentName="reserpine"
	 rdfs:label="reserpine"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class290550"
	 kb:currentName="Alpha_blockers"
	 rdfs:label="Alpha_blockers"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class290559"
	 kb:currentName="doxazosin"
	 rdfs:label="doxazosin"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class290568"
	 kb:currentName="prazosin"
	 rdfs:label="prazosin"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class290577"
	 kb:currentName="terazosin"
	 rdfs:label="terazosin"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class290586"
	 kb:currentName="Calcium_channel_antagonists"
	 rdfs:label="Calcium_channel_antagonists"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class290595"
	 kb:currentName="Dihydropyridines"
	 rdfs:label="Dihydropyridines"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class290604"
	 kb:currentName="amlodipine"
	 rdfs:label="amlodipine"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class290613"
	 kb:currentName="amlodipine_besylate"
	 rdfs:label="amlodipine_besylate"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class290622"
	 kb:currentName="felodipine"
	 rdfs:label="felodipine"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class290631"
	 kb:currentName="felodipine_SA"
	 rdfs:label="felodipine_SA"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class290640"
	 kb:currentName="isradipine"
	 rdfs:label="isradipine"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class290649"
	 kb:currentName="isradipine_SA"
	 rdfs:label="isradipine_SA"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class290658"
	 kb:currentName="nicardipine"
	 rdfs:label="nicardipine"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class290667"
	 kb:currentName="nicardipine_SA"
	 rdfs:label="nicardipine_SA"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class290676"
	 kb:currentName="nifedipine"
	 rdfs:label="nifedipine"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class290685"
	 kb:currentName="nifedipine_SA"
	 rdfs:label="nifedipine_SA"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class290694"
	 kb:currentName="nimodipine"
	 rdfs:label="nimodipine"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class290703"
	 kb:currentName="nisoldipine"
	 rdfs:label="nisoldipine"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class290712"
	 kb:currentName="nisoldipine_SA"
	 rdfs:label="nisoldipine_SA"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class290721"
	 kb:currentName="Non-Dihydropyridines"
	 rdfs:label="Non-Dihydropyridines"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class290730"
	 kb:currentName="bepridil"
	 rdfs:label="bepridil"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class290739"
	 kb:currentName="diltiazem"
	 rdfs:label="diltiazem"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class290748"
	 kb:currentName="diltiazem_SA"
	 rdfs:label="diltiazem_SA"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class290757"
	 kb:currentName="verapamil"
	 rdfs:label="verapamil"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class290766"
	 kb:currentName="verapamil_SA"
	 rdfs:label="verapamil_SA"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class290775"
	 kb:currentName="Direct_vasodilators"
	 rdfs:label="Direct_vasodilators"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class290784"
	 kb:currentName="flosequinan"
	 rdfs:label="flosequinan"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class290793"
	 kb:currentName="hydralazine"
	 rdfs:label="hydralazine"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class290802"
	 kb:currentName="minoxidil"
	 rdfs:label="minoxidil"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class290811"
	 kb:currentName="Metoprolol_and_terazosin"
	 rdfs:label="Metoprolol_and_terazosin"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class290820"
	 kb:currentName="Metoprolol_and_felodopine"
	 rdfs:label="Metoprolol_and_felodopine"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class290829"
	 kb:currentName="Thiazide_Diuretics"
	 rdfs:label="Thiazide_Diuretics"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class290838"
	 kb:currentName="bendroflumethiazide"
	 rdfs:label="bendroflumethiazide"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class290847"
	 kb:currentName="bendroflumethiazide_SA"
	 rdfs:label="bendroflumethiazide_SA"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class290856"
	 kb:currentName="benzthiazide"
	 rdfs:label="benzthiazide"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class290865"
	 kb:currentName="chlorothiazide"
	 rdfs:label="chlorothiazide"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class290874"
	 kb:currentName="chlorthalidone"
	 rdfs:label="chlorthalidone"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class290883"
	 kb:currentName="cyclothiazide"
	 rdfs:label="cyclothiazide"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class290892"
	 kb:currentName="hydrochlorothiazide"
	 rdfs:label="hydrochlorothiazide"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class290901"
	 kb:currentName="hydroflumethiazide"
	 rdfs:label="hydroflumethiazide"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class290910"
	 kb:currentName="indapamide"
	 rdfs:label="indapamide"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class290919"
	 kb:currentName="methyclothiazide"
	 rdfs:label="methyclothiazide"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class290928"
	 kb:currentName="metolazone"
	 rdfs:label="metolazone"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class290937"
	 kb:currentName="polythiazide"
	 rdfs:label="polythiazide"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class290946"
	 kb:currentName="quinethazone"
	 rdfs:label="quinethazone"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class290955"
	 kb:currentName="trichlormethiazide"
	 rdfs:label="trichlormethiazide"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class290964"
	 kb:currentName="Non-Cardiac_Drugs"
	 rdfs:label="Non-Cardiac_Drugs"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class290973"
	 kb:currentName="cylcosporine"
	 rdfs:label="cylcosporine"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class290982"
	 kb:currentName="amiodarone"
	 rdfs:label="amiodarone"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class290991"
	 kb:currentName="tamsulosin"
	 rdfs:label="tamsulosin"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class291000"
	 kb:currentName="sotalol"
	 rdfs:label="sotalol"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class291009"
	 kb:currentName="Diuretics"
	 rdfs:label="Diuretics"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class291018"
	 kb:currentName="Loop_diuretics"
	 rdfs:label="Loop_diuretics"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class291027"
	 kb:currentName="bumetanide"
	 rdfs:label="bumetanide"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class291036"
	 kb:currentName="ethacrynic_acid"
	 rdfs:label="ethacrynic_acid"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class291045"
	 kb:currentName="furosemide"
	 rdfs:label="furosemide"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class291054"
	 kb:currentName="torsemide"
	 rdfs:label="torsemide"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class2925"
	 kb:currentName="E955.22"
	 rdfs:label="E955.22"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class2948"
	 kb:currentName="E955.3"
	 rdfs:label="E955.3"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class2971"
	 kb:currentName="E955.31"
	 rdfs:label="E955.31"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class2994"
	 kb:currentName="E955.32"
	 rdfs:label="E955.32"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class3017"
	 kb:currentName="E955.4"
	 rdfs:label="E955.4"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class303"
	 rdfs:label="annotation_library_Class303"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class3040"
	 kb:currentName="E955.41"
	 rdfs:label="E955.41"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class3063"
	 kb:currentName="E955.42"
	 rdfs:label="E955.42"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class3086"
	 kb:currentName="E955.5"
	 rdfs:label="E955.5"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class3109"
	 kb:currentName="E955.51"
	 rdfs:label="E955.51"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class3132"
	 kb:currentName="E955.52"
	 rdfs:label="E955.52"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class3155"
	 kb:currentName="E955.6"
	 rdfs:label="E955.6"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class3178"
	 kb:currentName="E955.7"
	 rdfs:label="E955.7"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class3201"
	 kb:currentName="E955.9"
	 rdfs:label="E955.9"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class3224"
	 kb:currentName="E956"
	 rdfs:label="E956"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class3247"
	 kb:currentName="E956.1"
	 rdfs:label="E956.1"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class326"
	 rdfs:label="annotation_library_Class326"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class3270"
	 kb:currentName="E956.2"
	 rdfs:label="E956.2"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class3293"
	 kb:currentName="E957.0"
	 rdfs:label="E957.0"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class3316"
	 kb:currentName="E957.01"
	 rdfs:label="E957.01"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class3339"
	 kb:currentName="E957.02"
	 rdfs:label="E957.02"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class3362"
	 kb:currentName="E957.1"
	 rdfs:label="E957.1"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class3385"
	 kb:currentName="E957.11"
	 rdfs:label="E957.11"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class3408"
	 kb:currentName="E957.12"
	 rdfs:label="E957.12"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class3431"
	 kb:currentName="E957.2"
	 rdfs:label="E957.2"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class3454"
	 kb:currentName="E957.21"
	 rdfs:label="E957.21"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class3477"
	 kb:currentName="E957.22"
	 rdfs:label="E957.22"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class349"
	 rdfs:label="annotation_library_Class349"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class3500"
	 kb:currentName="E957.9"
	 rdfs:label="E957.9"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class3523"
	 kb:currentName="E957.91"
	 rdfs:label="E957.91"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class3546"
	 kb:currentName="E957.92"
	 rdfs:label="E957.92"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class3569"
	 kb:currentName="E958.0"
	 rdfs:label="E958.0"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class3592"
	 kb:currentName="E958.01"
	 rdfs:label="E958.01"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class3615"
	 kb:currentName="E958.02"
	 rdfs:label="E958.02"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class3638"
	 kb:currentName="E958.1"
	 rdfs:label="E958.1"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class3661"
	 kb:currentName="E958.11"
	 rdfs:label="E958.11"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class3684"
	 kb:currentName="E958.12"
	 rdfs:label="E958.12"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class3707"
	 kb:currentName="E958.2"
	 rdfs:label="E958.2"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class372"
	 rdfs:label="annotation_library_Class372"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class3730"
	 kb:currentName="E958.21"
	 rdfs:label="E958.21"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class3753"
	 kb:currentName="E958.22"
	 rdfs:label="E958.22"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class3776"
	 kb:currentName="E958.3"
	 rdfs:label="E958.3"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class3799"
	 kb:currentName="E958.31"
	 rdfs:label="E958.31"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class3822"
	 kb:currentName="E958.32"
	 rdfs:label="E958.32"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class3845"
	 kb:currentName="E958.4"
	 rdfs:label="E958.4"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class3868"
	 kb:currentName="E958.41"
	 rdfs:label="E958.41"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class3891"
	 kb:currentName="E958.42"
	 rdfs:label="E958.42"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class3914"
	 kb:currentName="E958.5"
	 rdfs:label="E958.5"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class3937"
	 kb:currentName="E958.51"
	 rdfs:label="E958.51"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class395"
	 rdfs:label="annotation_library_Class395"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class3960"
	 kb:currentName="E958.52"
	 rdfs:label="E958.52"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class3983"
	 kb:currentName="E958.6"
	 rdfs:label="E958.6"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class40002"
	 kb:currentName="CCS-15.6"
	 rdfs:label="CCS-15.6"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class40007"
	 kb:currentName="Medical_Domain_Class"
	 rdfs:label="Medical_Domain_Class"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class4006"
	 kb:currentName="E958.61"
	 rdfs:label="E958.61"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class4029"
	 kb:currentName="E958.62"
	 rdfs:label="E958.62"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class4052"
	 kb:currentName="E958.7"
	 rdfs:label="E958.7"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class4075"
	 kb:currentName="E958.71"
	 rdfs:label="E958.71"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class4098"
	 kb:currentName="E958.72"
	 rdfs:label="E958.72"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class4121"
	 kb:currentName="E958.8"
	 rdfs:label="E958.8"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class4144"
	 kb:currentName="E958.81"
	 rdfs:label="E958.81"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class4167"
	 kb:currentName="E958.82"
	 rdfs:label="E958.82"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class418"
	 rdfs:label="annotation_library_Class418"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class4190"
	 kb:currentName="E958.9"
	 rdfs:label="E958.9"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class4213"
	 kb:currentName="E959"
	 rdfs:label="E959"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class4236"
	 kb:currentName="PTSD"
	 rdfs:label="PTSD"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class4259"
	 kb:currentName="Depression"
	 rdfs:label="Depression"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class4282"
	 kb:currentName="Bipolar"
	 rdfs:label="Bipolar"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class4305"
	 kb:currentName="Dementia"
	 rdfs:label="Dementia"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class4328"
	 kb:currentName="Psychosis"
	 rdfs:label="Psychosis"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class4351"
	 kb:currentName="Schizophrenia"
	 rdfs:label="Schizophrenia"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class4374"
	 kb:currentName="Panic Disorder"
	 rdfs:label="Panic Disorder"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class4397"
	 kb:currentName="Medium_Risk_Psych_Diseases"
	 rdfs:label="Medium_Risk_Psych_Diseases"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class441"
	 rdfs:label="annotation_library_Class441"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class4420"
	 kb:currentName="Cognitive_Impairment"
	 rdfs:label="Cognitive_Impairment"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class4443"
	 kb:currentName="Homeless"
	 rdfs:label="Homeless"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class4466"
	 kb:currentName="V60.0"
	 rdfs:label="V60.0"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class4489"
	 kb:currentName="Mentally disabled"
	 rdfs:label="Mentally disabled"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class4512"
	 kb:currentName="Autism"
	 rdfs:label="Autism"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class4535"
	 kb:currentName="Mental retardation"
	 rdfs:label="Mental retardation"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class464"
	 rdfs:label="annotation_library_Class464"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class487"
	 rdfs:label="annotation_library_Class487"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class50"
	 rdfs:label="annotation_library_Class50"/>
<kb:Guideline_Reference rdf:about="&kb;annotation_library_Class50000"
	 kb:GuidelineName="VA Diabetes Guideline"
	 kb:guideline_id="1"
	 rdfs:label="VA Diabetes Guideline"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class510"
	 rdfs:label="annotation_library_Class510"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class5316"
	 kb:currentName="CCS-5"
	 rdfs:label="CCS-5"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class533"
	 rdfs:label="annotation_library_Class533"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class556"
	 rdfs:label="annotation_library_Class556"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class579"
	 rdfs:label="annotation_library_Class579"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class60001"
	 kb:currentName="dilated eye exam"
	 rdfs:label="dilated eye exam">
	<kb:associatedAnnotations rdf:resource="&kb;Concept260"/>
</kb:Ontology_Class>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class60002"
	 kb:currentName="comprehensive eye exam"
	 rdfs:label="comprehensive eye exam">
	<kb:associatedAnnotations rdf:resource="&kb;Concept261"/>
</kb:Ontology_Class>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class60003"
	 kb:currentName="Acute ischemia/rest pain"
	 rdfs:label="Acute ischemia/rest pain">
	<kb:associatedAnnotations rdf:resource="&kb;Concept267"/>
</kb:Ontology_Class>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class60004"
	 kb:currentName="DM-Type2"
	 rdfs:label="DM-Type2">
	<kb:associatedAnnotations rdf:resource="&kb;Concept276"/>
</kb:Ontology_Class>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class60005"
	 kb:currentName="CCS-3.3.2"
	 rdfs:label="CCS-3.3.2">
	<kb:associatedAnnotations rdf:resource="&kb;Concept278"/>
</kb:Ontology_Class>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class60006"
	 kb:currentName="Insulin"
	 rdfs:label="Insulin">
	<kb:associatedAnnotations rdf:resource="&kb;Concept280"/>
</kb:Ontology_Class>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class60007"
	 kb:currentName="CV autonomic neuropathy"
	 rdfs:label="CV autonomic neuropathy">
	<kb:associatedAnnotations rdf:resource="&kb;Concept288"/>
</kb:Ontology_Class>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class60008"
	 kb:currentName="chronic severe hyperglycemia"
	 rdfs:label="chronic severe hyperglycemia">
	<kb:associatedAnnotations rdf:resource="&kb;Concept290"/>
</kb:Ontology_Class>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class60009"
	 kb:currentName="Foot deformities"
	 rdfs:label="Foot deformities">
	<kb:associatedAnnotations rdf:resource="&kb;Concept294"/>
</kb:Ontology_Class>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class60010"
	 kb:currentName="History of foot ulcer or non-traumatic LEA"
	 rdfs:label="History of foot ulcer or non-traumatic LEA">
	<kb:associatedAnnotations rdf:resource="&kb;Concept299"/>
</kb:Ontology_Class>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class60011"
	 kb:currentName="athlete’s foot"
	 rdfs:label="athlete’s foot">
	<kb:associatedAnnotations rdf:resource="&kb;Concept314"/>
</kb:Ontology_Class>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class60012"
	 kb:currentName="Limb threatening condition"
	 rdfs:label="Limb threatening condition">
	<kb:associatedAnnotations rdf:resource="&kb;Concept321"/>
</kb:Ontology_Class>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class60013"
	 kb:currentName="risk for foot ulcer"
	 rdfs:label="risk for foot ulcer">
	<kb:associatedAnnotations rdf:resource="&kb;Concept323"/>
</kb:Ontology_Class>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class60014"
	 kb:currentName="Diabetes-Mellitus-Type1"
	 rdfs:label="Diabetes-Mellitus-Type1">
	<kb:associatedAnnotations rdf:resource="&kb;Concept254"/>
</kb:Ontology_Class>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class60015"
	 rdfs:label="annotation_library_Class60015"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class602"
	 rdfs:label="annotation_library_Class602"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class625"
	 rdfs:label="annotation_library_Class625"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class648"
	 rdfs:label="annotation_library_Class648"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class671"
	 rdfs:label="annotation_library_Class671"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class694"
	 rdfs:label="annotation_library_Class694"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class70003"
	 rdfs:label="annotation_library_Class70003"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class70014"
	 kb:currentName="Minor wound healed"
	 rdfs:label="Minor wound healed">
	<kb:associatedAnnotations rdf:resource="&kb;Concept326"/>
</kb:Ontology_Class>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class70015"
	 kb:currentName="PPG"
	 rdfs:label="PPG">
	<kb:associatedAnnotations rdf:resource="&kb;Concept331"/>
</kb:Ontology_Class>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class70016"
	 kb:currentName="mild microvasular disease"
	 rdfs:label="mild microvasular disease">
	<kb:associatedAnnotations rdf:resource="&kb;Concept334"/>
</kb:Ontology_Class>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class717"
	 rdfs:label="annotation_library_Class717"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class73"
	 rdfs:label="annotation_library_Class73"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class740"
	 rdfs:label="annotation_library_Class740"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class763"
	 rdfs:label="annotation_library_Class763"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class786"
	 rdfs:label="annotation_library_Class786"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class80000"
	 kb:currentName="trauma"
	 rdfs:label="trauma">
	<kb:associatedAnnotations rdf:resource="&kb;Concept291"/>
</kb:Ontology_Class>
<kb:Module_Reference rdf:about="&kb;annotation_library_Class80001"
	 kb:Module="G"
	 kb:ModuleID="3"
	 kb:Module_Name="Glycemic Control"
	 rdfs:label="3:G: Glycemic Control"/>
<kb:Module_Reference rdf:about="&kb;annotation_library_Class80002"
	 kb:Module="F"
	 kb:ModuleID="2"
	 kb:Module_Name="FOOT CARE"
	 rdfs:label="2:F: FOOT CARE"/>
<kb:Module_Reference rdf:about="&kb;annotation_library_Class80003"
	 kb:Module="E"
	 kb:ModuleID="1"
	 kb:Module_Name="Screening for Retinopathy"
	 rdfs:label="1:E: Screening for Retinopathy"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class809"
	 rdfs:label="annotation_library_Class809"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class832"
	 rdfs:label="annotation_library_Class832"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class855"
	 rdfs:label="annotation_library_Class855"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class878"
	 rdfs:label="annotation_library_Class878"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class90003"
	 kb:currentName=":UNDEFINED"
	 rdfs:label=":UNDEFINED"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class901"
	 rdfs:label="annotation_library_Class901"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class924"
	 rdfs:label="annotation_library_Class924"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class947"
	 rdfs:label="annotation_library_Class947"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class96"
	 rdfs:label="annotation_library_Class96"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class970"
	 rdfs:label="annotation_library_Class970"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Class993"
	 rdfs:label="annotation_library_Class993"/>
<kb:Comment rdf:about="&kb;annotation_library_Instance_0"
	 kb:author="swt"
	 rdfs:label="annotation_library_Instance_0">
	<kb:body>Need to reconciled Diabetes_Mellitus class (and its subclasses) with HCUP concepts. ATHENA-specific concepts should have "Coding System" of ATHENA.</kb:body>
	<kb:created rdf:resource="&kb;annotation_library_Instance_1"/>
	<kb:annotates rdf:resource="&kb;annotation_library_Instance_2"/>
</kb:Comment>
<kb:Timestamp rdf:about="&kb;annotation_library_Instance_1"
	 kb:date="01/09/2008 15:45:33 PST"
	 kb:sequence="0"
	 rdfs:label="01/09/2008 15:45:33 PST"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Instance_10000"
	 kb:currentName="trauma to lower extremity"
	 rdfs:label="trauma to lower extremity"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Instance_100000"
	 kb:currentName="Breaks in the skin"
	 rdfs:label="Breaks in the skin">
	<kb:associatedAnnotations rdf:resource="&kb;Concept265"/>
</kb:Ontology_Class>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Instance_100014"
	 kb:currentName="Changes in the size of foot"
	 rdfs:label="Changes in the size of foot">
	<kb:associatedAnnotations rdf:resource="&kb;Concept304"/>
</kb:Ontology_Class>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Instance_100028"
	 kb:currentName="Erythema"
	 rdfs:label="Erythema">
	<kb:associatedAnnotations rdf:resource="&kb;Concept283"/>
</kb:Ontology_Class>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Instance_100042"
	 kb:currentName="Evaluation for foot deformity"
	 rdfs:label="Evaluation for foot deformity">
	<kb:associatedAnnotations rdf:resource="&kb;Concept298"/>
</kb:Ontology_Class>
<kb:Comment rdf:about="&kb;annotation_library_Instance_100056"
	 kb:author="Susana Martins"
	 rdfs:label="annotation_library_Instance_100056">
	<kb:body>There already exists a foot defomitiy under HCUP hierarchy, is it ok to put guideline defined concepts there or should we create a different class for the guideline concept  of foot deformity?</kb:body>
	<kb:created rdf:resource="&kb;annotation_library_Instance_100057"/>
	<kb:annotates rdf:resource="&kb;annotation_library_Instance_70141"/>
</kb:Comment>
<kb:Timestamp rdf:about="&kb;annotation_library_Instance_100057"
	 kb:date="03/09/2008 18:14:29 PDT"
	 kb:sequence="0"
	 rdfs:label="03/09/2008 18:14:29 PDT"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Instance_100058"
	 kb:currentName="Evaluation for LE arterial disease"
	 rdfs:label="Evaluation for LE arterial disease">
	<kb:associatedAnnotations rdf:resource="&kb;Concept292"/>
</kb:Ontology_Class>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Instance_100074"
	 kb:currentName="Extensive callus"
	 rdfs:label="Extensive callus">
	<kb:associatedAnnotations rdf:resource="&kb;Concept307"/>
</kb:Ontology_Class>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Instance_100088"
	 kb:currentName="Nail deformities"
	 rdfs:label="Nail deformities">
	<kb:associatedAnnotations rdf:resource="&kb;Concept310"/>
</kb:Ontology_Class>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Instance_100102"
	 kb:currentName="Pallor on elevation"
	 rdfs:label="Pallor on elevation">
	<kb:associatedAnnotations rdf:resource="&kb;Concept297"/>
</kb:Ontology_Class>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Instance_100116"
	 kb:currentName="Pitting edema"
	 rdfs:label="Pitting edema">
	<kb:associatedAnnotations rdf:resource="&kb;Concept309"/>
</kb:Ontology_Class>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Instance_100130"
	 kb:currentName="Tinea pedis"
	 rdfs:label="Tinea pedis">
	<kb:associatedAnnotations rdf:resource="&kb;Concept308"/>
</kb:Ontology_Class>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Instance_100162"
	 kb:currentName="minor lesion"
	 rdfs:label="minor lesion">
	<kb:associatedAnnotations rdf:resource="&kb;Concept273"/>
</kb:Ontology_Class>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Instance_100176"
	 kb:currentName="Patient and family foot education"
	 rdfs:label="Patient and family foot education">
	<kb:associatedAnnotations rdf:resource="&kb;Concept275"/>
</kb:Ontology_Class>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Instance_100190"
	 kb:currentName="patient’s footwear"
	 rdfs:label="patient’s footwear">
	<kb:associatedAnnotations rdf:resource="&kb;Concept305"/>
</kb:Ontology_Class>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Instance_100204"
	 kb:currentName="Findings"
	 rdfs:label="Findings"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Instance_100241"
	 kb:currentName="Defined concept"
	 rdfs:label="Defined concept"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Instance_100399"
	 kb:currentName="Medical_Conditions_Class"
	 rdfs:label="Medical_Conditions_Class"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Instance_100544"
	 kb:currentName="Systemic or Ascending (Worsening) Infection"
	 rdfs:label="Systemic or Ascending (Worsening) Infection">
	<kb:associatedAnnotations rdf:resource="&kb;Concept270"/>
</kb:Ontology_Class>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Instance_110000"
	 rdfs:label="annotation_library_Instance_110000"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Instance_120000"
	 kb:currentName="onychomycosis"
	 rdfs:label="onychomycosis">
	<kb:associatedAnnotations rdf:resource="&kb;Concept315"/>
</kb:Ontology_Class>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Instance_120028"
	 kb:currentName="dry skin"
	 rdfs:label="dry skin">
	<kb:associatedAnnotations rdf:resource="&kb;Concept316"/>
</kb:Ontology_Class>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Instance_120042"
	 kb:currentName="painful corns"
	 rdfs:label="painful corns">
	<kb:associatedAnnotations rdf:resource="&kb;Concept313"/>
</kb:Ontology_Class>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Instance_120056"
	 kb:currentName="minor calluses"
	 rdfs:label="minor calluses">
	<kb:associatedAnnotations rdf:resource="&kb;Concept317"/>
</kb:Ontology_Class>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Instance_120070"
	 kb:currentName="uncomplicated nail trimming"
	 rdfs:label="uncomplicated nail trimming">
	<kb:associatedAnnotations rdf:resource="&kb;Concept318"/>
</kb:Ontology_Class>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Instance_120084"
	 kb:currentName="improper foot hygiene"
	 rdfs:label="improper foot hygiene">
	<kb:associatedAnnotations rdf:resource="&kb;Concept319"/>
</kb:Ontology_Class>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Instance_120098"
	 kb:currentName="Footwear prescriptions"
	 rdfs:label="Footwear prescriptions">
	<kb:associatedAnnotations rdf:resource="&kb;Concept324"/>
</kb:Ontology_Class>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Instance_130000"
	 kb:currentName="CCS-1.2.2"
	 rdfs:label="CCS-1.2.2"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Instance_130011"
	 kb:currentName="CCS-1.1.2"
	 rdfs:label="CCS-1.1.2"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Instance_130052"
	 kb:currentName="CCS-13.6.1"
	 rdfs:label="CCS-13.6.1"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Instance_130063"
	 kb:currentName="Signs"
	 rdfs:label="Signs"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Instance_130077"
	 kb:currentName="Symptoms"
	 rdfs:label="Symptoms"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Instance_130241"
	 kb:currentName="CCS-7"
	 rdfs:label="CCS-7"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Instance_130252"
	 kb:currentName="CCS-7.4.4"
	 rdfs:label="CCS-7.4.4"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Instance_130263"
	 kb:currentName="CCS-12"
	 rdfs:label="CCS-12"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Instance_130274"
	 kb:currentName="patient history data"
	 rdfs:label="patient history data"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Instance_130308"
	 kb:currentName="Clinical reminders"
	 rdfs:label="Clinical reminders"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Instance_130322"
	 kb:currentName="Pedal pulses dm"
	 rdfs:label="Pedal pulses dm"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Instance_130344"
	 kb:currentName="Sensory exam (foot dm)"
	 rdfs:label="Sensory exam (foot dm)"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Instance_130380"
	 rdfs:label="annotation_library_Instance_130380"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Instance_130398"
	 kb:currentName="Risk level dm"
	 rdfs:label="Risk level dm"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Instance_130414"
	 kb:currentName="Diabetic foot exam in this facility in past year not coded"
	 rdfs:label="Diabetic foot exam in this facility in past year not coded"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Instance_130428"
	 kb:currentName="Diabetic foot exam at other facility in past year"
	 rdfs:label="Diabetic foot exam at other facility in past year"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Instance_130442"
	 kb:currentName="bilateral LE amputation"
	 rdfs:label="bilateral LE amputation"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Instance_130456">
	<kb:currentName xml:space='preserve'><![CDATA[Life expectancy <6m]]></kb:currentName>
	<rdfs:label xml:space='preserve'><![CDATA[Life expectancy <6m]]></rdfs:label>
</kb:Ontology_Class>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Instance_130470"
	 kb:currentName="Screening no longer indicated"
	 rdfs:label="Screening no longer indicated"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Instance_130484"
	 kb:currentName="No longer diabetic"
	 rdfs:label="No longer diabetic"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Instance_140000"
	 kb:currentName="minor foot problem"
	 rdfs:label="minor foot problem">
	<kb:associatedAnnotations rdf:resource="&kb;Concept312"/>
</kb:Ontology_Class>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Instance_150000"
	 kb:currentName="nail or callus care"
	 rdfs:label="nail or callus care"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Instance_160000"
	 kb:currentName="primary care provider"
	 rdfs:label="primary care provider"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Instance_17"
	 kb:currentName="CCS-3.2"
	 rdfs:label="CCS-3.2"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Instance_180020"
	 kb:currentName="HbA1C"
	 rdfs:label="HbA1C">
	<kb:associatedAnnotations rdf:resource="&kb;annotation_library_Instance_230000"/>
</kb:Ontology_Class>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Instance_190000"
	 kb:currentName="Blood_Glucose_Regulation_Agent"
	 rdfs:label="Blood_Glucose_Regulation_Agent"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Instance_190003"
	 kb:currentName="GLIPIZIDE"
	 rdfs:label="GLIPIZIDE"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Instance_190013"
	 kb:currentName="Medications_Class"
	 rdfs:label="Medications_Class"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Instance_190024"
	 kb:currentName="Oral_Hypoglycemic_Agent"
	 rdfs:label="Oral_Hypoglycemic_Agent"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Instance_190056"
	 kb:currentName="GLIMEPIRIDE"
	 rdfs:label="GLIMEPIRIDE"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Instance_190066"
	 kb:currentName="CHLORPROPAMIDE"
	 rdfs:label="CHLORPROPAMIDE"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Instance_190086"
	 kb:currentName="ACETOHEXAMIDE"
	 rdfs:label="ACETOHEXAMIDE"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Instance_190096"
	 kb:currentName="ACARBOSE"
	 rdfs:label="ACARBOSE"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Instance_190118"
	 kb:currentName="GLYBURIDE"
	 rdfs:label="GLYBURIDE"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Instance_190128"
	 kb:currentName="METFORMIN"
	 rdfs:label="METFORMIN"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Instance_190138"
	 kb:currentName="NATEGLINIDE"
	 rdfs:label="NATEGLINIDE"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Instance_190148"
	 kb:currentName="PIOGLITAZONE"
	 rdfs:label="PIOGLITAZONE"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Instance_2"
	 kb:currentName="Diabetes_Mellitus"
	 rdfs:label="Diabetes_Mellitus">
	<kb:associatedAnnotations rdf:resource="&kb;annotation_library_Instance_0"/>
</kb:Ontology_Class>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Instance_20000"
	 kb:currentName="Asian_or_Pacific-Islander"
	 rdfs:label="Asian_or_Pacific-Islander"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Instance_200010"
	 kb:currentName="REPAGLINIDE"
	 rdfs:label="REPAGLINIDE"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Instance_200020"
	 kb:currentName="ROSIGLITAZONE"
	 rdfs:label="ROSIGLITAZONE"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Instance_20003"
	 kb:currentName="Alkaline_phosphatase"
	 rdfs:label="Alkaline_phosphatase"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Instance_200030"
	 kb:currentName="SITAGLIPTIN"
	 rdfs:label="SITAGLIPTIN"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Instance_200046"
	 kb:currentName="TOLAZAMIDE"
	 rdfs:label="TOLAZAMIDE"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Instance_200060"
	 kb:currentName="TOLBUTAMIDE"
	 rdfs:label="TOLBUTAMIDE"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Instance_200074"
	 kb:currentName="TROGLITAZONE"
	 rdfs:label="TROGLITAZONE"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Instance_210000"
	 kb:currentName="SULFONYLUREAS"
	 rdfs:label="SULFONYLUREAS"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Instance_210074"
	 kb:currentName="SULFONYLUREAS_1STGEN"
	 rdfs:label="SULFONYLUREAS_1STGEN"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Instance_210088"
	 kb:currentName="SULFONYLUREAS_2NDGEN"
	 rdfs:label="SULFONYLUREAS_2NDGEN"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Instance_210152"
	 kb:currentName="BIGUANIDE"
	 rdfs:label="BIGUANIDE"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Instance_210176"
	 kb:currentName="ALPHA-GLUCOSIDASE_INHIBITORS"
	 rdfs:label="ALPHA-GLUCOSIDASE_INHIBITORS"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Instance_210210"
	 kb:currentName="THIAZOLIDINEDIONES"
	 rdfs:label="THIAZOLIDINEDIONES"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Instance_210244"
	 kb:currentName="MEGLITINIDES"
	 rdfs:label="MEGLITINIDES"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Instance_210288"
	 kb:currentName="DIPEPTIDYL_PEPTIDASE-4_INHIBITOR"
	 rdfs:label="DIPEPTIDYL_PEPTIDASE-4_INHIBITOR"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Instance_220002"
	 kb:currentName=":THING"
	 rdfs:label=":THING"/>
<kb:Comment rdf:about="&kb;annotation_library_Instance_230000"
	 kb:author="Martha Michel"
	 kb:body="Is this a blood chemistry test?"
	 rdfs:label="annotation_library_Instance_230000">
	<kb:annotates rdf:resource="&kb;annotation_library_Instance_180020"/>
	<kb:created rdf:resource="&kb;annotation_library_Instance_230001"/>
</kb:Comment>
<kb:Timestamp rdf:about="&kb;annotation_library_Instance_230001"
	 kb:date="05/07/2008 14:15:27 PDT"
	 kb:sequence="0"
	 rdfs:label="05/07/2008 14:15:27 PDT"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Instance_230002"
	 kb:currentName="Mild neuropathy"
	 rdfs:label="Mild neuropathy">
	<kb:associatedAnnotations rdf:resource="&kb;Concept348"/>
</kb:Ontology_Class>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Instance_230016"
	 kb:currentName="microalbuminuria"
	 rdfs:label="microalbuminuria"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Instance_230034"
	 kb:currentName="peripheral neuropathy"
	 rdfs:label="peripheral neuropathy">
	<kb:associatedAnnotations rdf:resource="&kb;Concept349"/>
</kb:Ontology_Class>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Instance_230070"
	 kb:currentName="Advanced microvascular disease"
	 rdfs:label="Advanced microvascular disease">
	<kb:associatedAnnotations rdf:resource="&kb;Concept336"/>
</kb:Ontology_Class>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Instance_230086"
	 kb:currentName="Weight loss"
	 rdfs:label="Weight loss"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Instance_230102"
	 kb:currentName="METFORMIN_ER"
	 rdfs:label="METFORMIN_ER"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Instance_230116"
	 kb:currentName="MIGLITOL"
	 rdfs:label="MIGLITOL"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Instance_230134"
	 kb:currentName="hypoglycemia"
	 rdfs:label="hypoglycemia">
	<kb:associatedAnnotations rdf:resource="&kb;Concept352"/>
	<kb:associatedAnnotations rdf:resource="&kb;annotation_library_Instance_250006"/>
	<kb:associatedAnnotations rdf:resource="&kb;annotation_library_Instance_250010"/>
</kb:Ontology_Class>
<kb:Comment rdf:about="&kb;annotation_library_Instance_230152"
	 kb:author="Martha Michel"
	 rdfs:label="annotation_library_Instance_230152">
	<kb:body>not clearly defined in DM guideline - what about this definition? "...including coma, seizures, or frequent need for emergency resuscitation"</kb:body>
	<kb:created rdf:resource="&kb;annotation_library_Instance_230153"/>
</kb:Comment>
<kb:Timestamp rdf:about="&kb;annotation_library_Instance_230153"
	 kb:date="05/07/2008 15:46:08 PDT"
	 kb:sequence="1"
	 rdfs:label="05/07/2008 15:46:08 PDT"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Instance_230720"
	 kb:currentName="Duration of Diabetes"
	 rdfs:label="Duration of Diabetes"/>
<kb:Comment rdf:about="&kb;annotation_library_Instance_230734"
	 kb:author="Martha Michel"
	 kb:body="what about planned pregnancy?"
	 rdfs:label="annotation_library_Instance_230734">
	<kb:created rdf:resource="&kb;annotation_library_Instance_230735"/>
	<kb:annotates rdf:resource="&kb;annotation_library_Instance_30"/>
</kb:Comment>
<kb:Timestamp rdf:about="&kb;annotation_library_Instance_230735"
	 kb:date="05/08/2008 11:50:55 PDT"
	 kb:sequence="0"
	 rdfs:label="05/08/2008 11:50:55 PDT"/>
<kb:Comment rdf:about="&kb;annotation_library_Instance_240000"
	 kb:author="Susana Martins"
	 rdfs:label="annotation_library_Instance_240000">
	<kb:body>Not sure how to model any measurement above target in past year. I guess it has to be the query?</kb:body>
	<kb:created rdf:resource="&kb;annotation_library_Instance_240001"/>
</kb:Comment>
<kb:Timestamp rdf:about="&kb;annotation_library_Instance_240001"
	 kb:date="05/10/2008 11:06:45 PDT"
	 kb:sequence="0"
	 rdfs:label="05/10/2008 11:06:45 PDT"/>
<kb:Comment rdf:about="&kb;annotation_library_Instance_250006"
	 kb:author="Martha Michel"
	 kb:body="(Enter the annotation text here)"
	 rdfs:label="annotation_library_Instance_250006">
	<kb:annotates rdf:resource="&kb;annotation_library_Instance_230134"/>
	<kb:created rdf:resource="&kb;annotation_library_Instance_250007"/>
</kb:Comment>
<kb:Timestamp rdf:about="&kb;annotation_library_Instance_250007"
	 kb:date="05/13/2008 11:37:23 PDT"
	 kb:sequence="0"
	 rdfs:label="05/13/2008 11:37:23 PDT"/>
<kb:Comment rdf:about="&kb;annotation_library_Instance_250010"
	 kb:author="Martha Michel"
	 kb:body="(Enter the annotation text here)"
	 rdfs:label="annotation_library_Instance_250010">
	<kb:annotates rdf:resource="&kb;annotation_library_Instance_230134"/>
	<kb:created rdf:resource="&kb;annotation_library_Instance_250011"/>
</kb:Comment>
<kb:Timestamp rdf:about="&kb;annotation_library_Instance_250011"
	 kb:date="05/13/2008 11:37:55 PDT"
	 kb:sequence="2"
	 rdfs:label="05/13/2008 11:37:55 PDT"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Instance_260000"
	 kb:currentName="Target_parameters"
	 rdfs:label="Target_parameters"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Instance_260014"
	 kb:currentName="target_HBA1c"
	 rdfs:label="target_HBA1c"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Instance_270540"
	 kb:currentName="recurrent episodes of incapacitating hyperglycemia"
	 rdfs:label="recurrent episodes of incapacitating hyperglycemia"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Instance_270554"
	 kb:currentName="poor recognition of hypoglycemia"
	 rdfs:label="poor recognition of hypoglycemia"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Instance_270568"
	 kb:currentName="psychosocial problems that complicate management"
	 rdfs:label="psychosocial problems that complicate management"/>
<kb:Comment rdf:about="&kb;annotation_library_Instance_28"
	 kb:author="swt"
	 rdfs:label="annotation_library_Instance_28">
	<kb:body>Check to see whether it is appropriate to have the ATHENA Pregnancy concept here in the HCUP hierarchy.</kb:body>
	<kb:created rdf:resource="&kb;annotation_library_Instance_29"/>
	<kb:annotates rdf:resource="&kb;annotation_library_Instance_30"/>
</kb:Comment>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Instance_280000"
	 kb:currentName="BMIGT25"
	 rdfs:label="BMIGT25"/>
<kb:Timestamp rdf:about="&kb;annotation_library_Instance_29"
	 kb:date="01/09/2008 15:49:56 PST"
	 kb:sequence="12"
	 rdfs:label="01/09/2008 15:49:56 PST"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Instance_30"
	 kb:currentName="Pregnancy"
	 rdfs:label="Pregnancy">
	<kb:associatedAnnotations rdf:resource="&kb;annotation_library_Instance_230734"/>
	<kb:associatedAnnotations rdf:resource="&kb;annotation_library_Instance_28"/>
</kb:Ontology_Class>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Instance_30000"
	 kb:currentName="Acute ocular changes"
	 rdfs:label="Acute ocular changes">
	<kb:associatedAnnotations rdf:resource="&kb;Concept256"/>
</kb:Ontology_Class>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Instance_30016"
	 kb:currentName="change in ocular function"
	 rdfs:label="change in ocular function">
	<kb:associatedAnnotations rdf:resource="&kb;Concept277"/>
</kb:Ontology_Class>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Instance_30032"
	 kb:currentName="Eye procedures"
	 rdfs:label="Eye procedures"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Instance_30060"
	 kb:currentName="chronic severe hypoglycemia"
	 rdfs:label="chronic severe hypoglycemia"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Instance_30074"
	 kb:currentName="uncontrolled htn"
	 rdfs:label="uncontrolled htn"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Instance_30100"
	 kb:currentName="diabetic neuropathy"
	 rdfs:label="diabetic neuropathy"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Instance_30116"
	 kb:currentName="lower extremity amputation related to DM"
	 rdfs:label="lower extremity amputation related to DM">
	<kb:associatedAnnotations rdf:resource="&kb;Concept295"/>
</kb:Ontology_Class>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Instance_30130"
	 kb:currentName="Retinopathy"
	 rdfs:label="Retinopathy">
	<kb:associatedAnnotations rdf:resource="&kb;Concept253"/>
</kb:Ontology_Class>
<kb:Comment rdf:about="&kb;annotation_library_Instance_31"
	 kb:author="swt"
	 rdfs:label="annotation_library_Instance_31">
	<kb:body>Check to see whether we need Hypertension_Defined concept. In Lipid guideline, we defined hypertension as ICD9 code OR SBP/DBP > 140/90 OR on anti-hypertensive agents.</kb:body>
	<kb:created rdf:resource="&kb;annotation_library_Instance_32"/>
	<kb:annotates rdf:resource="&kb;annotation_library_Instance_33"/>
</kb:Comment>
<kb:Timestamp rdf:about="&kb;annotation_library_Instance_32"
	 kb:date="01/09/2008 15:57:22 PST"
	 kb:sequence="13"
	 rdfs:label="01/09/2008 15:57:22 PST"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Instance_33"
	 kb:currentName="Hypertension_Defined"
	 rdfs:label="Hypertension_Defined">
	<kb:associatedAnnotations rdf:resource="&kb;annotation_library_Instance_31"/>
</kb:Ontology_Class>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Instance_5"
	 kb:currentName="CCS-3.3"
	 rdfs:label="CCS-3.3"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Instance_50000"
	 kb:currentName="ophtalmologyst"
	 rdfs:label="ophtalmologyst"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Instance_60000"
	 kb:currentName="eye care provider"
	 rdfs:label="eye care provider"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Instance_70000">
	<kb:currentName>Lack of sensation to Semmes-Weinstein 5.07 monofilament at one or more noncallused plantar sites</kb:currentName>
	<rdfs:label>Lack of sensation to Semmes-Weinstein 5.07 monofilament at one or more noncallused plantar sites</rdfs:label>
	<kb:associatedAnnotations rdf:resource="&kb;Concept272"/>
</kb:Ontology_Class>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Instance_70022"
	 kb:currentName="Evidence of LE arterial disease"
	 rdfs:label="Evidence of LE arterial disease">
	<kb:associatedAnnotations rdf:resource="&kb;Concept286"/>
</kb:Ontology_Class>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Instance_70077"
	 kb:currentName="Dorsalis pedis pulses"
	 rdfs:label="Dorsalis pedis pulses"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Instance_70091"
	 kb:currentName="Tibialis posterior pulses"
	 rdfs:label="Tibialis posterior pulses"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Instance_70113"
	 kb:currentName="dependent rubor with pallor on elevation"
	 rdfs:label="dependent rubor with pallor on elevation"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Instance_70127"
	 kb:currentName="history of rest pain or claudication"
	 rdfs:label="history of rest pain or claudication"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Instance_70141"
	 kb:currentName="Foot deformities"
	 rdfs:label="Foot deformities">
	<kb:associatedAnnotations rdf:resource="&kb;annotation_library_Instance_100056"/>
</kb:Ontology_Class>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Instance_70157"
	 kb:currentName="hammer toes"
	 rdfs:label="hammer toes"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Instance_70171"
	 kb:currentName="claw toe"
	 rdfs:label="claw toe"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Instance_70185"
	 kb:currentName="Charcot’s arthropathy"
	 rdfs:label="Charcot’s arthropathy"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Instance_70199"
	 kb:currentName="bunions"
	 rdfs:label="bunions"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Instance_70213"
	 rdfs:label="annotation_library_Instance_70213"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Instance_70223"
	 kb:currentName="metatarsal head deformities"
	 rdfs:label="metatarsal head deformities"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Instance_70249"
	 rdfs:label="annotation_library_Instance_70249"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Instance_70269"
	 kb:currentName="Foot procedures"
	 rdfs:label="Foot procedures"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Instance_70285"
	 kb:currentName="Visual inspection (foot dm)"
	 rdfs:label="Visual inspection (foot dm)"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Instance_70299"
	 kb:currentName="Foot risk assessment"
	 rdfs:label="Foot risk assessment">
	<kb:associatedAnnotations rdf:resource="&kb;Concept266"/>
</kb:Ontology_Class>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Instance_8"
	 kb:currentName="CCS-3"
	 rdfs:label="CCS-3"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Instance_80000"
	 kb:currentName="_DUMMY-FRAMES-METACLASS"
	 rdfs:label="_DUMMY-FRAMES-METACLASS"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Instance_80010"
	 rdfs:label="annotation_library_Instance_80010"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Instance_80020"
	 kb:currentName="_DUMMY-FRAMES-METASLOT"
	 rdfs:label="_DUMMY-FRAMES-METASLOT"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Instance_80030"
	 kb:currentName="_DUMMY-FRAMES-METAFACET"
	 rdfs:label="_DUMMY-FRAMES-METAFACET"/>
<kb:Ontology_Property rdf:about="&kb;annotation_library_Instance_80043"
	 kb:currentName="_REFERENCES"
	 rdfs:label="_REFERENCES"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Instance_90002"
	 rdfs:label="annotation_library_Instance_90002"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Instance_90032"
	 kb:currentName="Systemic infection"
	 rdfs:label="Systemic infection"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Instance_90060"
	 rdfs:label="annotation_library_Instance_90060"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Instance_90074"
	 kb:currentName="Puncture wound"
	 rdfs:label="Puncture wound">
	<kb:associatedAnnotations rdf:resource="&kb;Concept285"/>
</kb:Ontology_Class>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Instance_90088"
	 kb:currentName="Ingrown toenail"
	 rdfs:label="Ingrown toenail">
	<kb:associatedAnnotations rdf:resource="&kb;Concept269"/>
</kb:Ontology_Class>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Instance_90102"
	 kb:currentName="Hemorrhagic Callus With or Without Cellulitis"
	 rdfs:label="Hemorrhagic Callus With or Without Cellulitis">
	<kb:associatedAnnotations rdf:resource="&kb;Concept293"/>
</kb:Ontology_Class>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Instance_90126"
	 kb:currentName="podiatrist"
	 rdfs:label="podiatrist"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Instance_90140"
	 kb:currentName="vascular specialist"
	 rdfs:label="vascular specialist"/>
<kb:Ontology_Class rdf:about="&kb;annotation_library_Instance_90154"
	 kb:currentName="foot care specialist"
	 rdfs:label="foot care specialist">
	<kb:associatedAnnotations rdf:resource="&kb;Concept271"/>
</kb:Ontology_Class>
<kb:Ontology_Class rdf:about="&kb;annotation_newspaper_Instance_2"
	 kb:currentName="Author"
	 rdfs:label="Author"/>
<kb:Ontology_Property rdf:about="&kb;annotation_newspaper_Instance_5"
	 kb:currentName="advertisements"
	 rdfs:label="advertisements"/>
</rdf:RDF>
